<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H2805CFE039BE4B0F945B09F6C77FBC7B" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 6 IH: 21st Century Cures Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 6</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150519">May 19, 2015</action-date>
			<action-desc><sponsor name-id="U000031">Mr. Upton</sponsor> (for himself, <cosponsor name-id="D000197">Ms. DeGette</cosponsor>, <cosponsor name-id="P000373">Mr. Pitts</cosponsor>, <cosponsor name-id="P000034">Mr. Pallone</cosponsor>, and <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To accelerate the discovery, development, and delivery of 21st century cures, and for other
			 purposes.</official-title>
	</form>
	<legis-body id="HCFC0635C03DE4FD78AF2C7F6D182683F" style="OLC">
		<section id="H38330EA8589E493D9E845CDB4B704C80" section-type="section-one"><enum>1.</enum><header>Short title; table of contents</header>
 <subsection id="H910AABDC65734BBC98269E40B7B736AD"><enum>(a)</enum><header>Short title</header><text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>21st Century Cures Act</short-title></quote>.</text> </subsection><subsection id="HCF15658621CC47B38EC058CBCBD81C9A"><enum>(b)</enum><header>Table of contents</header><text display-inline="yes-display-inline">The table of contents for this Act is as follows:</text>
				<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
					<toc-entry idref="H38330EA8589E493D9E845CDB4B704C80" level="section">Sec. 1. Short title; table of contents.</toc-entry>
					<toc-entry idref="HAB36A7AB5B8C488BAFDDE6BAADFFEC56" level="title">Title I—Discovery</toc-entry>
					<toc-entry idref="HFC37F39DB6C4411BA27E4E471CD5925B" level="subtitle">Subtitle A—National Institutes of Health Funding</toc-entry>
					<toc-entry idref="HE42A1E4BEB4E445D8E61E4C2BE6FED0F" level="section">Sec. 1001. National Institutes of Health reauthorization.</toc-entry>
					<toc-entry idref="HDD1C6CA93763407A80DD07C94D4CA08E" level="section">Sec. 1002. NIH Innovation Fund.</toc-entry>
					<toc-entry idref="H10F20A56C2884C9B9F0108E49A6B6CAC" level="subtitle">Subtitle B—National Institutes of Health Planning and Administration</toc-entry>
					<toc-entry idref="HCFA19AE3FC544E369E4E11C2501127B9" level="section">Sec. 1021. NIH research strategic plan.</toc-entry>
					<toc-entry idref="H96E344CB49014488834B0307090490F6" level="section">Sec. 1022. Increasing accountability at the National Institutes of Health.</toc-entry>
					<toc-entry idref="H77A7DCACD6D7416AB23B7D0A77F21BD5" level="section">Sec. 1023. Reducing administrative burdens of researchers.</toc-entry>
					<toc-entry idref="H4827323C5C4D4A0EA61293CBEFD05314" level="section">Sec. 1024. Exemption for the National Institutes of Health from the Paperwork Reduction Act
			 requirements.</toc-entry>
					<toc-entry idref="H3FB351CF772C4405B9C4F8E732D46D73" level="section">Sec. 1025. NIH travel.</toc-entry>
					<toc-entry idref="HF71E7D23FF8C4389A258C4207B6450FD" level="section">Sec. 1026. Other transactions authority.</toc-entry>
					<toc-entry idref="H9EA54B036BC9492DB5B00094DC2AB018" level="section">Sec. 1027. NCATS phase IIB restriction.</toc-entry>
					<toc-entry idref="H12079AFA5F3A4D2F8FB97D7340330D5F" level="section">Sec. 1028. High-risk, high-reward research.</toc-entry>
					<toc-entry idref="H2E4190F933C64EFA8CCCF6060C870873" level="subtitle">Subtitle C—Supporting Young Emerging Scientists</toc-entry>
					<toc-entry idref="H7A45136526C741F5A1EE26D8F2C419AC" level="section">Sec. 1041. Improvement of loan repayment programs of National Institutes of Health.</toc-entry>
					<toc-entry idref="HB57A12DF621B4FDE8FAEC7237F100411" level="section">Sec. 1042. Report.</toc-entry>
					<toc-entry idref="H11A52EDB70604195B4A3AE173D0FBC56" level="subtitle">Subtitle D—Capstone Grant Program</toc-entry>
					<toc-entry idref="H0CFBBD80EFD44F798CE82B63328DBAAC" level="section">Sec. 1061. Capstone award.</toc-entry>
					<toc-entry idref="H5BE910FD76A84278AD6A1E7D2D1DFF9D" level="subtitle">Subtitle E—Promoting Pediatric Research through the National Institutes of Health</toc-entry>
					<toc-entry idref="H711ECED3917042B6BBC63816566E96A8" level="section">Sec. 1081. National Pediatric Research Network.</toc-entry>
					<toc-entry idref="HA9E87563C0A140EAA7D0211D92FD4BD3" level="section">Sec. 1082. Global Pediatric Clinical Study Network Sense of Congress.</toc-entry>
					<toc-entry idref="HF247851C5FF6444AB33048E273BF032F" level="section">Sec. 1083. Appropriate age groupings in clinical research.</toc-entry>
					<toc-entry idref="H759B5C8C926443328FE2F70F4ACBD5DB" level="subtitle">Subtitle F—Advancement of National Institutes of Health Research and Data Access</toc-entry>
					<toc-entry idref="HF5E084903982448D86FE0608AB6DDD57" level="section">Sec. 1101. Sharing of data generated through NIH-funded research.</toc-entry>
					<toc-entry idref="H63B5725A00B44108B081D7E079F61FCB" level="section">Sec. 1102. Standardization of data in Clinical Trial Registry Data Bank on eligibility for clinical
			 trials.</toc-entry>
					<toc-entry idref="H8BFDC068659C416E9CAC29971FF1BB1C" level="subtitle">Subtitle G—Facilitating Collaborative Research</toc-entry>
					<toc-entry idref="HC3A825BC09D44C088992984ABB953292" level="section">Sec. 1121. Clinical Trial Data System.</toc-entry>
					<toc-entry idref="HCB8FF9A534DB4BDAB61DE6E763D7A1CD" level="section">Sec. 1122. National neurological diseases surveillance system.</toc-entry>
					<toc-entry idref="H6845D13E37D946EBB1DEABEC5A350ADB" level="section">Sec. 1123. Data on natural history of diseases.</toc-entry>
					<toc-entry idref="H705FB451D71143AB920B1BC84BFE173E" level="section">Sec. 1124. Accessing, sharing, and using health data for research purposes.</toc-entry>
					<toc-entry idref="HF3C41797A9914794A9C456635C4F76D1" level="subtitle">Subtitle H—Council for 21st Century Cures</toc-entry>
					<toc-entry idref="HAE79876EBDC448FEA58405BB11700C65" level="section">Sec. 1141. Council for 21st Century Cures.</toc-entry>
					<toc-entry idref="H7A8DD206F91D44058087642576F12427" level="title">Title II—Development</toc-entry>
					<toc-entry idref="HF62F90257FF447A589E2FF7636D385FA" level="subtitle">Subtitle A—Patient-Focused Drug Development</toc-entry>
					<toc-entry idref="H5D08EB3099FE4CCCB5CC556E49B8EA14" level="section">Sec. 2001. Development and use of patient experience data to enhance structured risk-benefit
			 assessment framework.</toc-entry>
					<toc-entry idref="HB5E20171BCA745E58EFA7EABD890B5AD" level="subtitle">Subtitle B—Qualification and Use of Drug Development Tools</toc-entry>
					<toc-entry idref="H891A499D80804A47A34A1471D131A470" level="section">Sec. 2021. Qualification of drug development tools.</toc-entry>
					<toc-entry idref="H8FA07A513C4142959330B35E0EF54090" level="section">Sec. 2022. Accelerated approval development plan.</toc-entry>
					<toc-entry idref="HA9B50CBF3BC04A11AD57E0F0912A4AB0" level="subtitle">Subtitle C—FDA advancement of Precision Medicine</toc-entry>
					<toc-entry idref="H1380543FFF2C4156915D1D7D164B6CC7" level="section">Sec. 2041. Precision medicine guidance and other programs of Food and Drug Administration.</toc-entry>
					<toc-entry idref="HD896A79E2D664CD68A0C994F0518BEAB" level="subtitle">Subtitle D—Modern Trial Design and Evidence Development</toc-entry>
					<toc-entry idref="HC9EFCBA15B174020AB9BD501512A7FC7" level="section">Sec. 2061. Broader application of Bayesian statistics and adaptive trial designs.</toc-entry>
					<toc-entry idref="HC817FAC6BDCC485C8FE20DC24AE1E00F" level="section">Sec. 2062. Utilizing evidence from clinical experience.</toc-entry>
					<toc-entry idref="HCDCAEB68339141F2A1A7124625928912" level="section">Sec. 2063. Streamlined data review program.</toc-entry>
					<toc-entry idref="H7C14DFDD87414763A6D58F872D3DA084" level="subtitle">Subtitle E—Expediting Patient Access</toc-entry>
					<toc-entry idref="H70A6DDD649364A8E87C1F41747A475D4" level="section">Sec. 2081. Sense of Congress.</toc-entry>
					<toc-entry idref="HB89E081072364A3FB8562480833E823C" level="section">Sec. 2082. Expanded access policy.</toc-entry>
					<toc-entry idref="HE834E83F6EFE434E8920730A87A85697" level="section">Sec. 2083. Finalizing draft guidance on expanded access.</toc-entry>
					<toc-entry idref="H41C7B86B8C7947769DF494ECDF556613" level="subtitle">Subtitle F—Facilitating responsible manufacturer communications</toc-entry>
					<toc-entry idref="H366E62F7B39544F18EFDDC8F91A8542E" level="section">Sec. 2101. Facilitating dissemination of health care economic information.</toc-entry>
					<toc-entry idref="HA1329DD82F2F414E99C5417C3D5E144D" level="section">Sec. 2102. Facilitating responsible communication of scientific and medical developments.</toc-entry>
					<toc-entry idref="H74AEB3CB4ECD44B18D2F0DFBEDCE8042" level="subtitle">Subtitle G—Antibiotic Drug Development</toc-entry>
					<toc-entry idref="HCE897BE5B6B74AA0BFF48AD0439E2F85" level="section">Sec. 2121. Approval of certain drugs for use in a limited population of patients.</toc-entry>
					<toc-entry idref="H4E60E47A4C6B403CAFD9D8838036A28D" level="section">Sec. 2122. Susceptibility test interpretive criteria for microorganisms.</toc-entry>
					<toc-entry idref="HE6E432A3BB5346DEAB351656E2F3A6A9" level="section">Sec. 2123. Encouraging the development and use of new antimicrobial drugs.</toc-entry>
					<toc-entry idref="H674937B6246140B598BC49DD92CF1F5F" level="subtitle">Subtitle H—Vaccine Access, Certainty, and Innovation</toc-entry>
					<toc-entry idref="H19FBB7A069AA4DE5B62862599BF49FB3" level="section">Sec. 2141. Timely review of vaccines by the Advisory Committee on Immunization Practices.</toc-entry>
					<toc-entry idref="H754773847F7E4C988C54855DBA9CC3A1" level="section">Sec. 2142. Review of processes and consistency of ACIP recommendations.</toc-entry>
					<toc-entry idref="H69663CF4A85040C2AEB7B957FD3C7BC3" level="section">Sec. 2143. Meetings between CDC and vaccine developers.</toc-entry>
					<toc-entry idref="H84C0155E55F34C0EB650B6C557731E3D" level="subtitle">Subtitle I—Orphan product extensions now; incentives for certain products for limited populations</toc-entry>
					<toc-entry idref="H01E5BE63C7B149B8885A77B28EDF8BAF" level="section">Sec. 2151. Extension of exclusivity periods for a drug approved for a new indication for a rare
			 disease or condition.</toc-entry>
					<toc-entry idref="H8043BBB8501945F4B04B172427F7A427" level="section">Sec. 2152. Reauthorization of rare pediatric disease priority review voucher incentive program.</toc-entry>
					<toc-entry idref="HF4B63ECBAD6C433C8F49C9548012487B" level="subtitle">Subtitle J—Domestic Manufacturing and Export Efficiencies</toc-entry>
					<toc-entry idref="H7DE767DA3DED49D69CBF1C0E09346AAA" level="section">Sec. 2161. Grants for studying the process of continuous drug manufacturing.</toc-entry>
					<toc-entry idref="H7C6D60CDEBDF4D509F4DB522A907E716" level="section">Sec. 2162. Re-exportation among members of the European Economic Area.</toc-entry>
					<toc-entry idref="H20696360AA2C44D0AE53DB73721A35EA" level="subtitle">Subtitle K—Enhancing combination products review</toc-entry>
					<toc-entry idref="HB4EAF68F4E7B48D290149F4761022F69" level="section">Sec. 2181. Enhancing combination products review.</toc-entry>
					<toc-entry idref="HC3F2225AD0234E1787128AF372B1D3DD" level="subtitle">Subtitle L—Priority Review for Breakthrough Devices</toc-entry>
					<toc-entry idref="H663CB1EAF455469D811A60131CE133E7" level="section">Sec. 2201. Priority review for breakthrough devices.</toc-entry>
					<toc-entry idref="H1F0CDC0CBDE341ADA6ACEDE542726AF8" level="subtitle">Subtitle M—Medical Device Regulatory Process Improvements</toc-entry>
					<toc-entry idref="H889C35499F0D4CE6B8564CEDE83CABF9" level="section">Sec. 2221. Third-party quality system assessment.</toc-entry>
					<toc-entry idref="H82EA095CEBBF488ABCAD3F2EC0C8D514" level="section">Sec. 2222. Valid scientific evidence.</toc-entry>
					<toc-entry idref="H9C1C0759DBF04A77AB35F705086F7C24" level="section">Sec. 2223. Training and oversight in least burdensome appropriate means concept.</toc-entry>
					<toc-entry idref="HEC0D9146130F4D1B8889515967C6BC2C" level="section">Sec. 2224. Recognition of standards.</toc-entry>
					<toc-entry idref="H04E36891A1B04EDF9E97796DFA713E47" level="section">Sec. 2225. Easing regulatory burden with respect to certain class I and class II devices.</toc-entry>
					<toc-entry idref="H0A46E9AE8BDE40A68BBF94244CB6ED58" level="section">Sec. 2226. Advisory committee process.</toc-entry>
					<toc-entry idref="H9038248F875246BDAD7D125E7B6A5A7A" level="section">Sec. 2227. Humanitarian device exemption application.</toc-entry>
					<toc-entry idref="H2B9EBE91C1BD4A69B3CB2E8220B90B65" level="section">Sec. 2228. CLIA waiver study design guidance for in vitro diagnostics.</toc-entry>
					<toc-entry idref="HEEEED248ECE94AE8A5CD2D9D396FCEAE" level="subtitle">Subtitle N—Sensible Oversight for Technology Which Advances Regulatory Efficiency</toc-entry>
					<toc-entry idref="H40ADF390FEF9414C9E15DB9387D75685" level="section">Sec. 2241. Health software.</toc-entry>
					<toc-entry idref="H4369F70167C74BD09132147A9C9A5D7C" level="section">Sec. 2242. Applicability and inapplicability of regulation.</toc-entry>
					<toc-entry idref="H30B6A7B764E94C54814B39F74E295BD3" level="section">Sec. 2243. Exclusion from definition of device.</toc-entry>
					<toc-entry idref="HC3AC028E78C74D23B3BF1283368B9EBD" level="subtitle">Subtitle O—Streamlining Clinical Trials</toc-entry>
					<toc-entry idref="HFAC71E4CFA1946D9AA9B7C92F3238320" level="section">Sec. 2261. Protection of human subjects in research; applicability of rules.</toc-entry>
					<toc-entry idref="H6EB5257560704273A5424B058B38A584" level="section">Sec. 2262. Use of non-local institutional review boards for review of investigational device
			 exemptions and human device exemptions.</toc-entry>
					<toc-entry idref="HE84697CA1F754B7D97B25A6118CA08A4" level="section">Sec. 2263. Alteration or waiver of informed consent for clinical investigations.</toc-entry>
					<toc-entry idref="HBA64A44EA434413A8B7B6AE2BC6C32F7" level="subtitle">Subtitle P—Improving Scientific Expertise and Outreach at FDA</toc-entry>
					<toc-entry idref="HDF7368CE140C4B10916057A82517D058" level="section">Sec. 2281. Silvio O. Conte Senior Biomedical Research Service.</toc-entry>
					<toc-entry idref="HF8E56FA9EE264844AE44E70A9372EF9C" level="section">Sec. 2282. Enabling FDA scientific engagement.</toc-entry>
					<toc-entry idref="HAD3F4113A9BE4D11990A1311D9478E42" level="section">Sec. 2283. Reagan-Udall Foundation for the Food and Drug Administration.</toc-entry>
					<toc-entry idref="H439B98A959E34C7E95CDCD8419EC1356" level="section">Sec. 2284. Collection of certain voluntary information exempted from Paperwork Reduction Act.</toc-entry>
					<toc-entry idref="HE47AC840EE1B4A349798FB9E8E6C459D" level="title">Title III—Delivery</toc-entry>
					<toc-entry idref="HC34FE10F22154B9A9DF35ED448747734" level="subtitle">Subtitle A—Interoperability</toc-entry>
					<toc-entry idref="H66C23E4AD7B748BCBAD6DCDCBAE4E4C0" level="section">Sec. 3001. Ensuring interoperability of health information technology.</toc-entry>
					<toc-entry idref="H02B594E18AA04C8CB4C044E0F648477F" level="subtitle">Subtitle B—Telehealth</toc-entry>
					<toc-entry idref="H2C474EE1F5174FF5AF83E373FD819AD8" level="section">Sec. 3021. Telehealth services under the Medicare program.</toc-entry>
					<toc-entry idref="H0C146A8F3E6E4739BB4422811DF4646D" level="subtitle">Subtitle C—Encouraging Continuing Medical Education for Physicians</toc-entry>
					<toc-entry idref="H3875530BFDCC4C8DAC5B8DCD35E26BBB" level="section">Sec. 3041. Exempting from manufacturer transparency reporting certain transfers used for
			 educational purposes.</toc-entry>
					<toc-entry idref="H4A8163D4282942DF97EE7274ED39BF31" level="subtitle">Subtitle D—Disposable Medical Technologies</toc-entry>
					<toc-entry idref="HFB81D616CC084E5187E9F38264171020" level="section">Sec. 3061. Treatment of certain items and devices.</toc-entry>
					<toc-entry idref="H8F7E549A022149588140535BB3160F41" level="subtitle">Subtitle E—Local coverage decision reforms</toc-entry>
					<toc-entry idref="H2AD977BBF6E24E5D9ED349A954290801" level="section">Sec. 3081. Improvements in the Medicare local coverage determination (LCD) process.</toc-entry>
					<toc-entry idref="H8741C6606BE64649B332DF4F63A7884F" level="subtitle">Subtitle F—Medicare Pharmaceutical and Technology Ombudsman</toc-entry>
					<toc-entry idref="H9195E09868454103971F3079FEC99645" level="section">Sec. 3101. Medicare pharmaceutical and technology ombudsman.</toc-entry>
					<toc-entry idref="HDDBC17EE482547C7B616D9BFC26B426C" level="subtitle">Subtitle G—Medicare site-of-Service price transparency</toc-entry>
					<toc-entry idref="HCA6C98C710E94BFE87774A8BF90159EB" level="section">Sec. 3121. Medicare site-of-Service price transparency.</toc-entry>
					<toc-entry idref="HA992C319BFCA4C99B991A643B0804079" level="subtitle">Subtitle H—Medicare Part D Patient Safety and Drug Abuse Prevention</toc-entry>
					<toc-entry idref="HC1CF106758AF48A492E1B9D655472648" level="section">Sec. 3141. Programs to prevent prescription drug abuse under Medicare parts C and D.</toc-entry>
				</toc>
			</subsection></section><title id="HAB36A7AB5B8C488BAFDDE6BAADFFEC56"><enum>I</enum><header>Discovery</header>
			<subtitle id="HFC37F39DB6C4411BA27E4E471CD5925B"><enum>A</enum><header>National Institutes of Health Funding</header>
 <section id="HE42A1E4BEB4E445D8E61E4C2BE6FED0F" section-type="subsequent-section"><enum>1001.</enum><header>National Institutes of Health reauthorization</header><text display-inline="no-display-inline">Section 402A(a)(1) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282a">42 U.S.C. 282a(a)(1)</external-xref>) is amended—</text> <paragraph id="HB15CCAAD706349B8AA6CCB451B53A699"><enum>(1)</enum><text>in subparagraph (B), by striking at the end <quote>and</quote>;</text>
 </paragraph><paragraph id="HEE9D6A0F8B39439AB009000E0C492585"><enum>(2)</enum><text>in subparagraph (C), by striking at the end the period and inserting <quote>; and</quote>; and</text> </paragraph><paragraph id="H1BEE1AE6542E444FAA1556526015EDD0"><enum>(3)</enum><text>by adding at the end the following new subparagraphs:</text>
						<quoted-block display-inline="no-display-inline" id="H9D6E9823FE5B4E2EA22B04D3A58D0A1F" style="OLC">
 <subparagraph id="HB015219A57BF486ABA0C9B0967460717"><enum>(D)</enum><text display-inline="yes-display-inline">$31,811,000,000 for fiscal year 2016;</text> </subparagraph><subparagraph id="H6806F5C26AED4C1A867419F85CA12C8B"><enum>(E)</enum><text>$33,331,000,000 for fiscal year 2017; and</text>
 </subparagraph><subparagraph id="H6A3E8D0E4BDD458EA9B61D275B1479EC"><enum>(F)</enum><text>$34,851,000,000 for fiscal year 2018.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></section><section commented="no" id="HDD1C6CA93763407A80DD07C94D4CA08E" section-type="subsequent-section"><enum>1002.</enum><header>NIH Innovation Fund</header> <subsection commented="no" id="H460B9CCD93F742A5BE900D31F01A322F"><enum>(a)</enum><header>Use of Innovation Fund</header><text display-inline="yes-display-inline">Section 402(b) of the Public Health Service Act is amended—</text>
 <paragraph commented="no" id="H1DE17C153C78441686A2456D2BDF00B5"><enum>(1)</enum><text>in paragraph (23), by striking at the end <quote>and</quote>;</text> </paragraph><paragraph commented="no" id="H8A1EBB45C2F9447BBC1906E80EEC1769"><enum>(2)</enum><text>in paragraph (24), by striking at the end the period and inserting <quote>; and</quote>; and</text>
 </paragraph><paragraph commented="no" id="HA8CEF30C21BB4A228BAF4602CAA30C73"><enum>(3)</enum><text>by inserting after paragraph (24), the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="H30EFCD09F8E347839F98D22B89114B3A" style="OLC"> <paragraph commented="no" id="H4BA27D37AD3047309487CC374A38205B"><enum>(25)</enum><text display-inline="yes-display-inline">shall, with respect to funds appropriated under section 402A(e) to the NIH Innovation Fund, allocate such funds to the national research institutes and national centers for conducting and supporting innovation fund initiatives identified under paragraph (3) of such section.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection commented="no" id="H50EFEE741C934AE0B0B888DA538F81E9"><enum>(b)</enum><header>Establishment of Innovation Fund</header><text>Section 402A of the Public Health Service Act is amended—</text> <paragraph commented="no" id="H39B1A3879FC3445F8DDE7753541998D1"><enum>(1)</enum><text>by redesignating subsection (e) as subsection (f); and</text>
 </paragraph><paragraph commented="no" id="HEFF828A4D74349E89FF10B7C71C42EB8"><enum>(2)</enum><text>by inserting after subsection (d) the following new subsection:</text> <quoted-block display-inline="no-display-inline" id="H38B0BA947E8A408BB21A7ECA81DEC615" style="OLC"> <subsection commented="no" id="H83D17E0E132B4A4A8C74DA89333EB4BA"><enum>(e)</enum><header>NIH Innovation Fund</header> <paragraph commented="no" id="HD08791343B26415592DDA998A3ACCF45"><enum>(1)</enum><header>Establishment</header><text display-inline="yes-display-inline">For the purpose of allocations under section 402(b)(25), there is established a fund to be known as the NIH Innovation Fund. The Director of NIH shall, with respect to funds appropriated to the NIH Innovation Fund, allocate such funds to support biomedical research through the funding of basic, translational, and clinical research.</text>
									</paragraph><paragraph commented="no" id="H800CD77CAC7A4AC187FAA1308148EE5C"><enum>(2)</enum><header>Amounts made available to Fund</header>
 <subparagraph commented="no" id="H6BA2B2FE9B3F4954B7AD0378791D5920"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subparagraph (B), there is authorized to be appropriated, and appropriated, to the NIH Innovation Fund out of any funds in the Treasury not otherwise appropriated, $2,000,000,000 for each of fiscal years 2016 through 2020. The amounts appropriated to the Fund by the preceding sentence shall be in addition to any amounts otherwise made available to the National Institutes of Health.</text>
 </subparagraph><subparagraph commented="no" id="H773CB7CCC6F2401E8A73B9CDBCE8FC56"><enum>(B)</enum><header>Availability subject to appropriations</header><text display-inline="yes-display-inline">Amounts in the Fund shall not be available except to the extent and in such amounts as are provided in advance in appropriation Acts.</text>
 </subparagraph><subparagraph id="H309CB46D48DB48CEB8B87FB234845D12"><enum>(C)</enum><header>Allocation of amounts</header><text>Of the amounts made available from the NIH Innovation Fund for allocations under section 402(b)(25) for a fiscal year—</text>
 <clause id="H33A9E65D344A41ECABAB8539D34E89E2"><enum>(i)</enum><text display-inline="yes-display-inline">not less than $500,000,000 shall be for the Accelerating Advancement Program under paragraph (5);</text> </clause><clause id="H42ECDF570CB6415EAABA65D1787A2FB1"><enum>(ii)</enum><text display-inline="yes-display-inline">not less than 35 percent of such amounts remaining after subtracting the allocation for the Accelerating Advancement Program shall be for early stage investigators as defined in subsection (7);</text>
 </clause><clause id="H31EC012E015B4DBFBB452D920FB33B66"><enum>(iii)</enum><text display-inline="yes-display-inline">not less than 20 percent of such amounts remaining after subtracting the allocation for the Accelerating Advancement Program shall be for high-risk, high-reward research under section 409K; and</text>
 </clause><clause id="H5B3E433503F04A599176CF384D6EE25F"><enum>(iv)</enum><text>not more than 10 percent of such amounts (without subtracting the allocation for the Accelerating Advancement Program) shall be for intramural research.</text>
 </clause></subparagraph><subparagraph id="H3110FD8F50CB411986106B7945E2F8B0"><enum>(D)</enum><header>Inapplicability of certain provisions</header><text>Amounts in the NIH Innovation Fund shall not be subject to—</text> <clause id="H7FFC982CFBD540E3910ACC6015DB1AC0"><enum>(i)</enum><text>any transfer authority of the Secretary or the Director of NIH under section 241, subsection (c), subsection (d), or any other provision of law (other than section 402(b)(25) and this subsection); or</text>
 </clause><clause id="HD90A0FA1C2414381949D1F32CDFC44E4"><enum>(ii)</enum><text>the Nonrecurring expenses fund under section 223 of division G of the Consolidated Appropriations Act, 2008 (<external-xref legal-doc="usc" parsable-cite="usc/42/3514a">42 U.S.C. 3514a</external-xref>).</text>
 </clause></subparagraph></paragraph><paragraph commented="no" id="H7CC2E6B742B344E588EA158C76376235"><enum>(3)</enum><header>Authorized uses</header><text>Amounts in the NIH Innovation Fund established under paragraph (1) may be used only to conduct or support innovative biomedical research through the following:</text>
 <subparagraph commented="no" id="HD2E8800813694F608FFFED41E2DB3146"><enum>(A)</enum><text display-inline="yes-display-inline">Research in which—</text> <clause id="H5734950BE1EE42F48EB861D5564C6E68"><enum>(i)</enum><text>a principal investigator has a specific project or specific objectives; and</text>
 </clause><clause id="H644A51445C7E4E94AF75715C58FA0151"><enum>(ii)</enum><text>funding is tied to pursuit of such project or objectives.</text> </clause></subparagraph><subparagraph id="HF4666387138B445CB7167D172556C38A"><enum>(B)</enum><text>Research in which—</text>
 <clause id="H9B46362BC61C4DE0B82219005E041C21"><enum>(i)</enum><text>a principal investigator has shown promise in biomedical research; and</text> </clause><clause id="HC828BFFA2368470EA0DD9AC5DB14D120"><enum>(ii)</enum><text>funding is not tied to a specific project or specific objectives.</text>
 </clause></subparagraph><subparagraph id="H41F3CB4F461244B8B62287F8F9D85AE9"><enum>(C)</enum><text display-inline="yes-display-inline">Research to be carried out by an early stage investigator (as defined in paragraph (7)).</text> </subparagraph><subparagraph id="H7E74D56D1D9B453198EA057A111F4F6A"><enum>(D)</enum><text>Research to be carried out by a small business concern (as defined in section 3 of the Small Business Act).</text>
 </subparagraph><subparagraph id="HB3A670E66269428CBB7A3ACEBF8C19B2"><enum>(E)</enum><text>The Accelerating Advancement Program under paragraph (5).</text> </subparagraph><subparagraph id="HD771F843F41A4B7694D033BF29D7AA0D"><enum>(F)</enum><text>Development and implementation of the strategic plan under paragraph (6).</text>
 </subparagraph></paragraph><paragraph id="H6227E848776147CEB2813FF783265F2B"><enum>(4)</enum><header>Coordination</header><text>In funding programs and activities through the NIH Innovation Fund, the Secretary, acting through the Director of NIH, shall—</text>
 <subparagraph id="HD6FAD7D91F684384AC6937B8536501FF"><enum>(A)</enum><text>ensure coordination among the national research institutes, the national centers, and other departments, agencies, and offices of the Federal Government; and</text>
 </subparagraph><subparagraph id="HF9D58C51A6514984A8D7241A66278EC6"><enum>(B)</enum><text>minimize unnecessary duplication.</text> </subparagraph></paragraph><paragraph id="HEACF71476DB94B21ABF3A6838E30FADD"><enum>(5)</enum><header>Accelerating Advancement Program</header><text display-inline="yes-display-inline">The Director of NIH shall establish a program, to be known as the Accelerating Advancement Program, under which—</text>
 <subparagraph id="H228CC9AB3C164BD5BAFF46C11C62A7E3"><enum>(A)</enum><text>the Director of NIH partners with national research institutes and national centers to accomplish important biomedical research objectives; and</text>
 </subparagraph><subparagraph id="HDC86848885DA446FB38E4E6A7D26ACCA"><enum>(B)</enum><text>for every $1 made available by the Director of NIH to a national research institute or national center for a research project, the institute or center makes $1 available for such project from funds that are not derived from the NIH Innovation Fund.</text>
										</subparagraph></paragraph><paragraph id="H6C83B9299A054C28B0D2295514D2792A"><enum>(6)</enum><header>Strategic plan</header>
 <subparagraph id="H024E12BA10E34213B067E5F5C3A23E70"><enum>(A)</enum><header>In general</header><text>The Director of NIH shall ensure that scientifically based strategic planning is implemented in support of research priorities, including through development, use, and updating of a research strategic plan that—</text>
 <clause id="HE11F2325177C4666B93D062B44814FC2"><enum>(i)</enum><text>is designed to increase the efficient and effective focus of biomedical research in a manner that leverages the best scientific opportunities through a deliberative planning process;</text>
 </clause><clause id="HE846B6D1EB0A4D9BBE0C712E372A09D5"><enum>(ii)</enum><text>identifies areas, to be known as strategic focus areas, in which the resources of the NIH Innovation Fund can contribute to the goals of expanding knowledge to address, and find more effective treatments for, unmet medical needs in the United States, including the areas of—</text>
 <subclause id="H279D464B967045ACBB1623F6A9743F4B"><enum>(I)</enum><text>biomarkers;</text> </subclause><subclause id="H0B9BDC0FA56F4205A45710F333282FBB"><enum>(II)</enum><text>precision medicine;</text>
 </subclause><subclause id="H59F8AFA20F5C45A7A6DA21DD773E0B6F"><enum>(III)</enum><text display-inline="yes-display-inline">infectious diseases, including pathogens listed as a qualifying pathogen under section 505E(f) of the Federal Food, Drug, and Cosmetic Act or listed or designated as a tropical disease under section 524 of such Act; and</text>
 </subclause><subclause id="HC7B7847830AA4FF9BE5B72250F30B974"><enum>(IV)</enum><text>antibiotics;</text> </subclause></clause><clause id="HBB304A697EC04DDE9402D6EB69AFE081"><enum>(iii)</enum><text>includes objectives for each such strategic focus area; and</text>
 </clause><clause id="HA8110B6849E04869B4B44FE829A73F91"><enum>(iv)</enum><text>ensures that basic research remains a priority.</text> </clause></subparagraph><subparagraph id="H2A13601585E346FBA603620019FD4EF3"><enum>(B)</enum><header>Updates and reviews</header><text display-inline="yes-display-inline">The Director shall review and, as appropriate, update the research strategic plan under subparagraph (A) not less than every 18 months.</text>
 </subparagraph></paragraph><paragraph id="HF58754410D9B4A2288E980C5D3E0D7F0"><enum>(7)</enum><header>Definition</header><text>In this subsection, the term <quote>early stage investigator</quote> means an investigator who—</text> <subparagraph id="HAC0FCAD88F3245249B39CF21E8525AE5"><enum>(A)</enum><text display-inline="yes-display-inline">will be the principal investigator or the program director of the proposed research;</text>
 </subparagraph><subparagraph id="H30CFC14D5A0946959D8FF27686E5FE1F"><enum>(B)</enum><text>has never been awarded, or has been awarded only once, a substantial, competing grant by the National Institutes of Health for independent research; and</text>
 </subparagraph><subparagraph id="H31E29EC8C2994C00A55E9F9AE6B1A7D2"><enum>(C)</enum><text>is within 10 years of having completed—</text> <clause id="HECF39665B3314C5087F690A560C2D371"><enum>(i)</enum><text>the investigator’s terminal degree; or</text>
 </clause><clause id="H93AD30BAEE124E109A786D59F1DC5277"><enum>(ii)</enum><text>a medical residency (or the equivalent).</text></clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></subsection><subsection id="HBB48228E446D456CBD539200C405F016"><enum>(c)</enum><header>Supplement, not supplant; prohibition against transfer</header><text display-inline="yes-display-inline">Funds appropriated pursuant to section 402A(e) of the Public Health Service Act, as inserted by subsection (b)—</text>
 <paragraph id="H42D0C8739E7B4F3C8E28479DF01C4BC8"><enum>(1)</enum><text>shall be used to supplement, not supplant, the funds otherwise allocated by the National Institutes of Health for biomedical research; and</text>
 </paragraph><paragraph id="H5B82E3DEE4844D7A97F9825B2169EC34"><enum>(2)</enum><text display-inline="yes-display-inline">notwithstanding any transfer authority in any appropriation Act, shall not be used for any purpose other than allocating funds for conducting and supporting innovation fund initiatives as described in section 402(b)(25) of the Public Health Service Act, as added by subsection (a).</text>
						</paragraph></subsection></section></subtitle><subtitle id="H10F20A56C2884C9B9F0108E49A6B6CAC"><enum>B</enum><header>National Institutes of Health Planning and Administration</header>
 <section id="HCFA19AE3FC544E369E4E11C2501127B9"><enum>1021.</enum><header>NIH research strategic plan</header><text display-inline="no-display-inline">Section 402 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282</external-xref>) is amended—</text> <paragraph id="HC1A3D4C063FD4318BF1325CDDDFA4CCD"><enum>(1)</enum><text>in subsection (b), by amending paragraph (5) to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="H71B47308151241BE8BC29060DCC79239" style="OLC">
 <paragraph id="HA8D5377582D240C5B9B5095EF11050BF"><enum>(5)</enum><text display-inline="yes-display-inline">shall ensure that scientifically based strategic planning is implemented in support of research priorities as determined by the agencies of the National Institutes of Health, including through development, use, and updating of the research strategic plan under subsection (m);</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H6806E891779644A0B7E825151CE8935F"><enum>(2)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H81A3EE9106A84986A9E929F6151A63F7" style="OLC"> <subsection id="HA25FB4CFABD349EA9C36C02F30BB7311"><enum>(m)</enum><header>Research strategic plan</header> <paragraph id="H1F3E46BFD3834DCC95D65C962D1D86FF"><enum>(1)</enum><header>Five-year plans for biomedical research strategy</header> <subparagraph id="H94BED8F4A959439786397316E91BD867"><enum>(A)</enum><header>In general</header><text>For each successive five-year period beginning with the period of fiscal years 2016 through 2020, the Director of NIH, in consultation with the entities described in subparagraph (B), shall develop and maintain a biomedical research strategic plan that—</text>
 <clause id="H8945F1B5F24F43AE8C64793438BA15B5"><enum>(i)</enum><text>is designed to increase the efficient and effective focus of biomedical research in a manner that leverages the best scientific opportunities through a deliberative planning process;</text>
 </clause><clause id="H93954CA888464EDC98EE7422AC92488D"><enum>(ii)</enum><text>identifies areas, to be known strategic focus areas, in which the resources of the National Institutes of Health can best contribute to the goal of expanding knowledge on human health in the United States through biomedical research; and</text>
 </clause><clause id="HBD109D6D2B6D456A885EFAE37B82F62D"><enum>(iii)</enum><text>includes objectives for each such strategic focus area.</text> </clause></subparagraph><subparagraph id="H5B8AEA4963BB44708D3DE7E0DE6988BB"><enum>(B)</enum><header>Entities described</header><text>The entities described in this subparagraph are the directors of the national research institutes and national centers, researchers, patient advocacy groups, and industry leaders.</text>
 </subparagraph></paragraph><paragraph id="HF0B076E9D8D44D628B35B48C79B94CDA"><enum>(2)</enum><header>Use of plan</header><text>The Director of NIH and the directors of the national research institutes and national centers shall use the strategic plan—</text>
 <subparagraph id="H27F93C9E612940B2B0166DE43BC48207"><enum>(A)</enum><text display-inline="yes-display-inline">to identify research opportunities; and</text> </subparagraph><subparagraph id="H39D44116EC394A789829D7DE88D66135"><enum>(B)</enum><text display-inline="yes-display-inline">to develop individual strategic plans for the research activities of each of the national research institutes and national centers that—</text>
 <clause id="H111AAA33191B4C90B1B199ABB1BBB07B"><enum>(i)</enum><text>have a common template; and</text> </clause><clause id="HC00B85AA7FC445E3AD4F78DBDE525C41"><enum>(ii)</enum><text display-inline="yes-display-inline">identify strategic focus areas in which the resources of the national research institutes and national centers can best contribute to the goal of expanding knowledge on human health in the United States through biomedical research.</text>
										</clause></subparagraph></paragraph><paragraph display-inline="no-display-inline" id="HF61F4C6AFD6B409DB5D9A71988721199"><enum>(3)</enum><header>Contents of plans</header>
 <subparagraph id="HADF342D68D514E2CA74702FAC8CC9FB8"><enum>(A)</enum><header>Strategic focus areas</header><text display-inline="yes-display-inline">The strategic focus areas identified pursuant to paragraph (1)(A)(ii) shall—</text> <clause id="HDDC94ADF376843F1B7CE691E8DA355BB"><enum>(i)</enum><text>be identified in a manner that—</text>
 <subclause id="HEAF60E6C64B64FB4B3C3505DA9B8CF43"><enum>(I)</enum><text>considers the return on investment to the United States public through the investments of the National Institutes of Health in biomedical research; and</text>
 </subclause><subclause id="H04E679F4A228417986536C45C29EEDD0"><enum>(II)</enum><text>contributes to expanding knowledge to improve the United States public’s health through biomedical research; and</text>
 </subclause></clause><clause id="H3264A94374994A1E9D826974370A411D"><enum>(ii)</enum><text>include overarching and trans-National Institutes of Health strategic focus areas, to be known as Mission Priority Focus Areas, which best serve the goals of preventing or eliminating the burden of a disease or condition and scientifically merit enhanced and focused research over the next 5 years.</text>
 </clause></subparagraph><subparagraph id="H6079CA33042A4005B8041623416450EF"><enum>(B)</enum><header>Rare and pediatric diseases and conditions</header><text>In developing and maintaining a strategic plan under this subsection, the Director of NIH shall ensure that rare and pediatric diseases and conditions remain a priority.</text>
 </subparagraph></paragraph><paragraph id="H4BD7C49D10964279B25889119D88BD72"><enum>(4)</enum><header>Initial plan</header><text display-inline="yes-display-inline">Not later than 270 days after the date of enactment of this subsection, the Director of NIH and the directors of the national research institutes and national centers shall—</text>
 <subparagraph id="H08C3A463B30B41BFB6008CA354980155"><enum>(A)</enum><text>complete the initial strategic plan required by paragraphs (1) and (2); and</text> </subparagraph><subparagraph id="H801E69215DF14665A1B45F6C91E58130"><enum>(B)</enum><text>make such initial strategic plan publicly available on the website of the National Institutes of Health.</text>
									</subparagraph></paragraph><paragraph id="H5D0EAE8D215A413DB264750A12B4D4CD"><enum>(5)</enum><header>Review; updates</header>
 <subparagraph id="H44994BE61B1F43989D5203EBEF22B99C"><enum>(A)</enum><header>Progress reviews</header><text display-inline="yes-display-inline">Not less than annually, the Director of NIH, in consultation with the directors of the national research institutes and national centers, shall conduct progress reviews for each strategic focus area identified under paragraph (1)(A)(ii).</text>
 </subparagraph><subparagraph id="H0479217F8FEF4C54A202AEA8AEFAECD7"><enum>(B)</enum><header>Updates</header><text display-inline="yes-display-inline">Not later than the end of the 5-year period covered by the initial strategic plan under this subsection, and every 5 years thereafter, the Director of NIH, in consultation with the directors of the national research institutes and national centers, stakeholders in the scientific field, advocates, and the public at large, shall—</text>
 <clause id="H11A0F9EC34234DC6947EAA358BDD5CCF"><enum>(i)</enum><text>conduct a review of the plan, including each strategic focus area identified under paragraph (2)(B); and</text>
 </clause><clause id="H55AD7D9BC6C94CC0A49EE820EF95FEF7"><enum>(ii)</enum><text>update such plan in accordance with this section.</text></clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></section><section id="H96E344CB49014488834B0307090490F6" section-type="subsequent-section"><enum>1022.</enum><header>Increasing accountability at the National Institutes of Health</header> <subsection id="HEF15B5779D5E4BA9A807E65B8BA0CD88"><enum>(a)</enum><header>Appointment and terms of directors of national research institutes and national centers</header><text display-inline="yes-display-inline">Subsection (a) of section 405 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284</external-xref>) is amended to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="H1EE50171A367438E8BB737ED9490865E" style="OLC">
							<subsection id="HE5FE7102AFEE47D68AAC95ECD393BCCA"><enum>(a)</enum><header>Appointment; terms</header>
 <paragraph id="H4BE0C3D9DCC343C399EA549305625D2F"><enum>(1)</enum><header>Appointment</header><text display-inline="yes-display-inline">The Director of the National Cancer Institute shall be appointed by the President and the directors of the other national research institutes, as well as the directors of the national centers, shall be appointed by the Director of NIH. The directors of the national research institutes, as well as national centers, shall report directly to the Director of NIH.</text>
								</paragraph><paragraph id="H63A71DCD34B949BF9FDBFE5162694301"><enum>(2)</enum><header>Terms</header>
 <subparagraph id="H0209A5FE65D548299F028247125D18D5"><enum>(A)</enum><header>In general</header><text>The term of office of a director of a national research institute or national center shall be 5 years.</text>
 </subparagraph><subparagraph id="H19B1E9DCF60C45039D7E8B555EBD7C97"><enum>(B)</enum><header>Removal</header><text>The director of a national research institute or national center may be removed from office by the Director of NIH prior to the expiration of such director’s 5-year term.</text>
 </subparagraph><subparagraph id="H96329B409294438CA5775A1522224D5E"><enum>(C)</enum><header>Reappointment</header><text>At the end of the term of a director of a national research institute or national center, the director may be reappointed. There is no limit on the number of terms a director may serve.</text>
 </subparagraph><subparagraph id="HF8DBE41C82A0474BAED98B38D250DC1A"><enum>(D)</enum><header>Vacancies</header><text>If the office of a director of a national research institute or national center becomes vacant before the end of such director’s term, the director appointed to fill the vacancy shall be appointed for a 5-year term starting on the date of such appointment.</text>
 </subparagraph><subparagraph id="HC977B227C9C24577A749978A3E65939F"><enum>(E)</enum><header>Transitional provision</header><text>Each director of a national research institute or national center serving on the date of enactment of the <short-title>21st Century Cures Act</short-title> is deemed to be appointed for a 5-year term under this subsection starting on such date of enactment.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" id="H1AE36DF254484F90ACF0B5DF1D24FF28"><enum>(b)</enum><header>Compensation to consultants or individual scientists</header><text>Section 202 of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1993 (<external-xref legal-doc="public-law" parsable-cite="pl/102/394">Public Law 102–394</external-xref>; <external-xref legal-doc="usc" parsable-cite="usc/42/238f">42 U.S.C. 238f</external-xref> note) is amended by striking <quote>portable structures;</quote> and all that follows and inserting <quote>portable structures.</quote>.</text>
 </subsection><subsection id="HF7205C8EE95B4A24B4EB95378FAA5BB1"><enum>(c)</enum><header>Review of certain awards by directors</header><text display-inline="yes-display-inline">Section 405(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284(b)</external-xref>) is amended by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H7B752675FE504294A05094D20D0D1AAF" style="OLC">
 <paragraph id="H76FBD38D7622405A9185178E630CFC4E" indent="up1"><enum>(3)</enum><text display-inline="yes-display-inline">Before an award is made by a national research institute or by a national center for a grant for a research program or project (commonly referred to as an <quote>R-series grant</quote>), other than an award constituting a noncompeting renewal of such grant, or a noncompeting administrative supplement to such grant, the director of such national research institute or national center—</text>
 <subparagraph id="HE6B8E700E2784011A6D375EC1DF8F028"><enum>(A)</enum><text>shall review and approve the award; and</text> </subparagraph><subparagraph id="H3CAEA96061234D1D810871FD375D47C0"><enum>(B)</enum><text>shall take into consideration—</text>
 <clause commented="no" id="H91E7C831A6EE49D09148CA74EBE78BB4"><enum>(i)</enum><text display-inline="yes-display-inline">the mission of the national research institute or national center and the scientific priorities identified in the strategic plan under section 402(m); and</text>
 </clause><clause id="HF7E5B8E63C544D258D0500F20A55773D"><enum>(ii)</enum><text>whether other agencies are funding programs or projects to accomplish the same goal.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HD44C28F3170447E4A7BD7BCBE1E0E7FC"><enum>(d)</enum><header>IOM study on duplication in Federal biomedical research</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall enter into an arrangement with the Institute of Medicine of the National Academies (or, if the Institute declines, another appropriate entity) under which the Institute (or other appropriate entity) not later than 2 years after the date of enactment of this Act will—</text>
 <paragraph id="H8371D2DE48EA4A2F941F783EC2514871"><enum>(1)</enum><text>complete a study on the extent to which biomedical research conducted or supported by Federal agencies is duplicative; and</text>
 </paragraph><paragraph id="H37ABF6C642C94011A90854FA48E0C835"><enum>(2)</enum><text>submit a report to the Congress on the results of such study, including recommendations on how to prevent such duplication.</text>
						</paragraph></subsection></section><section commented="no" id="H77A7DCACD6D7416AB23B7D0A77F21BD5" section-type="subsequent-section"><enum>1023.</enum><header>Reducing administrative burdens of researchers</header>
 <subsection commented="no" id="H00A7F3DC11684106AE965594B54B3948"><enum>(a)</enum><header>Implementation of measures To reduce administrative burdens</header><text display-inline="yes-display-inline">The Director of the National Institutes of Health shall implement measures to reduce the administrative burdens of researchers funded by the National Institutes of Health, taking into account the recommendations, evaluations, and plans researched by the following entities:</text>
 <paragraph commented="no" id="HDFADC47A6DAF4ECAA627488E602C877C"><enum>(1)</enum><text>The Scientific Management Review Board.</text> </paragraph><paragraph commented="no" id="HA53A6971FBD84696ACDD7CA292C00328"><enum>(2)</enum><text>The National Academy of Sciences.</text>
 </paragraph><paragraph commented="no" id="H3E9859E023274032A65237ACFC441C24"><enum>(3)</enum><text>The 2007 and 2012 Faculty Burden Survey conducted by The Federal Demonstration Partnership.</text> </paragraph><paragraph commented="no" id="H8B3377E82F8244C5B3E150AAF69B0DF2"><enum>(4)</enum><text>Relevant recommendations from the Research Business Models Working Group.</text>
 </paragraph></subsection><subsection commented="no" id="H08089350513F440A9CDB3E86154D32DA"><enum>(b)</enum><header>Reports</header><text display-inline="yes-display-inline">The Director of the National Institutes of Health shall submit to Congress a report on the extent to which the Director has implemented measures pursuant to subsection (a).</text>
 </subsection></section><section id="H4827323C5C4D4A0EA61293CBEFD05314"><enum>1024.</enum><header>Exemption for the National Institutes of Health from the Paperwork Reduction Act requirements</header><text display-inline="no-display-inline">Section 3518(c)(1) of title 44, United States Code, is amended—</text> <paragraph id="H6D73DF627F064B6E90453CBF23300AAE"><enum>(1)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking <quote>; or</quote> and inserting a semicolon;</text>
 </paragraph><paragraph id="H93CA7355EE434622897407951124A506"><enum>(2)</enum><text display-inline="yes-display-inline">in subparagraph (D), by striking the period at the end and inserting <quote>; or</quote>; and</text> </paragraph><paragraph id="H1A826716B47248109C8FC45BA08F95C4"><enum>(3)</enum><text>by inserting at the end the following new subparagraph:</text>
						<quoted-block display-inline="no-display-inline" id="H646D752F750A470FA8982AA3CD0E45E9" style="USC">
 <subparagraph id="H978E4855421947CAB2759066F5027F15"><enum>(E)</enum><text display-inline="yes-display-inline">during the conduct of research by the National Institutes of Health.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></section><section commented="no" id="H3FB351CF772C4405B9C4F8E732D46D73"><enum>1025.</enum><header>NIH travel</header><text display-inline="no-display-inline">It is the sense of Congress that participation in or sponsorship of scientific conferences and meetings is essential to the mission of the National Institutes of Health.</text>
 </section><section id="HF71E7D23FF8C4389A258C4207B6450FD"><enum>1026.</enum><header>Other transactions authority</header><text display-inline="no-display-inline">Section 480 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/287a">42 U.S.C. 287a</external-xref>) is amended—</text> <paragraph id="H2EDBF9D4C2F14593BB79AED1D44D25C2"><enum>(1)</enum><text>in subsection (b), by striking <quote>the appropriation of funds as described in subsection (g)</quote> and inserting <quote>the availability of funds as described in subsection (f)</quote>;</text>
 </paragraph><paragraph id="H378AC94FAAA54C40B4A325CAE8051AE7"><enum>(2)</enum><text>in subsection (e)(3), by amending subparagraph (C) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="HDCD70180B78A4B50BD382E7B7C9E3CC4" style="OLC"> <subparagraph id="H8759B5221EAE4587BCCC3655012D92EF"><enum>(C)</enum><header>Other Transactions Authority</header><text display-inline="yes-display-inline">The Director of the Center shall have other transactions authority in entering into transactions to fund projects in accordance with the terms and conditions of this section.</text></subparagraph><after-quoted-block>;</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HC7B5209CE4544A6AB52FDE1FA5B36048"><enum>(3)</enum><text>by striking subsection (f); and</text> </paragraph><paragraph id="H6B6E72606E594FBDBBDCD1534B8C8ED7"><enum>(4)</enum><text>by redesignating subsection (g) as subsection (f).</text>
 </paragraph></section><section id="H9EA54B036BC9492DB5B00094DC2AB018"><enum>1027.</enum><header>NCATS phase IIB restriction</header><text display-inline="no-display-inline">Section 479 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/287">42 U.S.C. 287</external-xref>) is amended—</text> <paragraph id="HE391EBDE8B864727835C078A330BF625"><enum>(1)</enum><text>prior to making the amendments under paragraph (2), by striking <quote>IIB</quote> each place it appears and inserting <quote>III</quote>; and</text>
 </paragraph><paragraph id="H9E067E5384814CDD9F89D2D536090814"><enum>(2)</enum><text>by striking <quote>IIA</quote> each place it appears and inserting <quote>IIB</quote>.</text> </paragraph></section><section id="H12079AFA5F3A4D2F8FB97D7340330D5F"><enum>1028.</enum><header>High-risk, high-reward research</header><text display-inline="no-display-inline">Part B of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284 et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H61E7673824BE4CAA943E99937F248C91" style="OLC">
 <section id="HFD3E41CB8E2245B7B6F951B672E222F1"><enum>409K.</enum><header>High-risk, high-reward research program</header><text display-inline="no-display-inline">The director of each national research institute shall, as appropriate—</text> <paragraph id="HB791008F0F88490D99633A3F2FF6D7A3"><enum>(1)</enum><text>establish programs to conduct or support research projects that pursue innovative approaches to major contemporary challenges in biomedical research that involve inherent high risk, but have the potential to lead to breakthroughs; and</text>
 </paragraph><paragraph id="HFED56FB5CAAB4362ABBB523383058C07"><enum>(2)</enum><text>set aside a specific percentage of funding, to be determined by the Director of NIH for each national research institute, for such projects.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle><subtitle id="H2E4190F933C64EFA8CCCF6060C870873"><enum>C</enum><header>Supporting Young Emerging Scientists</header>
				<section id="H7A45136526C741F5A1EE26D8F2C419AC"><enum>1041.</enum><header>Improvement of loan repayment programs of National Institutes of Health</header>
 <subsection id="H46BF9423C7294428997F70BBDB5A25DE"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Part G of title IV of the Public Health Service (<external-xref legal-doc="usc" parsable-cite="usc/42/288">42 U.S.C. 288 et seq.</external-xref>) is amended—</text> <paragraph id="H1B081F78850542E88AAEC2193F201134"><enum>(1)</enum><text>by redesignating the second section 487F (<external-xref legal-doc="usc" parsable-cite="usc/42/288-6">42 U.S.C. 288–6</external-xref>; pediatric research loan repayment program) as section 487G; and</text>
 </paragraph><paragraph id="H6AC12D0FD2F34F89915802DA639CCF89"><enum>(2)</enum><text>by inserting after section 487G, as so redesignated, the following:</text> <quoted-block id="H02D2D52ED31E452B8E8037AB9185F95F" style="OLC"> <section id="H53A137B417A746B0BAD20619BCBBDE6E"><enum>487H.</enum><header>Loan repayment program</header> <subsection id="HF3AB090547CC42398D081E67AE4AE72C"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish a program, based on workforce and scientific needs, of entering into contracts with qualified health professionals under which such health professionals agree to engage in research in consideration of the Federal Government agreeing to pay, for each year of engaging in such research, not more than $50,000 of the principal and interest of the educational loans of such health professionals.</text>
 </subsection><subsection id="H371F3E87833946DD8629A0172A5C410D"><enum>(b)</enum><header>Adjustment for inflation</header><text>Beginning with respect to fiscal year 2017, the Secretary may increase the maximum amount specified in subsection (a) by an amount that is determined by the Secretary, on an annual basis, to reflect inflation.</text>
 </subsection><subsection id="H8383310FDBEE4E5C99EB6A9E71B32BB3"><enum>(c)</enum><header>Limitation</header><text>The Secretary may not enter into a contract with a health professional pursuant to subsection (a) unless such professional has a substantial amount of educational loans relative to income.</text>
 </subsection><subsection id="H893D81CA82DE4166BEBB8AAFA10B8A42"><enum>(d)</enum><header>Applicability of certain provisions regarding obligated service</header><text>Except to the extent inconsistent with this section, the provisions of sections 338B, 338C, and 338E shall apply to the program established under this section to the same extent and in the same manner as such provisions apply to the National Health Service Corps Loan Repayment Program established under section 338B.</text>
 </subsection><subsection id="H700EFC10A1354CC784AA40267EAA91A8"><enum>(e)</enum><header>Availability of appropriations</header><text>Amounts appropriated for a fiscal year for contracts under subsection (a) are authorized to remain available until the expiration of the second fiscal year beginning after the fiscal year for which the amounts were appropriated.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection><subsection id="H37E45A6CCC164454ACCAF5D39B8AC65B"><enum>(b)</enum><header>Update of other loan repayment programs</header>
 <paragraph id="H190DD85B84584137979DE7449DA19BF3"><enum>(1)</enum><text display-inline="yes-display-inline">Section 464z–5(a) of the Public Health Service Act (42 U.S.C.285t–2(a)) is amended—</text> <subparagraph id="HB3662AAF660848F599415A578435CA0E"><enum>(A)</enum><text>in subsection (a), by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text>
 </subparagraph><subparagraph id="HA1E13965891A4498AA4FCD09D722EAA3"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this subsection in the same manner as it applies to the maximum amount specified in subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="H6D3117F3BAAD41A1B5F9A1A92D577F79"><enum>(2)</enum><text>Section 487A(a) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288-1">42 U.S.C. 288–1(a)</external-xref>) is amended—</text> <subparagraph id="H87862EA1B72542FDBE53A01D35F3B5A4"><enum>(A)</enum><text>by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text>
 </subparagraph><subparagraph id="H913828A738B84B9C9ED37B3547C781C1"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this subsection in the same manner as it applies to the maximum amount specified in subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="H90BE0180F76E4FF3828358E2027779AE"><enum>(3)</enum><text display-inline="yes-display-inline">Section 487B(a) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288-2">42 U.S.C. 288–2(a)</external-xref>) is amended—</text> <subparagraph id="HD0C9FC16EDA9426985F61CDF116A1765"><enum>(A)</enum><text>by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text>
 </subparagraph><subparagraph id="H42F60050E8124F10993068B206B72855"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this subsection in the same manner as it applies to the maximum amount specified in such subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="HCA22173AC56542869153802CB0125247"><enum>(4)</enum><text display-inline="yes-display-inline">Section 487C(a)(1) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288-3">42 U.S.C. 288–3(a)(1)</external-xref>) is amended—</text> <subparagraph id="HBE708408E6A2438698ECAC6D2F18DE68"><enum>(A)</enum><text>by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text>
 </subparagraph><subparagraph id="HB11FE786B9A649E090BDCD0CF4FE7ED8"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this paragraph in the same manner as it applies to the maximum amount specified in such subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="H06F788B76231400FA7D1D9B397CBC40A"><enum>(5)</enum><text display-inline="yes-display-inline">Section 487E(a)(1) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288-5">42 U.S.C. 288–5(a)(1)</external-xref>) is amended—</text> <subparagraph id="H80D9E691E40E42C9B12E8E60909A7A05"><enum>(A)</enum><text>by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text>
 </subparagraph><subparagraph id="HBBE2ACDD6AB74E87925F6D5B5A2AFAD3"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this paragraph in the same manner as it applies to the maximum amount specified in such subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="H7D27D443C438410FA89249BE7A49A330"><enum>(6)</enum><text display-inline="yes-display-inline">Section 487F(a) of such Act (42 U.S.C. 288–5a(a)), as added by section 205 of <external-xref legal-doc="public-law" parsable-cite="pl/106/505">Public Law 106–505</external-xref>, is amended—</text>
 <subparagraph id="H5D50C0862328484BAFCA7D2FD68D39EF"><enum>(A)</enum><text>by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>; and</text> </subparagraph><subparagraph id="H95DF19FB7A754B799C8595590FA8FD38"><enum>(B)</enum><text>by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in this subsection in the same manner as it applies to the maximum amount specified in such subsection (a) of such section.</quote>.</text>
 </subparagraph></paragraph><paragraph id="H4CFC8C02724B4AE78E5E01F59AF0DB6A"><enum>(7)</enum><text display-inline="yes-display-inline">Section 487F of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288-6">42 U.S.C. 288–6</external-xref>, as added by section 1002(b) of <external-xref legal-doc="public-law" parsable-cite="pl/106/310">Public Law 106–310</external-xref>, is amended—</text>
 <subparagraph id="H14123C31DD734F2AA289D373CEC85598"><enum>(A)</enum><text>in subsection (a)(1), by striking <quote>$35,000</quote> and inserting <quote>$50,000</quote>;</text> </subparagraph><subparagraph id="HBC35ABDB2D49424B8C1AF7A5B0376651"><enum>(B)</enum><text>in subsection (b), by adding at the end the following new sentence: <quote>Subsection (b) of section 487H shall apply with respect to the maximum amount specified in subsection (a)(1) in the same manner as it applies to the maximum amount specified in such subsection (a) of such section.</quote>; and</text>
 </subparagraph><subparagraph id="H510CF70E73F44881B8DC69B440CAC7A9"><enum>(C)</enum><text>by redesignating such section as section 487G.</text> </subparagraph></paragraph></subsection></section><section id="HB57A12DF621B4FDE8FAEC7237F100411"><enum>1042.</enum><header>Report</header><text display-inline="no-display-inline">Not later than 18 months after the date of the enactment of this Act, the Director of the National Institutes of Health shall submit to Congress a report on efforts of the National Institutes of Health to attract, retain, and develop emerging scientists.</text>
				</section></subtitle><subtitle id="H11A52EDB70604195B4A3AE173D0FBC56"><enum>D</enum><header>Capstone Grant Program</header>
 <section id="H0CFBBD80EFD44F798CE82B63328DBAAC"><enum>1061.</enum><header>Capstone award</header><text display-inline="no-display-inline">Part G of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/288">42 U.S.C. 288 et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block id="H6380728C216D4A71BB6024DCA9FA18DD" style="OLC">
						<section id="H338A76C2132E4CD89BF73EF2D30DEA2C"><enum>490.</enum><header>Capstone award</header>
 <subsection id="HD8273C57C44E4B37B6C84044DC52FA90"><enum>(a)</enum><header>In general</header><text>The Secretary may make awards (each of which, hereafter in this section, referred to as a <quote>Capstone Award</quote>) to support outstanding scientists who have been funded by the National Institutes of Health.</text> </subsection><subsection id="H576F97B4FE5646E488DFBE3F63E62883"><enum>(b)</enum><header>Purpose</header><text display-inline="yes-display-inline">Capstone Awards shall be made to facilitate the successful transition or conclusion of research programs, or for other purposes, as determined by the Director of NIH, in consultation with the directors of the national research institutes and national centers.</text>
 </subsection><subsection id="H4CD8CA2256CE4DF19CFCE9898093DA29"><enum>(c)</enum><header>Duration and amount</header><text>The duration and amount of each Capstone Award shall be determined by the Director of NIH in consultation with the directors of the national research institutes and national centers.</text>
 </subsection><subsection id="H41443C278B6A4EEF930F30AF901FE5BF"><enum>(d)</enum><header>Limitation</header><text display-inline="yes-display-inline">Individuals who have received a Capstone Award shall not be eligible to have principle investigator status on subsequent awards from the National Institutes of Health.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle><subtitle id="H5BE910FD76A84278AD6A1E7D2D1DFF9D"><enum>E</enum><header>Promoting Pediatric Research through the National Institutes of Health</header>
 <section id="H711ECED3917042B6BBC63816566E96A8" section-type="subsequent-section"><enum>1081.</enum><header>National Pediatric Research Network</header><text display-inline="no-display-inline">Section 409D(d) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284h">42 U.S.C. 284h(d)</external-xref>) is amended—</text> <paragraph id="HE1DA665507DC4259AB0A813F8627D50D"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (1)—</text>
 <subparagraph id="H12320EB32E2C4DD294F4ACE370305C86"><enum>(A)</enum><text>by striking <quote>in consultation with the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and in collaboration with other appropriate national research institutes and national centers that carry out activities involving pediatric research</quote> and inserting <quote>in collaboration with the national research institutes and national centers that carry out activities involving pediatric research</quote>;</text>
 </subparagraph><subparagraph id="H2D9612E52F4F4DEEBD2F48B680617EA2"><enum>(B)</enum><text>by striking subparagraph (B);</text> </subparagraph><subparagraph id="H363B3FACCD154001BDA35342D0679811"><enum>(C)</enum><text display-inline="yes-display-inline">by striking <quote>may be comprised of, as appropriate</quote> and all that follows through <quote>the pediatric research consortia</quote> and inserting <quote>may be comprised of, as appropriate, the pediatric research consortia</quote>; and</text>
 </subparagraph><subparagraph id="H670CD7B2A6E549D9AAF09E1DD4E3A9BE"><enum>(D)</enum><text>by striking <quote>; or</quote> at the end and inserting a period; and</text> </subparagraph></paragraph><paragraph id="H8FF359EAB5E640899195F2E8F9F6341E"><enum>(2)</enum><text>in paragraph (1), paragraph (2)(A), the first sentence of paragraph (2)(E), and paragraph (4), by striking <quote>may</quote> each place it appears and inserting <quote>shall</quote>.</text>
 </paragraph></section><section id="HA9E87563C0A140EAA7D0211D92FD4BD3"><enum>1082.</enum><header>Global Pediatric Clinical Study Network Sense of Congress</header><text display-inline="no-display-inline">It is the sense of Congress that—</text> <paragraph id="HB338AC27E44B473C9496DB9EC289F29A"><enum>(1)</enum><text display-inline="yes-display-inline">the National Institutes of Health should encourage a global pediatric clinical study network through the allocation of grants, contracts, or cooperative agreements to supplement the salaries of new and early investigators who participate in the global pediatric clinical study network;</text>
 </paragraph><paragraph id="HF2810D5022FD4BB3A235AFA9244A1FCC"><enum>(2)</enum><text display-inline="yes-display-inline">National Institutes of Health grants, contracts, or cooperative agreements should be awarded, solely for the purpose of supplementing the salaries of new and early investigators, to entities that participate in the global pediatric clinical study network;</text>
 </paragraph><paragraph id="HF473A29E586E4E62AF86128BD0231D6C"><enum>(3)</enum><text>the Food and Drug Administration should engage the European Medicines Agency and other foreign regulatory entities during the formation of the global pediatric clinical study network to encourage their participation; and</text>
 </paragraph><paragraph id="HB3DE6B4B72874AE594DE5768A71F324A"><enum>(4)</enum><text>once a global pediatric clinical study network is established and becomes operational, the Food and Drug Administration should continue to engage the European Medicines Agency and other foreign regulatory entities to encourage and facilitate their participation in the network with the goal of enhancing the global reach of the network.</text>
					</paragraph></section><section id="HF247851C5FF6444AB33048E273BF032F"><enum>1083.</enum><header>Appropriate age groupings in clinical research</header>
 <subsection id="H791F42188B6F4370866B7155680B1047"><enum>(a)</enum><header>Input from experts</header><text display-inline="yes-display-inline">Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall convene a workshop of experts on pediatrics and experts on geriatrics to provide input on—</text>
 <paragraph id="H25BA8BEA85DB4AACB678D8132B353B6D"><enum>(1)</enum><text>appropriate age groupings to be included in research studies involving human subjects; and</text> </paragraph><paragraph id="HA745F2E528224993AEEAE2AD16320F11"><enum>(2)</enum><text>acceptable scientific justifications for excluding participants from a range of age groups from human subjects research studies.</text>
 </paragraph></subsection><subsection id="H6FD90315030F44118BD560441F6CD7D6"><enum>(b)</enum><header>Guidelines</header><text>Not later than 180 days after the conclusion of the workshop under subsection (a), the Director of the National Institutes of Health shall publish guidelines—</text>
 <paragraph id="H57CE445D458F41B3B09024DDE205F4CC"><enum>(1)</enum><text>addressing the consideration of age as an inclusion variable in research involving human subjects; and</text>
 </paragraph><paragraph id="H263E461E9F654875B5263BBA5E39B70C"><enum>(2)</enum><text>identifying criteria for justifications for any age-related exclusions in such research.</text> </paragraph></subsection><subsection id="HAA183B2148C04E0B8D44F6860F801A0A"><enum>(c)</enum><header>Public availability of findings and conclusions</header><text>The Director of the National Institutes of Health shall—</text>
 <paragraph id="H150500D65A454DA7A7BD58E1371C3A61"><enum>(1)</enum><text display-inline="yes-display-inline">make the findings and conclusion resulting from the workshop under subsection (a) available to the public on the website of the National Institutes of Health; and</text>
 </paragraph><paragraph id="HA742F4F16CE04AF2886870ED52DBE36E"><enum>(2)</enum><text>not less than biennially, disclose to the public on such website the number of children included in research that is conducted or supported by the National Institutes of Health, disaggregated by developmentally appropriate age group, race, and gender.</text>
						</paragraph></subsection></section></subtitle><subtitle id="H759B5C8C926443328FE2F70F4ACBD5DB"><enum>F</enum><header>Advancement of National Institutes of Health Research and Data Access</header>
 <section id="HF5E084903982448D86FE0608AB6DDD57"><enum>1101.</enum><header>Sharing of data generated through NIH-funded research</header><text display-inline="no-display-inline">Section 402 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="HC5B83518735548B6A1D9E604EA33D5F4" style="OLC">
						<subsection commented="no" id="HAB1A785A52C846F49CC8A6F5CD63A4FE"><enum>(m)</enum><header>Sharing of data generated through NIH-funded research</header>
 <paragraph id="HF83EB0D281C7419896736C5654B652FD"><enum>(1)</enum><header>Authority</header><text>Subject to paragraph (2), the Director of NIH may require recipients of the award of an NIH grant or other financial support, provided that the research is fully funded through such grant or other support, to share scientific data generated from research conducted through such support for research purposes.</text>
 </paragraph><paragraph id="HD127BA2873C543898058976A88F028F1"><enum>(2)</enum><header>Limitation</header><text>The Director of NIH shall not require the sharing of data that is inconsistent with applicable law and policy protecting—</text>
 <subparagraph id="H441684CC28F04EDFA617EB797624671F"><enum>(A)</enum><text>privacy and confidentiality;</text> </subparagraph><subparagraph id="H6D0DCD791F3242CAA1A733C34EAFFF00"><enum>(B)</enum><text>proprietary interests;</text>
 </subparagraph><subparagraph id="H9167E1D7A01E4AA18869825D5164A7E0"><enum>(C)</enum><text>business confidential information;</text> </subparagraph><subparagraph id="HA1DCB75F5AE141F39C707FCC55CA4C30"><enum>(D)</enum><text>intellectual property rights; and</text>
 </subparagraph><subparagraph id="HDAD3C812CA084541B0EC75FFDBC0CD6E"><enum>(E)</enum><text>other relevant rights.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </section><section display-inline="no-display-inline" id="H63B5725A00B44108B081D7E079F61FCB"><enum>1102.</enum><header>Standardization of data in Clinical Trial Registry Data Bank on eligibility for clinical trials</header> <subsection id="HB17BC972E9A649E49E83EA035E7E6040"><enum>(a)</enum><header>Standardization</header><text display-inline="yes-display-inline"></text>
 <paragraph id="H0D5E6B78F1CF4CCBA9634E803B36D227"><enum>(1)</enum><header>In general</header><text>Section 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>) is amended—</text> <subparagraph id="H4F156DB1759A44D4A57B2C13C8B33375"><enum>(A)</enum><text>by redesignating paragraph (7) as paragraph (8); and</text>
 </subparagraph><subparagraph id="HA8C5CF5D7F1E4752A37323CA543ABB1C"><enum>(B)</enum><text>by inserting after paragraph (6) the following:</text> <quoted-block display-inline="no-display-inline" id="HA22647CDAFDD406F8648C2575B7FB87F" style="OLC"> <paragraph id="HF768D840ECC6435984B984B656001215"><enum>(7)</enum><header>Standardization</header><text display-inline="yes-display-inline">The Director of NIH shall—</text>
 <subparagraph id="H6525E931F928453EA8FDDC3F405A3945"><enum>(A)</enum><text>ensure that the registry and results data bank is easily used by the public;</text> </subparagraph><subparagraph id="HA533EDDD996248E88C80513270677CEB"><enum>(B)</enum><text>ensure that entries in the registry and results data bank are easily compared;</text>
 </subparagraph><subparagraph id="H0F534A5F8478464BAE911BA0C9939D7F"><enum>(C)</enum><text display-inline="yes-display-inline">ensure that information required to be submitted to the registry and results data bank, including recruitment information under paragraph (2)(A)(ii)(II), is submitted by persons and posted by the Director of NIH in a standardized format and shall include at least—</text>
 <clause id="HDF6F06E307FF470D87F74402EAE8CBA6"><enum>(i)</enum><text display-inline="yes-display-inline">the disease or indication being studied;</text> </clause><clause id="H97CF9DAA465D412797C83E5E4E4B8E4C"><enum>(ii)</enum><text display-inline="yes-display-inline">inclusion criteria such as age, gender, diagnosis or diagnoses, lab values, or imaging results; and</text>
 </clause><clause id="H6D99879BC0BC4A6390AD11F250C7B8F4"><enum>(iii)</enum><text display-inline="yes-display-inline">exclusion criteria such as specific diagnosis or diagnoses, lab values, or prohibited medications; and</text>
 </clause></subparagraph><subparagraph id="HBDDCE347FD204116A914F6C3E60C9623"><enum>(D)</enum><text>to the extent possible, in carrying out this paragraph, make use of standard health care terminologies, such as the International Classification of Diseases or the Current Procedural Terminology, that facilitate electronic matching to data in electronic health records or other relevant health information technologies.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HFF27EF3D4B6644A7A214D8FD819FCC3D"><enum>(2)</enum><header>Conforming amendment</header><text display-inline="yes-display-inline">Clause (iv) of section 402(j)(2)(B) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)(2)(B)</external-xref>) is hereby stricken.</text>
 </paragraph></subsection><subsection id="H8C0DBA38FBFC4A0AB042B275171B0706"><enum>(b)</enum><header>Consultation</header><text display-inline="yes-display-inline">Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services shall consult with stakeholders (including patients, researchers, physicians, industry representatives, health information technology providers, the Food and Drug Administration, and standard setting organizations such as CDISC that have experience working with Federal agencies to standardize health data submissions) to receive advice on enhancements to the clinical trial registry data bank under section 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>) (including enhancements to usability, functionality, and search capability) that are necessary to implement paragraph (7) of section 402(j) of such Act, as added by subsection (a).</text>
 </subsection><subsection id="H2C7742BECE4B46FE8CE7A6E4D84ED4FE"><enum>(c)</enum><header>Applicability</header><text>Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services shall begin implementation of paragraph (7) of section 402(j) of the Public Health Service Act, as added by subsection (a).</text>
					</subsection></section></subtitle><subtitle id="H8BFDC068659C416E9CAC29971FF1BB1C"><enum>G</enum><header>Facilitating Collaborative Research</header>
				<section commented="no" id="HC3A825BC09D44C088992984ABB953292"><enum>1121.</enum><header>Clinical Trial Data System</header>
 <subsection commented="no" id="H8B84E52A82664973A8EDA5303EE1FEED"><enum>(a)</enum><header>Establishment</header><text display-inline="yes-display-inline">The Secretary, acting through the Commissioner of Food and Drugs and the Director of the National Institutes of Health, shall enter into a cooperative agreement, contract, or grant for a period of 7 years, to be known as the Clinical Trial Data System Agreement, with one or more eligible entities to implement a pilot program with respect to all clinical trial data obtained from qualified clinical trials for purposes of registered users conducting further research on such data.</text>
 </subsection><subsection commented="no" id="H3A10CCB8CE0C49299BFFBDE494B36E8A"><enum>(b)</enum><header>Application</header><text display-inline="yes-display-inline">Eligible entities seeking to enter into a cooperative agreement, contract, or grant with the Secretary under this section shall submit to the Secretary an application in such time and manner, and containing such information, as the Secretary may require in accordance with this section. The Secretary shall not enter into a cooperative agreement, contract, or grant with an eligible entity unless such entity submits an application including the following:</text>
 <paragraph commented="no" id="HDBEC699F0AA348CD8CBE6524BC790E6C"><enum>(1)</enum><text display-inline="yes-display-inline">A certification that the eligible entity is not currently and does not plan to be involved in sponsoring, operating, or participating in a clinical trial nor collaborating with another entity for the purposes of sponsoring, operating, or participating in a clinical trial.</text>
 </paragraph><paragraph commented="no" id="H2BC06C4F6B5A4D6C945EBD837CFBC7B5"><enum>(2)</enum><text display-inline="yes-display-inline">Information demonstrating that the eligible entity can compile clinical trial data in standardized formats using terminologies and standards that have been developed by recognized standards developing organizations with input from diverse stakeholder groups, and information demonstrating that the eligible entity can de-identify clinical trial data consistent with the requirements of section 164.514 of title 45, Code of Federal Regulations (or successor regulations).</text>
 </paragraph><paragraph id="H46A9841BAFDF4F2ABA21314DA2CA6AFB"><enum>(3)</enum><text display-inline="yes-display-inline">A description of the system the eligible entity will use to store and maintain such data, and information demonstrating that this system will comply with applicable standards and requirements for ensuring the security of the clinical trial data.</text>
 </paragraph><paragraph commented="no" id="H98084E3728B94D2FBAB63BCB112E3E5D"><enum>(4)</enum><text display-inline="yes-display-inline">A certification that the eligible entity will allow only registered users to access and use de-identified clinical trial data, gathered from qualified clinical trials, and that the eligible entity will allow each registered user to access and use such data only after such registered user agrees in writing to the terms described in (e)(4)(B), and such other carefully controlled contractual terms as may be defined by the Secretary.</text>
 </paragraph><paragraph commented="no" id="H6A11F898329D4C5C98FDF9EC5F991A76"><enum>(5)</enum><text display-inline="yes-display-inline">Evidence demonstrating the ability of the eligible entity to ensure that registered users disseminate the results of the research conducted in accordance with this section to interested parties to serve as a guide to future medical product development or scientific research.</text>
 </paragraph><paragraph commented="no" id="HB33F9E251ED84226AEA19C7C7D785B0F"><enum>(6)</enum><text display-inline="yes-display-inline">The plan of the eligible entity for securing funding for the activities it would conduct under the clinical trial data system agreement from governmental sources and private foundations, entities, and individuals.</text>
 </paragraph><paragraph commented="no" id="H81681275AAF2486981B71142936FCCBB"><enum>(7)</enum><text display-inline="yes-display-inline">Evidence demonstrating a proven track record of—</text> <subparagraph commented="no" id="H6A13C9BF850F439B899C51663E859CF8"><enum>(A)</enum><text>being a neutral third party in working with medical product manufacturers, academic institutions, and the Food and Drug Administration; and</text>
 </subparagraph><subparagraph commented="no" id="HAF65CE8BB895408385A0062C68FAA211"><enum>(B)</enum><text>having the ability to protect confidential data.</text> </subparagraph></paragraph><paragraph id="H4307D07C01C842E0961A8BE82C049BF4"><enum>(8)</enum><text display-inline="yes-display-inline">An agreement that the eligible entity will work with the Comptroller General of the United States for purposes of the study and report in subsection (d).</text>
 </paragraph></subsection><subsection commented="no" id="H2535A3F17FBC4864AA141E2D4026C29D"><enum>(c)</enum><header>Extension, expansion, termination</header><text display-inline="yes-display-inline">The Secretary, acting through the Commissioner of Food and Drugs and the Director of the National Institutes of Health, upon the expiration of the 7-year period referred to in subsection (a), may extend (including permanently), expand, or terminate the pilot program established under such subsection, in whole, or in part.</text>
					</subsection><subsection commented="no" id="H917865E07C744D0D883AFCC5A04E38BD"><enum>(d)</enum><header>Study and report</header>
 <paragraph id="H0D1E44B6CD7A40D1AA80046F888B747A"><enum>(1)</enum><header>In general</header><text>The Secretary shall conduct a study and issue a report to the Congress, with respect to the pilot program established under subsection (a), not later than 6 years after the date on which the pilot program is established under subsection (a).</text>
 </paragraph><paragraph commented="no" id="HDDC68CE53D6A4664A1CEF7D41C79F03E"><enum>(2)</enum><header>Study</header><text>The study under paragraph (1) shall—</text> <subparagraph commented="no" id="HE84671A8FCEA477FA965B65A65FF7E20"><enum>(A)</enum><text>review the effectiveness of the pilot program established under subsection (a); and</text>
 </subparagraph><subparagraph commented="no" id="H4BB9A609C4564B138243251629B9FBFC"><enum>(B)</enum><text>be designed to formulate recommendations on improvements to the program.</text> </subparagraph></paragraph><paragraph commented="no" id="HE53B980EC5F648B49FDBAD0E1FAD2D6A"><enum>(3)</enum><header>Report</header><text>The report under paragraph (1) shall contain at least the following information:</text>
 <subparagraph commented="no" id="H7180A79A289242FCA3736589DFA11A38"><enum>(A)</enum><text display-inline="yes-display-inline">The new discoveries, research inquiries, or clinical trials that have resulted from accessing clinical trial data under the pilot program established under subsection (a).</text>
 </subparagraph><subparagraph commented="no" id="H1328D069E48E44319EF90ADAD5CA4844"><enum>(B)</enum><text>The number of times scientists have accessed such data, disaggregated by research area and clinical trial phase.</text>
 </subparagraph><subparagraph commented="no" id="H05DB8C7143A441B0AAD9129B5D63D1DC"><enum>(C)</enum><text>An analysis of whether the program has helped reduce adverse events in clinical trials.</text> </subparagraph><subparagraph commented="no" id="HBC4F882C3F304B94802961B752EEE856"><enum>(D)</enum><text>An analysis of whether scientists have raised any concerns about the burden of having to share data with the system established under the program and a description, if any, of such burden.</text>
 </subparagraph><subparagraph commented="no" id="HE20AEDE92EB94402B03437529F43165B"><enum>(E)</enum><text>An emphasis of privacy and data integrity practices used in the program.</text> </subparagraph></paragraph></subsection><subsection commented="no" id="H7652199E12C04099B7F43E9A75EF0412"><enum>(e)</enum><header>Definitions</header><text>In this section:</text>
 <paragraph commented="no" id="H58F9869A6EB74DDCBF600808AA7C0979"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>eligible entity</quote> means an entity that has experienced personnel with clinical and other technical expertise in the biomedical sciences and biomedical ethics and that is—</text>
 <subparagraph commented="no" id="H32805A09110749BDB58A368A8EE27476"><enum>(A)</enum><text display-inline="yes-display-inline">an institution of higher education (as such term is defined in section 1001 of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>)) or a consortium of such institutions; or</text>
 </subparagraph><subparagraph commented="no" id="H179108C6BD674C55985328F0A137601F"><enum>(B)</enum><text display-inline="yes-display-inline">an organization described in section 501(c)(3) of title 26 of the Internal Revenue Code of 1986 and exempt from tax under section 501(a) of such title.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H7C7E23B23AD044FB863F6D4626D283A6"><enum>(2)</enum><text display-inline="yes-display-inline">The term <quote>medical product</quote> means a drug (as defined in subsection (g) of section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>)), a device (as defined in subsection (h) of such section), a biological product (as defined in section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>)), or any combination thereof.</text>
 </paragraph><paragraph commented="no" id="HFC68742539344FD4A8DB9423F07FC121"><enum>(3)</enum><text>The term <quote>qualified clinical trial</quote> means a clinical trial sponsored solely by an agency of the Department of Health and Human Services with respect to a medical product—</text>
 <subparagraph commented="no" id="H31D1D9DAF650416BAE349D60BCD17555"><enum>(A)</enum><text>that was—</text> <clause commented="no" id="HA4EE5547F44C44FEB5DD856098276FCB"><enum>(i)</enum><text>approved or cleared under section 505, 510(k), or 515, or has an exemption for investigational use in effect under section 505 or 520(m), of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/42/301">42 U.S.C. 301 et seq.</external-xref>); or</text>
 </clause><clause commented="no" id="H4AD9490D8B1E450FB5D10D8B5B5E3CD4"><enum>(ii)</enum><text>licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) or has an exemption for investigational use in effect under such section 351; or</text>
 </clause></subparagraph><subparagraph commented="no" id="H6A40593070504DF381C565FDD96E48AF"><enum>(B)</enum><text>that is an investigational product for which the original development was discontinued and with respect to which—</text>
 <clause commented="no" id="HA7464D18DE734418A11846E70A45D220"><enum>(i)</enum><text>no additional work to support approval, licensure, or clearance of such medical product is being or is planned to be undertaken by the sponsor of the original development program, its successors, assigns, or collaborators; and</text>
 </clause><clause commented="no" id="HF447B9FF21E046B2927163B411934053"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor of the original investigational development program has provided its consent to the Secretary for inclusion of data regarding such product in the system established under this section.</text>
 </clause></subparagraph></paragraph><paragraph id="H07BDA5C150404B0FBEFEF1D8E9BAFC15"><enum>(4)</enum><text>The term <quote>registered user</quote> means a scientific or medical researcher who has—</text> <subparagraph id="HF944CF273E874014A1DC87FE7988243F"><enum>(A)</enum><text>a legitimate biomedical research purpose for accessing information from the clinical trials data system and has appropriate qualifications to conduct such research; and</text>
 </subparagraph><subparagraph id="H6C2AD2141D654B7A8D6F25919331C34C"><enum>(B)</enum><text>agreed in writing not to transfer to any other person that is not a registered user de-identified clinical trial data from qualified clinical trials accessed through an eligible entity, use such data for reasons not specified in the research proposal, or seek to re-identify qualified clinical trial participants.</text>
 </subparagraph></paragraph><paragraph id="H578FA8F449B943CFB5669C7C3020133B"><enum>(5)</enum><text>The term <quote>Secretary</quote> means the Secretary of Health and Human Services.</text> </paragraph></subsection></section><section id="HCB8FF9A534DB4BDAB61DE6E763D7A1CD"><enum>1122.</enum><header>National neurological diseases surveillance system</header><text display-inline="no-display-inline">Part P of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280g">42 U.S.C. 280g et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="HDEC0A1A71C7D4BD6B77C5B1E1EA21D9B" style="OLC">
						<section id="HBE1CF6E01A3C4A0292009B1C4AD27DF0"><enum>399V–6</enum><header>Surveillance of neurological diseases</header>
 <subsection commented="no" id="H11AFA762D5B14347BE23559153BB2471"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in coordination with other agencies as determined appropriate by the Secretary, shall—</text>
 <paragraph commented="no" id="H01B5188A90A34AAD80A50619140D10FC"><enum>(1)</enum><text>enhance and expand infrastructure and activities to track the epidemiology of neurological diseases, including multiple sclerosis and Parkinson’s disease; and</text>
 </paragraph><paragraph commented="no" id="H5B09725FAB524EA8AB6E444F510C7CE3"><enum>(2)</enum><text>incorporate information obtained through such activities into a statistically sound, scientifically credible, integrated surveillance system, to be known as the National Neurological Diseases Surveillance System.</text>
 </paragraph></subsection><subsection commented="no" id="HED7853BD8BFB4992B2B8A9BD7D1B1B23"><enum>(b)</enum><header>Research</header><text>The Secretary shall ensure that the National Neurological Diseases Surveillance System is designed in a manner that facilitates further research on neurological diseases.</text>
 </subsection><subsection id="HE3C9D24FE2C245208DE1B14F3BE5ADD6"><enum>(c)</enum><header>Content</header><text>In carrying out subsection (a), the Secretary—</text> <paragraph id="HF70DF66B34BB4666B9A132257E0D1C10"><enum>(1)</enum><text>shall provide for the collection and storage of information on the incidence and prevalence of neurological diseases in the United States;</text>
 </paragraph><paragraph commented="no" id="H8B8CCF7355544C08ACE977D947140216"><enum>(2)</enum><text>to the extent practicable, shall provide for the collection and storage of other available information on neurological diseases, such as information concerning—</text>
 <subparagraph commented="no" id="H22265D9B464C40B497BF847C2BB30A05"><enum>(A)</enum><text>demographics and other information associated or possibly associated with neurological diseases, such as age, race, ethnicity, sex, geographic location, and family history;</text>
 </subparagraph><subparagraph commented="no" id="H1FC11870B998488EA1588E3E4CB1801C"><enum>(B)</enum><text>risk factors associated or possibly associated with neurological diseases, including genetic and environmental risk factors; and</text>
 </subparagraph><subparagraph commented="no" id="H9B639D4E59C3435B9FDFDCA6C7B32505"><enum>(C)</enum><text>diagnosis and progression markers;</text> </subparagraph></paragraph><paragraph id="H7B601C6F21A741FF813BBF901DB0B671"><enum>(3)</enum><text display-inline="yes-display-inline">may provide for the collection and storage of information relevant to analysis on neurological diseases, such as information concerning—</text>
 <subparagraph id="HC986447D40164A64985B8CEE6D00D685"><enum>(A)</enum><text>the epidemiology of the diseases;</text> </subparagraph><subparagraph id="H5577312A29A140A98C2C2808590DAD9B"><enum>(B)</enum><text>the natural history of the diseases;</text>
 </subparagraph><subparagraph id="H8C56CBD7C2444ABEA9200DBF39A9C8C9"><enum>(C)</enum><text>the prevention of the diseases;</text> </subparagraph><subparagraph id="HF32C3A2A271A4920BC5FB7872E3F000C"><enum>(D)</enum><text>the detection, management, and treatment approaches for the diseases; and</text>
 </subparagraph><subparagraph id="HF250F672CD4C4F67B19AEBB20BF53EDB"><enum>(E)</enum><text>the development of outcomes measures; and</text> </subparagraph></paragraph><paragraph id="HBBADCF01A8D54BA3B60B861E6E76F6B3"><enum>(4)</enum><text>may address issues identified during the consultation process under subsection (d).</text>
 </paragraph></subsection><subsection id="H6BCC21DC982A446A81B0B20E76526CDA"><enum>(d)</enum><header>Consultation</header><text>In carrying out this section, the Secretary shall consult with individuals with appropriate expertise, including—</text>
 <paragraph id="H4313BAC0A0D1462E903C0E2084408BC7"><enum>(1)</enum><text>epidemiologists with experience in disease surveillance or registries;</text> </paragraph><paragraph id="H3936AC63724B4E80AD2E59E2CE90716A"><enum>(2)</enum><text>representatives of national voluntary health associations that—</text>
 <subparagraph id="H6696C5A68EFE47D091A3D5E71F982A62"><enum>(A)</enum><text>focus on neurological diseases, including multiple sclerosis and Parkinson’s disease; and</text> </subparagraph><subparagraph id="H56F846740FDE4104B26C8FE1321C11E2"><enum>(B)</enum><text>have demonstrated experience in research, care, or patient services;</text>
 </subparagraph></paragraph><paragraph id="HD338256CECB34D4D90DCB8CF6439CF02"><enum>(3)</enum><text>health information technology experts or other information management specialists;</text> </paragraph><paragraph id="H9F83B02343CE4978B9F1583ADB4795A1"><enum>(4)</enum><text>clinicians with expertise in neurological diseases; and</text>
 </paragraph><paragraph id="H8DFC92D1FBE044708323C7EB91FC6768"><enum>(5)</enum><text>research scientists with experience conducting translational research or utilizing surveillance systems for scientific research purposes.</text>
 </paragraph></subsection><subsection id="H44EED120F73F4F2196AB424D0E857CF6"><enum>(e)</enum><header>Grants</header><text>The Secretary may award grants to, or enter into contracts or cooperative agreements with, public or private nonprofit entities to carry out activities under this section.</text>
 </subsection><subsection commented="no" id="HDDDAF2734E284A1ABF176D4787E179E1"><enum>(f)</enum><header>Coordination with other Federal, State, and local agencies</header><text>Subject to subsection (h), the Secretary shall make information and analysis in the National Neurological Diseases Surveillance System available, as appropriate—</text>
 <paragraph id="H46EFBDB36605480D9A6F0977928F193B"><enum>(1)</enum><text>to Federal departments and agencies, such as the National Institutes of Health, the Food and Drug Administration, the Centers for Medicare &amp; Medicaid Services, the Agency for Healthcare Research and Quality, the Department of Veterans Affairs, and the Department of Defense; and</text>
 </paragraph><paragraph id="H9B1CC52CB54E462ABEF6A230ED77D903"><enum>(2)</enum><text>to State and local agencies.</text> </paragraph></subsection><subsection id="H0049A10209C44B62B33493141C98AD95"><enum>(g)</enum><header>Public access</header><text>Subject to subsection (h), the Secretary shall make information and analysis in the National Neurological Diseases Surveillance System available, as appropriate, to the public, including researchers.</text>
 </subsection><subsection id="H0DF3106AADB7473182A8834D38246FFF"><enum>(h)</enum><header>Privacy</header><text display-inline="yes-display-inline">The Secretary shall ensure that privacy and security protections applicable to the National Neurological Diseases Surveillance System are at least as stringent as the privacy and security protections under HIPAA privacy and security law (as defined in section 3009(a)(2)).</text>
 </subsection><subsection id="H83C77415B6004B2684EE9E61821D3456"><enum>(i)</enum><header>Report</header><text>Not later than 4 years after the date of the enactment of this section, the Secretary shall submit a report to the Congress concerning the implementation of this section. Such report shall include information on—</text>
 <paragraph id="HF45FA4C4197741E4A5753864EAD516F5"><enum>(1)</enum><text>the development and maintenance of the National Neurological Diseases Surveillance System;</text> </paragraph><paragraph id="HC8AFDAED5F234E69A14808256FE39BC2"><enum>(2)</enum><text>the type of information collected and stored in the System;</text>
 </paragraph><paragraph id="H32053363217C49B491E614F394D0B889"><enum>(3)</enum><text>the use and availability of such information, including guidelines for such use; and</text> </paragraph><paragraph id="H9A2132411FF942D88ACC7368996632F8"><enum>(4)</enum><text>the use and coordination of databases that collect or maintain information on neurological diseases.</text>
 </paragraph></subsection><subsection id="HF4395BD7EAFD4A18A5B8DA90DF91C1CB"><enum>(j)</enum><header>Definition</header><text>In this section, the term <term>national voluntary health association</term> means a national nonprofit organization with chapters, other affiliated organizations, or networks in States throughout the United States.</text>
 </subsection><subsection id="H91DF781DA38F4E1DAA826570F28B1AFF"><enum>(k)</enum><header>Authorization of appropriations</header><text>To carry out this section, there is authorized to be appropriated $5,000,000 for each of fiscal years 2016 through 2020.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section><section id="H6845D13E37D946EBB1DEABEC5A350ADB"><enum>1123.</enum><header>Data on natural history of diseases</header>
 <subsection id="H725F011757F847A986AD7F12288037E8"><enum>(a)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of the Congress that studies on the natural history of diseases can help facilitate and expedite the development of medical products for such diseases.</text>
 </subsection><subsection id="H9E4991D7849B4B76A6B4B7B9BC29527C"><enum>(b)</enum><header>Authority</header><text display-inline="yes-display-inline">Part A of title II of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/202">42 U.S.C. 202 et seq.</external-xref>) is amended by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="H1C93B24A36A74283AEF0BAE91BD38A9B" style="OLC">
							<section id="H1B9753D8E047442BB87D218C41FAA340"><enum>229A.</enum><header>Data on natural history of diseases</header>
 <subsection id="HDD638242CA57476E8DC1D3A65FFC974C"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may, for the purposes described in subsection (b)—</text> <paragraph id="HB0E841B737C740B28D382711E81510F0"><enum>(1)</enum><text>participate in public-private partnerships engaged in one or more activities specified in subsection (c); and</text>
 </paragraph><paragraph id="H5D1ED4C925884F0DBAE247B7390F4ED2"><enum>(2)</enum><text>award grants to patient advocacy groups or other organizations determined appropriate by the Secretary.</text>
 </paragraph></subsection><subsection id="HACD47549977443BFB51B8B356FD7246D"><enum>(b)</enum><header>Purposes described</header><text display-inline="yes-display-inline">The purposes described in this subsection are to establish or facilitate the collection, maintenance, analysis, and interpretation of data regarding the natural history of diseases, with a particular focus on rare diseases.</text>
 </subsection><subsection id="HD2564EE161AA40E6939D9ABD5A42D0C0"><enum>(c)</enum><header>Activities of public-Private partnerships</header><text display-inline="yes-display-inline">The activities of public-private partnerships in which the Secretary may participate for purposes of this section include—</text>
 <paragraph id="H324423368B9A469796B6CE3A46A5CD96"><enum>(1)</enum><text>cooperating with other entities to sponsor or maintain disease registries, including disease registries and disease registry platforms for rare diseases;</text>
 </paragraph><paragraph id="H4A675336525A434191C8F88F0E5DEC3D"><enum>(2)</enum><text>developing or enhancing a secure information technology system that—</text> <subparagraph id="HA3DCC99530C4407FB55E1FB055423A88"><enum>(A)</enum><text>has the capacity to support data needs across a wide range of disease studies;</text>
 </subparagraph><subparagraph id="HF1FD39F2E86C41A6BA38F1BD1E563D46"><enum>(B)</enum><text>is easily modified as knowledge is gained during such studies; and</text> </subparagraph><subparagraph id="H15D2DC92ED8045C7B5D4BBA61C79D48A"><enum>(C)</enum><text>is capable of handling increasing amounts of data as more studies are carried out; and</text>
 </subparagraph></paragraph><paragraph id="HCFABB201F78B4A5DA6D6D883DA21EBC0"><enum>(3)</enum><text display-inline="yes-display-inline">providing advice to clinical researchers, patient advocacy groups, and other entities with respect to—</text>
 <subparagraph id="HBC9EF4499FDF4488AEF983C1FD1AF2AC"><enum>(A)</enum><text>the design and conduct of disease studies;</text> </subparagraph><subparagraph id="H8D6E6F62ADD84E30995FC8AEAE4771FF"><enum>(B)</enum><text>the modification of any such ongoing studies; and</text>
 </subparagraph><subparagraph id="H726C76CFFAFF47138CF5B76E3C3A2030"><enum>(C)</enum><text>addressing associated patient privacy issues.</text> </subparagraph></paragraph></subsection><subsection id="H069EEE53945C48019F39D7BDF3EB9530"><enum>(d)</enum><header>Availability of data on natural history of diseases</header><text display-inline="yes-display-inline">Data relating to the natural history of diseases obtained, aggregated, or otherwise maintained by a public-private partnership in which the Secretary participates under subsection (a) shall be made available, consistent with otherwise applicable Federal and State privacy laws, to the public (including patient advocacy groups, researchers, and drug developers) to help facilitate and expedite medical product development programs.</text>
 </subsection><subsection id="H48EB5CD96BBC46268AB7D52A540F5D9A"><enum>(e)</enum><header>Confidentiality</header><text display-inline="yes-display-inline">Notwithstanding subsection (d), nothing in this section authorizes the disclosure of any information that is a trade secret or commercial or financial information that is privileged or confidential and subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text>
 </subsection><subsection id="H1E5B4C6A914E412D9664FC1045D6CE3F"><enum>(f)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection></section><section id="H705FB451D71143AB920B1BC84BFE173E"><enum>1124.</enum><header>Accessing, sharing, and using health data for research purposes</header>
 <subsection id="HA752477BE027493E954BA50EDB7CC3CF"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The HITECH Act (title XIII of division A of <external-xref legal-doc="public-law" parsable-cite="pl/111/5">Public Law 111–5</external-xref>) is amended by adding at the end of subtitle D of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/17921">42 U.S.C. 17921 et seq.</external-xref>) the following:</text>
						<quoted-block display-inline="no-display-inline" id="H712A457B20B74AFFB56784261BD401A2" style="OLC">
							<part id="H11185921AED64AF690DC2E5FA56A2063"><enum>4</enum><header>Accessing, sharing, and using health data for research purposes</header>
 <section id="H08B9375C4E9744CD9686991DE0BE22A0"><enum>13441.</enum><header>References</header><text display-inline="no-display-inline">In this part:</text> <subsection id="HC5A20FFB536F47B7933562E5247CA3AB"><enum>(a)</enum><header>The Rule</header><text display-inline="yes-display-inline">References to <quote>the Rule</quote> refer to part 160 or part 164, as appropriate, of title 45, Code of Federal Regulations (or any successor regulation).</text>
 </subsection><subsection id="HB37FE03F64F94736A98050B74AAF9D45"><enum>(b)</enum><header>Part 164</header><text display-inline="yes-display-inline">References to a specified section of <quote>part 164</quote>, refer to such specified section of part 164 of title 45, Code of Federal Regulations (or any successor section).</text>
									</subsection></section><section id="H52C2A356465E43E8896FC00810896E98"><enum>13442.</enum><header>Defining health data research as part of health care operations</header>
 <subsection id="HF75B63A3DC8A460C8DDFE59F559BC638"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subsection (b), the Secretary shall revise or clarify the rule to allow the use and disclosure of protected health information by a covered entity for research purposes, including studies whose purpose is to obtain generalizable knowledge, to be treated as the use and disclosure of such information for health care operations described in subparagraph (1) of the definition of health care operations in section 164.501 of part 164.</text>
 </subsection><subsection id="H38DC3E32BF9548CAB583F2A4B6DA282C"><enum>(b)</enum><header>Modifications to rules for disclosures for health care operations</header><text display-inline="yes-display-inline">In applying section 164.506 of part 164 to the disclosure of protected health information described in subsection (a)—</text>
 <paragraph id="H017F2C92E560478CAC92161EEE05FDD5"><enum>(1)</enum><text>the Secretary shall revise or clarify the Rule so that the disclosure may be made by the covered entity to only—</text>
 <subparagraph id="H771E5185D1B04F84BF67138EB439FB39"><enum>(A)</enum><text>another covered entity for health care operations (as defined in such section 164.501 of part 164);</text> </subparagraph><subparagraph id="H724EDFC7348041B5B2950AD46A018CA8"><enum>(B)</enum><text display-inline="yes-display-inline">a business associate that has entered into a contract under section 164.504(e) of part 164 with a disclosing covered entity to perform health care operations; or</text>
 </subparagraph><subparagraph id="H0322B1DE64C34366ABE82F5BE0F51462"><enum>(C)</enum><text display-inline="yes-display-inline">a business associate that has entered into a contract under section 164.504(e) of part 164 for the purpose of data aggregation (as defined in such section 164.501 of part 164); and</text>
 </subparagraph></paragraph><paragraph id="H6D0CD020A4A445639630BA51DFFBA28A"><enum>(2)</enum><text>the Secretary shall further revise or clarify the Rule so that the limitation specified by section 164.506(c)(4) of part 164 does not apply to disclosures that are described by subsection (a).</text>
 </paragraph></subsection><subsection id="H302758B171C44B348E7C8F48B45062FD"><enum>(c)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">This section shall not be construed as prohibiting or restricting a use or disclosure of protected health information for research purposes that is otherwise permitted under part 164.</text>
									</subsection></section><section id="HD8FF99278DCD4F01A7472FAAC3CF1E6C"><enum>13443.</enum><header>Treating disclosures of protected health information for research similarly to disclosures of such
			 information for public health purposes</header>
 <subsection id="HC4C49BCFA80642159C38209231A90969"><enum>(a)</enum><header>Remuneration</header><text display-inline="yes-display-inline">The Secretary shall revise or clarify the Rule so that disclosures of protected health information for research purposes are not subject to the limitation on remuneration described in section 164.502(a)(5)(ii)(B)(2)(ii) of part 164.</text>
 </subsection><subsection id="H228C8FC6318E4072BB10459D9F42D1E3"><enum>(b)</enum><header>Permitted uses and disclosures</header><text display-inline="yes-display-inline">The Secretary shall revise or clarify the Rule so that research activities, including comparative research activities, related to the quality, safety, or effectiveness of a product or activity that is regulated by the Food and Drug Administration are included as public health activities for purposes of which a covered entity may disclose protected health information to a person described in section 164.512(b)(1)(iii) of part 164.</text>
 </subsection></section><section id="HBF0EF2A3608744A68A2CA8CBC5518ADB"><enum>13444.</enum><header>Permitting remote access to protected health information by researchers</header><text display-inline="no-display-inline">The Secretary shall revise or clarify the Rule so that subparagraph (B) of section 164.512(i)(1)(ii) of part 164 (prohibiting the removal of protected health information by a researcher) shall not prohibit remote access to health information by a researcher so long as—</text>
 <paragraph id="H07B7B48A09504770AABE52EAEFF58610"><enum>(1)</enum><text display-inline="yes-display-inline">appropriate security and privacy safeguards are maintained by the covered entity and the researcher; and</text>
 </paragraph><paragraph id="H99EC8A2336E04B5D84ABC9C3DF362368"><enum>(2)</enum><text>the protected health information is not copied or otherwise retained by the researcher.</text> </paragraph></section><section id="HD2284627ADEE44CB93B8BD8F5208C3CA"><enum>13445.</enum><header>Allowing one-time authorization of use and disclosure of protected health information for research purposes</header> <subsection id="H4FEC7FFAB0AC4594A06133417BBC89A3"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall revise or clarify the Rule to specify that an authorization for the use or disclosure of protected health information, with respect to an individual, for future research purposes shall be deemed to contain a sufficient description of the purpose of the use or disclosure if the authorization—</text>
 <paragraph id="HE7B7279A7A7D4D1C8613A4BD78ABA8ED"><enum>(1)</enum><text>sufficiently describes the purposes such that it would be reasonable for the individual to expect that the protected health information could be used or disclosed for such future research;</text>
 </paragraph><paragraph id="HEC2C80F3EA21498A8C800260E7A06414"><enum>(2)</enum><text>either—</text> <subparagraph id="H03731015803E42DF8C51C988A5D22D08"><enum>(A)</enum><text display-inline="yes-display-inline">states that the authorization will expire on a particular date or on the occurrence of a particular event; or</text>
 </subparagraph><subparagraph id="H18A27BF2B2084624A3443E65FEC81690"><enum>(B)</enum><text>states that the authorization will remain valid unless and until it is revoked by the individual; and</text>
 </subparagraph></paragraph><paragraph id="H22F0086650584E128E8776A6704CB207"><enum>(3)</enum><text>provides instruction to the individual on how to revoke such authorization at any time.</text> </paragraph></subsection><subsection id="H7CF6ADC891244CBD805D7352890F29E4"><enum>(b)</enum><header>Revocation of authorization</header><text display-inline="yes-display-inline">The Secretary shall revise or clarify the Rule to specify that, if an individual revokes an authorization for future research purposes such as is described by subsection (a), the covered entity may not make any further uses or disclosures based on that authorization, except, as provided in paragraph (b)(5) of section 164.508 of part 164, to the extent that the covered entity has taken action in reliance on the authorization.</text></subsection></section></part><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" id="HFD6011E822954E4D97941B0F2AACF442"><enum>(b)</enum><header>Revision of regulations</header><text display-inline="yes-display-inline">Not later than 12 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall revise and clarify the provisions of title 45, Code of Federal Regulations, for consistency with part 4 of subtitle D of the HITECH Act, as added by subsection (a).</text>
					</subsection></section></subtitle><subtitle id="HF3C41797A9914794A9C456635C4F76D1"><enum>H</enum><header>Council for 21st Century Cures</header>
 <section id="HAE79876EBDC448FEA58405BB11700C65" section-type="subsequent-section"><enum>1141.</enum><header>Council for 21st Century Cures</header><text display-inline="no-display-inline">Title II of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/202">42 U.S.C. 202 et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H56146C6A7D9B4A7993B2931FC39C2C59" style="OLC">
						<part id="H265E0BBE21314E52A5729A67C1D65B7E"><enum>E</enum><header>Council for 21st Century Cures</header>
 <section id="HBC7E6551838A4B6E838C4A420A9B87BE"><enum>281.</enum><header>Establishment</header><text display-inline="no-display-inline">A nonprofit corporation to be known as the Council for 21st Century Cures (referred to in this part as the <quote>Council</quote>) shall be established in accordance with this section. The Council shall be a public-private partnership headed by an Executive Director (referred to in this part as the <quote>Executive Director</quote>), appointed by the members of the Board of Directors. The Council shall not be an agency or instrumentality of the United States Government.</text>
 </section><section id="HCA9E764A21114184A68570E20A116EF2"><enum>281A.</enum><header>Purpose</header><text display-inline="no-display-inline">The purpose of the Council is to accelerate the discovery, development, and delivery in the United States of innovative cures, treatments, and preventive measures for patients.</text>
 </section><section id="HE4FD2918136846D7896D212CAB8DB07A"><enum>281B.</enum><header>Duties</header><text display-inline="no-display-inline">For the purpose described in section 281A, the Council shall—</text> <paragraph id="HCE1AAC34EC204D7B992169B9159E0705"><enum>(1)</enum><text display-inline="yes-display-inline">foster collaboration and coordination among the entities that comprise the Council, including academia, government agencies, industry, health care payors and providers, patient advocates, and others engaged in the cycle of discovery, development, and delivery of life-saving and health-enhancing innovative interventions;</text>
 </paragraph><paragraph id="HDEF7800E78BC4140856C086B353E4B1A"><enum>(2)</enum><text>undertake communication and dissemination activities;</text> </paragraph><paragraph id="H86898E8F01D540A5955341AAD8DFCE3D"><enum>(3)</enum><text>publish information on the activities funded under section 281D;</text>
 </paragraph><paragraph id="H4D214068817F44FC89E7C4323FE28C2E"><enum>(4)</enum><text display-inline="yes-display-inline">establish a strategic agenda for accelerating the discovery, development, and delivery in the United States of innovative cures, treatments, and preventive measures for patients;</text>
 </paragraph><paragraph id="H3AE9139671E741A8A0DE0DBEE379859A"><enum>(5)</enum><text>identify gaps and opportunities within and across the discovery, development, and delivery cycle;</text> </paragraph><paragraph id="H603CDC83030147F18EC8FCABC881C705"><enum>(6)</enum><text>develop and propose recommendations based on the gaps and opportunities so identified;</text>
 </paragraph><paragraph id="H8A93EB45AE4F47E999D80AD1C49BC1C1"><enum>(7)</enum><text>facilitate the interoperability of the components of the discovery, development, and delivery cycle;</text>
 </paragraph><paragraph id="HBB3B7A72869D48408C372443C68431B9"><enum>(8)</enum><text>propose recommendations that will facilitate precompetitive collaboration;</text> </paragraph><paragraph id="H99EABF84FF054D2196119D1DAB6254FA"><enum>(9)</enum><text>identify opportunities to work with, but not duplicate the efforts of, nonprofit organizations and other public-private partnerships; and</text>
 </paragraph><paragraph id="HEA8722F7B875473E8B64F2F8C7E8768D"><enum>(10)</enum><text>identify opportunities for collaboration with organizations operating outside of the United States, such as the Innovative Medicines Initiative of the European Union.</text>
								</paragraph></section><section id="H27989971A5C74DF8AE1D2969EF4D4AAC"><enum>281C.</enum><header>Organization; administration</header>
								<subsection id="H76B0F18A18CC4343830CD8D63962B694"><enum>(a)</enum><header>Board of directors</header>
									<paragraph id="H2B6259C06A94422F8C9E70C7B4467751"><enum>(1)</enum><header>Establishment</header>
 <subparagraph id="H0E5D3FB14FE746749C26604504DE395D"><enum>(A)</enum><header>In general</header><text>The Council shall have a Board of Directors (in this part referred to as the <quote>Board of Directors</quote>), which shall be composed of the ex officio members under subparagraph (B) and the appointed members under subparagraph (C). All members of the Board shall be voting members.</text>
 </subparagraph><subparagraph id="HEF2728072A7B4111A41820DBA2AA080D"><enum>(B)</enum><header>Ex officio members</header><text>The ex officio members of the Board shall be the following individuals or their designees:</text> <clause id="H6636FD5F234A443BB83668EA7D15EA74"><enum>(i)</enum><text>The Director of the National Institutes of Health.</text>
 </clause><clause id="H6B590C65DEB7429EABB1E4AD441E4110"><enum>(ii)</enum><text>The Commissioner of Food and Drugs.</text> </clause><clause id="HC6EF2E6D55D24BA3B0228CCC1F9920C7"><enum>(iii)</enum><text>The Administrator of the Centers for Medicare &amp; Medicaid Services.</text>
 </clause><clause id="H669CD353899B40E7BF8D1D9F8F6728A5"><enum>(iv)</enum><text display-inline="yes-display-inline">The heads of five other Federal agencies deemed by the Secretary to be engaged in biomedical research and development.</text>
 </clause></subparagraph><subparagraph id="H3B07BAABF5F148A68F6809AF33A17731"><enum>(C)</enum><header>Appointed members</header><text display-inline="yes-display-inline">The appointed members of the Board shall consist of 17 individuals, of whom—</text> <clause id="H4C8C6A549F4A4D9EBA94389C47AAF184"><enum>(i)</enum><text display-inline="yes-display-inline">8 shall be by the Comptroller General of the United States from a list of nominations submitted by leading trade associations—</text>
 <subclause id="H70E0824216C9493B8C5D0306314FFDC8"><enum>(I)</enum><text>4 of whom shall be representatives of the biopharmaceutical industry;</text> </subclause><subclause id="H764EB2D7A6814ABA8167319CD159F7F0"><enum>(II)</enum><text>2 of whom shall be representatives of the medical device industry; and</text>
 </subclause><subclause id="HDF319C6443E847DA867815E307ABF56F"><enum>(III)</enum><text>2 of whom shall be representatives of the information and digital technology industry; and</text> </subclause></clause><clause id="H92A073F9BC8B4F59A612A8B8112FA162"><enum>(ii)</enum><text display-inline="yes-display-inline">9 shall be appointed by the Comptroller General of the United States, after soliciting nominations—</text>
 <subclause id="H1A04D9E154A245449A6DE71DE3A030F5"><enum>(I)</enum><text>2 of whom shall be representatives of academic researchers;</text> </subclause><subclause id="H714A611418EC49A98B9C7170B272759D"><enum>(II)</enum><text>3 of whom shall be representative of patients;</text>
 </subclause><subclause id="H9C9B8AC762F4448F8DA2361A60410886"><enum>(III)</enum><text>2 of whom shall be representatives of health care providers; and</text> </subclause><subclause id="H2D75B71DDE5048D2B26AE53C5B4A27C6"><enum>(IV)</enum><text>2 of whom shall be representatives of health care plans and insurers.</text>
 </subclause></clause></subparagraph><subparagraph id="H1C137568B7BE4235A5A65010DB12C7E8"><enum>(D)</enum><header>Chair</header><text display-inline="yes-display-inline">The Chair of the Board shall be selected by the members of the Board by majority vote from among the members of the Board.</text>
										</subparagraph></paragraph><paragraph id="H07797ED07DE849D784A3B873E4A7026A"><enum>(2)</enum><header>Terms and vacancies</header>
 <subparagraph id="H481C23B946F54A578823F107362A6BD5"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The term of office of each member of the Board appointed under paragraph (1)(C) shall be 5 years.</text> </subparagraph><subparagraph id="H8F86D8595B584DAFB9764893681E3E01"><enum>(B)</enum><header>Vacancy</header><text display-inline="yes-display-inline">Any vacancy in the membership of the Board—</text>
 <clause id="HF6C76C41C1A24F38B883BA0077CF7275"><enum>(i)</enum><text>shall not affect the power of the remaining members to execute the duties of the Board; and</text> </clause><clause id="H36450172D5C942B9A7E358EB4674FBF4"><enum>(ii)</enum><text>shall be filled by appointment by the appointed members described in paragraph (1)(C) by majority vote.</text>
 </clause></subparagraph><subparagraph id="HB5E5553A391F4A2696462D83C84267E9"><enum>(C)</enum><header>Partial term</header><text display-inline="yes-display-inline">If a member of the Board does not serve the full term applicable under subparagraph (A), the individual appointed under subparagraph (B) to fill the resulting vacancy shall be appointed for the remainder of the term of the predecessor of the individual.</text>
 </subparagraph></paragraph><paragraph id="H9C1145F72C7B495EB9C0C437A5333EF5"><enum>(3)</enum><header>Responsibilities</header><text display-inline="yes-display-inline">Not later than 90 days after the date on which the Council is incorporated and its Board of Directors is fully constituted, the Board of Directors shall establish bylaws and policies for the Council that—</text>
 <subparagraph id="HD5745BD3FA764B76A8ECB6AC08F55652"><enum>(A)</enum><text display-inline="yes-display-inline">are published in the Federal Register and available for public comment;</text> </subparagraph><subparagraph id="HB64291D33A2840C5AC1A20BA0602043C"><enum>(B)</enum><text>establish policies for the selection and, as applicable, appointment of—</text>
 <clause id="H43295889AB4848ADAABCC4A5E607D169"><enum>(i)</enum><text display-inline="yes-display-inline">the officers, employees, agents, and contractors of the Council; and</text> </clause><clause id="HCB40719C37AF4D8BBF0E5F7EC96634E3"><enum>(ii)</enum><text display-inline="yes-display-inline">the members of any committees of the Council;</text>
 </clause></subparagraph><subparagraph id="HA9BFA1CD0540492B8064B28B51CCBCE8"><enum>(C)</enum><text display-inline="yes-display-inline">establish policies, including ethical standards, for the conduct of programs and other activities under section 281D; and</text>
 </subparagraph><subparagraph id="H7E0310D7BE184E87ADF10E6F2AAAE084"><enum>(D)</enum><text>establish specific duties of the Executive Director.</text> </subparagraph></paragraph><paragraph id="HA0E2CCB4F03A43FAB5DE6390B461FAED"><enum>(4)</enum><header>Meetings</header> <subparagraph id="H5387E3D6E0F3452983C1CD4A443DBC67"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">the Board of Directors shall—</text>
 <clause id="HF608B965473D4F93831FF4746E414F28"><enum>(i)</enum><text>meet on a quarterly basis; and</text> </clause><clause id="HAAB89742DB54467396EF58B3820DEE1C"><enum>(ii)</enum><text>submit to Congress, and make publicly available, the minutes of such meetings.</text>
 </clause></subparagraph><subparagraph id="HBD777A197F7E4C22A2FB8AB2F883E368"><enum>(B)</enum><header>Agenda</header><text display-inline="yes-display-inline">The Board of Directors shall, not later than 3 months after the incorporation of the Council—</text> <clause id="HF544441F6A134DC69EE33B48847714B5"><enum>(i)</enum><text>issue an agenda (in this part referred to as the <quote>agenda</quote>) outlining how the Council will achieve the purpose described in section 281A; and</text>
 </clause><clause id="H4F369904E1EA4D54AFF1F5F07F3FC505"><enum>(ii)</enum><text display-inline="yes-display-inline">annually thereafter, in consultation with the Executive Director, review and update such agenda.</text> </clause></subparagraph></paragraph></subsection><subsection id="H512437214DA049829093A8EBB76A417E"><enum>(b)</enum><header>Appointment and incorporation</header><text display-inline="yes-display-inline">Not later than 6 months after the date of enactment of the <short-title>21st Century Cures Act</short-title>—</text>
 <paragraph id="H8494166357A3436CAA560A6C95FED889"><enum>(1)</enum><text>the Comptroller General of the United States shall appoint the appointed members of the Board of Directors under subsection (a)(1)(C); and</text>
 </paragraph><paragraph id="H24760693FFB64399A20B41FA3D5B2AE9"><enum>(2)</enum><text>the ex officio members of the Board of Directors under subsection (a)(1)(B) shall serve as incorporators and shall take whatever actions are necessary to incorporate the Council.</text>
 </paragraph></subsection><subsection id="HA6BD5185578748FB8B1FF589F4887D44"><enum>(c)</enum><header>Nonprofit Status</header><text display-inline="yes-display-inline">In carrying out this part, the Board of Directors shall establish such policies and bylaws, and the Executive Director shall carry out such activities, as may be necessary to ensure that the Council maintains status as an organization that—</text>
 <paragraph id="H5DB7BA9E390B474F831F259B94BED899"><enum>(1)</enum><text>is described in subsection (c)(3) of <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501</external-xref> of the Internal Revenue Code of 1986; and</text> </paragraph><paragraph id="H19273818DE794591B61BD8BD7F0D24DF"><enum>(2)</enum><text>is, under subsection (a) of such section, exempt from taxation.</text>
 </paragraph></subsection><subsection id="H75BC3804943C4525AD382DA914CFDFF5"><enum>(d)</enum><header>Executive Director</header><text display-inline="yes-display-inline">The Executive Director shall—</text> <paragraph id="HD3BD070C0E0D49449083788D63AAFCC6"><enum>(1)</enum><text display-inline="yes-display-inline">be the chief executive officer of the Council; and</text>
 </paragraph><paragraph id="H3132A0AB246C44DBBF850EAC89A66D66"><enum>(2)</enum><text display-inline="yes-display-inline">subject to the oversight of the Board of Directors, be responsible for the day-to-day management of the Council.</text>
									</paragraph></subsection></section><section id="H13AC0DDBBA044F1B8B049267CF34B3E7"><enum>281D.</enum><header> Operational activities and assistance</header>
 <subsection id="H475FAAA61E144E3080B0591EBAFFDCD4"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Council shall establish a sufficient operational infrastructure to fulfill the duties specified in section 281B.</text>
 </subsection><subsection display-inline="no-display-inline" id="H82E35705F9134A50AB5DA77CAC398CB9"><enum>(b)</enum><header>Private sector matching funds</header><text>The Council may accept financial or in-kind support from participating entities or private foundations or organizations when such support is deemed appropriate.</text>
								</subsection></section><section id="H04278A94F9F3411295B9D44AF1F31D7B"><enum>281E.</enum><header>Termination; report</header>
 <subsection id="HB5C30DA368064FBA855DA711803C3245"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Council shall terminate on September 30, 2023.</text> </subsection><subsection id="H3B5034503BC247D09B32A789A1A7634F"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than one year after the date on which the Council is established and each year thereafter, the Executive Director shall submit to the appropriate congressional committees a report on the performance of the Council. In preparing such report, the Council shall consult with a nongovernmental consultant with appropriate expertise.</text>
 </subsection></section><section id="HDCA24ADC60414BCBA767550912667073"><enum>281F.</enum><header>Funding</header><text display-inline="no-display-inline">For the each of fiscal years 2016 through 2023, there is authorized to be appropriated $10,000,000 to the Council for purposes of carrying out the duties of the Council under this part.</text></section></part><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle></title><title id="H7A8DD206F91D44058087642576F12427"><enum>II</enum><header>Development</header>
			<subtitle id="HF62F90257FF447A589E2FF7636D385FA"><enum>A</enum><header>Patient-Focused Drug Development</header>
				<section id="H5D08EB3099FE4CCCB5CC556E49B8EA14"><enum>2001.</enum><header>Development and use of patient experience data to enhance structured risk-benefit assessment
			 framework</header>
 <subsection id="H7C0B423EF3D64245B685236D0E1698E0"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended—</text> <paragraph id="HB8223D18AB4840889EE1797FF7D4A903"><enum>(1)</enum><text>in subsection (d), by striking <quote>The Secretary shall implement</quote> and all that follows through <quote>premarket approval of a drug.</quote>; and</text>
 </paragraph><paragraph id="H1476324B13E44D85846D036DEB104BDF"><enum>(2)</enum><text>by adding at the end the following new subsections:</text> <quoted-block display-inline="no-display-inline" id="H79B1BF8A9D154BCAAE710B2DE3BEC233" style="OLC"> <subsection id="H4DFC09F0AF114E6A91C708170BD778F6"><enum>(x)</enum><header>Structured risk-Benefit assessment framework</header> <paragraph id="H264A0009306D48FEA9E3A41EC85F62AF"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall implement a structured risk-benefit assessment framework in the new drug approval process—</text>
 <subparagraph id="H16E9A9510FC84B359DB4499EE1A04443"><enum>(A)</enum><text>to facilitate the balanced consideration of benefits and risks; and</text> </subparagraph><subparagraph id="HB8225D7C65584A97AD194392DA9865D2"><enum>(B)</enum><text>to develop and implement a consistent and systematic approach to the discussion of, regulatory decisionmaking with respect to, and the communication of, the benefits and risks of new drugs.</text>
 </subparagraph></paragraph><paragraph id="H1A7F166F4A66466480A83FE0C280F82F"><enum>(2)</enum><header>Rule of construction</header><text>Nothing in paragraph (1) shall alter the criteria for evaluating an application for premarket approval of a drug.</text>
									</paragraph></subsection><subsection id="H60A6EA27FB1146A4A3F93D90AC90348E"><enum>(y)</enum><header>Development and use of patient experience data To enhance structured risk-Benefit assessment
			 framework</header>
 <paragraph id="HCC1A27E30C4640C5B3ED853662EC0A5F"><enum>(1)</enum><header>In general</header><text>Not later than two years after the date of the enactment of this subsection, the Secretary shall establish and implement processes under which—</text>
 <subparagraph id="H218FA0CDF3094AF2AC90964BCED5B395"><enum>(A)</enum><text display-inline="yes-display-inline">an entity seeking to develop patient experience data may submit to the Secretary—</text> <clause id="HC6CB389D2BDE4129AC811C6193CDC311"><enum>(i)</enum><text>initial research concepts for feedback from the Secretary; and</text>
 </clause><clause id="H833BB14BED984514808DD7E6BC96704E"><enum>(ii)</enum><text>with respect to patient experience data collected by the entity, draft guidance documents, completed data, and summaries and analyses of such data;</text>
 </clause></subparagraph><subparagraph id="H599D62C476EA4C32A88E62B9C3D5B21F"><enum>(B)</enum><text>the Secretary may request such an entity to submit such documents, data, and summaries and analyses; and</text>
 </subparagraph><subparagraph id="H9D78C9EF5F2F4C759D2D1483A601200D"><enum>(C)</enum><text>patient experience data may be developed and used to enhance the structured risk-benefit assessment framework under subsection (x).</text>
 </subparagraph></paragraph><paragraph id="H09DBFA30F77C47A581ABEA5BA1C5F1AE"><enum>(2)</enum><header>Patient experience data</header><text display-inline="yes-display-inline">In this subsection, the term <quote>patient experience data</quote> means data collected by patients, parents, caregivers, patient advocacy organizations, disease research foundations, medical researchers, research sponsors, or other parties determined appropriate by the Secretary that is intended to facilitate or enhance the Secretary’s risk-benefit assessments, including information about the impact of a disease or a therapy on patients’ lives.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection><subsection id="HA8D0BE016DE24DAF8CB5FBF4AB19C5CD"><enum>(b)</enum><header>Guidance</header>
 <paragraph id="H2491A4C7447C44E7BDAE9E8130D77699"><enum>(1)</enum><header>In general</header><text>The Secretary of Health and Human Services shall publish guidance on the implementation of subsection (y) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), as added by subsection (a). Such guidance shall include—</text>
 <subparagraph id="HB6076A90447247599AB5C41F3B275526"><enum>(A)</enum><text display-inline="yes-display-inline">with respect to draft guidance documents, data, or summaries and analyses submitted to the Secretary under paragraph (1)(A) of such subsection, guidance—</text>
 <clause id="HA69155739F3E45D8ADF1CFDB73DD666E"><enum>(i)</enum><text display-inline="yes-display-inline">specifying the timelines for the review of such documents, data, or summaries and analyses by the Secretary; and</text>
 </clause><clause id="H5057592134C342289D6AA2F219B56236"><enum>(ii)</enum><text display-inline="yes-display-inline">on how the Secretary will use such documents, data, or summaries and analyses to update any guidance documents published under this subsection or publish new guidance;</text>
 </clause></subparagraph><subparagraph id="H3E35EBE5C2534BDDB6FD0640FA2B8B8B"><enum>(B)</enum><text display-inline="yes-display-inline">with respect to the collection and analysis of patient experience data (as defined in paragraph (2) of such subsection (y)), guidance on—</text>
 <clause id="H048A57E9262F4846980FE3A7E2E8DF71"><enum>(i)</enum><text display-inline="yes-display-inline">methodological considerations for the collection of patient experience data, which may include structured approaches to gathering information on—</text>
 <subclause id="HD9F2E6AF322C48FBB3A4908A525B4C69"><enum>(I)</enum><text display-inline="yes-display-inline">the experience of a patient living with a particular disease;</text> </subclause><subclause id="H5A3FD9F462984F16B4C3187AFC1748E3"><enum>(II)</enum><text display-inline="yes-display-inline">the burden of living with or managing the disease;</text>
 </subclause><subclause id="H55C2C05E092F494B8C206E794902AE5F"><enum>(III)</enum><text>the impact of the disease on daily life and long-term functioning; and</text> </subclause><subclause id="H476851BC00D9436794993DEE5EDF65DA"><enum>(IV)</enum><text>the effect of current therapeutic options on different aspects of the disease; and</text>
 </subclause></clause><clause id="H38F830580CDA4D59A11047F159F10155"><enum>(ii)</enum><text>the establishment and maintenance of registries designed to increase understanding of the natural history of a disease;</text>
 </clause></subparagraph><subparagraph id="HC46E5653A14B448AAC84E566943BEA77"><enum>(C)</enum><text display-inline="yes-display-inline">methodological approaches that may be used to assess patients’ beliefs with respect to the benefits and risks in the management of the patient’s disease; and</text>
 </subparagraph><subparagraph id="H0A980B12BB9E443E851BBFADABB4184D"><enum>(D)</enum><text>methodologies, standards, and potential experimental designs for patient-reported outcomes.</text> </subparagraph></paragraph><paragraph id="H9C01BA093212419FA075EAF7A6C43F03"><enum>(2)</enum><header>Timing</header><text display-inline="yes-display-inline">Not later than 3 years after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue draft guidance on the implementation of subsection (y) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), as added by subsection (a). The Secretary shall issue final guidance on the implementation of such subsection not later than one year after the date on which the comment period for the draft guidance closes.</text>
						</paragraph><paragraph id="H5E4957AF3A4347CC85D7FAE5706B71E6"><enum>(3)</enum><header>Workshops</header>
 <subparagraph id="H02D93E181F8E46E3BEB22CFF5AB5938A"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 6 months after the date of the enactment of this Act and once every 6 months during the following 12-month period, the Secretary of Health and Human Services shall convene a workshop to obtain input regarding methodologies for developing the guidance under paragraph (1), including the collection of patient experience data.</text>
 </subparagraph><subparagraph id="H677861F44BE8458EB53299BB4DEAA255"><enum>(B)</enum><header>Attendees</header><text>A workshop convened under this paragraph shall include—</text> <clause id="H314B6940C93A4E3D9BD52D122E21F061"><enum>(i)</enum><text>patients;</text>
 </clause><clause id="H81816453238C4703974015EE65413AB9"><enum>(ii)</enum><text display-inline="yes-display-inline">representatives from patient advocacy organizations, biopharmaceutical companies, and disease research foundations;</text>
 </clause><clause id="H2B15C18C5233471E884AF0600E8FD7D9"><enum>(iii)</enum><text>representatives of the reviewing divisions of the Food and Drug Administration; and</text> </clause><clause id="H16FEFD1619C84931B74C876BF433B9A5"><enum>(iv)</enum><text>methodological experts with significant expertise in patient experience data.</text>
 </clause></subparagraph></paragraph><paragraph id="HFFCB93E13FD947CDA0D7BE5689380F98"><enum>(4)</enum><header>Public meeting</header><text display-inline="yes-display-inline">Not later than 90 days after the date on which the draft guidance is published under this subsection, the Secretary of Health and Human Services shall convene a public meeting to solicit input on the guidance.</text>
						</paragraph></subsection></section></subtitle><subtitle commented="no" id="HB5E20171BCA745E58EFA7EABD890B5AD"><enum>B</enum><header>Qualification and Use of Drug Development Tools</header>
				<section commented="no" id="H891A499D80804A47A34A1471D131A470" section-type="subsequent-section"><enum>2021.</enum><header>Qualification of drug development tools</header>
 <subsection commented="no" id="HA128BD0EB01C4FE88DD5DAD0042233BB"><enum>(a)</enum><header>Findings</header><text display-inline="yes-display-inline">Congress finds the following:</text> <paragraph commented="no" id="H4EF4E5BB8B2B4146A1A56B56D25834B7"><enum>(1)</enum><text display-inline="yes-display-inline">Development of new drugs has become increasingly challenging and resource intensive.</text>
 </paragraph><paragraph commented="no" id="H575B777F36DD475EA4E8EE5E7CD5BEB8"><enum>(2)</enum><text>Development of drug development tools can benefit the availability of new medical therapies by helping to translate scientific discoveries into clinical applications.</text>
 </paragraph><paragraph commented="no" id="H4EA8DDD982144053BB0F44A839D9DE0C"><enum>(3)</enum><text>Biomedical research consortia (as defined in section 507(f) of section 507 of the Federal Food, Drug, and Cosmetic Act, as added by subsection (c)) can play a valuable role in helping develop and qualify drug development tools.</text>
 </paragraph></subsection><subsection commented="no" id="HA6E7FAE12CA946D782B7A0C3919462CD"><enum>(b)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of Congress that—</text> <paragraph commented="no" id="H26936FC00BDD4B12BD641AADFDC5EC1B"><enum>(1)</enum><text>Congress should promote and facilitate a collaborative effort among the biomedical research consortia described in subsection (a)(3)—</text>
 <subparagraph commented="no" id="HD5CCEC32655C41E993252E1806EF1A96"><enum>(A)</enum><text>to develop, through a transparent public process, data standards and scientific approaches to data collection accepted by the medical and clinical research community for purposes of qualifying drug development tools;</text>
 </subparagraph><subparagraph commented="no" id="H6CE71705964C4DE6B5EF0DF8B032547A"><enum>(B)</enum><text>to coordinate efforts toward developing and qualifying drug development tools in key therapeutic areas; and</text>
 </subparagraph><subparagraph commented="no" id="HD657A3C9352E40088B4DD08C79C9C28E"><enum>(C)</enum><text>to encourage the development of accessible databases for collecting relevant drug development tool data for such purposes; and</text>
 </subparagraph></paragraph><paragraph commented="no" id="HCC60DDEE6619454B877CF10C22CC358D"><enum>(2)</enum><text display-inline="yes-display-inline">an entity seeking to qualify a drug development tool should be encouraged, in addition to consultation with the Secretary, to consult with biomedical research consortia and other individuals and entities with expert knowledge and insights that may assist the requestor and benefit the process for such qualification.</text>
 </paragraph></subsection><subsection commented="no" id="H25B654962148456593EFB3EC946ED7B2"><enum>(c)</enum><header>Qualification of drug development tools</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 506F the following new section:</text>
						<quoted-block display-inline="no-display-inline" id="H6BC897117A314E90857D23CE8DE2E20A" style="OLC">
							<section commented="no" id="HF42E6EEDA9304F9CB8A2A391E0A3AFD5"><enum>507.</enum><header>Qualification of drug development tools</header>
								<subsection commented="no" id="H37EE921B565446839A2371233A260AD4"><enum>(a)</enum><header>Process for qualification</header>
 <paragraph commented="no" id="HD6FB7B3668A14E8CBB49D957E578628B"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish a process for the qualification of drug development tools for a proposed context of use under which—</text>
										<subparagraph commented="no" id="H45D4E997335C41FBA0D921C93CB9B5A2"><enum>(A)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H1AF871C2D4D04AC3A00A466DC67DB948"><enum>(i)</enum><text>a requestor initiates such process by submitting a letter of intent to the Secretary; and</text> </clause><clause commented="no" id="H615288F599164EEA852709E5160BD672" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">the Secretary shall accept or decline to accept such letter of intent;</text>
											</clause></subparagraph><subparagraph commented="no" id="H6355034336054AD99872C40C73BD03E1"><enum>(B)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="HBB8DD41A1F1248D781F5102F0B9305F1"><enum>(i)</enum><text>if the Secretary accepts the letter of intent, a requestor shall submit a qualification plan to the Secretary; and</text>
 </clause><clause commented="no" id="H401C3C389DBC413C837911025AE9DEAC" indent="up1"><enum>(ii)</enum><text>the Secretary shall accept or decline to accept the qualification plan; and</text> </clause></subparagraph><subparagraph commented="no" id="HCCF23E22D82C46A08F066DD285C88CC1"><enum>(C)</enum> <clause commented="no" display-inline="yes-display-inline" id="HA0F5A668A7C8430F97F2520580E8CE71"><enum>(i)</enum><text>if the Secretary accepts the qualification plan, the requestor submits to the Secretary a full qualification package;</text>
 </clause><clause commented="no" id="H5C210495D9914D4C8166ED1018380D4E" indent="up1"><enum>(ii)</enum><text>the Secretary shall determine whether to accept such qualification package for review; and</text> </clause><clause commented="no" id="H464067E2CEE64F729F16768FB1F29437" indent="up1"><enum>(iii)</enum><text display-inline="yes-display-inline">if the Secretary accepts such qualification package for review, conduct such review in accordance with this section.</text>
											</clause></subparagraph></paragraph><paragraph commented="no" id="H02024E70D6EB4BF9BA7AB4C92EB8C909"><enum>(2)</enum><header>Acceptance and review of submissions</header>
 <subparagraph commented="no" id="HFC529074F80B49CC92B81475CD95CFA4"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The succeeding provisions of this paragraph shall apply with respect to the treatment of a letter of intent, a qualification plan, or a full qualification package submitted under paragraph (1) (referred to in this paragraph as <quote>qualification submissions</quote>).</text>
 </subparagraph><subparagraph id="H1E1CDF798D8949599CEC867291E3B008"><enum>(B)</enum><header>Acceptance factors; non-acceptance</header><text display-inline="yes-display-inline">The Secretary shall determine whether to accept a qualification submission based on factors which may include the scientific merit of the submission and the available resources of the Food and Drug Administration to review the qualification submission. A determination not to accept a submission under paragraph (1) shall not be construed as a final determination by the Secretary under this section regarding the qualification of a drug development tool for its proposed context of use.</text>
 </subparagraph><subparagraph commented="no" id="H343D79F73CEC4C02B56E27C5D8FEE03B"><enum>(C)</enum><header>Prioritization of qualification review</header><text>The Secretary may prioritize the review of a full qualification package submitted under paragraph (1) with respect to a drug development tool, based on factors determined appropriate by the Secretary, including—</text>
 <clause commented="no" id="H3C03A2F63B954F4BB5BC8A5030756DC7"><enum>(i)</enum><text display-inline="yes-display-inline">as applicable, the severity, rarity, or prevalence of the disease or condition targeted by the drug development tool and the availability or lack of alternative treatments for such disease or condition; and</text>
 </clause><clause commented="no" id="H333715B1BABF420A941F90DF19106901"><enum>(ii)</enum><text display-inline="yes-display-inline">the identification, by the Secretary or by biomedical research consortia and other expert stakeholders, of such a drug development tool and its proposed context of use as a public health priority.</text>
 </clause></subparagraph><subparagraph commented="no" id="HA2433F5BDFF44A86965F19A4AE8213CF"><enum>(D)</enum><header>Engagement of external experts</header><text display-inline="yes-display-inline">The Secretary may, for purposes of the review of qualification submissions, through the use of cooperative agreements, grants, or other appropriate mechanisms, consult with biomedical research consortia and may consider the recommendations of such consortia with respect to the review of any qualification plan submitted under paragraph (1) or the review of any full qualification package under paragraph (3).</text>
 </subparagraph></paragraph><paragraph commented="no" id="HC220F6733B664AD6837FF540082185F1"><enum>(3)</enum><header>Review of full qualification package</header><text>The Secretary shall—</text> <subparagraph commented="no" id="H09AA20BE00A148F4B5A77BD6437C6161"><enum>(A)</enum><text display-inline="yes-display-inline">conduct a comprehensive review of a full qualification package accepted under paragraph (1)(C); and</text>
 </subparagraph><subparagraph commented="no" id="H83FED5B0E2F14933BE0B2EDF823C781A"><enum>(B)</enum><text display-inline="yes-display-inline">determine whether the drug development tool at issue is qualified for its proposed context of use.</text> </subparagraph></paragraph><paragraph commented="no" id="HB76734FA3DDA40CAA6F4D1DEF41FA776"><enum>(4)</enum><header>Qualification</header><text display-inline="yes-display-inline">The Secretary shall determine whether a drug development tool is qualified for a proposed context of use based on the scientific merit of a full qualification package reviewed under paragraph (3).</text>
									</paragraph></subsection><subsection commented="no" id="HFD2DF91A7B5247D48604DB8D568F319E"><enum>(b)</enum><header>Effect of qualification</header>
 <paragraph commented="no" id="H6E578E8733F34DB3887B46255D6E2A31"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">A drug development tool determined to be qualified under subsection (a)(4) for a proposed context of use specified by the requestor may be used by any person in such context of use for the purposes described in paragraph (2).</text>
 </paragraph><paragraph commented="no" id="H572D7FE60A67420C8339D2F1B98B82FE"><enum>(2)</enum><header>Use of a drug development tool</header><text display-inline="yes-display-inline">Subject to paragraph (3), a drug development tool qualified under this section may be used for—</text> <subparagraph commented="no" id="H7CD5267911BF4728A79523D46F1D3AE4"><enum>(A)</enum><text display-inline="yes-display-inline">supporting or obtaining approval or licensure (as applicable) of a drug or biological product (including in accordance with section 506(c)) under section 505 of this Act or section 351 of the Public Health Service Act; or</text>
 </subparagraph><subparagraph commented="no" id="H07B8E631E2334EBFB9BD23C37829B528"><enum>(B)</enum><text display-inline="yes-display-inline">supporting the investigational use of a drug or biological product under section 505(i) of this Act or section 351(a)(3) of the Public Health Service Act.</text>
										</subparagraph></paragraph><paragraph commented="no" id="H3BE431540F2D4A9290C4D051BDD26B38"><enum>(3)</enum><header>Rescission or modification</header>
 <subparagraph commented="no" id="H3C8268DC5FD84BA9BCCFA3728E3204CF"><enum>(A)</enum><header>In general</header><text>The Secretary may rescind or modify a determination under this section to qualify a drug development tool if the Secretary determines that the drug development tool is not appropriate for the proposed context of use specified by the requestor. Such a determination may be based on new information that calls into question the basis for such qualification.</text>
 </subparagraph><subparagraph commented="no" id="HC94DFDB827B546F39DE99711D361C706"><enum>(B)</enum><header>Meeting for review</header><text>If the Secretary rescinds or modifies under subparagraph (A) a determination to qualify a drug development tool, the requestor involved shall be granted a request for a meeting with the Secretary to discuss the basis of the Secretary’s decision to rescind or modify the determination before the effective date of the rescission or modification.</text>
										</subparagraph></paragraph></subsection><subsection commented="no" id="H452DE57E0D2643DB806771A67F1E5D24"><enum>(c)</enum><header>Transparency</header>
 <paragraph commented="no" id="H5CFDE41C93BE48B98A7A70D200264407"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to paragraph (3), the Secretary shall make publicly available, and update on at least a biannual basis, on the Internet website of the Food and Drug Administration the following:</text>
 <subparagraph commented="no" id="HE999FA6AD75040E4AE06D50F61478000"><enum>(A)</enum><text display-inline="yes-display-inline">Information with respect to each qualification submission under the qualification process under subsection (a), including—</text>
 <clause commented="no" id="H4A24FC8D9FBE4256A21FEDF8DB4E23A2"><enum>(i)</enum><text>the stage of the review process applicable to the submission;</text> </clause><clause commented="no" id="HF894F3B46AC54ABD9E0501AF474A9C06"><enum>(ii)</enum><text>the date of the most recent change in stage status;</text>
 </clause><clause commented="no" id="HFC9941B365A34BAEBC9CE8C6CCC512BC"><enum>(iii)</enum><text display-inline="yes-display-inline">whether the external scientific experts were utilized in the development of a qualification plan or the review of a full qualification package; and</text>
 </clause><clause id="H9C73B783C15E424E8E07C4088D3685AF"><enum>(iv)</enum><text display-inline="yes-display-inline">submissions from requestors under the qualification process under subsection (a), including any data and evidence contained in such submissions, and any updates to such submissions.</text>
 </clause></subparagraph><subparagraph commented="no" id="HA5AE07CDDEEF496383DA1FA51756AEA3"><enum>(B)</enum><text display-inline="yes-display-inline">The Secretary’s formal written determinations in response to such qualification submissions.</text> </subparagraph><subparagraph commented="no" id="H4A8EBBBB483240ADA5FE4FE6D1900A98"><enum>(C)</enum><text>Any rescissions or modifications under subsection (b)(3) of a determination to qualify a drug development tool.</text>
 </subparagraph><subparagraph commented="no" id="HE4A66375AD9140C584329051FBA4C9DC"><enum>(D)</enum><text>Summary reviews that document conclusions and recommendations for determinations to qualify drug development tools under subsection (a).</text>
 </subparagraph><subparagraph commented="no" id="H0AA13132928D415984078231BBB5E079"><enum>(E)</enum><text>A comprehensive list of—</text> <clause id="H740261C4B25F450B9FD1C35DDD6BDC7B"><enum>(i)</enum><text>all drug development tools qualified under subsection (a); and</text>
 </clause><clause id="H1E4783A7D8E84FFAAD07872AED04B947"><enum>(ii)</enum><text display-inline="yes-display-inline">all surrogate endpoints which were the basis of approval or licensure (as applicable) of a drug or biological product (including in accordance with section 506(c)) under section 505 of this Act or section 351 of the Public Health Service Act.</text>
 </clause></subparagraph></paragraph><paragraph commented="no" id="H934E3A55D08A4D64B6CF6308905BA5E8"><enum>(2)</enum><header>Relation to Trade Secrets Act</header><text display-inline="yes-display-inline">Information made publicly available by the Secretary under paragraph (1) shall be considered a disclosure authorized by law for purposes of section 1905 of title 18, United States Code.</text>
 </paragraph><paragraph commented="no" id="H15F4DDF657474E68839386A0657AA99F"><enum>(3)</enum><header>Applicability</header><text display-inline="yes-display-inline">Nothing in this section shall be construed as authorizing the Secretary to disclose any information contained in an application submitted under section 505 of this Act or section 351 of the Public Health Service Act that is confidential commercial or trade secret information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text>
 </paragraph></subsection><subsection commented="no" id="HDB36F8F0AEE5430286D4603B076FD96F"><enum>(d)</enum><header>Rule of construction</header><text>Nothing in this section shall be construed—</text> <paragraph commented="no" id="H4A6D889738CB489190709889A8278BFC"><enum>(1)</enum><text display-inline="yes-display-inline">to alter the standards of evidence under subsection (c) or (d) of section 505, including the substantial evidence standard in such subsection (d), or under section 351 of the Public Health Service Act (as applicable); or</text>
 </paragraph><paragraph commented="no" id="H6C8BAF34180446129FFEFD57120E0627"><enum>(2)</enum><text display-inline="yes-display-inline">to limit the authority of the Secretary to approve or license products under to this Act or the Public Health Service Act, as applicable (as in effect before the date of the enactment of the 21st Century Cures Act).</text>
 </paragraph></subsection><subsection commented="no" id="H941BA1CDAE344BA7BCDD5F1E977A89DA"><enum>(e)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There are authorized to be appropriated to carry out this section, $10,000,000 for each of fiscal years 2016 through 2020.</text>
 </subsection><subsection commented="no" id="H55E35C4724A94FD48F433648EF72692C"><enum>(f)</enum><header>Definitions</header><text>In this section:</text> <paragraph commented="no" id="H71CE727A00F74D11B07B274FBDD6742C"><enum>(1)</enum><header>Biomarker</header> <subparagraph commented="no" display-inline="yes-display-inline" id="H74D3102F4A64431A92FC28A8590DE71C"><enum>(A)</enum><text>The term <quote>biomarker</quote> means a characteristic (such as a physiologic, pathologic, or anatomic characteristic or measurement) that is objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to a therapeutic intervention; and</text>
 </subparagraph><subparagraph commented="no" id="H637B8487E8C443F899764A511E2C61B8" indent="up1"><enum>(B)</enum><text>such term includes a surrogate endpoint.</text> </subparagraph></paragraph><paragraph commented="no" id="H854275FEB1C441789358CD3CA67D47AC"><enum>(2)</enum><header>Biomedical research consortia</header><text display-inline="yes-display-inline">The term <quote>biomedical research consortia</quote> means collaborative groups that may take the form of public-private partnerships and may include government agencies, institutions of higher education (as defined in section 101(a) of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>)), patient advocacy groups, industry representatives, clinical and scientific experts, and other relevant entities and individuals.</text>
									</paragraph><paragraph commented="no" id="HE48BC16991084850B0703A8D795D0495"><enum>(3)</enum><header>Clinical outcome assessment</header>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HFAF798FD2C094326AD1BFF70268F7034"><enum>(A)</enum><text>The term <quote>clinical outcome assessment</quote> means a measurement of a patient’s symptoms, overall mental state, or the effects of a disease or condition on how the patient functions; and</text>
 </subparagraph><subparagraph commented="no" id="HFEB857CAE7A841469F7A544FB682372D" indent="up1"><enum>(B)</enum><text>such term includes a patient-reported outcome.</text> </subparagraph></paragraph><paragraph commented="no" id="H686722098A0A4E16AFE1F284D5B95D9F"><enum>(4)</enum><header>Context of use</header><text>The term <quote>context of use</quote> means, with respect to a drug development tool, a statement that describes the circumstances under which the drug development tool is to be used in drug development and regulatory review.</text>
 </paragraph><paragraph commented="no" id="H3B8E3B85ECDC46539C721772AF55F1B8"><enum>(5)</enum><header>Drug development tool</header><text>The term <quote>drug development tool</quote> includes—</text> <subparagraph commented="no" id="H93E009ABBC494DD6A9BF330B74308E72"><enum>(A)</enum><text>a biomarker;</text>
 </subparagraph><subparagraph commented="no" id="HD4C0C2A61A764827BE480D724830463D"><enum>(B)</enum><text>a clinical outcome assessment; and</text> </subparagraph><subparagraph commented="no" id="H901EB0F2DC0C4EEF9069FAAC8D0C00D6"><enum>(C)</enum><text>any other method, material, or measure that the Secretary determines aids drug development and regulatory review for purposes of this section.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H51BE6685A64C43CE86BD7DED62E8FBC8"><enum>(6)</enum><header>Patient-reported outcome</header><text>The term <quote>patient-reported outcome</quote> means a measurement based on a report from a patient regarding the status of the patient’s health condition without amendment or interpretation of the patient’s report by a clinician or any other person.</text>
 </paragraph><paragraph commented="no" id="H096B0CB57E7441C399E8E74EC2BC9FCD"><enum>(7)</enum><header>Qualification</header><text>The terms <quote>qualification</quote> and <quote>qualified</quote> mean a determination by the Secretary that a drug development tool and its proposed context of use can be relied upon to have a specific interpretation and application in drug development and regulatory review under this Act.</text>
 </paragraph><paragraph commented="no" id="HA7B16AC281834D29B0DB5ACE9FC7C4A3"><enum>(8)</enum><header>Requestor</header><text display-inline="yes-display-inline">The term <quote>requestor</quote> means an entity or entities, including a drug sponsor or a biomedical research consortia, seeking to qualify a drug development tool for a proposed context of use under this section.</text>
 </paragraph><paragraph commented="no" id="H13E8DA431B73410B9078EC2BED768AA3"><enum>(9)</enum><header>Surrogate endpoint</header><text>The term <quote>surrogate endpoint</quote> means a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure, that is not itself a direct measurement of clinical benefit, and—</text>
 <subparagraph commented="no" id="H3B7B4567B67A430CAF894FEA3B268D85"><enum>(A)</enum><text display-inline="yes-display-inline">is known to predict clinical benefit and could be used to support traditional approval of a drug or biological product; or</text>
 </subparagraph><subparagraph commented="no" id="H12B5680F954449A4A1F62BA205D0089C"><enum>(B)</enum><text>is reasonably likely to predict clinical benefit and could be used to support the accelerated approval of a drug or biological product in accordance with section 506(c).</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection><subsection commented="no" id="H324E741FCF8949AEB16F7F30CE2D158A"><enum>(d)</enum><header>Guidance</header>
 <paragraph commented="no" id="HD1D4AE3835AC4782922C5ABA34D4158F"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall, in consultation with biomedical research consortia (as defined in subsection (f) of section 507 the Federal Food, Drug, and Cosmetic Act (as added by subsection (c))) and other interested parties through a collaborative public process, issue guidance to implement such section 507 that—</text>
 <subparagraph commented="no" id="HFF8A2A3B77824FF3B759E1FB89A06A11"><enum>(A)</enum><text display-inline="yes-display-inline">provides a conceptual framework describing appropriate standards and scientific approaches to support the development of biomarkers delineated under the taxonomy established under paragraph (3);</text>
 </subparagraph><subparagraph commented="no" id="HAC299EFF591741D1971A82AFB0D3A75A"><enum>(B)</enum><text>makes recommendations for demonstrating that a surrogate endpoint is reasonably likely to predict clinical benefit for the purpose of supporting the accelerated approval of a drug under section 506(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(c)</external-xref>);</text>
 </subparagraph><subparagraph commented="no" id="H41E51C4212224AC58DA58CC6A66E4BDA"><enum>(C)</enum><text display-inline="yes-display-inline">with respect to the qualification process under such section 507—</text> <clause commented="no" id="HF6FDF3E8DA564B10935CF2701F5473C9"><enum>(i)</enum><text display-inline="yes-display-inline">describes the requirements that entities seeking to qualify a drug development tool under such section shall observe when engaging in such process;</text>
 </clause><clause commented="no" id="H9F36BC6D2FA4456F8FCBE1F91C7F6225"><enum>(ii)</enum><text>outlines reasonable timeframes for the Secretary’s review of letters, qualification plans, or full qualification packages submitted under such process; and</text>
 </clause><clause commented="no" id="HED07683590D74594A347DF34D442B245"><enum>(iii)</enum><text>establishes a process by which such entities or the Secretary may consult with biomedical research consortia and other individuals and entities with expert knowledge and insights that may assist the Secretary in the review of qualification plans and full qualification submissions under such section; and</text>
 </clause></subparagraph><subparagraph commented="no" id="H127798B52CA14085971664214D7EAC51"><enum>(D)</enum><text>includes such other information as the Secretary determines appropriate.</text> </subparagraph></paragraph><paragraph commented="no" id="HF3FDA44EA4ED4A989F01267D4479E8C4"><enum>(2)</enum><header>Timing</header><text display-inline="yes-display-inline">Not later than 24 months after the date of the enactment of this Act, the Secretary shall issue draft guidance under paragraph (1) on the implementation of section 507 of the Federal Food, Drug, and Cosmetic Act (as added by subsection (c)). The Secretary shall issue final guidance on the implementation of such section not later than 6 months after the date on which the comment period for the draft guidance closes.</text>
						</paragraph><paragraph commented="no" id="HE4EE1ADAFBA4412BA889F3F3F8698EA7"><enum>(3)</enum><header>Taxonomy</header>
 <subparagraph commented="no" id="H64A229B4014F48A1A4C9A5D4C041E5D4"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For purposes of informing guidance under this subsection, the Secretary shall, in consultation with biomedical research consortia and other interested parties through a collaborative public process, establish a taxonomy for the classification of biomarkers (and related scientific concepts) for use in drug development.</text>
 </subparagraph><subparagraph commented="no" id="HC67622280BD040FE8D96AEB7E976C5A0"><enum>(B)</enum><header>Public availability</header><text>Not later than 12 months after the date of the enactment of this Act, the Secretary shall make such taxonomy publicly available in draft form for public comment. The Secretary shall finalize the taxonomy not later than 12 months after the close of the public comment period.</text>
							</subparagraph></paragraph></subsection><subsection commented="no" id="HC8814BE598294693A4B8175C1B9DCF67"><enum>(e)</enum><header>Meeting and report</header>
 <paragraph commented="no" id="H43BBB666FD144C1B93FDF6E3711D8F64"><enum>(1)</enum><header>Meeting</header><text display-inline="yes-display-inline">Not later than 12 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall convene a public meeting to describe and solicit public input regarding the qualification process under section 507 of the Federal Food, Drug, and Cosmetic Act, as added by subsection (c).</text>
 </paragraph><paragraph commented="no" id="HF58DF24844EA4698934AE3BA13812481"><enum>(2)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 5 years after the date of the enactment of this Act, the Secretary shall make publicly available on the Internet website of the Food and Drug Administration a report. Such report shall include, with respect to the qualification process under section 507 of the Federal Food, Drug, and Cosmetic Act, as added by subsection (c), information on—</text>
 <subparagraph commented="no" display-inline="no-display-inline" id="H725ABFD0B9834FECB8B8178B43EAB82F"><enum>(A)</enum><text>the number of requests submitted, as a letter of intent, for qualification of a drug development tool (as defined in subsection (f) of such section);</text>
 </subparagraph><subparagraph commented="no" id="H9096894C684245BCA43C0DC84E33D8C1"><enum>(B)</enum><text display-inline="yes-display-inline">the number of such requests accepted and determined to be eligible for submission of a qualification plan or full qualification package (as such terms are defined in such subsection), respectively;</text>
 </subparagraph><subparagraph commented="no" id="H23E80167E9B84033B52944438C085CB9"><enum>(C)</enum><text display-inline="yes-display-inline">the number of such requests for which external scientific experts were utilized in the development of a qualification plan or review of a full qualification package; and</text>
 </subparagraph><subparagraph commented="no" id="H6D17E35B3B5A4CCCB12B7D4CEF21695E"><enum>(D)</enum><text display-inline="yes-display-inline">the number of qualification plans and full qualification packages, respectively, submitted to the Secretary; and</text>
 </subparagraph></paragraph><paragraph commented="no" id="H4744B96BFFDF42AF8E67D60B14076986"><enum>(3)</enum><text>the drug development tools qualified through such qualification process, specified by type of tool, such as a biomarker or clinical outcome assessment (as such terms are defined in subsection (f) of such section 507).</text>
						</paragraph></subsection></section><section commented="no" id="H8FA07A513C4142959330B35E0EF54090" section-type="subsequent-section"><enum>2022.</enum><header>Accelerated approval development plan</header>
 <subsection commented="no" id="HBCCF70F7832D4AD3804CE0F8E875CD2B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended by adding the following subsection:</text>
						<quoted-block display-inline="no-display-inline" id="H848B7C9223134F1AB90B2CA5ACFB1F79" style="OLC">
							<subsection commented="no" id="H99DA70C44B304138A753A070D8F3C7A1"><enum>(g)</enum><header>Accelerated approval development plan</header>
 <paragraph commented="no" id="H1613CEF59F0C45C0852C45CA89D1A49B"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a drug that the Secretary determines may be eligible for accelerated approval in accordance with subsection (c), the sponsor of such drug may request, at any time after the submission of an application for the investigation of the drug under section 505(i) of this Act or section 351(a)(3) of the Public Health Service Act, that the Secretary agree to an accelerated approval development plan described in paragraph (2).</text>
 </paragraph><paragraph commented="no" id="H6A78DE17E54B4568B84BF40D0117A6DA"><enum>(2)</enum><header>Plan described</header><text display-inline="yes-display-inline">A plan described in this paragraph, with respect to a drug described in paragraph (1), is an accelerated approval development plan, which shall include agreement on—</text>
 <subparagraph commented="no" id="HE3474973077D440A8CCE2CACCB304DFE"><enum>(A)</enum><text display-inline="yes-display-inline">the surrogate endpoint to be assessed under such plan;</text> </subparagraph><subparagraph commented="no" id="HB23100B398464C42856C3C5DB0A7C63E"><enum>(B)</enum><text display-inline="yes-display-inline">the design of the study that will utilize the surrogate endpoint; and</text>
 </subparagraph><subparagraph commented="no" id="H006F921ADB674252B680A56509785717"><enum>(C)</enum><text display-inline="yes-display-inline">the magnitude of the effect of the drug on the surrogate endpoint that is the subject of the agreement that would be sufficient to form the primary basis of a claim that the drug is effective.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H2F59D06BB7504C76A6F317F400F64FE0"><enum>(3)</enum><header>Modification; termination</header><text display-inline="yes-display-inline">The Secretary may require the sponsor of a drug that is the subject of an accelerated approval development plan to modify or terminate the plan if additional data or information indicates that—</text>
 <subparagraph commented="no" id="H7721533B39104D02BFF49E8AF50F65AF"><enum>(A)</enum><text display-inline="yes-display-inline">the plan as originally agreed upon is no longer sufficient to demonstrate the safety and effectiveness of the drug involved; or</text>
 </subparagraph><subparagraph commented="no" id="HA12771B3FB0D42D29D7550E26B882D68"><enum>(B)</enum><text display-inline="yes-display-inline">the drug is no longer eligible for accelerated approval under subsection (c).</text> </subparagraph></paragraph><paragraph commented="no" id="HD32D4DFEF69A4126A5BD135921429216"><enum>(4)</enum><header>Sponsor consultation</header><text display-inline="yes-display-inline">If the Secretary requires the modification or termination of an accelerated approval development plan under paragraph (3), the sponsor shall be granted a request for a meeting to discuss the basis of the Secretary’s decision before the effective date of the modification or termination.</text>
 </paragraph><paragraph commented="no" id="HE1F3EB5641FA4869ABAD90C68C324784"><enum>(5)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <quote>accelerated approval development plan</quote> means a development plan agreed upon by the Secretary and the sponsor submitting the plan that contains study parameters for the use of a surrogate endpoint that—</text>
 <subparagraph commented="no" id="H13DB36CADBA34342A9E5F19AA23E3142"><enum>(A)</enum><text>is reasonably likely to predict clinical benefit; and</text> </subparagraph><subparagraph commented="no" id="H16A3044E8B0E4A8C902B600A8A8F1DBC"><enum>(B)</enum><text>is intended to be the basis of the accelerated approval of a drug in accordance with subsection (c).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" id="HFE21A383BCD3473F8397518F9D1E4A89"><enum>(b)</enum><header>Technical amendments</header><text>Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended—</text> <paragraph commented="no" id="H33667FB4341B48959F53352F3872E022"><enum>(1)</enum><text>by striking <quote><header-in-text level="subsection" style="OLC"><enum-in-header>(f)<header-in-text level="subsection" style="OLC"> Awareness efforts</header-in-text></enum-in-header></header-in-text></quote> and inserting <quote><header-in-text level="subsection" style="OLC"><enum-in-header>(e) <header-in-text level="subsection" style="OLC">Awareness efforts</header-in-text></enum-in-header></header-in-text></quote>; and</text>
 </paragraph><paragraph commented="no" id="H57954BB97864403CA5B5196D19958C04"><enum>(2)</enum><text>by striking <quote><header-in-text level="subsection" style="OLC"><enum-in-header>(e) <header-in-text level="subsection" style="OLC">Construction</header-in-text></enum-in-header></header-in-text></quote> and inserting <quote><header-in-text level="subsection" style="OLC"><enum-in-header>(f) <header-in-text level="subsection" style="OLC">Construction</header-in-text></enum-in-header></header-in-text></quote>.</text> </paragraph></subsection></section></subtitle><subtitle commented="no" id="HA9B50CBF3BC04A11AD57E0F0912A4AB0"><enum>C</enum><header>FDA advancement of Precision Medicine</header> <section commented="no" id="H1380543FFF2C4156915D1D7D164B6CC7"><enum>2041.</enum><header>Precision medicine guidance and other programs of Food and Drug Administration</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H0CB03F9F3C934F53A6191A24F9A46D82" style="OLC">
						<subchapter commented="no" id="HCCA5DDA1213044A3B3BFBEA4B78459E1"><enum>J</enum><header>Precision Medicine</header>
							<section commented="no" id="HA1832B3C92634B7C9AF2A3A542073954"><enum>591.</enum><header>General agency guidance on precision medicine</header>
 <subsection commented="no" id="HCC52B3992D0848F69E5C978F9456FF06"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall issue and periodically update guidance to assist sponsors in the development of a precision drug or biological product. Such guidance shall—</text>
 <paragraph commented="no" id="HA07BEFDCC18F46ABB385CB80EC87BEE6"><enum>(1)</enum><text>define the term <quote>precision drug or biological product</quote>; and</text> </paragraph><paragraph commented="no" id="H5AF9C81FE65143C1921FF51804035C9E"><enum>(2)</enum><text>address the topics described in subsection (b).</text>
 </paragraph></subsection><subsection commented="no" id="H5C22D912FD2147EE97C602B80FB3883F"><enum>(b)</enum><header>Certain issues</header><text>The topics to be addressed by guidance under subsection (a) are—</text> <paragraph commented="no" id="H67913F53B80D46839FDE4415B7E793CA"><enum>(1)</enum><text display-inline="yes-display-inline">the evidence needed to support the use of biomarkers (as defined in section 507(e)) that identify subsets of patients as likely responders to therapies in order to streamline the conduct of clinical trials;</text>
 </paragraph><paragraph commented="no" id="H7FDE65D05110482A89B14161372EF137"><enum>(2)</enum><text>recommendations for the design of studies to demonstrate the validity of a biomarker as a predictor of drug or biological product response;</text>
 </paragraph><paragraph commented="no" id="H0D7C2B8FC3394F89B08E08B39C3DE47F"><enum>(3)</enum><text>the manner and extent to which a benefit-risk assessment may be affected when clinical trials are limited to patient population subsets that are identified using biomarkers;</text>
 </paragraph><paragraph commented="no" id="H158F371835BE4F5FB1CD6EEACD545A1B"><enum>(4)</enum><text>the development of companion diagnostics in the context of a drug development program; and</text> </paragraph><paragraph commented="no" id="HDEADB0F6C59642B4B6CD9267317E6378"><enum>(5)</enum><text>considerations for developing biomarkers that inform prescribing decisions for a drug or biological product, and when information regarding a biomarker may be included in the approved prescription labeling for a precision drug or biological product.</text>
 </paragraph></subsection><subsection commented="no" id="HE88DE83B6E114E52886D85975543A964"><enum>(c)</enum><header>Date certain for initial guidance</header><text>The Secretary shall issue guidance under subsection (a) not later than 18 months after the date of the enactment of the 21st Century Cures Act.</text>
								</subsection></section><section commented="no" id="HA816C0B090004C04AFA8DBADAFF89B11"><enum>592.</enum><header>Precision medicine regarding orphan-drug and expedited-approval programs</header>
 <subsection id="H8228022FB33F4EB89A5FA24C43607D47"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline"><italic></italic>In the case of a precision drug or biological product that is the subject of an application submitted under section 505(b)(1), or section 351(a) of the Public Health Service Act, for the treatment of a serious or life-threatening disease or condition and has been designated under section 526 as a drug for a rare disease or condition, the Secretary may—</text>
 <paragraph id="HD20FCB45CE8740AFA0B9E54897E16EE0"><enum>(1)</enum><text display-inline="yes-display-inline">consistent with applicable standards for approval, rely upon data or information previously submitted by the sponsor of the precision drug or biological product, or another sponsor, provided that the sponsor of the precision drug or biological product has obtained a contractual right of reference to such other sponsor’s data and information, in an application approved under section 505(c) or licensed under section 351(a) of the Public Health Service Act, as applicable—</text>
 <subparagraph id="HA4CB4034A438427A8424D9DBFA9A4F53"><enum>(A)</enum><text>for a different drug or biological product; or</text> </subparagraph><subparagraph id="HD63930F547F541C4BC462FC6EB47CE13"><enum>(B)</enum><text>for a different indication for such precision drug or biological product,</text>
										</subparagraph><continuation-text continuation-text-level="paragraph">in order to expedite clinical development for a precision drug or biological product that is using
			 the same or similar approach as that used to support approval of the prior
 approved application or license, as appropriate; and</continuation-text></paragraph><paragraph commented="no" id="HDD8D608F8B1A476BA1111DA348528458"><enum>(2)</enum><text>as appropriate, consider the application for approval of such precision drug or biological product to be eligible for expedited review and approval programs described in section 506, including accelerated approval in accordance with subsection (c) of such section.</text>
 </paragraph></subsection><subsection id="HEEC0C8EFDF27432386D8913ACF671B85"><enum>(b)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in this section shall be construed to—</text> <paragraph id="H37E0AAE692114A4EAAF238F07EBD9991"><enum>(1)</enum><text>limit the authority of the Secretary to approve products pursuant to this Act and the Public Health Service Act as authorized prior to the date of enactment of this section; or</text>
 </paragraph><paragraph id="H6278974422C044C490B12CD3AA60CAA6"><enum>(2)</enum><text>confer any new rights, beyond those authorized under this Act prior to enactment of this section, with respect to a sponsor’s ability to reference information contained in another application submitted under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act.</text></paragraph></subsection></section></subchapter><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle><subtitle id="HD896A79E2D664CD68A0C994F0518BEAB"><enum>D</enum><header>Modern Trial Design and Evidence Development</header>
				<section commented="no" id="HC9EFCBA15B174020AB9BD501512A7FC7" section-type="subsequent-section"><enum>2061.</enum><header>Broader application of Bayesian statistics and adaptive trial designs</header>
					<subsection commented="no" id="HB8D11E00797B42EDAFC46C61FE5FF000"><enum>(a)</enum><header>Proposals for use of innovative statistical methods in clinical protocols for drugs and biological
 products</header><text display-inline="yes-display-inline">For purposes of assisting sponsors in incorporating adaptive trial design and Bayesian methods into proposed clinical protocols and applications for new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) and biological products under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), the Secretary shall conduct a public meeting and issue guidance in accordance with subsection (b).</text>
					</subsection><subsection commented="no" id="H5D7582FCA1474A0EA52E4306A05D98B3"><enum>(b)</enum><header>Guidance addressing use of adaptive trial designs and Bayesian methods</header>
 <paragraph commented="no" id="HE3D3F08FA36F4EEFA881ABC1EA40D1D3"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs (in this subsection referred to as the <quote>Secretary</quote>), shall—</text>
 <subparagraph commented="no" id="H378B32B338314251947D3A7D17EDA320"><enum>(A)</enum><text display-inline="yes-display-inline">update and finalize the draft guidance addressing the use of adaptive trial design for drugs and biological products; and</text>
 </subparagraph><subparagraph commented="no" id="H1105EFC2281A42E4B9F937DF9E70E880"><enum>(B)</enum><text display-inline="yes-display-inline">issue draft guidance on the use of Bayesian methods in the development and regulatory review and approval or licensure of drugs and biological products.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H2BFD4AA599414430B62171DF0D577545"><enum>(2)</enum><header>Contents</header><text>The guidances under paragraph (1) shall address—</text> <subparagraph commented="no" id="H2239DD192F0B408FBE2FC25E13820798"><enum>(A)</enum><text display-inline="yes-display-inline">the use of adaptive trial designs and Bayesian methods in clinical trials, including clinical trials proposed or submitted to help satisfy the substantial evidence standard under section 505(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(d)</external-xref>);</text>
 </subparagraph><subparagraph commented="no" id="H07106AA280504B46BE4731C4F26F5216"><enum>(B)</enum><text display-inline="yes-display-inline">how sponsors may obtain feedback from the Secretary on technical issues related to modeling and simulations prior to—</text>
 <clause commented="no" id="H9861BC4F65994EF49A139FEE405BC67E"><enum>(i)</enum><text>completion of such modeling or simulations; or</text> </clause><clause commented="no" id="H73899F54FBD5456FA6136604D14A5444"><enum>(ii)</enum><text>the submission of resulting information to the Secretary;</text>
 </clause></subparagraph><subparagraph commented="no" id="H6AD68049C6034C77A6A4CCB2E97F3153"><enum>(C)</enum><text display-inline="yes-display-inline">the types of quantitative and qualitative information that should be submitted for review; and</text> </subparagraph><subparagraph commented="no" id="H94FEAB5ABCB141FA96C7F23CABFAF2AA"><enum>(D)</enum><text display-inline="yes-display-inline">recommended analysis methodologies.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HD31F6C8911654D24B45552BAF9AB9250"><enum>(3)</enum><header>Public meeting</header><text display-inline="yes-display-inline">Prior to updating or developing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patient advocacy organizations, and disease research foundations, through a public meeting to be held not later than 1 year after the date of enactment of this Act.</text>
 </paragraph><paragraph commented="no" id="H17DCAC601B0049049C72CD1C402BE863"><enum>(4)</enum><header>Schedule</header><text>The Secretary shall publish—</text> <subparagraph commented="no" id="HC5BD7F060D63493AA6736222300AB17D"><enum>(A)</enum><text>the final guidance required by paragraph (1)(A) not later than 18 months after the date of the public meeting required by paragraph (3); and</text>
 </subparagraph><subparagraph commented="no" id="H27416C9808AE44ABA3278EC4C8028144"><enum>(B)</enum><text display-inline="yes-display-inline">the guidance required by paragraph (1)(B) not later than 48 months after the date of the public meeting required by paragraph (3).</text>
 </subparagraph></paragraph></subsection></section><section commented="no" id="HC817FAC6BDCC485C8FE20DC24AE1E00F"><enum>2062.</enum><header>Utilizing evidence from clinical experience</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act, as amended by section 2021, is further amended by inserting after section 505E of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) the following:</text>
					<quoted-block display-inline="no-display-inline" id="H4EABFE757E044735B5257B80E265B6F9" style="OLC">
						<section commented="no" id="H86C04DD97F2A4D35B716CE5D938EC15F"><enum>505F.</enum><header>Utilizing evidence from clinical experience</header>
 <subsection commented="no" id="H9F4BD471C185452E91132F7C0C3698A6"><enum>(a)</enum><header>In general</header><text>The Secretary shall establish a program to evaluate the potential use of evidence from clinical experience—</text>
 <paragraph commented="no" id="HA6AEC8028C4049FBB95FFF7DD4CD88D4"><enum>(1)</enum><text>to help support the approval of a new indication for a drug approved under section 505(b); and</text> </paragraph><paragraph commented="no" id="H39A535A2ACC74C6DA0D28AA5126C1A5A"><enum>(2)</enum><text>to help support or satisfy postapproval study requirements.</text>
 </paragraph></subsection><subsection commented="no" id="H803E221FBD484FC2999C2F82DEEAB2E9"><enum>(b)</enum><header>Evidence from clinical experience defined</header><text>In this section, the term <quote>evidence from clinical experience</quote> means data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than randomized clinical trials, including from observational studies, registries, and therapeutic use.</text>
							</subsection><subsection commented="no" id="H8E45ABE9C7B74835B5582982D13A451E"><enum>(c)</enum><header>Program framework</header>
 <paragraph commented="no" id="H557289BD4DC741A6873CDC4AA1209173"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this section, the Secretary shall establish a draft framework for implementation of the program under this section.</text>
 </paragraph><paragraph commented="no" id="HE0D2EC4BD3EE4C81B4CB3F1BD0676D6E"><enum>(2)</enum><header>Contents of framework</header><text>The framework shall include information describing—</text> <subparagraph commented="no" id="HD408F0FB0FD043589460B1C96814C3FA"><enum>(A)</enum><text>the current sources of data developed through clinical experience, including ongoing safety surveillance, registry, claims, and patient-centered outcomes research activities;</text>
 </subparagraph><subparagraph commented="no" id="HCFBBF62F5AB84DE3925D8570F820F955"><enum>(B)</enum><text>the gaps in current data collection activities;</text> </subparagraph><subparagraph commented="no" id="H8C0EC4D224C54DD381478ACA5FC3B1B4"><enum>(C)</enum><text>the current standards and methodologies for collection and analysis of data generated through clinical experience; and</text>
 </subparagraph><subparagraph commented="no" id="H0C4EADCA026A4A2CA89DC88881051F94"><enum>(D)</enum><text>the priority areas, remaining challenges, and potential pilot opportunities that the program established under this section will address.</text>
									</subparagraph></paragraph><paragraph commented="no" id="H47D48C2F6BFA4D7C9CC8B555FDC1F0B5"><enum>(3)</enum><header>Consultation</header>
 <subparagraph id="H54593A1CFC374D01A291E2B2D2A564C5"><enum>(A)</enum><header>In general</header><text>In developing the program framework under this subsection, the Secretary shall consult with regulated industry, academia, medical professional organizations, representatives of patient advocacy organizations, disease research foundations, and other interested parties.</text>
 </subparagraph><subparagraph id="HBD1DE3C2415C4B54B060E85D062540FE"><enum>(B)</enum><header>Process</header><text display-inline="yes-display-inline">The consultation under subparagraph (A) may be carried out through approaches such as—</text> <clause id="HA0681E0D2C85402695E4AC98883D37AC"><enum>(i)</enum><text>a public-private partnership with the entities described in such subparagraph in which the Secretary may participate; or</text>
 </clause><clause id="H7D53940035CB44ED90172FC90C65432B"><enum>(ii)</enum><text>a contract, grant, or other arrangement, as determined appropriate by the Secretary with such a partnership or an independent research organization.</text>
 </clause></subparagraph></paragraph></subsection><subsection commented="no" id="H84C1A0E6DA4542359E9E401C21706766"><enum>(d)</enum><header>Program implementation</header><text>The Secretary shall, not later than 24 months after the date of enactment of this section and in accordance with the framework established under subsection (c), implement the program to evaluate the potential use of evidence from clinical experience.</text>
 </subsection><subsection commented="no" id="HEC81A41A194D4C0E8EEC9D27314BB55D"><enum>(e)</enum><header>Guidance for industry</header><text display-inline="yes-display-inline">The Secretary shall—</text> <paragraph commented="no" id="HE2643A7FFF29473AB0263F573463674C"><enum>(1)</enum><text>utilize the program established in subsection (d), its activities, and any subsequent pilots or written reports, to inform a guidance for industry on—</text>
 <subparagraph commented="no" id="H12CAE029FDF7465DBE8D647CB33E03BA"><enum>(A)</enum><text>the circumstances under which sponsors of drugs and the Secretary may rely on evidence from clinical experience for the purposes described in subsection (a)(1) or (a)(2); and</text>
 </subparagraph><subparagraph commented="no" id="HAB5DBDC16B1C474A8958E6B6595A4B7D"><enum>(B)</enum><text>the appropriate standards and methodologies for collection and analysis of evidence from clinical experience submitted for such purposes;</text>
 </subparagraph></paragraph><paragraph commented="no" id="H96C67FFB426741F78B7FB57AA4E25943"><enum>(2)</enum><text>not later than 36 months after the date of enactment of this section, issue draft guidance for industry as described in paragraph (1); and</text>
 </paragraph><paragraph commented="no" id="H6D5B98D492B44FD9B5A546EDFB9A0879"><enum>(3)</enum><text>not later than 48 months after the date of enactment of this section, after providing an opportunity for public comment on the draft guidance, issue final guidance.</text>
								</paragraph></subsection><subsection commented="no" id="H2886EDC8FCE441FCAFEF36BDD201613F"><enum>(f)</enum><header>Rule of construction</header>
 <paragraph commented="no" id="H9D50208FF90045E4B55C05446BC2A7BE"><enum>(1)</enum><text>Subject to paragraph (2), nothing in this section prohibits the Secretary from using evidence from clinical experience for purposes not specified in this section, provided the Secretary determines that sufficient basis exists for any such non-specified use.</text>
 </paragraph><paragraph commented="no" id="H5BBF715003954A50AC5CADEE7A6A8884"><enum>(2)</enum><text>This section shall not be construed to alter—</text> <subparagraph commented="no" id="H949E280923A84EFE961B4A5F14ED742C"><enum>(A)</enum><text>the standards of evidence under—</text>
 <clause commented="no" id="H635A06660F404AF4A761A527177EA6D4"><enum>(i)</enum><text>subsection (c) or (d) of section 505, including the substantial evidence standard in such subsection (d); or</text>
 </clause><clause commented="no" id="HAF3B77B4EDAB495A89CA01F82B3C5845"><enum>(ii)</enum><text>section 351(a) of the Public Health Service Act; or</text> </clause></subparagraph><subparagraph commented="no" id="H38F1494888E04280902DA09CCA0DFB39"><enum>(B)</enum><text>the Secretary’s authority to require postapproval studies or clinical trials, or the standards of evidence under which studies or trials are evaluated.</text>
									</subparagraph></paragraph></subsection></section><section commented="no" id="HFD8E353DF09C48BFA0199F7B1B4D46DE"><enum>505G.</enum><header>Collecting evidence from clinical experience through targeted extensions of the Sentinel System</header>
 <subsection commented="no" id="H8A3BDDA180DD46CEADBC7067C74881C4"><enum>(a)</enum><header>In general</header><text>The Secretary shall, in parallel to implementing the program established in section 505F and in order to build capacity for utilizing the evidence from clinical experience described in that section, identify and execute pilot demonstrations to extend existing use of the Sentinel System surveillance infrastructure authorized under section 505(k).</text>
							</subsection><subsection commented="no" id="HCC0B4023B81548BDBE810112D4AB5E26"><enum>(b)</enum><header>Pilot demonstrations</header>
 <paragraph commented="no" id="HBC9601DD97684C018F98146EFA19C430"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary—</text> <subparagraph commented="no" id="H33998E18E4D04216B4A1349CF7D6E536"><enum>(A)</enum><text display-inline="yes-display-inline">shall design and implement pilot demonstrations to utilize data captured through the Sentinel System surveillance infrastructure authorized under section 505(k) for purposes of, as appropriate—</text>
 <clause commented="no" id="H76C2A12712C1414ABC87B903DA430B8A"><enum>(i)</enum><text display-inline="yes-display-inline">generating evidence from clinical experience to improve characterization or assessment of risks or benefits of a drug approved under section 505(c);</text>
 </clause><clause commented="no" id="HB5941E3D213143B4B429F670ECAF771B"><enum>(ii)</enum><text display-inline="yes-display-inline">protecting the public health; or</text> </clause><clause commented="no" id="H607D8A82062944F384E8D7575ADF126E"><enum>(iii)</enum><text display-inline="yes-display-inline">advancing patient-centered care; and</text>
 </clause></subparagraph><subparagraph commented="no" id="H93A4A99364CE4FB28EDF393B8C564098"><enum>(B)</enum><text display-inline="yes-display-inline">may make strategic linkages with sources of complementary public health data and infrastructure the Secretary determines appropriate and necessary.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H09E5393573324BE69D1A4B4E0B59EF91"><enum>(2)</enum><header>Consultation</header><text>In developing the pilot demonstrations under this subsection, the Secretary shall—</text> <subparagraph commented="no" id="HFC7D525325C34EE4A2A9E9AE0C8F1CE9"><enum>(A)</enum><text>consult with regulated industry, academia, medical professional organizations, representatives of patient advocacy organizations, disease research foundations, and other interested parties through a public process; and</text>
 </subparagraph><subparagraph commented="no" id="HB5F5CAF2A16D47B69957D63016A9B0E2"><enum>(B)</enum><text display-inline="yes-display-inline">develop a framework to promote appropriate transparency and dialogue about research conducted under these pilot demonstrations, including by—</text>
 <clause commented="no" id="HE742CCA826D54BC8B96A276CA34F4086"><enum>(i)</enum><text display-inline="yes-display-inline">providing adequate notice to a sponsor of a drug approved under section 505 or section 351 of the Public Health Service Act of the Secretary’s intent to conduct analyses of such sponsor’s drug or drugs under these pilot demonstrations;</text>
 </clause><clause commented="no" id="HD9985BE086B043389BC0E1240925C72A"><enum>(ii)</enum><text>providing adequate notice of the findings related to analyses described in clause (i) and an opportunity for the sponsor of such drug or drugs to comment on such findings; and</text>
 </clause><clause commented="no" id="H06F84CC67E7D40898FC56D28928D49B5"><enum>(iii)</enum><text>ensuring the protection from public disclosure of any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text>
 </clause></subparagraph></paragraph><paragraph commented="no" id="H6437047BD5FB4860928F8FDCEAA5B782"><enum>(3)</enum><header>Public health exemption</header><text>The Secretary may—</text> <subparagraph commented="no" id="HFF34F6F3C18643FB98C604E2B402CCEE"><enum>(A)</enum><text>deem such pilot demonstrations public health activities, permitting the use and disclosure of protected health information as described in section 164.512(b)(1)(iii) of title 45, Code of Federal Regulations (or any successor regulation) and exempted as a public health activity as described in section 46.101(b)(5) of title 46, Code of Federal Regulations (or any successor regulation); and</text>
 </subparagraph><subparagraph commented="no" id="HC710020B03AD405E85CC5E29D9E2DC47"><enum>(B)</enum><text display-inline="yes-display-inline">deem safety surveillance performed at the request of the Food and Drug Administration or under such jurisdiction by a sponsor with responsibility for a drug approved under this section or section 351 of the Public Health Services Act using the Sentinel System surveillance infrastructure authorized under section 505(k), including use of analytic tools and querying capabilities developed to implement the active postmarket surveillance system described in this section, public health activities as described in section 164.512(b)(1)(iii) of title 45, Code of Federal Regulations (or any successor regulation) and exempted as a public health activity as described in section 46.101(b)(5) of title 46, Code of Federal Regulations (or any successor regulation).</text>
 </subparagraph></paragraph></subsection><subsection commented="no" id="HB703DFB992D24CE5889F47A24D54216C"><enum>(c)</enum><header>Authorization of appropriations</header><text>There are authorized to be appropriated to carry out this section $3,000,000 for each of fiscal years 2016 through 2020.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section><section id="HCDCAEB68339141F2A1A7124625928912"><enum>2063.</enum><header>Streamlined data review program</header>
 <subsection id="H9BDA59803CFE4B869F7FA4FA99D8F96F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act, as amended by section 2062, is further amended by inserting after section 505G of such Act the following:</text>
						<quoted-block id="HE8B464287C1F4AEA83C8FE9F041FA09B" style="OLC">
							<section id="HAB3CA798607048C6A94C7C246E9872BB"><enum>505H.</enum><header>Streamlined data review program</header>
 <subsection id="H9DD4797550CB4D0FBC3B281D6E1035D1"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish a streamlined data review program under which a holder of an approved application submitted under section 505(b)(1) or under section 351(a) of the Public Health Service Act may, to support the approval or licensure (as applicable) of the use of the drug that is the subject of such approved application for a new qualified indication, submit qualified data summaries.</text>
 </subsection><subsection id="HD6F05ADD60E14014B5029C8570F124EA"><enum>(b)</enum><header>Eligibility</header><text display-inline="yes-display-inline">In carrying out the streamlined data review program under subsection (a), the Secretary may authorize the holder of the approved application to include one or more qualified data summaries described in subsection (a) in a supplemental application if—</text>
 <paragraph id="H3231AF54FC354895BCD701F79D1BA0AB"><enum>(1)</enum><text>the drug has been approved under section 505(c) of this Act or licensed under section 351(a) of the Public Health Service Act for one or more indications, and such approval or licensure remains in effect;</text>
 </paragraph><paragraph id="HEB085F31765D4BA78D32D238EF9CBECE"><enum>(2)</enum><text display-inline="yes-display-inline">the supplemental application is for approval or licensure (as applicable) under such section 505(c) or 351(a) of the use of the drug for a new qualified indication under such section 505(c) or 351(a);</text>
 </paragraph><paragraph id="H0EF1A1CA952846C59354B4A7ECFDC6F6"><enum>(3)</enum><text display-inline="yes-display-inline">there is an existing database acceptable to the Secretary regarding the safety of the drug developed for one or more indications of the drug approved under such section 505(c) or licensed under such section 351(a);</text>
 </paragraph><paragraph id="HDE92C47DF3384CF5943276729B4F78DC"><enum>(4)</enum><text>the supplemental application incorporates or supplements the data submitted in the application for approval or licensure referred to in paragraph (1); and</text>
 </paragraph><paragraph id="H9B9060EFA1774F9AA5075766E88BC11A"><enum>(5)</enum><text display-inline="yes-display-inline">the full data sets used to develop the qualified data summaries are submitted, unless the Secretary determines that the full data sets are not required.</text>
 </paragraph></subsection><subsection id="HCFA08870A0794A2486218C455791361B"><enum>(c)</enum><header>Public availability of information on program</header><text display-inline="yes-display-inline">The Secretary shall post on the public website of the Food and Drug Administration and update annually—</text>
 <paragraph id="HC2C519BC7ADA42AEB50D9B0C86FC9EB9"><enum>(1)</enum><text>the number of applications reviewed under the streamlined data review program;</text> </paragraph><paragraph id="H98C1DDAAF4634F7DB345FCBF41A292E5"><enum>(2)</enum><text>the average time for completion of review under the streamlined data review program versus other review of applications for new indications; and</text>
 </paragraph><paragraph id="HA487C493B90E4E6EAFE7A2B5D130F293"><enum>(3)</enum><text>the number of applications reviewed under the streamlined data review program for which the Food and Drug Administration made use of full data sets in addition to the qualified data summary.</text>
 </paragraph></subsection><subsection id="H11A79DFA561D431D9D31F318960F7B67"><enum>(d)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text> <paragraph id="HEEB937CC262C46CB86524ABDA86F44A4"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>qualified indication</quote> means—</text>
 <subparagraph id="H60EF774CA8254F4194BEEF74463F861A"><enum>(A)</enum><text display-inline="yes-display-inline">an indication for the treatment of cancer, as determined appropriate by the Secretary; or</text> </subparagraph><subparagraph id="H95BA2456E58541D4BD230D18CC384D12"><enum>(B)</enum><text>such other types of indications as the Secretary determines to be subject to the streamlined data review program under this section.</text>
 </subparagraph></paragraph><paragraph id="H0FDB8397D3FB4F9592F1C0BA0811A7CB"><enum>(2)</enum><text>The term <quote>qualified data summary</quote> means a summary of clinical data intended to demonstrate safety and effectiveness with respect to a qualified indication for use of a drug.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H68F57210AAD54E9CBA90B22D9709DA1A"><enum>(b)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of Congress that the streamlined data review program under section 505H of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), should enable the Food and Drug Administration to make approval decisions for certain supplemental applications based on qualified data summaries (as defined in such section 505H).</text>
 </subsection><subsection id="H3C4CC39181734BE18817AB8AC6C6A21F"><enum>(c)</enum><header>Guidance; regulations</header><text>The Commissioner of Food and Drugs—</text> <paragraph id="H1BA12BCE2ADF442CB6A07E8767A4146C"><enum>(1)</enum><text display-inline="yes-display-inline">shall—</text>
 <subparagraph id="HA62398CD04694454A301369F9FF940D1"><enum>(A)</enum><text>issue final guidance for implementation of the streamlined data review program established under section 505H of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), not later than 24 months after the date of enactment of this Act; and</text>
 </subparagraph><subparagraph id="H9B1FD03D995D41DDB177D22D9BF062AD"><enum>(B)</enum><text>include in such guidance the process for expanding the types of indications to be subject to the streamlined data review program, as authorized by section 505H(c)(1)(B) of such Act; and</text>
 </subparagraph></paragraph><paragraph id="H9C52A377EA0C4A839FC7B3011797C99F"><enum>(2)</enum><text>in addition to issuing guidance under paragraph (1), may issue such regulations as may be necessary for implementation of the program.</text>
						</paragraph></subsection></section></subtitle><subtitle id="H7C14DFDD87414763A6D58F872D3DA084"><enum>E</enum><header>Expediting Patient Access</header>
 <section id="H70A6DDD649364A8E87C1F41747A475D4"><enum>2081.</enum><header>Sense of Congress</header><text display-inline="no-display-inline">It is the sense of Congress that the Food and Drug Administration should continue to expedite the approval of drugs designated as breakthrough therapies pursuant to section 506(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(a)</external-xref>) by approving drugs so designated as early as possible in the clinical development process, regardless of the phase of development, provided that the Secretary of Health and Human Services determines that an application for such a drug meets the standards of evidence of safety and effectiveness under section 505 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), including the substantial evidence standard under subsection (d) of such section or under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>).</text>
 </section><section commented="no" id="HB89E081072364A3FB8562480833E823C"><enum>2082.</enum><header>Expanded access policy</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 561 (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>) the following:</text>
					<quoted-block display-inline="no-display-inline" id="H041FBF6D715842BB928ECD895045C533" style="OLC">
						<section id="HBA2F04A7881C47CD83AD6786E4AE337D"><enum>561A.</enum><header>Expanded access policy required for investigational drugs</header>
 <subsection id="HB16627F4B59744A897E659174F2C854C"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The manufacturer or distributor of one or more investigational drugs for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions shall make publicly available the policy of the manufacturer or distributor on evaluating and responding to requests submitted under section 561(b) for provision of such a drug. A manufacturer or distributor may satisfy the requirement of the preceding sentence by posting such policy as generally applicable to all of such manufacturer’s of distributor’s investigational drugs.</text>
 </subsection><subsection id="HD70254193C834A4C8AD2316682A01B06"><enum>(b)</enum><header>Content of policy</header><text>A policy described in subsection (a) shall include making publicly available—</text> <paragraph id="H560C7E315F3345D1AF658CAEFF4A5FED"><enum>(1)</enum><text>contact information for the manufacturer or distributor to facilitate communication about requests described in subsection (a);</text>
 </paragraph><paragraph id="H34FBCC586C684E61B215E3395A5F1B60"><enum>(2)</enum><text display-inline="yes-display-inline">procedures for making such requests;</text> </paragraph><paragraph id="H076BBD4D0B8042718F6FB1EBD114857E"><enum>(3)</enum><text display-inline="yes-display-inline">the general criteria the manufacturer or distributor will consider or use to approve such requests; and</text>
 </paragraph><paragraph id="HFAE4667CE6D944FB81E53549CFCE9C7A"><enum>(4)</enum><text display-inline="yes-display-inline">the length of time the manufacturer or distributor anticipates will be necessary to acknowledge receipt of such requests.</text>
 </paragraph></subsection><subsection id="H064DD67F17C94F128E869F5BDB68CCFE"><enum>(c)</enum><header>No guarantee of access</header><text>The posting of policies by manufacturers and distributors under subsection (a) shall not serve as a guarantee of access to any specific investigational drug by any individual patient.</text>
 </subsection><subsection id="H5F9A25917CD047709DC7458611391DEE"><enum>(d)</enum><header>Revised policy</header><text>A manufacturer or distributor that has made a policy publicly available as required by this section may revise the policy at any time.</text>
 </subsection><subsection id="H16FB76B3A87D4781A02CF98BD1B66718"><enum>(e)</enum><header>Application</header><text>This section shall apply to a manufacturer or distributor with respect to an investigational drug beginning on the later of—</text>
 <paragraph id="HFDB1C33185DD43839C7E0A4C7BF43557"><enum>(1)</enum><text>the date that is 60 days after the date of enactment of the <short-title>21st Century Cures Act</short-title>; or</text> </paragraph><paragraph id="H115E7B981EAB4C3B82F8D7776C0850EB"><enum>(2)</enum><text display-inline="yes-display-inline">the first initiation of a phase 2 or phase 3 study (as such terms are defined in section 312.21(b) and (c) of title 21, Code of Federal Regulations (or any successor regulations)) with respect to such investigational new drug.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section><section commented="no" id="HE834E83F6EFE434E8920730A87A85697"><enum>2083.</enum><header>Finalizing draft guidance on expanded access</header>
 <subsection commented="no" id="HA2A0858941E14897BAA18E21E4746B44"><enum>(a)</enum><header>In general</header><text>Not later than 12 months after the date of enactment of this Act, the Secretary of Health and Human Services shall finalize the draft guidance entitled <quote>Expanded Access to Investigational Drugs for Treatment Use—Qs &amp; As</quote> and dated May 2013.</text>
 </subsection><subsection commented="no" id="H374F9979A6664AF6941D58E936EC3267"><enum>(b)</enum><header>Contents</header><text display-inline="yes-display-inline">The final guidance referred to in subsection (a) shall clearly define how the Secretary of Health and Human Services interprets and uses adverse drug event data reported by investigators in the case of data reported from use under a request submitted under section 561(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb(b)</external-xref>).</text>
					</subsection></section></subtitle><subtitle id="H41C7B86B8C7947769DF494ECDF556613"><enum>F</enum><header>Facilitating responsible manufacturer communications</header>
 <section commented="no" id="H366E62F7B39544F18EFDDC8F91A8542E"><enum>2101.</enum><header>Facilitating dissemination of health care economic information</header><text display-inline="no-display-inline">Section 502(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352(a)</external-xref>) is amended—</text> <paragraph commented="no" id="HF31941B426494EB3B86D737E8F554417"><enum>(1)</enum><text>by striking <quote>(a) If its</quote> and inserting <quote>(a)(1) If its</quote>;</text>
 </paragraph><paragraph commented="no" id="HB438494D34AC42FCAB767A8657F11762"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>a formulary committee, or other similar entity, in the course of the committee or the entity carrying out its responsibilities for the selection of drugs for managed care or other similar organizations</quote> and inserting <quote>a payor, formulary committee, or other similar entity with knowledge and expertise in the area of health care economic analysis, carrying out its responsibilities for the selection of drugs for coverage or reimbursement</quote>;</text>
 </paragraph><paragraph commented="no" id="H11F4E104DBD94E82A3A47520AE977510"><enum>(3)</enum><text>by striking <quote>directly relates</quote> and inserting <quote>relates</quote>;</text> </paragraph><paragraph commented="no" id="HFD68AC77ADD74F33923A9E27B9037FDD"><enum>(4)</enum><text display-inline="yes-display-inline">by striking <quote>and is based on competent and reliable scientific evidence. The requirements set forth in section 505(a) or in section 351(a) of the Public Health Service Act shall not apply to health care economic information provided to such a committee or entity in accordance with this paragraph</quote> and inserting <quote>, is based on competent and reliable scientific evidence, and includes, where applicable, a conspicuous and prominent statement describing any material differences between the health care economic information and the labeling approved for the drug under section 505 or under section 351 of the Public Health Service Act. The requirements set forth in section 505(a) or in subsections (a) and (k) of section 351 of the Public Health Service Act shall not apply to health care economic information provided to such a payor, committee, or entity in accordance with this paragraph</quote>; and</text>
 </paragraph><paragraph commented="no" id="H2F1721F7C76943CDBB741207CDCFA6F0"><enum>(5)</enum><text>by striking <quote>In this paragraph, the term</quote> and all that follows and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="H94DD0D614E07439089C39D754A54A098" style="OLC"> <paragraph commented="no" id="H1A196DBAC5E047918FDB5746F1AAF9DE" indent="up1"><enum>(2)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="H40B14D34E67C44C7827DDD1F4BF504CA"><enum>(A)</enum><text>For purposes of this paragraph, the term <quote>health care economic information</quote> means any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug. Such analyses may be comparative to the use of another drug, to another health care intervention, or to no intervention.</text>
 </subparagraph><subparagraph id="H881E2A65460F44E18825D53182899E1E" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Such term does not include any analysis that relates only to an indication that is not approved under section 505 or under section 351 of the Public Health Service Act for such drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></section><section id="HA1329DD82F2F414E99C5417C3D5E144D" section-type="subsequent-section"><enum>2102.</enum><header>Facilitating responsible communication of scientific and medical developments</header>
 <subsection id="H23D059A9212B4FDBA725191D3C958E5D"><enum>(a)</enum><header>Guidance</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services shall issue draft guidance on facilitating the responsible dissemination of truthful and non-misleading scientific and medical information not included in the approved labeling of drugs and devices.</text>
 </subsection><subsection id="H7D0A9E99D78440FABE942D88BDDB2009"><enum>(b)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the terms <quote>drug</quote> and <quote>device</quote> have the meaning given to such terms in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text>
					</subsection></section></subtitle><subtitle id="H74AEB3CB4ECD44B18D2F0DFBEDCE8042"><enum>G</enum><header>Antibiotic Drug Development</header>
				<section id="HCE897BE5B6B74AA0BFF48AD0439E2F85"><enum>2121.</enum><header>Approval of certain drugs for use in a limited population of patients</header>
 <subsection id="H0DE11DBA04E24DC1A51192CCCDC607D6"><enum>(a)</enum><header>Purpose</header><text>The purpose of this section is to help expedite the development and availability of treatments for serious or life-threatening bacterial or fungal infections in patients with unmet needs, while maintaining safety and effectiveness standards for such treatments, taking into account the severity of the infection and the availability or lack of alternative treatments.</text>
 </subsection><subsection commented="no" id="HB64BBA4C14DA495E8C6A3C65A3A952F7"><enum>(b)</enum><header>Approval of certain antibacterial and antifungal drugs</header><text>Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), as amended by section 2001, is further amended by adding at the end the following new subsection:</text>
						<quoted-block id="H19F2B904BAB34BFE9B8A4D54551D7B28" style="OLC">
							<subsection commented="no" id="HA57C1213FEA94EF3A0A3F7705C9998C4"><enum>(z)</enum><header>Approval of certain antibacterial and antifungal drugs for use in a limited population of patients</header>
 <paragraph commented="no" id="H78AE61BC463E445ABB1D5D86734D6ED4"><enum>(1)</enum><header>Process</header><text>At the request of the sponsor of an antibacterial or antifungal drug that is intended to treat a serious or life-threatening infection, the Secretary—</text>
 <subparagraph commented="no" id="H1D6C987B87CB4F1DADC75581FB063405"><enum>(A)</enum><text display-inline="yes-display-inline">may execute a written agreement with the sponsor on the process for developing data to support an application for approval of such drug, for use in a limited population of patients in accordance with this subsection;</text>
 </subparagraph><subparagraph commented="no" id="H0D411445527B48DC8ADE352BB3F973B3"><enum>(B)</enum><text>shall proceed with the development and approval of such a drug in accordance with this subsection only if a written agreement is reached under subparagraph (A);</text>
 </subparagraph><subparagraph commented="no" id="H70F5414FF0374D8099689C6AEECA6155"><enum>(C)</enum><text>shall provide the sponsor with an opportunity to request meetings under paragraph (2);</text> </subparagraph><subparagraph commented="no" id="HC9825D7CACA94957BCC0ED64DEF0FF59"><enum>(D)</enum><text display-inline="yes-display-inline">if a written agreement is reached under subparagraph (A), may approve the drug under this subsection for such use —</text>
 <clause commented="no" id="H4763E044F90948EDB2063F856472CCE0"><enum>(i)</enum><text>in a limited population of patients for which there is an unmet medical need;</text> </clause><clause commented="no" id="HEAF14D5289E548259A363BF188E45B49"><enum>(ii)</enum><text>based on a streamlined development program; and</text>
 </clause><clause commented="no" id="H31D03D720D9C4D2EB197072D3DC40966"><enum>(iii)</enum><text>only if the standards for approval under subsections (c) and (d) of this section or licensure under section 351 of the Public Health Service Act, as applicable, are met; and</text>
 </clause></subparagraph><subparagraph commented="no" id="HB694F394E19D4C1F97451EAE8CCCB4DA"><enum>(E)</enum><text>in approving a drug in accordance with this subsection, subject to subparagraph (D)(iii), may rely upon—</text>
 <clause commented="no" id="H4D7C4B5DDBD04C11B2A12416BAC14B7F"><enum>(i)</enum><text>traditional endpoints, alternate endpoints, or a combination of traditional and alternate endpoints, and, as appropriate, data sets of a limited size; and</text>
										</clause><clause commented="no" id="H90443728ED964F269482F0B9D3A0BE9C"><enum>(ii)</enum>
 <subclause commented="no" display-inline="yes-display-inline" id="HBA0604F673B94E6F8F4A475D5912F8B3"><enum>(I)</enum><text>additional data, including preclinical, pharmacologic, or pathophysiologic evidence;</text> </subclause><subclause commented="no" id="HD88782D2173946F2A51B97BCC77B655F" indent="up1"><enum>(II)</enum><text>nonclinical susceptibility and pharmacokinetic data;</text>
 </subclause><subclause id="H6793C95239F94727A7EA92BDFF2DAD4A" indent="up1"><enum>(III)</enum><text>data from phase 2 clinical trials; and</text> </subclause><subclause commented="no" id="H35B479FBC87C48EAA424A8984C005A3E" indent="up1"><enum>(IV)</enum><text>such other confirmatory evidence as the Secretary determines appropriate to approve the drug.</text>
											</subclause></clause></subparagraph></paragraph><paragraph commented="no" id="H79A8B257A0E14715A93337EE18A400F7"><enum>(2)</enum><header>Formal meetings</header>
 <subparagraph commented="no" id="HAD65BBFF87D641D5ACB6CDF3697FCE17"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">To help expedite and facilitate the development and review of a drug for which a sponsor intends to request approval in accordance with this subsection, the Secretary may, at the request of the sponsor, conduct meetings that provide early consultation, timely advice, and sufficient opportunities to develop an agreement described in paragraph (1)(A) and help the sponsor design and conduct a drug development program as efficiently as possible, including the following types of meetings:</text>
 <clause commented="no" id="H1241CC9F9F90472891161CE16124ED63"><enum>(i)</enum><text>An early consultation meeting.</text> </clause><clause commented="no" id="H415197A727974AACB7DE2331A5744304"><enum>(ii)</enum><text>An assessment meeting.</text>
 </clause><clause commented="no" id="H030BC2CF4DF448549DB0179C984D280A"><enum>(iii)</enum><text>A postapproval meeting.</text> </clause></subparagraph><subparagraph commented="no" id="H1CD526890E074816BEC876292BE92B9F"><enum>(B)</enum><header>No altering of goals</header><text>Nothing in this paragraph shall be construed to alter agreed upon goals and procedures identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012.</text>
 </subparagraph><subparagraph commented="no" id="H86D7240B5363433DBAC17D5B76D5BB4F"><enum>(C)</enum><header>Breakthrough therapies</header><text>In the case of a drug designated as a breakthrough therapy under section 506(a), the sponsor of such drug may elect to utilize meetings provided under such section with respect to such drug in lieu of meetings described in subparagraph (A).</text>
 </subparagraph></paragraph><paragraph commented="no" id="H33F6730ACF564E8383746A412E7A8F24"><enum>(3)</enum><header>Labeling requirement</header><text display-inline="yes-display-inline">The labeling of an antibacterial or antifungal drug approved in accordance with this subsection shall contain the statement <quote>Limited Population</quote> in a prominent manner and adjacent to, and not more prominent than, the brand name of the product. The prescribing information for such antibacterial or antifungal drug required by section 201.57 of title 21, Code of Federal Regulations (or any successor regulation) shall also include the following statement: <quote>This drug is indicated for use in a limited and specific population of patients.</quote>.</text>
 </paragraph><paragraph commented="no" id="H0A8E1FD921934A038242D708C8629CB8"><enum>(4)</enum><header>Promotional materials</header><text>The provisions of section 506(c)(2)(B) shall apply with respect to approval in accordance with this subsection to the same extent and in the same manner as such provisions apply with respect to accelerated approval in accordance with section 506(c)(1).</text>
 </paragraph><paragraph commented="no" id="H566C1841CF304D97B00E346FDFA0FAAB"><enum>(5)</enum><header>Termination of requirements or conditions</header><text>If a drug is approved in accordance with this subsection for an indication in a limited population of patients and is subsequently approved or licensed under this section or section 351 of the Public Health Service Act, other than in accordance with this subsection, for—</text>
 <subparagraph commented="no" id="HF29003215B734B8FA9841EC6657A6A45"><enum>(A)</enum><text>the same indication and the same conditions of use, the Secretary shall remove any labeling requirements or postmarketing conditions that were made applicable to the drug under this subsection; or</text>
 </subparagraph><subparagraph commented="no" id="H715E748E74124222AFA5116C93A13E0D"><enum>(B)</enum><text>a different indication or condition of use, the Secretary shall not apply the labeling requirements and postmarketing conditions that were made applicable to the drug under this subsection to the subsequent approval of the drug for such different indication or condition of use.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H79853DCFB99C42E7A7A16DB22C26A6CD"><enum>(6)</enum><header>Relation to other provisions</header><text display-inline="yes-display-inline">Nothing in this subsection shall be construed to prohibit the approval of a drug for use in a limited population of patients in accordance with this subsection, in combination with—</text>
 <subparagraph commented="no" id="H6C6E9B53961A4B28B28CA1C1F7B179E6"><enum>(A)</enum><text>an agreement on the design and size of a clinical trial pursuant to subparagraphs (B) and (C) of subsection (b)(5);</text>
 </subparagraph><subparagraph commented="no" id="H4D2F595AA027440CBCD7297ABADA6DA3"><enum>(B)</enum><text>designation and treatment of the drug as a breakthrough therapy under section 506(a);</text> </subparagraph><subparagraph commented="no" id="H86F3F2AE5B9940509E90EC1F37FB3B84"><enum>(C)</enum><text>designation and treatment of the drug as a fast track product under section 506(b); or</text>
 </subparagraph><subparagraph commented="no" id="H5EE4F9348E124A1AB6173CD3A2D5BBC1"><enum>(D)</enum><text>accelerated approval of the drug in accordance with section 506(c).</text> </subparagraph></paragraph><paragraph commented="no" id="HFBD021E9175342A292DBDEAC8E2A970A"><enum>(7)</enum><header>Rule of construction</header><text>Nothing in this subsection shall be construed—</text>
 <subparagraph commented="no" id="HD50B1F4C980144A5911F50BBACE0EF32"><enum>(A)</enum><text>to alter the standards of evidence under subsection (c) or (d) (including the substantial evidence standard in subsection (d));</text>
 </subparagraph><subparagraph commented="no" id="HE0A99666CB0D4487884700B93F02CBB5"><enum>(B)</enum><text>to waive or otherwise preclude the application of requirements under subsection (o);</text> </subparagraph><subparagraph commented="no" id="H209ACC057CD64FCE88BB61803747DAEE"><enum>(C)</enum><text>to otherwise, in any way, limit the authority of the Secretary to approve products pursuant to this Act and the Public Health Service Act as authorized prior to the date of enactment of this subsection; or</text>
 </subparagraph><subparagraph commented="no" id="HCAF998CF078E45E4B3DF7F86811F02E3"><enum>(D)</enum><text>to restrict in any manner, the prescribing of antibiotics or other products by health care providers, or to otherwise limit or restrict the practice of health care.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HE78AC08C97DD4EB3A7BCF178EECCCC9E"><enum>(8)</enum><header>Effective immediately</header><text>The Secretary shall have the authorities vested in the Secretary by this subsection beginning on the date of enactment of this subsection, irrespective of when and whether the Secretary promulgates final regulations or guidance.</text>
 </paragraph><paragraph commented="no" id="HF5280E58DF214983A56D679DF8283E20"><enum>(9)</enum><header>Definitions</header><text>In this subsection:</text> <subparagraph commented="no" id="H1D726BBCDAD44727854649E01CDED4C9"><enum>(A)</enum><header>Early consultation meeting</header><text>The term <quote>early consultation meeting</quote> means a pre-investigational new drug meeting or an end-of-phase 1 meeting that—</text>
 <clause commented="no" id="H5FD62A3A7A2141ADA6BACF43B04D337B"><enum>(i)</enum><text>is conducted to review and reach a written agreement—</text> <subclause commented="no" id="HF5D73566D2234DCF82784DB155704318"><enum>(I)</enum><text>on the scope of the streamlined development plan for a drug for which a sponsor intends to request approval in accordance with this subsection; and</text>
 </subclause><subclause commented="no" id="H8F3BE6961DB947FD985450668E362E68"><enum>(II)</enum><text display-inline="yes-display-inline">which, as appropriate, may include agreement on the design and size of necessary preclinical and clinical studies early in the development process, including clinical trials whose data are intended to form the primary basis for an effectiveness claim; and</text>
 </subclause></clause><clause commented="no" id="HEE7EB7AB3FFB44B08950D93DA420C119"><enum>(ii)</enum><text>provides an opportunity to discuss expectations of the Secretary regarding studies or other information that the Secretary deems appropriate for purposes of applying paragraph (5), relating to the termination of labeling requirements or postmarketing conditions.</text>
 </clause></subparagraph><subparagraph commented="no" id="HDF1A124942C840C7BD22EA0C60F2487F"><enum>(B)</enum><header>Assessment meeting</header><text>The term <quote>assessment meeting</quote> means an end-of-phase 2 meeting, pre-new drug application meeting, or pre-biologics license application meeting conducted to resolve questions and issues raised during the course of clinical investigations, and details addressed in the written agreement regarding postapproval commitments or expansion of approved uses.</text>
 </subparagraph><subparagraph commented="no" id="H8ABB563E9AA2469484655D24A2523779"><enum>(C)</enum><header>Postapproval meeting</header><text>The term <quote>postapproval meeting</quote> means a meeting following initial approval or licensure of the drug for use in a limited population, to discuss any issues identified by the Secretary or the sponsor regarding postapproval commitments or expansion of approved uses.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HF0F2C098A0764D71BFFE97523F9AB8D3"><enum>(c)</enum><header>Guidance</header><text>Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue draft guidance describing criteria, process, and other general considerations for demonstrating the safety and effectiveness of antibacterial and antifungal drugs to be approved for use in a limited population in accordance with section 505(z) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (b).</text>
					</subsection><subsection id="H7EA9687CC1D04948B9F9E277D8308500"><enum>(d)</enum><header>Conforming amendments</header>
 <paragraph id="HE642FF1DBF324D0DA378083BFC4BAA55"><enum>(1)</enum><header>Licensure of certain biological products</header><text>Section 351(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(j)</external-xref>) is amended—</text> <subparagraph id="H4362B776692549D3980597ED81B7369F"><enum>(A)</enum><text>by striking <quote>(j)</quote> and inserting <quote>(j)(1)</quote>;</text>
 </subparagraph><subparagraph id="H7E4E03A03F744D3385258D61F66B3CAE"><enum>(B)</enum><text>by inserting <quote>505(z),</quote> after <quote>505(p),</quote>; and</text> </subparagraph><subparagraph id="HB6461D70467449F7A61D5A88D0C64C5A"><enum>(C)</enum><text>by adding at the end the following new paragraph:</text>
								<quoted-block id="H3849310338DD45DBBDA232208A0A4DE2" style="OLC">
 <paragraph id="H283038D243A546F1BE4CF2A03674A160" indent="up1"><enum>(2)</enum><text>In applying section 505(z) of the Federal Food, Drug, and Cosmetic Act to the licensure of biological products under this section—</text>
 <subparagraph id="HBCEA9B871C56499D9FB293E81FB281AD"><enum>(A)</enum><text>references to an antibacterial or antifungal drug that is intended to treat a serious or life-threatening infection shall be construed to refer to a biological product intended to treat a serious or life-threatening bacterial or fungal infection; and</text>
 </subparagraph><subparagraph id="H0225EAA1A192416794BD4B8138E5FC85"><enum>(B)</enum><text>references to approval of a drug under section 505(c) of such Act shall be construed to refer to a licensure of a biological product under subsection (a) of this section.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HE7F55748675C442F80FDA4E28E3EFF3D"><enum>(2)</enum><header>Misbranding</header><text display-inline="yes-display-inline">Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by adding at the end the following new subsection:</text>
							<quoted-block display-inline="no-display-inline" id="H70AFF65E069B46CEBAB6F3A8F6A82C14" style="traditional">
 <subsection id="H47FE0BC5B0784819BCEBF9EA752255B3"><enum>(dd)</enum><text display-inline="yes-display-inline">If it is a drug approved in accordance with section 505(z) and its labeling does not meet the requirements under paragraph (3) of such subsection, subject to paragraph (5) of such subsection.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection><subsection id="H12CEFC4548594D27AE3D1D6CF5794A84"><enum>(e)</enum><header>Evaluation</header>
 <paragraph id="H94D94756A273458E8A3C03BB21A0B89A"><enum>(1)</enum><header>Assessment</header><text>Not later than 48 months after the date of enactment of this Act, the Secretary of Health and Human Services shall publish for public comment an assessment of the program established under section 505(z) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (b). Such assessment shall determine if the limited-use pathway established under such section 505(z) has improved or is likely to improve patient access to novel antibacterial or antifungal treatments and assess how the pathway could be expanded to cover products for serious or life-threatening diseases or conditions beyond bacterial and fungal infections.</text>
 </paragraph><paragraph id="H760D23CFF6324186886309C9B790692D"><enum>(2)</enum><header>Meeting</header><text display-inline="yes-display-inline">Not later than 90 days after the date of the publication of such assessment, the Secretary, acting through the Commissioner of Food and Drugs shall hold a public meeting to discuss the findings of the assessment, during which public stakeholders may present their views on the success of the program established under section 505(z) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (b), and the appropriateness of expanding such program.</text>
 </paragraph></subsection><subsection id="HA06065D53E104C80B603951937755029"><enum>(f)</enum><header>Expansion of program</header><text>If the Secretary of Health and Human Services determines, based on the assessment under subsection (e)(1), evaluation of the assessment, and any other relevant information, that the public health would benefit from expansion of the limited-use pathway established under section 505(z) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (b)) beyond the drugs approved in accordance with such section, the Secretary may expand such limited-use pathway in accordance with such a determination. The approval of any drugs under any such expansion shall be subject to the considerations and requirements described in such section 505(z) for purposes of expansion to other serious or life-threatening diseases or conditions.</text>
 </subsection><subsection id="HE90AE0BC81404508926E97BEDC8136DB"><enum>(g)</enum><header>Monitoring</header><text>The Public Health Service Act is amended by inserting after section 317T (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-22">42 U.S.C. 247b–22</external-xref>) the following:</text>
						<quoted-block display-inline="no-display-inline" id="HE84FA92C1A294BFEA6F2D6DC6950A1BE" style="OLC">
							<section id="H6EAD1009B6FD46BAB1F1EE6C590B1904"><enum>317U.</enum><header>Monitoring antibacterial and antifungal drug use and resistance</header>
 <subsection id="HADABC1C6757D4F0F98CF7C968C386641"><enum>(a)</enum><header>Monitoring</header><text>The Secretary shall use an appropriate monitoring system to monitor—</text> <paragraph id="H3E198E85724A44C487B41D53D908E6F1"><enum>(1)</enum><text>the use of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to section 505(z) of the Federal Food, Drug, and Cosmetic Act; and</text>
 </paragraph><paragraph id="HEE35E595DFE544C7A4DD0D9FE9D7C82E"><enum>(2)</enum><text>changes in bacterial and fungal resistance to drugs.</text> </paragraph></subsection><subsection id="H66FE140603E74E11A58A649C43AA0820"><enum>(b)</enum><header>Public availability of data</header><text>The Secretary shall make summaries of the data derived from monitoring under this section publicly available for the purposes of—</text>
 <paragraph id="H293BB7F768174DC0BB218394EFFB96F1"><enum>(1)</enum><text>improving the monitoring of important trends in antibacterial and antifungal resistance; and</text> </paragraph><paragraph id="H6909E09CACFE4EF5B3A6B00C76688747"><enum>(2)</enum><text>ensuring appropriate stewardship of antibacterial and antifungal drugs, including those receiving approval or licensure for a limited population pursuant to section 505(z) of the Federal Food, Drug, and Cosmetic Act.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection></section><section commented="no" id="H4E60E47A4C6B403CAFD9D8838036A28D"><enum>2122.</enum><header>Susceptibility test interpretive criteria for microorganisms</header>
 <subsection commented="no" id="H4CE90994876342DC82F1777BFF6C7AEA"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 511 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">21 U.S.C. 360a</external-xref>) is amended to read as follows:</text>
						<quoted-block id="H0BFE7140887D4FA5BEA6F19B0DD7170F" style="OLC">
							<section commented="no" id="HAB561754F0EB4EDA91DB4C4305FCD67A"><enum>511.</enum><header>Identifying and updating susceptibility test interpretive criteria for microorganisms</header>
								<subsection commented="no" id="H454C432AC6234A7CA83E998632804705"><enum>(a)</enum><header>Purpose; Identification of criteria</header>
 <paragraph commented="no" id="H5CA4A665C17D4171A6C0A423FBE4EF37"><enum>(1)</enum><header>Purpose</header><text>The purpose of this section is to provide the Secretary with an expedited, flexible method for—</text> <subparagraph commented="no" id="HF009D5B0F3A240378FB73E45DB27A03C"><enum>(A)</enum><text>clearance or premarket approval of antimicrobial susceptibility testing devices utilizing updated, recognized susceptibility test interpretive criteria to characterize the in vitro susceptibility of particular bacteria, fungi, or other microorganisms to antimicrobial drugs; and</text>
 </subparagraph><subparagraph commented="no" id="HEB61B5BBE27F4D6EA5FF03071D13B4C1"><enum>(B)</enum><text>providing public notice of the availability of recognized interpretive criteria to meet premarket submission requirements or other requirements under this Act for antimicrobial susceptibility testing devices.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HF77BA41C16F546BAA3098DFF72D580A5"><enum>(2)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall identify appropriate susceptibility test interpretive criteria with respect to antimicrobial drugs—</text>
 <subparagraph commented="no" id="H501D05C5BAE94B4FB56FED753112117F"><enum>(A)</enum><text display-inline="yes-display-inline">if such criteria are available on the date of approval of the drug under section 505 of this Act or licensure of the drug under section 351 of the Public Health Service Act (as applicable), upon such approval or licensure; or</text>
 </subparagraph><subparagraph commented="no" id="H482FA1BB64E7432DA85B7D47EB4D66E8"><enum>(B)</enum><text>if such criteria are unavailable on such date, on the date on which such criteria are available for such drug.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H4F0E51D0497E47CCA005BF8A5A901BD2"><enum>(3)</enum><header>Bases for initial identification</header><text display-inline="yes-display-inline">The Secretary shall identify appropriate susceptibility test interpretive criteria under paragraph (2), based on the Secretary’s review of, to the extent available and relevant—</text>
 <subparagraph commented="no" id="H97A5BBE0A67948E0812140F44FC67000"><enum>(A)</enum><text>preclinical and clinical data, including pharmacokinetic, pharmacodynamic, and epidemiological data;</text>
 </subparagraph><subparagraph commented="no" id="HB2C72920E13E44059D6BF70067939BDC"><enum>(B)</enum><text>Bayesian and pharmacometric statistical methodologies; and</text> </subparagraph><subparagraph commented="no" id="H63871054EDB44E6487E0C685E9E4A161"><enum>(C)</enum><text>such other evidence and information as the Secretary considers appropriate.</text>
										</subparagraph></paragraph></subsection><subsection commented="no" id="H9F384137705A4CAC9200770E73F4BAC5"><enum>(b)</enum><header>Susceptibility test Interpretive Criteria Website</header>
 <paragraph commented="no" id="H6840E49264F348099138946AC7346B04"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of the enactment of the <short-title>21st Century Cures Act</short-title>, the Secretary shall establish, and maintain thereafter, on the website of the Food and Drug Administration, a dedicated website that contains a list of any appropriate new or updated susceptibility test interpretive criteria standards in accordance with paragraph (2) (referred to in this section as the <quote>Interpretive Criteria Website</quote>).</text>
									</paragraph><paragraph commented="no" id="H4C09E8DE1AF447C68AE3CB6A6587A009"><enum>(2)</enum><header>Listing of susceptibility test interpretive criteria standards</header>
 <subparagraph commented="no" id="HD09972EA0C9D4955838522BEB1361BFE"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The list described in paragraph (1) shall consist of any new or updated susceptibility test interpretive criteria standards that are—</text>
 <clause commented="no" id="HC3B060C876FC47288C9498FF38108D67"><enum>(i)</enum><text display-inline="yes-display-inline">established by a nationally or internationally recognized standard development organization that—</text> <subclause commented="no" id="H79046DBE05AD4B93B1FE5D1FCA325790"><enum>(I)</enum><text display-inline="yes-display-inline">establishes and maintains procedures to address potential conflicts of interest and ensure transparent decisionmaking;</text>
 </subclause><subclause commented="no" id="HD8BE9C1BCDDB425F9ECFF7C186FCD426"><enum>(II)</enum><text display-inline="yes-display-inline">holds open meetings to ensure that there is an opportunity for public input by interested parties, and establishes and maintains processes to ensure that such input is considered in decisionmaking; and</text>
 </subclause><subclause commented="no" id="H1BB49F37B6964991916E506704B747EE"><enum>(III)</enum><text display-inline="yes-display-inline">permits its standards to be made publicly available, through the National Library of Medicine or another similar source acceptable to the Secretary; and</text>
 </subclause></clause><clause commented="no" id="H940E92D34CD44724A2875EABBA44EE5B"><enum>(ii)</enum><text display-inline="yes-display-inline">recognized in whole, or in part, by the Secretary under subsection (c).</text> </clause></subparagraph><subparagraph commented="no" id="H5858E2547691478996FF28F393F27C3D"><enum>(B)</enum><header>Other list</header><text display-inline="yes-display-inline">The Interpretive Criteria Website shall, in addition to the list described in subparagraph (A), include a list of interpretive criteria, if any, that the Secretary has determined to be appropriate with respect to legally marketed antimicrobial drugs, where—</text>
 <clause commented="no" id="H325AB2E7DB684C9BB398B6515C4C8F1F"><enum>(i)</enum><text>the Secretary does not recognize, in whole or in part, an interpretive criteria standard described under subparagraph (A) otherwise applicable to such a drug;</text>
 </clause><clause commented="no" id="HB729BA0E4A2E43C3BF2FBB787AF95A00"><enum>(ii)</enum><text>the Secretary withdraws under subsection (c)(1)(B) recognition of a standard, in whole or in part, otherwise applicable to such a drug;</text>
 </clause><clause commented="no" id="HCE91249990284E7189BBFCA82F3E1A28"><enum>(iii)</enum><text>the Secretary approves an application under section 505 of this Act or section 351 of the Public Health Service Act, as applicable, with respect to marketing of such a drug for which there are no relevant interpretive criteria included in a standard recognized by the Secretary under subsection (c); or</text>
 </clause><clause commented="no" id="HFB42C895F2944C3E9B3739BCBF8E480D"><enum>(iv)</enum><text>because the characteristics of such a drug differ from other drugs with the same active ingredient, the interpretive criteria with respect to such drug—</text>
 <subclause commented="no" id="H58C814BDE0274C4CA52BE75B7556DF7C"><enum>(I)</enum><text>differ from otherwise applicable interpretive criteria included in a standard listed under subparagraph (A) or interpretive criteria otherwise listed under this subparagraph; and</text>
 </subclause><subclause commented="no" id="H42FA25CB47AC475EB61C0B90F467DCD4"><enum>(II)</enum><text>are determined by the Secretary to be appropriate for the drug.</text> </subclause></clause></subparagraph><subparagraph commented="no" id="HD9E106B4C2D645F58B2E883B969D4D23"><enum>(C)</enum><header>Required statements of limitations of information</header><text>The Interpretive Criteria Website shall include the following:</text>
 <clause commented="no" id="H4308349FB28E43C6861A24886762CD70"><enum>(i)</enum><text>A statement that—</text> <subclause commented="no" id="H0C1FB77F66204DACA7BD1A2D30A9D985"><enum>(I)</enum><text>the website provides information about the susceptibility of bacteria, fungi, or other microorganisms to a certain drug (or drugs); and</text>
 </subclause><subclause commented="no" id="HB5552C7C9AD54561A488A295D2EDADD1"><enum>(II)</enum><text>the safety and efficacy of the drug in treating clinical infections due to such bacteria, fungi, or other microorganisms may not have been established in adequate and well-controlled clinical trials and the clinical significance of such susceptibility information in such trials is unknown.</text>
 </subclause></clause><clause commented="no" id="H4FD76C3BF9C4438ABE9F94288243B0BB"><enum>(ii)</enum><text>A statement that directs health care practitioners to consult the approved product labeling for specific drugs to determine the uses for which the Food and Drug Administration has approved the product.</text>
 </clause><clause commented="no" id="HE1844FE1E9B24CC0B29E58DE16C303CF"><enum>(iii)</enum><text>Any other statement that the Secretary determines appropriate to adequately convey the limitations of the data supporting susceptibility test interpretive criteria standard listed on the website.</text>
 </clause></subparagraph></paragraph><paragraph commented="no" id="H90050FF6FF0E4E30B121A0FD3E549AC5"><enum>(3)</enum><header>Notice</header><text>Not later than the date on which the Interpretive Criteria Website is established, the Secretary shall publish a notice of that establishment in the Federal Register.</text>
 </paragraph><paragraph commented="no" id="HDC2F6AAC55AA4C48BD67D68585BA9527"><enum>(4)</enum><header>Inapplicability of misbranding provision</header><text display-inline="yes-display-inline">The inclusion in the approved labeling of an antimicrobial drug of a reference or hyperlink to the Interpretive Criteria Website, in and of itself, shall not cause the drug to be misbranded in violation of section 502, or the regulations promulgated thereunder.</text>
 </paragraph><paragraph commented="no" id="H9291C9C6387147E78FD82CB94DB36F47"><enum>(5)</enum><header>Trade secrets and confidential information</header><text display-inline="yes-display-inline">Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code.</text>
									</paragraph></subsection><subsection commented="no" id="H4A6BB8DE15BB4546AB33A4396E762075"><enum>(c)</enum><header>Recognition of susceptibility test interpretive criteria from standard development organizations</header>
 <paragraph commented="no" id="H9E3AC82658094D4E9DEA8FE8E60CD879"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning on the date of the establishment of the Interpretive Criteria Website, and at least every 6 months thereafter, the Secretary shall—</text>
 <subparagraph commented="no" id="H8CE62259E46547F0B1FA162CEC2BE6F0"><enum>(A)</enum><text>evaluate any appropriate new or updated susceptibility test interpretive criteria standards established by a nationally or internationally recognized standard development organization described in subsection (b)(2)(A)(i); and</text>
 </subparagraph><subparagraph commented="no" id="H8AC295BB8F274C359199AEBBF9BB4B57"><enum>(B)</enum><text>publish on the public website of the Food and Drug Administration a notice<italic></italic>—</text> <clause commented="no" id="H8DF7FF0A278E43BF852818CDF254A119"><enum>(i)</enum><text display-inline="yes-display-inline">withdrawing recognition of any different susceptibility test interpretive criteria standard, in whole or in part;</text>
 </clause><clause commented="no" id="H9B255C278B9B4BC5A8D6365B6430865D"><enum>(ii)</enum><text>recognizing the new or updated standards;</text> </clause><clause commented="no" id="H4818CC1CD5384903B4409A3A83E0E668"><enum>(iii)</enum><text>recognizing one or more parts of the new or updated interpretive criteria specified in such a standard and declining to recognize the remainder of such standard; and</text>
 </clause><clause commented="no" id="H6677211B1CA44429859AE4FDA994F4EE"><enum>(iv)</enum><text>making any necessary updates to the lists under subsection (b)(2).</text> </clause></subparagraph></paragraph><paragraph commented="no" id="HA5B42B5A600C47FCAE8503372859A8AC"><enum>(2)</enum><header>Bases for updating interpretive criteria standards</header><text display-inline="yes-display-inline">In evaluating new or updated susceptibility test interpretive criteria standards under paragraph (1)(A), the Secretary may consider—</text>
 <subparagraph commented="no" id="HF61C1E28FC8E437083FF003819A9069C"><enum>(A)</enum><text>the Secretary’s determination that such a standard is not applicable to a particular drug because the characteristics of the drug differ from other drugs with the same active ingredient;</text>
 </subparagraph><subparagraph commented="no" id="H5CA361B71AC64E5A905DC7F79C311FE0"><enum>(B)</enum><text>information provided by interested third parties, including public comment on the annual compilation of notices published under paragraph (3);</text>
 </subparagraph><subparagraph commented="no" id="H599674360DC24C898578C176A1AB615A"><enum>(C)</enum><text>any bases used to identify susceptibility test interpretive criteria under subsection (a)(2); and</text> </subparagraph><subparagraph commented="no" id="H229F67D1DC344BBF922F1DA7B8958858"><enum>(D)</enum><text>such other information or factors as the Secretary determines appropriate.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H5E41C5FF93B6430A88047F33E6247DD4"><enum>(3)</enum><header>Annual compilation of notices</header><text display-inline="yes-display-inline">Each year, the Secretary shall compile the notices published under paragraph (1)(B) and publish such compilation in the Federal Register and provide for public comment. If the Secretary receives comments, the Secretary will review such comments and, if the Secretary determines appropriate, update pursuant to this subsection susceptibility test interpretive criteria standards—</text>
 <subparagraph commented="no" id="H02BBA85618684408AD0D375037029C7D"><enum>(A)</enum><text>recognized by the Secretary under this subsection; or</text> </subparagraph><subparagraph commented="no" id="H9C2C1F3C1CE34346BE508DD3EEFBBC29"><enum>(B)</enum><text>otherwise listed on the Interpretive Criteria Website under subsection (b)(2).</text>
 </subparagraph></paragraph><paragraph commented="no" id="H9A0A3060CECE4908800C8FA6086FE646"><enum>(4)</enum><header>Relation to section 514(<enum-in-header>c</enum-in-header>)</header><text display-inline="yes-display-inline">Any susceptibility test interpretive standard recognized under this subsection or any criteria otherwise listed under subsection (b)(2)(B) shall be deemed to be recognized as a standard by the Secretary under section 514(c)(1).</text>
 </paragraph><paragraph commented="no" id="HA5F71F8C6D874C9C8BFFFD6F01C75C3E"><enum>(5)</enum><header>Voluntary use of interpretive criteria</header><text>Nothing in this section prohibits a person from seeking approval or clearance of a drug or device, or changes to the drug or the device, on the basis of susceptibility test interpretive criteria standards which differ from those recognized pursuant to paragraph (1).</text>
									</paragraph></subsection><subsection commented="no" id="H1296EBADBFAF450092060CC8A9E9B893"><enum>(d)</enum><header>Antimicrobial drug labeling</header>
 <paragraph commented="no" id="H5514243952D64226BF602413A049F8FB"><enum>(1)</enum><header>Drugs marketed prior to establishment of Interpretive Criteria Website</header><text>With respect to an antimicrobial drug lawfully introduced or delivered for introduction into interstate commerce for commercial distribution before the establishment of the Interpretive Criteria Website, a holder of an approved application under section 505 or section 351 of the Public Health Service Act, as applicable, for each such drug—</text>
 <subparagraph commented="no" id="H5DC0EFA894C04488AB69781106200EE6"><enum>(A)</enum><text display-inline="yes-display-inline">not later than 1 year after establishment of the Interpretive Criteria Website, shall submit to the Secretary a supplemental application for purposes of changing the drug’s labeling to substitute a reference or hyperlink to such Website for any susceptibility test interpretive criteria and related information; and</text>
 </subparagraph><subparagraph commented="no" id="H7EC90B117AE640FAA6C02D0BA636B7F0"><enum>(B)</enum><text>may begin distribution of the drug involved upon receipt by the Secretary of the supplemental application for such change.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H5CA639851FEA44F698C6E9D0A6E0F47D"><enum>(2)</enum><header>Drugs marketed subsequent to establishment of Interpretive Criteria Website</header><text display-inline="yes-display-inline">With respect to antimicrobial drugs lawfully introduced or delivered for introduction into interstate commerce for commercial distribution on or after the date of the establishment of the Interpretive Criteria Website, the labeling for such a drug shall include, in lieu of susceptibility test interpretive criteria and related information, a reference to such Website.</text>
									</paragraph></subsection><subsection commented="no" id="H2D4951835BE7459CB5506EC5A23399CA"><enum>(e)</enum><header>Special condition for marketing of antimicrobial susceptibility testing devices</header>
 <paragraph commented="no" id="HBD499BC51F774729BE7F8406B1868CF4"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding sections 501, 502, 510, 513, and 515, if the conditions specified in paragraph (2) are met (in addition to other applicable provisions under this chapter) with respect to an antimicrobial susceptibility testing device described in subsection (f)(1), the Secretary may authorize the marketing of such device for a use described in such subsection.</text>
 </paragraph><paragraph commented="no" id="H5792339CDC09463191E72CA72BDC2F32"><enum>(2)</enum><header>Conditions applicable to antimicrobial susceptibility testing devices</header><text display-inline="yes-display-inline">The conditions specified in this paragraph are the following:</text> <subparagraph commented="no" id="HA062EB9E41F54F3D94A8DE7A22A88808"><enum>(A)</enum><text>The device is used to make a determination of susceptibility using susceptibility test interpretive criteria that are—</text>
 <clause commented="no" id="H5FF7EF469FDB4C46A15FAAD6F4708825"><enum>(i)</enum><text>included in a standard recognized by the Secretary under subsection (c); or</text> </clause><clause commented="no" id="H2F0228C157F44C8792A8370431B5366F"><enum>(ii)</enum><text>otherwise listed on the Interpretive Criteria Website under subsection (b)(2).</text>
 </clause></subparagraph><subparagraph commented="no" id="H223370E5F092438382EFA4B17A68559D"><enum>(B)</enum><text>The labeling of such device prominently and conspicuously—</text> <clause commented="no" id="H0B0B9686C5EB48C4944B5DF1E763A703"><enum>(i)</enum><text display-inline="yes-display-inline"><italic></italic><italic></italic>includes a statement that—</text>
 <subclause commented="no" id="H3B9443AD2C3D425EA06915094309E932"><enum>(I)</enum><text>the device provides information about the susceptibility of bacteria and fungi to certain drugs; and</text>
 </subclause><subclause commented="no" id="H9D4824B42AE044A3A8661D08113B70FB"><enum>(II)</enum><text display-inline="yes-display-inline">the safety and efficacy of such drugs in treating clinical infections due to such bacteria or fungi may not have been established in adequate and well-controlled clinical trials and the clinical significance of such susceptibility information in those instances is unknown;</text>
 </subclause></clause><clause commented="no" id="H3B45B7583906456A997EA10FC0466571"><enum>(ii)</enum><text display-inline="yes-display-inline">includes a statement directing health care practitioners to consult the approved labeling for drugs tested using such a device, to determine the uses for which the Food and Drug Administration has approved such drugs; and</text>
 </clause><clause commented="no" id="H3DB7E32D6A7C4B2589E6BC8842D7A36E"><enum>(iii)</enum><text display-inline="yes-display-inline">includes any other statement the Secretary determines appropriate to adequately convey the limitations of the data supporting the interpretive criteria described in subparagraph (A).</text>
 </clause></subparagraph></paragraph></subsection><subsection commented="no" id="HC88AEADD6F5E41C382F9A41C8E9BB662"><enum>(f)</enum><header>Definitions</header><text>In this section:</text> <paragraph commented="no" id="H3E78D1466A214066BC24A61DC5620C16"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>antimicrobial susceptibility testing device</quote> means a device that utilizes susceptibility test interpretive criteria to determine and report the in vitro susceptibility of certain microorganisms to a drug (or drugs).</text>
 </paragraph><paragraph commented="no" id="HCF535E03BD5347DBA387B68E43429998"><enum>(2)</enum><text>The term <quote>qualified infectious disease product</quote> means a qualified infectious disease product designated under section 505E(d).</text> </paragraph><paragraph commented="no" id="H532DE65B9799459BAEB347C75E8C503A"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>susceptibility test interpretive criteria</term> means—</text>
 <subparagraph commented="no" id="H6929B6F448564974B4837AEFB68DFE0F"><enum>(A)</enum><text>one or more specific numerical values which characterize the susceptibility of bacteria or other microorganisms to the drug tested; and</text>
 </subparagraph><subparagraph commented="no" id="H0C2A4EEDB69A4B51908163A024655157"><enum>(B)</enum><text>related categorizations of such susceptibility, including categorization of the drug as susceptible, intermediate, resistant, or such other term as the Secretary determines appropriate.</text>
										</subparagraph></paragraph><paragraph commented="no" id="H908C0195ECFD4ED2A52DC8F5B72EA45E"><enum>(4)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HC5230B61A9C94255963D97572E8BD5D2"><enum>(A)</enum><text>The term <quote>antimicrobial drug</quote> means, subject to subparagraph (B), a systemic antibacterial or antifungal drug that—</text> <clause commented="no" id="H37B3B5EFB6B643819D93C8F880D83EBC" indent="up1"><enum>(i)</enum><text display-inline="yes-display-inline">is intended for human use in the treatment of a disease or condition caused by a bacterium or fungus;</text>
 </clause><clause commented="no" id="H40CED916C45D4CC59301E0A159F9AA7B" indent="up1"><enum>(ii)</enum><text>may include a qualified infectious disease product designated under section 505E(d); and</text> </clause><clause commented="no" id="HB97F658BC0994B58BC25D07124EFE8E8" indent="up1"><enum>(iii)</enum><text>is subject to section 503(b)(1).</text>
 </clause></subparagraph><subparagraph commented="no" id="H33B95CE1046645B6AA2EC03381905908" indent="up1"><enum>(B)</enum><text>If provided by the Secretary through regulations, such term may include—</text> <clause commented="no" id="H10377E1C03F54D1BBC5BFFBC98CE6A85"><enum>(i)</enum><text display-inline="yes-display-inline">drugs other than systemic antibacterial and antifungal drugs; and</text>
 </clause><clause commented="no" id="HA2F3CD23ED9342AAA7E607E6652729D4"><enum>(ii)</enum><text display-inline="yes-display-inline">biological products (as such term is defined in section 351 of the Public Health Service Act) to the extent such products exhibit antimicrobial activity. <italic></italic></text>
 </clause></subparagraph></paragraph></subsection><subsection commented="no" id="HFC0867F6A4F34119840BE5BF13A5B57E"><enum>(g)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in this section shall be construed—</text> <paragraph commented="no" id="H53B8DFE2637546F1AC6381FB27836ADD"><enum>(1)</enum><text>to alter the standards of evidence—</text>
 <subparagraph commented="no" id="H7B089757EA8D4DC28EDB86A52A700436"><enum>(A)</enum><text>under subsection (c) or (d) of section 505, including the substantial evidence standard in section 505(d), or under section 351 of the Public Health Service Act (as applicable); or</text>
 </subparagraph><subparagraph commented="no" id="HE1EB8640A8A3474C84E2A18A4A3A8413"><enum>(B)</enum><text>with respect to marketing authorization for devices, under section 510, 513, or 515;</text> </subparagraph></paragraph><paragraph commented="no" id="H88A46A965B2747F7A7D37B2D3FEDE82A"><enum>(2)</enum><text>to apply with respect to any drug, device, or biological product, in any context other than—</text>
 <subparagraph id="H577CAFEEDEED41F198280814156B6A41"><enum>(A)</enum><text>an antimicrobial drug; or</text> </subparagraph><subparagraph id="H7F39853AF55F4E47B12968527518CD17"><enum>(B)</enum><text display-inline="yes-display-inline">an antimicrobial susceptibility testing device that uses susceptibility test interpretive criteria to characterize and report the in vitro susceptibility of certain bacteria, fungi, or other microorganisms to antimicrobial drugs in accordance with this section; or</text>
 </subparagraph></paragraph><paragraph commented="no" id="H1AD9CD705E0B4E02967289A06433D9B1"><enum>(3)</enum><text>unless specifically stated, to have any effect on authorities provided under other sections of this Act, including any regulations issued under such sections.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection><subsection commented="no" id="HEC76029162034EC4A83EE7B3B1198E6A"><enum>(b)</enum><header>Conforming amendments</header>
 <paragraph commented="no" id="HE2421F0129F945FEA9F1BB105E2DBA5B"><enum>(1)</enum><header>Repeal of related authority</header><text>Section 1111 of the Food and Drug Administration Amendments Act of 2007 (42 U.S.C. 247d–5a; relating to identification of clinically susceptible concentrations of antimicrobials) is repealed.</text>
 </paragraph><paragraph commented="no" id="HA4CF95C1F4784D529100A95CA9D3E8A0"><enum>(2)</enum><header>Misbranding</header><text display-inline="yes-display-inline">Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>), as amended by section 2121, is further amended by adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="H1168A069E3F2459D9017CE1622F77F96" style="traditional">
 <subsection commented="no" id="H7FA0D194A5D84AB0BB96F18A3302AC80"><enum>(ee)</enum><text display-inline="yes-display-inline">If it is an antimicrobial drug and its labeling fails to conform with the requirements under section 511(d).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph commented="no" id="H0DA94E1C940A40999549B3207A2D9CAC"><enum>(3)</enum><header>Recognition of interpretive criteria as device standard</header><text display-inline="yes-display-inline">Section 514(c)(1)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360d">21 U.S.C. 360d(c)(1)(A)</external-xref>) is amended by inserting after <quote>the Secretary shall, by publication in the Federal Register</quote> the following: <quote>(or, with respect to susceptibility test interpretive criteria or standards recognized or otherwise listed under section 511, by posting on the Interpretive Criteria Website in accordance with such section)</quote>.<italic></italic></text>
 </paragraph></subsection><subsection commented="no" id="H20CCAA1F85E14FACA18F56845A78C9AF"><enum>(c)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than two years after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate a report on the progress made in implementing section 511 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360a">21 U.S.C. 360a</external-xref>), as amended by this section.</text>
 </subsection><subsection commented="no" id="HBA0BFA2BF4094FD782D2822912687B5E"><enum>(d)</enum><header>Requests for updates to Interpretive Criteria Website</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/35">Chapter 35</external-xref> of title 44, United States Code, shall not apply to the collection of information from interested parties regarding the updating of lists under paragraph (2) of subsection (b) section 511 of the Federal Food, Drug, and Cosmetic Act (as amended by subsection (a)) and posted on the Interpretive Criteria Website established under paragraph (1) of such subsection (b).</text>
 </subsection><subsection commented="no" id="H919CDE3AB80A41659D8D9A55C284E0B4"><enum>(e)</enum><header>No effect on health care practice</header><text>Nothing in this subtitle (including the amendments made by this subtitle) shall be construed to restrict, in any manner, the prescribing or administering of antibiotics or other products by health care practitioners, or to limit the practice of health care.</text>
					</subsection></section><section id="HE6E432A3BB5346DEAB351656E2F3A6A9" section-type="subsequent-section"><enum>2123.</enum><header>Encouraging the development and use of new antimicrobial drugs</header>
					<subsection id="H09DA9A0572E346049B74D759A26EF9C8"><enum>(a)</enum><header>Additional payment for new antimicrobial drugs under Medicare</header>
 <paragraph id="HC45C32176A204143909C75D371D66223"><enum>(1)</enum><header>In general</header><text>Section 1886(d)(5) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(d)(5)</external-xref>) is amended by adding at the end the following new subparagraph:</text>
							<quoted-block id="H6B9415F3336C434786AB28A42A4A3177" style="OLC">
								<subparagraph commented="no" id="H69014BA82C594AEC81BC41D61B0B874E" indent="up2"><enum>(M)</enum>
									<clause commented="no" display-inline="yes-display-inline" id="H70124730F44F4668BE1995B3E5493A38"><enum>(i)</enum>
 <subclause commented="no" display-inline="yes-display-inline" id="HF9A144BFF19C40FEAD85920C90E5DC80"><enum>(I)</enum><text>Effective for discharges beginning on or after October 1, 2017, the Secretary shall, after notice and opportunity for public comment (in the publications required by subsection (e)(5) for a fiscal year or otherwise), provide for additional payment to be made under this subsection in accordance with the provisions of this subparagraph with respect to discharges by eligible hospitals that involve new antimicrobial drugs in the amount, subject to clause (vi), provided for under section 1847A.</text>
 </subclause><subclause id="H83178D4E66314C6B853903B06E4EBC39" indent="up2"><enum>(II)</enum><text display-inline="yes-display-inline">Additional payments to be made under this subsection shall be with respect to discharges involving a new antimicrobial drug that occur during the four-fiscal-year period beginning on which an inpatient hospital code is issued with respect to the drug.</text>
 </subclause></clause><clause commented="no" id="HA1F66841765A4932B1C8EB2AFE7E543D" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">For purposes of this subparagraph, the term <term>new antimicrobial drug</term> means a product that is approved for use, or a product for which an indication is first approved for use, by the Food and Drug Administration on or after December 1, 2014, and that the Food and Drug Administration determines—</text>
 <subclause commented="no" display-inline="no-display-inline" id="HF3A6349E23D74F33BC9F382A2DF01F6A"><enum>(I)</enum><text display-inline="yes-display-inline">either—</text> <item commented="no" display-inline="no-display-inline" id="H68C6A7A2591C4BF28951DE95C800FD7D"><enum>(aa)</enum><text>is intended to treat an infection caused by, or likely to be caused by, a qualifying pathogen (as defined under section 505E(f) of the Federal Food, Drug, and Cosmetic Act); or</text>
 </item><item id="HF63975026FEC422FA642C5EED990D061"><enum>(bb)</enum><text>meets the definition of a qualified infectious disease product under section 505E(g) of the Federal Food, Drug, and Cosmetic Act;</text>
 </item></subclause><subclause commented="no" id="HA36020113F204AE793B909E11134CC32"><enum>(II)</enum><text>is intended to treat an infection for which there is an <quote>unmet medical need</quote>; and</text> </subclause><subclause commented="no" id="H7EA46D3F86ED4BD39ECD2F0E44556452"><enum>(III)</enum><text>is intended to treat an infection associated with high rates of mortality or significant patient morbidity, as determined in consultation with the infectious disease professional community.</text>
 </subclause></clause><clause commented="no" id="HDAC8FF4B352940B4B6B44AF824A17AD6" indent="up1"><enum>(iii)</enum><text display-inline="yes-display-inline">For purposes of this subparagraph, the term <quote>eligible hospital</quote> means a hospital that participates in the National Healthcare Safety Network of the Centers for Disease Control and Prevention (or, to the extent a similar surveillance system reporting program that includes reporting about antimicrobial drugs is determined by the Secretary to be available to such hospitals, such similar surveillance system as the Secretary may specify).</text>
 </clause><clause commented="no" id="H037F70D41BCF468B959F16C6D989A276" indent="up1"><enum>(iv)</enum><text display-inline="yes-display-inline">The Secretary may only revoke a determination of a product under this subparagraph as a new antimicrobial drug if the Secretary finds that the request for such determination contained an untrue statement of material fact.</text>
 </clause><clause commented="no" id="HFB9B3719984D45A59FCCC21071527537" indent="up1"><enum>(v)</enum><text display-inline="yes-display-inline">Not later than October 1, 2017, the Secretary shall first publish in the Federal Register a list of the new antimicrobial drugs. Each fiscal year thereafter, the Secretary shall publish a list of the new antimicrobial drugs for such fiscal year as part of the annual rulemaking under this subsection.</text>
									</clause><clause id="H92123900342D4EEEB452FE11D0F72A6B" indent="up1"><enum>(vi)</enum>
 <subclause commented="no" display-inline="yes-display-inline" id="H147397AA212841A8BEB95C6FAC451379"><enum>(I)</enum><text display-inline="yes-display-inline">The total of the additional payments made under this subsection pursuant to this subparagraph for discharges in a fiscal year (as estimated by the Secretary as part of the rulemaking under this subsection for the fiscal year) may not exceed the applicable percentage (specified in subclause (II)) of the total program payments estimated to be made under this subsection for all discharges in such fiscal year (as calculated by the Secretary as part of the rulemaking under this subsection for the fiscal year). For purposes of the preceding sentence, in the case that, with respect to a fiscal year, such additional payments are made only with respect to discharges during a portion of such fiscal year, the reference to <quote>all discharges in such fiscal year</quote> shall be considered a reference to all discharges during such portion of such fiscal year.</text>
 </subclause><subclause id="H2411F4B0213A4DD4B6577A81BDCAF2EC" indent="up1"><enum>(II)</enum><text>For purposes of subclause (I), the term <quote>applicable percentage</quote> means, for fiscal year 2018 and each fiscal year thereafter, 0.06807 percent.</text> </subclause><subclause id="HB1EDDAA2729F4915BDD13020B88D4C88" indent="up1"><enum>(III)</enum><text display-inline="yes-display-inline">If the Secretary estimates before the beginning of a fiscalyear that the amount of the additional payments under this subsection pursuant to this subparagraph for the fiscal year (or portion thereof) as determined under subclause (I) will exceed the limit established under such subclause, the Secretary shall reduce pro rata the amount of each of the additional payments under this subsection pursuant to this subparagraph for such fiscal year (or portion thereof) in order to ensure that the aggregate additional payments under this subsection pursuant to this paragraph (as so estimated) do not exceed such limit.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph><paragraph id="H2A90140FF8BC470D8BC32A7BA0F39467"><enum>(2)</enum><header>Conforming amendments</header>
 <subparagraph id="H9DFD4C03ED914DA5AFBB03FD506D161F"><enum>(A)</enum><header>No duplicative NTAP payments</header><text>Section 1886(d)(5)(K)(i) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(d)(5)(K)(i)</external-xref>) is amended by inserting <quote>and with respect to which an additional payment is not made pursuant to subparagraph (M),</quote> after <quote>2001,</quote>.</text>
 </subparagraph><subparagraph id="H0E5E5AF7345449B084B4B041041A98E7"><enum>(B)</enum><header>Access to price information</header><text display-inline="yes-display-inline">Section 1927(b)(3)(A)(iii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(b)(3)(A)(iii)</external-xref>) is amended—</text> <clause id="H0E68671A6AE14EEEBB64EF4394A00FE8"><enum>(i)</enum><text>in subclause (II), by inserting <quote>, or under section 1886(d) pursuant to paragraph (5)(M) of such section,</quote> after <quote>1847A,</quote>; and</text>
 </clause><clause id="H4A759E299B7E4215B6217EB4F1A3AA3D"><enum>(ii)</enum><text>in the matter following subclause (III), by inserting <quote>or section 1886(d)(5)(M)</quote> after <quote>1881(b)(13)(A)(ii)</quote>.</text> </clause></subparagraph></paragraph></subsection><subsection id="H76B3A450C08349A2BAF72447BFA03B45"><enum>(b)</enum><header>Study and report on removing barriers to development of new antimicrobial drugs</header> <paragraph commented="no" id="H7E4586E6CF324943B20BB5ED165E4C79"><enum>(1)</enum><header>Study</header><text>The Comptroller General of the United States shall conduct a study to—</text>
 <subparagraph commented="no" id="HEE322B74FD634CC591455712B193268C"><enum>(A)</enum><text>identify and examine the barriers that prevent the development of new antimicrobial drugs, as defined in section 1886(d)(5)(M)(iii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(d)(5)(M)(iii)</external-xref>); and</text>
 </subparagraph><subparagraph commented="no" id="H558FB043453D43E2849CBA2CC74835D5"><enum>(B)</enum><text>develop recommendations for actions to be taken in order to overcome any barriers identified under subparagraph (A).</text>
 </subparagraph></paragraph><paragraph id="H85470E6AAA714B1CBDA8D04DDB2B19CE"><enum>(2)</enum><header>Consideration</header><text display-inline="yes-display-inline">In conducting such study, the Comptroller General shall take into account the perspectives of the Director of the National Institutes of Health, the Commissioner of the Food and Drugs, and the Director of the Centers for Disease Control and Prevention.</text>
 </paragraph><paragraph commented="no" display-inline="no-display-inline" id="H795AFC92A8554004A71DE9146A12DD26"><enum>(3)</enum><header>Report</header><text>Not later than 1 year after the date of the enactment of this Act, the Comptroller General shall submit to Congress a report on the study conducted under paragraph (1).</text>
						</paragraph></subsection></section></subtitle><subtitle commented="no" id="H674937B6246140B598BC49DD92CF1F5F"><enum>H</enum><header>Vaccine Access, Certainty, and Innovation</header>
 <section commented="no" id="H19FBB7A069AA4DE5B62862599BF49FB3"><enum>2141.</enum><header>Timely review of vaccines by the Advisory Committee on Immunization Practices</header><text display-inline="no-display-inline">Section 2102(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300aa-2">42 U.S.C. 300aa–2(a)</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H74D703ABA2AF4844B69560179A086D86" style="OLC">
						<paragraph commented="no" id="HA1B3873E49C743D294B2C0C666AACCA6"><enum>(10)</enum><header>Advisory Committee on Immunization Practices</header>
 <subparagraph commented="no" id="HE0A2970C462645E4885D03BA1F3D0BA5"><enum>(A)</enum><header>Standard periods of time for making recommendations</header><text display-inline="yes-display-inline">Upon the licensure of any vaccine or any new indication for a vaccine, the Director of the Program shall direct the Advisory Committee on Immunization Practices, at its next regularly scheduled meeting, to consider the use of the vaccine.</text>
 </subparagraph><subparagraph commented="no" id="H9BFEDEDC65F74C7B950E0F46E2AEE74B"><enum>(B)</enum><header>Expedited review pursuant to request by sponsor or manufacturer</header><text display-inline="yes-display-inline">If the Advisory Committee does not make recommendations with respect to the use of a vaccine at the Advisory Committee’s first regularly scheduled meeting after the licensure of the vaccine or any new indication for the vaccine, the Advisory Committee, at the request of the sponsor of the vaccine, shall make such recommendations on an expedited basis.</text>
 </subparagraph><subparagraph commented="no" id="HF7B99A767320460B9137D671B2B4E775"><enum>(C)</enum><header>Expedited review for breakthrough therapies and for use during public health emergencies</header><text display-inline="yes-display-inline">If a vaccine is designated as a breakthrough therapy under section 506 of the Federal Food, Drug, and Cosmetic Act and is licensed under section 351 of this Act, the Advisory Committee shall make recommendations with respect to the use of the vaccine on an expedited basis.</text>
 </subparagraph><subparagraph commented="no" id="H4876B07207AF498084DFF77E1FDD9C5B"><enum>(D)</enum><header>Definition</header><text display-inline="yes-display-inline">In this paragraph, the terms <quote>Advisory Committee on Immunization Practices</quote> and <quote>Advisory Committee</quote> mean the advisory committee on immunization practices established by the Secretary pursuant to section 222, acting through the Director of the Centers for Disease Control and Prevention.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</section><section commented="no" id="H754773847F7E4C988C54855DBA9CC3A1"><enum>2142.</enum><header>Review of processes and consistency of ACIP recommendations</header>
 <subsection commented="no" id="H52DE880B766444FE9712A3C6063A7952"><enum>(a)</enum><header>Review</header><text display-inline="yes-display-inline">The Director of the Centers for Disease Control and Prevention shall conduct a review of the process used by the Advisory Committee on Immunization Practices to evaluate consistency in formulating and issuing recommendations pertaining to vaccines.</text>
 </subsection><subsection commented="no" id="HC43EE721849E4519BCB22D5E94A5DE48"><enum>(b)</enum><header>Considerations</header><text>The review under subsection (a) shall include assessment of—</text> <paragraph commented="no" id="HF3E095425FC7477093600B8A4164DC08"><enum>(1)</enum><text>the criteria used to evaluate new and existing vaccines;</text>
 </paragraph><paragraph commented="no" id="H2834F65FD1414E66AF770A9BD0DAD837"><enum>(2)</enum><text>the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to the review and analysis of scientific and economic data, including the scientific basis for such approach; and</text>
 </paragraph><paragraph commented="no" id="H265256CE1D954DCF96EFC87074432B77"><enum>(3)</enum><text display-inline="yes-display-inline">the extent to which the processes used by the working groups of the Advisory Committee on Immunization Practices are consistent among groups.</text>
 </paragraph></subsection><subsection commented="no" id="H60B41796F56744FB9C2A2F1783566E04"><enum>(c)</enum><header>Stakeholders</header><text>In carrying out the review under subsection (a), the Director of the Centers for Disease Control and Prevention shall solicit input from vaccine stakeholders.</text>
 </subsection><subsection commented="no" id="H1CE45CF1BBF446608E140699CD501089"><enum>(d)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention shall submit to the appropriate committees of the Congress and make publicly available a report on the results of the review under subsection (a), including recommendations on improving the consistency of the process described in such subsection.</text>
 </subsection><subsection commented="no" id="HCB54021456FC4088A9CCF8D88103E672"><enum>(e)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <quote>Advisory Committee on Immunization Practices</quote> means the advisory committee on immunization practices established by the Secretary of Health and Human Services pursuant to section 222 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/217a">42 U.S.C. 217a</external-xref>), acting through the Director of the Centers for Disease Control and Prevention.</text>
 </subsection></section><section commented="no" id="H69663CF4A85040C2AEB7B957FD3C7BC3"><enum>2143.</enum><header>Meetings between CDC and vaccine developers</header><text display-inline="no-display-inline">Section 310 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/242o">42 U.S.C. 242o</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block id="H994F004BD5914EB8A3C800A8221484B7" style="OLC">
						<subsection commented="no" id="H72B1AB5DD6244058B250C2939D29DFD4"><enum>(c)</enum>
 <paragraph commented="no" display-inline="yes-display-inline" id="H3B65FC66525043E59960B680A296929C"><enum>(1)</enum><text>In this subsection, the term <quote>vaccine developer</quote> means a nongovernmental entity engaged in—</text> <subparagraph commented="no" id="H36CFFAC376994DD7B2DA11F86A04C6DF" indent="up1"><enum>(A)</enum> <clause commented="no" display-inline="yes-display-inline" id="H6A56ED3B7DC64A83B9D8DA4CAEF0290C"><enum>(i)</enum><text>the development of a vaccine with the intent to pursue licensing of the vaccine by the Food and Drug Administration; or</text>
 </clause><clause commented="no" id="HBA029FAADF0D4181B320E6AD4D649ECC" indent="up1"><enum>(ii)</enum><text>the production of a vaccine licensed by the Food and Drug Administration; and</text> </clause></subparagraph><subparagraph commented="no" id="H6183CCC9F1C54144B1667ACEAABD7177" indent="up1"><enum>(B)</enum><text>vaccine research.</text>
								</subparagraph></paragraph><paragraph commented="no" id="H2661DCDF7968474CA9F64C4D232B965C" indent="up1"><enum>(2)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HB0F86F8272CC41329486A0AE39C33E96"><enum>(A)</enum><text display-inline="yes-display-inline">Upon the submission of a written request for a meeting by a vaccine developer, that includes a justification for the meeting, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall convene a meeting of representatives of the vaccine developer and experts from the Centers for Disease Control and Prevention in immunization programs, epidemiology, and other relevant areas at which the Director (or the Director’s designee), for the purpose of informing the vaccine developer’s understanding of public health needs and priorities, shall provide the perspectives of the Centers for Disease Control and Prevention and other relevant Federal agencies regarding—</text>
 <clause commented="no" id="H38A3ED5B9FCC44EAAA63DF1791EC01B1" indent="up1"><enum>(i)</enum><text>public health needs, epidemiology, and implementation considerations with regard to a vaccine developer’s potential vaccine profile; and</text>
 </clause><clause commented="no" id="H2D2F55F368604F0089603394B5866897" indent="up1"><enum>(ii)</enum><text>potential implications of such perspectives for the vaccine developer’s vaccine research and development planning.</text>
 </clause></subparagraph><subparagraph commented="no" id="HC450D0AED6B04DA1B6697746AE651759" indent="up1"><enum>(B)</enum><text>In addition to the representatives specified in subparagraph (A), the Secretary may, with the agreement of the vaccine developer requesting a meeting under such subparagraph, include in such meeting representatives of—</text>
 <clause commented="no" id="HDC015230B4334BAC89A28433A22CC0A9"><enum>(i)</enum><text>the Food and Drug Administration; and</text> </clause><clause commented="no" id="HC1723FC0EADB4223B9B6485D09E0CAA3"><enum>(ii)</enum><text>the National Vaccine Program.</text>
 </clause></subparagraph><subparagraph commented="no" id="H8418432B0C1A47DB95E1AEB5C8899D31" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">The Secretary shall convene a meeting requested under subparagraph (A) not later than 120 days after receipt of the request for the meeting.</text>
								</subparagraph></paragraph><paragraph commented="no" id="H9DF112DADC094C28886709E3C3C5043C" indent="up1"><enum>(3)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="H7AC339D54A3B4BF6973D342381E40F34"><enum>(A)</enum><text display-inline="yes-display-inline">Upon the submission of a written request by a vaccine developer, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall provide to the vaccine developer any age-based or other demographically assessed disease epidemiological analyses or data that—</text>
 <clause commented="no" id="H05DE1E17CA7B4A4A8AF86A118B134025" indent="up1"><enum>(i)</enum><text>are specified in the request;</text> </clause><clause commented="no" id="HD59E8A22E2F2465DA18D2A4784CEEEB9" indent="up1"><enum>(ii)</enum><text>have been published;</text>
 </clause><clause commented="no" id="HF36545F440574247969221F1CDC6BF0A" indent="up1"><enum>(iii)</enum><text>have been performed by or are in the possession of the Centers;</text> </clause><clause commented="no" id="H2626A17250964317A25DBD5EF498B06B" indent="up1"><enum>(iv)</enum><text display-inline="yes-display-inline">are not a trade secret or commercial or financial information that is privileged or confidential and subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code; and</text>
 </clause><clause commented="no" id="H56DBA05310104047850D75D2A164ABF2" indent="up1"><enum>(v)</enum><text>do not contain individually identifiable information.</text> </clause></subparagraph><subparagraph commented="no" id="H6CABEB1D26134D5DACA09F5C7E43AF95" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">The Secretary shall provide analyses requested by a vaccine manufacturer under subparagraph (A) not later than 120calendar days after receipt of the request for the analyses.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H0F8FC8076B0D4346A88CC41C8AB592D0" indent="up1"><enum>(4)</enum><text>The Secretary shall promptly notify a vaccine developer if—</text> <subparagraph commented="no" id="HD088ADA0B9F7465FA117818FFD722242"><enum>(A)</enum><text display-inline="yes-display-inline">the Secretary becomes aware of any change to information that was—</text>
 <clause commented="no" id="H5AE8C03D0EA14498995D559092D1A7CC"><enum>(i)</enum><text>shared by the Secretary with the vaccine developer during a meeting under paragraph (2); or</text> </clause><clause commented="no" id="H7C764C4A1C0F45EF9CF520C7BEDF6FA1"><enum>(ii)</enum><text>provided by the Secretary to the vaccine developer in one or more analyses under paragraph (3); and</text>
 </clause></subparagraph><subparagraph commented="no" id="HDF3C3E71282D400588E2AC4DBFCBA668"><enum>(B)</enum><text>the change may have implications for the vaccine developer’s vaccine research and development.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </section></subtitle><subtitle id="H84C0155E55F34C0EB650B6C557731E3D"><enum>I</enum><header>Orphan product extensions now; incentives for certain products for limited populations</header> <section id="H01E5BE63C7B149B8885A77B28EDF8BAF"><enum>2151.</enum><header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition</header> <subsection id="H4D0F8BEE74EE4B5387F3210F17BE2D07"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act, as amended by section 2063, is further amended by inserting after section 505F of such Act the following:</text>
						<quoted-block display-inline="no-display-inline" id="H9A2F154D4A69465FB8FF654A4058B303" style="OLC">
							<section id="HAA29BB4D868F48018ACFCBE0589134CE"><enum>505G.</enum><header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or
			 condition</header>
								<subsection id="H147120BC3EBE446DB0E857629D6EFEB7"><enum>(a)</enum><header>Designation</header>
 <paragraph id="H1EA24674BDC843A9A2CBADB9F555CF5D"><enum>(1)</enum><header>In general</header><text>The Secretary shall designate a drug as a drug approved for a new indication to prevent, diagnose, or treat a rare disease or condition for purposes of granting the extensions under subsection (b) if—</text>
 <subparagraph commented="no" id="HA01C446315AC42B8B9181086E98E1E40"><enum>(A)</enum><text display-inline="yes-display-inline">prior to approval of an application or supplemental application for the new indication, the drug was approved or licensed for marketing under section 505(c) of this Act or section 351(a) of the Public Health Service Act, but was not so approved or licensed for the new indication;</text>
										</subparagraph><subparagraph id="H9D3D5714F0C54CC8A20D63B876A13186"><enum>(B)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H5068497D378848BA831AF9F960F9CCB6"><enum>(i)</enum><text>the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent, diagnose, or treat the rare disease or condition; and</text>
 </clause><clause commented="no" id="HD74B0C343818404D9B44780E9FE5FF2C" indent="up1"><enum>(ii)</enum><text>the Secretary approves the application or supplemental application; and</text> </clause></subparagraph><subparagraph id="HA5E73AB7F53F4B1A9C79F761CF419039"><enum>(C)</enum><text display-inline="yes-display-inline">the application or supplemental application for the new indication contains the consent of the applicant to notice being given by the Secretary under paragraph (4) respecting the designation of the drug.</text>
 </subparagraph></paragraph><paragraph id="H7661C49D35E74437BB1C25566D354E31"><enum>(2)</enum><header>Revocation of designation</header><text display-inline="yes-display-inline"></text> <subparagraph id="HF8FFF96400E840ECBD45DEA9B0D5E26A"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraph (B), a designation under this subsection shall not be revoked for any reason.</text>
 </subparagraph><subparagraph id="H77FEC98F501D4E5AA5BA4B6DB88ACD20"><enum>(B)</enum><header>Exception</header><text>The Secretary may revoke a designation of a drug under paragraph (1) if the Secretary finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact.</text>
 </subparagraph></paragraph><paragraph id="HFF3D181B9BC44DD49FBBD77F8DB93B52"><enum>(3)</enum><header>Notification prior to discontinuance of production for solely commercial reasons</header><text>A designation of a drug under paragraph (1) shall be subject to the condition that the sponsor of the drug will notify the Secretary of any discontinuance of the production of the drug for solely commercial reasons at least one year before such discontinuance.</text>
 </paragraph><paragraph id="HB5E5663BE77445EDA163F0D3DAA1DFFD"><enum>(4)</enum><header>Notice to public</header><text>Notice respecting the designation of a drug under paragraph (1) shall be made available to the public.</text>
 </paragraph></subsection><subsection id="HD8F93EF7EE324CE5BB008E894A275D41"><enum>(b)</enum><header>Extension</header><text>If the Secretary designates a drug as a drug approved for a new indication for a rare disease or condition, as described in subsection (a)(1)—</text>
									<paragraph id="H814D90ED0D254C618CDA33AA91671E36"><enum>(1)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="HBD8D5E6AC7194A97911A42E485AE2C65"><enum>(A)</enum><text>the 4-, 5-, and 7 <fraction>½</fraction>-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505, and the 7-year period described in section 527, as applicable, shall be extended by 6 months; or</text>
 </subparagraph><subparagraph id="HE50EE930379B4370986F9A76006C74A7" indent="up1"><enum>(B)</enum><text>the 4- and 12-year periods described in subparagraphs (A) and (B) of section 351(k)(7) of the Public Health Service Act and the 7-year period described in section 527, as applicable, shall be extended by 6 months; and</text>
										</subparagraph></paragraph><paragraph id="HD38E4432996545FB991073E4EDBA58ED"><enum>(2)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="H1187C4ED1C8A4E269AC42FC85D240C44"><enum>(A)</enum><text>if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of section 505 or a listed patent for which a certification has been submitted under subsections (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions); or</text>
 </subparagraph><subparagraph id="H62D1B7B67A7947C384348019BDAB19CB" indent="up1"><enum>(B)</enum><text>if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of section 505, and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions).</text>
 </subparagraph></paragraph></subsection><subsection id="H0C2B94389F4D4251A8747E59A2883ADA"><enum>(c)</enum><header>Relation to pediatric and qualified infectious disease product exclusivity</header><text>Any extension under subsection (b) of a period shall be in addition to any extension of the periods under sections 505A and 505E of this Act and section 351(m) of the Public Health Service Act, as applicable, with respect to the drug.</text>
 </subsection><subsection id="H9E3E3BB0864C4C22A9B530ED3B67822D"><enum>(d)</enum><header>Limitations</header><text>The extension described in subsection (b) shall not apply if the drug designated under subsection (a)(1) has previously received an extension by operation of subsection (b).</text>
 </subsection><subsection id="H0808C1FA6D19492886DB51C0EA456DF7"><enum>(e)</enum><header>Definition</header><text>In this section, the term <term>rare disease or condition</term> has the meaning given to such term in section 526(a)(2).</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HCE120E7E3F964A6BBD71784B701EC1D5"><enum>(b)</enum><header>Application</header><text display-inline="yes-display-inline">Section 505G of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies only with respect to a drug for which an application or supplemental application described in subsection (a)(1)(B)(i) of such section 505G is first approved under section 505(c) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)</external-xref>) or section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>) on or after the date of the enactment of this Act.</text>
					</subsection><subsection id="H3355E903981B4752B3E6369F8F9B8597"><enum>(c)</enum><header>Conforming amendments</header>
 <paragraph id="HE0207C05DE8E4B478BF2741314D5EE3F"><enum>(1)</enum><header>Relation to pediatric exclusivity for drugs</header><text display-inline="yes-display-inline">Section 505A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>) is amended—</text> <subparagraph id="HB04470056BF548D18140F94345FC80E3"><enum>(A)</enum><text>in subsection (b), by adding at the end the following:</text>
								<quoted-block display-inline="no-display-inline" id="H9E7B301AA97F46189562BF8E29E54CDB" style="OLC">
 <paragraph id="HE5E7AF56712F4D0092DA5C37D98EE3BA"><enum>(3)</enum><header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in subsection (b)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (b)(1) shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="H9FDC42BF64E54850ADD21B91B1E880F6"><enum>(B)</enum><text>in subsection (c), by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HAEDCA79A05064B5EA6602D0739FBAE1D" style="OLC"> <paragraph id="H8A4B54579DE243C8A31B97CAEE0CE06C"><enum>(3)</enum><header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in subsection (c)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (c)(1) shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="H12DB53AF3EEF4715A50B5DB1F6231DE8"><enum>(2)</enum><header>Relation to exclusivity for new qualified infectious disease products that are drugs</header><text>Subsection (b) of section 505E of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) is amended—</text>
 <subparagraph id="H5FFA2B7E7E23432DA7BCC3DB8278B758"><enum>(A)</enum><text>by amending the subsection heading to read as follows: <quote><header-in-text level="subsection" style="OLC">Relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition</header-in-text></quote>; and</text>
 </subparagraph><subparagraph id="H437C6394DE464272A641A734FCB2140E"><enum>(B)</enum><text>by striking <quote>any extension of the period under section 505A</quote> and inserting <quote>any extension of the periods under sections 505A and 505G, as applicable,</quote>.</text> </subparagraph></paragraph><paragraph id="HB8E72ED6F746497482A064F2104F375B"><enum>(3)</enum><header>Relation to pediatric exclusivity for biological products</header><text display-inline="yes-display-inline">Section 351(m) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(m)</external-xref>) is amended by adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="HBA806C1231F64ED78AA8FEAD03DCAE5F" style="OLC">
								<paragraph id="H0729B329310244D1B43CED5E53460EC9"><enum>(5)</enum><header>Relation to exclusivity for a biological product approved for a new indication for a rare disease
 or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in paragraphs (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in such paragraphs shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection></section><section commented="no" id="H8043BBB8501945F4B04B172427F7A427"><enum>2152.</enum><header>Reauthorization of rare pediatric disease priority review voucher incentive program</header>
 <subsection commented="no" id="H3B54576880F74D27805ED004CCACD25D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) is amended—</text> <paragraph commented="no" id="H16DC1F4665E043BD861A31BED713BB75"><enum>(1)</enum><text>in subsection (a)—</text>
 <subparagraph commented="no" id="H4040EAC4BE4D4B4CA4B0E006A9803A7E"><enum>(A)</enum><text>in paragraph (3), by amending subparagraph (A) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H4B4D27D191FA44129B47E6B6BA2B8A5D" style="OLC"> <subparagraph commented="no" id="HBA831ECB98894AB59FD7173D7BDFC347"><enum>(A)</enum><text display-inline="yes-display-inline">The disease is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph commented="no" id="H5430E17C327741D89C35EC851119989B"><enum>(B)</enum><text>in paragraph (4)(A)—</text> <clause commented="no" id="H2E2F2F0A68DA40AD86C369CA19293443"><enum>(i)</enum><text>in subparagraph (E), by striking <quote>and</quote>;</text>
 </clause><clause commented="no" id="HFE0D42605DCD417980C3E7D94824E827"><enum>(ii)</enum><text>in subparagraph (F), by striking the period and inserting <quote>; and</quote>; and</text> </clause><clause commented="no" id="H90E39DC39E3548598EF4635BB096B029"><enum>(iii)</enum><text>by adding at the end the following:</text>
									<quoted-block id="HB57A1A0FBCCD4C20B6D486214D9C96B4" style="OLC">
 <subparagraph commented="no" id="H8B0DD54019DC4FF5B8029C8F10D45370"><enum>(G)</enum><text>is for a drug or biological product for which a priority review voucher has not been issued under section 524 (relating to tropical disease products).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph commented="no" id="HB0AB7705F9EF49CBBB20EEEB9EE4B6E4"><enum>(2)</enum><text>in subsection (b), by striking paragraph (5) and inserting the following:</text> <quoted-block id="H61A02DDD1241428A98BB8D07EC2D95BF" style="OLC"> <paragraph commented="no" id="HC68A057EA20C4067954536E6C087BCD9"><enum>(5)</enum><header>Termination of authority</header><text>The Secretary may not award any priority review vouchers under paragraph (1) after December 31, 2018.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection><subsection commented="no" id="HE765F754B9214566B05441897C6FA033"><enum>(b)</enum><header>GAO study and report</header>
 <paragraph commented="no" id="H7F2C9567F4074FB791E8B2E12713AAA9"><enum>(1)</enum><header>Study</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall conduct a study on the effectiveness of awarding priority review vouchers under section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) in providing incentives for the development of drugs that treat or prevent rare pediatric diseases that would not otherwise have been developed. In conducting such study, the Comptroller General shall examine the following:</text>
 <subparagraph commented="no" id="H93B330F9A5F64B8895D0E4F53B98095A"><enum>(A)</enum><text display-inline="yes-display-inline">The indications for which each drug for which a priority review voucher was awarded under such section 529 was approved under section 505 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text>
 </subparagraph><subparagraph commented="no" id="H3F6E4A0385D6417ABC9CCDA1B5A3B779"><enum>(B)</enum><text display-inline="yes-display-inline">Whether the priority review voucher impacted a sponsor’s decision to invest in developing a drug to treat or prevent a rare pediatric disease.</text>
 </subparagraph><subparagraph commented="no" id="H762DC07DEE7D4902A73AFAED4BBC7E3E"><enum>(C)</enum><text display-inline="yes-display-inline">An analysis of the drugs that utilized such priority review vouchers, which shall include—</text> <clause commented="no" id="H3AF5E7DA9CEF4A8593A8BA2688BB7388"><enum>(i)</enum><text display-inline="yes-display-inline">the indications for which such drugs were approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>);</text>
 </clause><clause commented="no" id="H7FBEBEC54C6942B7A20EF046AFB91012"><enum>(ii)</enum><text display-inline="yes-display-inline">whether unmet medical needs were addressed through the approval of such drugs, including, for each such drug—</text>
 <subclause commented="no" id="H3E2CC4C1C661435699FEED6A2E6FF3FB"><enum>(I)</enum><text display-inline="yes-display-inline">if an alternative therapy was previously available to treat the indication; and</text> </subclause><subclause commented="no" id="H03D0FB84E75F497E8AE779D9D9693D59"><enum>(II)</enum><text display-inline="yes-display-inline">the benefit or advantage the drug provided over another available therapy;</text>
 </subclause></clause><clause commented="no" id="H4A956139493C4FEB905CB2AE854AE94A"><enum>(iii)</enum><text display-inline="yes-display-inline">the number of patients potentially treated by such drugs;</text> </clause><clause id="HE0A612D3983E48BA917F12D805459102"><enum>(iv)</enum><text>the value of the priority review voucher if transferred; and</text>
 </clause><clause commented="no" id="HA6A4FE451B77415588D687EEB825349B"><enum>(v)</enum><text display-inline="yes-display-inline">the length of time between the date on which a priority review voucher was awarded and the date on which it was used.</text>
 </clause></subparagraph><subparagraph commented="no" id="H2E880DACA4634A4C80A9455CBC0AD6E0"><enum>(D)</enum><text display-inline="yes-display-inline">With respect to the priority review voucher program under section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>)—</text>
 <clause id="H29C047FD408E4FED940EA29A079D7B4E"><enum>(i)</enum><text>the resources used by, and burden placed on, the Food and Drug Administration in implementing such program, including the effect of such program on the Food and Drug Administration’s review of drugs for which a priority review voucher was not awarded or used;</text>
 </clause><clause id="H465F81BAE4444A4EAF21CB7ABC0B84C3"><enum>(ii)</enum><text display-inline="yes-display-inline">the impact of the priority review voucher program on the public health as a result of the expedited review of applications for drugs that treat or prevent non-serious indications that are generally used by the broader public; and</text>
 </clause><clause commented="no" id="H645EC859FEF14A8BBCBB24ACEAF37071"><enum>(iii)</enum><text display-inline="yes-display-inline">alternative approaches to improving such program so that the program is appropriately targeted towards providing incentives for the development of clinically important drugs that—</text>
 <subclause commented="no" id="H96046890038F4238AF3840BBDF6A4CE1"><enum>(I)</enum><text>prevent or treat rare pediatric diseases; and</text> </subclause><subclause commented="no" id="H57157BA564B946DB9BC7B117C0598826"><enum>(II)</enum><text>would likely not otherwise have been developed to prevent or treat such diseases.</text>
 </subclause></clause></subparagraph></paragraph><paragraph commented="no" id="H4C41FF3794784B87B808265733C012A9"><enum>(2)</enum><header>Report</header><text>Not later than December 31, 2017, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor and Pensions of the Senate a report containing the results of the study of conducted under paragraph (1).</text>
						</paragraph></subsection></section></subtitle><subtitle id="HF4B63ECBAD6C433C8F49C9548012487B"><enum>J</enum><header>Domestic Manufacturing and Export Efficiencies</header>
				<section id="H7DE767DA3DED49D69CBF1C0E09346AAA" section-type="subsequent-section"><enum>2161.</enum><header>Grants for studying the process of continuous drug manufacturing</header>
 <subsection id="HED8A1F78071341188200C29528484611"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs may award grants to institutions of higher education and nonprofit organizations for the purpose of studying and recommending improvements to the process of continuous manufacturing of drugs and biological products and similar innovative monitoring and control techniques.</text>
 </subsection><subsection id="H829532A0F01845E499619B7E3FEFE660"><enum>(b)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="H3B121304DF624D7AB9607B2733CE16E8"><enum>(1)</enum><text>The term <quote>drug</quote> has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>).</text>
 </paragraph><paragraph id="HBFB9346E032E4AA5ADA8FDF00FBCBDBF"><enum>(2)</enum><text>The term <quote>biological product</quote> has the meaning given to such term in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>).</text>
 </paragraph><paragraph id="HBEA9915C547F4D7B83C035841BB11FBC"><enum>(3)</enum><text>The term <quote>institution of higher education</quote> has the meaning given to such term in section 101 of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>).</text>
 </paragraph></subsection><subsection id="HBC8E84A31837446F823579D3355520BA"><enum>(c)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated $5,000,000 for each of fiscal years 2016 through 2020 to carry out this section.</text>
 </subsection></section><section commented="no" id="H7C6D60CDEBDF4D509F4DB522A907E716"><enum>2162.</enum><header>Re-exportation among members of the European Economic Area</header><text display-inline="no-display-inline">Section 1003 of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/953">21 U.S.C. 953</external-xref>) is amended—</text> <paragraph commented="no" id="HC82F47B7D7FF4AFABAF0C8429C2C9EB9"><enum>(1)</enum><text>in subsection (f)—</text>
 <subparagraph id="HF99B45FFE10E4506A34C3A105E5E5E70"><enum>(A)</enum><text>in paragraph (5)—</text> <clause commented="no" id="HB8B4A0E61BE648ED83B3864FF8DE1792"><enum>(i)</enum><text>by striking <quote>(5)</quote> and inserting <quote>(5)(A)</quote>;</text>
 </clause><clause commented="no" id="H6CBBB6A1E77E4BF28F60BA2E4764B869"><enum>(ii)</enum><text>by inserting <quote>, except that the controlled substance may be exported from the second country to another country that is a member of the European Economic Area</quote> before the period at the end; and</text>
 </clause><clause commented="no" id="HB4AFA4AA9A43498A9AB8600836D069B3"><enum>(iii)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HAA076BD28A564C25A52FB8C180D576EC" style="OLC"> <subparagraph commented="no" id="H0FF775D2D521480CBAC2ABD19E8B43C8" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Subsequent to any re-exportation described in subparagraph (A), a controlled substance may continue to be exported from any country that is a member of the European Economic Area to any other such country, provided that—</text>
 <clause commented="no" id="HAC3529824BD041E29F5D0B796A6B1F57"><enum>(i)</enum><text>the conditions applicable with respect to the first country under paragraphs (1), (2), (3), (4), (6), and (7) are met by each subsequent country from which the controlled substance is exported pursuant to this paragraph; and</text>
 </clause><clause commented="no" id="H4158A16ABA2B491D9FFC952FC4814576"><enum>(ii)</enum><text>the conditions applicable with respect to the second country under such paragraphs are met by each subsequent country to which the controlled substance is exported pursuant to this paragraph.</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause></subparagraph><subparagraph id="HF9ABD57C8F5746C9892BFC1D22951F2F"><enum>(B)</enum><text>in paragraph (6)—</text> <clause id="H9ADE57DAD8B040CE85E8C4C793CC820F"><enum>(i)</enum><text>by striking <quote>(6)</quote> and inserting <quote>(6)(A)</quote>; and</text>
 </clause><clause id="H684856164B90434EB04897267ABA2F11"><enum>(ii)</enum><text>by adding at the end the following:</text> <quoted-block id="H7D3D7AE7027C4624A41D07E65A99E72F" style="OLC"> <subparagraph id="H2CA6504865214FB9828CA5D84CB2E2A8" indent="up1"><enum>(B)</enum><text>In the case of re-exportation among members of the European Economic Area, within 30 days after each re-exportation, the person who exported the controlled substance from the United States delivers to the Attorney General—</text>
 <clause id="H42D64267E2C34F79B76E01CFC1DD45F6"><enum>(i)</enum><text>documentation certifying that such re-exportation has occurred; and</text> </clause><clause id="H55DEAB0E7A6D4596B8DE11B47E6B1F9A"><enum>(ii)</enum><text>information concerning the consignee, country, and product.</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph commented="no" id="HFBDC8043FA9C4FE8A11E7950F9223569"><enum>(2)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HD892E8CD16234BA29EFBCD78D8971643" style="OLC"> <subsection commented="no" id="HC9315AF4B3B946ACA086DB2C01BEB0C9"><enum>(g)</enum><header>Limitation</header><text display-inline="yes-display-inline">The Attorney General shall not promulgate nor enforce any regulation, subregulatory guidance, or enforcement policy which impedes re-exportation among European Economic Area countries (as provided in subsection (f)(5)), including by promulgating or enforcing any requirement that—</text>
 <paragraph commented="no" id="HCFE5FA6D3C6C472BB38077EB2363E187"><enum>(1)</enum><text>re-exportation from the first country to the second country or re-exportation from the second country to another country (as such terms are used in subsection (f)) occur within a specified period of time; or</text>
 </paragraph><paragraph commented="no" id="H5E15505ADC3C45C3BADED1A1B41EA0BB"><enum>(2)</enum><text display-inline="yes-display-inline">information concerning the consignee, country, and product be provided prior to exportation of the controlled substance from the United States or prior to each re-exportation among members of the European Economic Area.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></section></subtitle><subtitle id="H20696360AA2C44D0AE53DB73721A35EA"><enum>K</enum><header>Enhancing combination products review</header>
 <section id="HB4EAF68F4E7B48D290149F4761022F69"><enum>2181.</enum><header>Enhancing combination products review</header><text display-inline="no-display-inline">Section 503(g)(4)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(g)(4)(C)</external-xref>) is amended by adding at the end the following new clause:</text>
					<quoted-block display-inline="no-display-inline" id="H046714FA7F224268B45A68E1AED53BCC" style="traditional">
 <clause id="H42D81AB9AF19427093491FB4D14C694D" indent="up2"><enum>(iii)</enum><text display-inline="yes-display-inline">Not later than 18 months after the date of the enactment of the <short-title>21st Century Cures Act</short-title>, the Secretary shall issue final guidance that describes the responsibilities of each agency center regarding its review of combination products. The Secretary shall, after soliciting public comment, review and update the guidance periodically.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle><subtitle id="HC3F2225AD0234E1787128AF372B1D3DD"><enum>L</enum><header>Priority Review for Breakthrough Devices</header>
				<section id="H663CB1EAF455469D811A60131CE133E7"><enum>2201.</enum><header>Priority review for breakthrough devices</header>
 <subsection id="HE39B172952D84A3F9A477902D885A0BD"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act is amended—</text> <paragraph id="HC96645D0161E4D1995E5F26480BC9101"><enum>(1)</enum><text>in section 515(d)—</text>
 <subparagraph id="H22BA076881954077AB6D763C4B33616C"><enum>(A)</enum><text>by striking paragraph (5); and</text> </subparagraph><subparagraph id="H125B720BF5E94F9BBCD5EA6187FB6A28"><enum>(B)</enum><text>by redesignating paragraph (6) as paragraph (5); and</text>
 </subparagraph></paragraph><paragraph id="H1ABE2C36EC28429699370E02AEFED9FA"><enum>(2)</enum><text>by inserting after section 515A (<external-xref legal-doc="usc" parsable-cite="usc/21/360e-1">21 U.S.C. 360e–1</external-xref>) the following:</text> <quoted-block id="H1EA5A5FCC9284F43A2322A26B57FF85B" style="OLC"> <section id="H835D532E29C1425CB8036ABA74D052D7"><enum>515B.</enum><header>Priority review for breakthrough devices</header> <subsection id="HAA6926BF04744785960EC8B25D3570F1"><enum>(a)</enum><header>In general</header><text>In order to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions, the Secretary shall establish<italic></italic> a program to provide priority review for devices—</text>
 <paragraph id="HC8CBA3A77A8946EEBA9BF5A022B373A1"><enum>(1)</enum><text>representing breakthrough technologies;</text> </paragraph><paragraph id="HC83387472F564341A509540924B95354"><enum>(2)</enum><text>for which no approved alternatives exist;</text>
 </paragraph><paragraph id="HD4E248472FDE4B7CA3EC6D9E259A1C82"><enum>(3)</enum><text display-inline="yes-display-inline">offering significant advantages over existing approved or cleared alternatives, including the potential to, compared to existing approved or cleared alternatives, reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’ ability to manage their own care (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or</text>
 </paragraph><paragraph id="HD52C40EEB59F426B9608FC03F0216E03"><enum>(4)</enum><text display-inline="yes-display-inline">the availability of which is in the best interest of patients.</text> </paragraph></subsection><subsection id="H751520DAC5E944F781F3B05A7800BE5F"><enum>(b)</enum><header>Request for designation</header><text>A sponsor of a device may request that the Secretary designate the device for priority review under this section. Any such request for designation may be made at any time prior to the submission of an application under section 515(c), a petition for classification under section 513(f)(2), or a notification under section 510(k).</text>
									</subsection><subsection id="H32850B04D0694571A409699A80AC772B"><enum>(c)</enum><header>Designation process</header>
 <paragraph id="H73CA8EF9D3AF4A80BC228ECA69E6A100"><enum>(1)</enum><header>In general</header><text>Not later than 60 calendar days after the receipt of a request under subsection (b), the Secretary shall determine whether the device that is the subject of the request meets the criteria described in subsection (a). If the Secretary determines that the device meets the criteria, the Secretary shall designate the device for priority review.</text>
 </paragraph><paragraph id="HC9F80C791CD84F0EA5B7B7EEF9C83158"><enum>(2)</enum><header>Review</header><text>Review of a request under subsection (b) shall be undertaken by a team that is composed of experienced staff and managers of the Food and Drug Administration and is chaired by a senior manager. <italic></italic></text>
 </paragraph><paragraph id="H022567A09F3D43FE83C4A493442ADE65"><enum>(3)</enum><header>Designation determination</header><text display-inline="yes-display-inline">A determination approving or denying a request under subsection (b) shall be considered a significant decision under section 517A and the Secretary shall provide a written, substantive summary of the basis for the determination in accordance with section 517A(a).</text>
										</paragraph><paragraph id="H0D29EEBB4CD045228ABC58A3E8BFAED1"><enum>(4)</enum><header>Reconsideration</header>
 <subparagraph id="H738B97398B5A44EF8830D7E7DA19E1AD"><enum>(A)</enum><header>Request for reconsideration</header><text display-inline="yes-display-inline">Any person whose request under subsection (b) is denied may, within 30 days of the denial, request reconsideration of the denial in accordance with section 517A(b)—</text>
 <clause id="HF60CD494A65A4C8EA4445225D2E999DB"><enum>(i)</enum><text>based upon the submission of documents by such person; or</text> </clause><clause id="H07720789AC3A487C871E90E7EFAA4DFD"><enum>(ii)</enum><text>based upon such documents and a meeting or teleconference.</text>
 </clause></subparagraph><subparagraph id="H8E1A533BC6724E17BB6E477938F8718C"><enum>(B)</enum><header>Response</header><text display-inline="yes-display-inline">Reconsideration of a designation determination under this paragraph shall be conducted in accordance with section 517A(b).</text>
 </subparagraph></paragraph><paragraph id="H6A53248C992E40588E72458F264A21DF"><enum>(5)</enum><header>Withdrawal</header><text display-inline="yes-display-inline">If the Secretary approves a priority review designation for a device under this section, the Secretary may not withdraw the designation based on the fact that the criteria specified in subsection (a) are no longer met because of the subsequent clearance or approval of another device that was designated under—</text>
 <subparagraph id="HC40B013A9AEB4686B10AE317BF6310A1"><enum>(A)</enum><text display-inline="yes-display-inline">this section; or</text> </subparagraph><subparagraph id="H3015F4A46F3A443C8411987EC32B56DC"><enum>(B)</enum><text display-inline="yes-display-inline">section 515(d)(5) (as in effect immediately prior to the enactment of the 21st Century Cures Act).</text>
											</subparagraph></paragraph></subsection><subsection id="H4A018788E34140798D98358B0F1F075A"><enum>(d)</enum><header>Priority review</header>
 <paragraph id="HB938E288BE054656AC8D78BC887D1E85"><enum>(1)</enum><header>Actions</header><text display-inline="yes-display-inline">For purposes of expediting the development and review of devices designated under subsection (c), the Secretary shall—</text>
 <subparagraph id="H00CA501CDFB74690BD78A570490455AD"><enum>(A)</enum><text>assign a team of staff, including a team leader with appropriate subject matter expertise and experience, for each device for which a request is submitted under subsection (b);</text>
 </subparagraph><subparagraph id="H009D29037D0B4A969F6A7B389247531F"><enum>(B)</enum><text>provide for oversight of the team by senior agency personnel to facilitate the efficient development of the device and the efficient review of any submission described in subsection (b) for the device;</text>
 </subparagraph><subparagraph id="HBEC257FF4A634087AF1D0F1CE19C7FB3"><enum>(C)</enum><text>adopt an efficient process for timely dispute resolution;</text> </subparagraph><subparagraph id="H404D6970CC2247CD8923CC45BE4AD810"><enum>(D)</enum><text>provide for interactive communication with the sponsor of the device during the review process;</text>
 </subparagraph><subparagraph id="H3073C34B7CBF4365A53022710AF1D5D1"><enum>(E)</enum><text>expedite the Secretary’s review of manufacturing and quality systems compliance, as applicable;</text> </subparagraph><subparagraph id="H6C88663E3D5C4786949F7E1CED5D7ED7"><enum>(F)</enum><text display-inline="yes-display-inline">disclose to the sponsor in advance the topics of any consultation concerning the sponsor’s device that the Secretary intends to undertake with external experts or an advisory committee and provide the sponsor an opportunity to recommend such external experts;</text>
 </subparagraph><subparagraph id="HCCAFE7E00E3E421F8B69405B6803B84E"><enum>(G)</enum><text display-inline="yes-display-inline">for applications submitted under section 515(c), provide for advisory committee input, as the Secretary determines appropriate (including in response to the request of the sponsor); and</text>
 </subparagraph><subparagraph id="H24BE484580704A74BD4D08CADDFA02D1"><enum>(H)</enum><text display-inline="yes-display-inline">assign staff to be available within a reasonable time to address questions by institutional review committees concerning the conditions and clinical testing requirements applicable to the investigational use of the device pursuant to an exemption under section 520(g).</text>
 </subparagraph></paragraph><paragraph id="H4E12B9BB442B4273BA54BB67121EA58C"><enum>(2)</enum><header>Additional actions</header><text display-inline="yes-display-inline">In addition to the actions described in paragraph (1), for purposes of expediting the development and review of devices designated under subsection (c), the Secretary, in collaboration with the device sponsor, may, as appropriate—</text>
 <subparagraph id="H8099F1F6589E4E3AA6E06F529FCAF82D"><enum>(A)</enum><text>coordinate with the sponsor regarding early agreement on a data development plan;</text> </subparagraph><subparagraph id="H91199069B99C4A1C92340D4B5890FFC7"><enum>(B)</enum><text>take steps to ensure that the design of clinical trials is as efficient as practicable, such as through adoption of shorter or smaller clinical trials, application of surrogate endpoints, and use of adaptive trial designs and Bayesian statistics, to the extent scientifically appropriate;</text>
 </subparagraph><subparagraph id="HF473DCFF0AAF47D3835E714D9BA5A173"><enum>(C)</enum><text>facilitate, to the extent scientifically appropriate, expedited and efficient development and review of the device through utilization of timely postmarket data collection, with regard to applications for approval under section 515(c); and</text>
 </subparagraph><subparagraph id="HA5AD1C31CCB9431E835E8A233CB60C94"><enum>(D)</enum><text>agree to clinical protocols that the Secretary will consider binding on the Secretary and the sponsor, subject to—</text>
 <clause id="H008531C2398346B08FDC7E678B1D1A43"><enum>(i)</enum><text>changes agreed to by the sponsor and the Secretary;</text> </clause><clause id="H4F635ADB17654921867E32EE14FD3D63"><enum>(ii)</enum><text>changes that the Secretary determines are required to prevent an unreasonable risk to the public health; or</text>
 </clause><clause id="H69491515F17B472B85835AC5202B9279"><enum>(iii)</enum><text>the identification of a substantial scientific issue determined by the Secretary to be essential to the safety or effectiveness of the device involved.</text>
												</clause></subparagraph></paragraph></subsection><subsection id="H5E17A57A558F46579241B1005B5B7169"><enum>(e)</enum><header>Priority review guidance</header>
 <paragraph id="H0E37CD2723F542538727BF4BCD6ABEF8"><enum>(1)</enum><header>Content</header><text>The Secretary shall issue guidance on the implementation of this section. Such guidance shall include the following:</text>
 <subparagraph id="HEEE58FC801A34BE9807577A6D8382609"><enum>(A)</enum><text>The process for a person to seek a priority review designation.</text> </subparagraph><subparagraph id="H4BEEC805BE4147E2AF698F15D5A3E0ED"><enum>(B)</enum><text>A template for requests under subsection (b).</text>
 </subparagraph><subparagraph id="H6796F5448320474D8B751C93756E5570"><enum>(C)</enum><text>The criteria the Secretary will use in evaluating a request for priority review.</text> </subparagraph><subparagraph id="HF0BD13D8F44C4EEDA627A42990715E17"><enum>(D)</enum><text>The standards the Secretary will use in assigning a team of staff, including team leaders, to review devices designated for priority review, including any training required for such personnel on effective and efficient review.</text>
 </subparagraph></paragraph><paragraph id="H26D5AD07A578453FAAD921C2C6FB9E5F"><enum>(2)</enum><header>Process</header><text>Prior to finalizing the guidance under paragraph (1), the Secretary shall propose such guidance for public comment.</text>
										</paragraph></subsection><subsection id="HD63E0072A5184496B5CE2DD3955B4006"><enum>(f)</enum><header>Construction</header>
 <paragraph id="H42AF06B5CCBD45AA8214E8A3A7F66C17"><enum>(1)</enum><header>Purpose</header><text>This section is intended to encourage the Secretary and provide the Secretary sufficient authorities to apply efficient and flexible approaches to expedite the development of, and prioritize the agency’s review of, devices that represent breakthrough technologies.</text>
 </paragraph><paragraph id="HC67EA5C121A3457F9B1F4441D6DBC5F3"><enum>(2)</enum><header>Construction</header><text display-inline="yes-display-inline"><italic></italic>Nothing in this section shall be construed to alter the criteria and standards for evaluating an application pursuant to section 515(c), a report and request for classification under section 513(f)(2), or a report under section 510(k), including the recognition of valid scientific evidence as described in section 513(a)(3)(B), and consideration of the least burdensome means of evaluating device effectiveness or demonstrating substantial equivalence between devices with differing technological characteristics, as applicable. Nothing in this section alters the authority of the Secretary to act on an application pursuant to section 515(d) before completion of an establishment inspection, as the Secretary deems appropriate.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H304C1E4EE4184CC89B6C3FF2DC0AF30A"><enum>(b)</enum><header>Conforming amendment related to designation determinations</header><text>Section 517A(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360g-1">21 U.S.C. 360g–1(a)(1)</external-xref>) is amended by inserting <quote>a request for designation under section 515B,</quote> after <quote>an application under section 515,</quote>.</text>
					</subsection></section></subtitle><subtitle id="H1F0CDC0CBDE341ADA6ACEDE542726AF8"><enum>M</enum><header>Medical Device Regulatory Process Improvements</header>
				<section id="H889C35499F0D4CE6B8564CEDE83CABF9"><enum>2221.</enum><header>Third-party quality system assessment</header>
 <subsection id="HF3489723F9D749769A43C3237E0F4B42"><enum>(a)</enum><header>Establishment of third-Party quality system assessment program</header><text>Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 524A (<external-xref legal-doc="usc" parsable-cite="usc/21/360n-1">21 U.S.C. 360n–1</external-xref>) the following new section:</text>
						<quoted-block id="H1A111A8FE64E4F3897E17ED36DDBE780" style="OLC">
							<section id="HC7927711EB804E36A5DBC8E773BAF170"><enum>524B.</enum><header>Third-party quality system assessment</header>
								<subsection id="H17033F3C34584C8E9BB0063326D63CE0"><enum>(a)</enum><header>Accreditation and assessment</header>
 <paragraph id="H628A716D54D34E0CA02CB36C6A8856C6"><enum>(1)</enum><header>In general; certification of device quality system</header><text>The Secretary shall, in accordance with this section, establish a third-party quality system assessment program—</text>
 <subparagraph id="H570BE11298FC42059C1606BFFA6967A1"><enum>(A)</enum><text>to accredit persons to assess whether a requestor’s quality system, including its design controls, can reasonably assure the safety and effectiveness of in-scope devices subject to device-related changes (as defined in paragraph (2));</text>
 </subparagraph><subparagraph id="HB1F1648849654D4B9DA8093326113F0C"><enum>(B)</enum><text>under which accredited persons shall, as applicable, certify that a requestor’s quality system meets the criteria issued under paragraph (5) with respect to the in-scope devices at issue; and</text>
 </subparagraph><subparagraph id="HB71B1056669B4418A53E4653017A4192"><enum>(C)</enum><text display-inline="yes-display-inline">under which the Secretary shall rely on such certifications for purposes of determining the safety and effectiveness of in-scope devices subject to the device-related changes involved, in lieu of compliance with the following submission requirements:</text>
 <clause id="H67093F53C915467A827D932CC995428F"><enum>(i)</enum><text display-inline="yes-display-inline">A thirty-day notice (as defined in paragraph (2)).</text> </clause><clause id="H29255ADF39874CBCBFB1EE0791F40691"><enum>(ii)</enum><text display-inline="yes-display-inline">A Special PMA supplement (as defined in paragraph (2)).</text>
 </clause></subparagraph></paragraph><paragraph id="H633ADE9C1B1341E8BA1089241CAD7116"><enum>(2)</enum><header>Definitions</header><text>For purposes of this section─</text> <subparagraph id="HA8C7FBBE32EE4BAC81AA7A1C0DCABD61"><enum>(A)</enum><text>the term <quote>device-related changes</quote> means changes made by a requestor with respect to in-scope devices, which are—</text>
 <clause id="H98D63E39874E4DAD9AAFEDB84E313D60"><enum>(i)</enum><text>manufacturing changes subject to a 30-day notice;</text> </clause><clause id="H42FBA37232564737ADE623AB3F2F22C6"><enum>(ii)</enum><text>changes that qualify for a Special PMA supplement; and</text>
 </clause><clause id="HB5F6C7D6AC264A6BAF9D5C29723F9BA6"><enum>(iii)</enum><text>such other changes relating to the devices or the device manufacturing process as the Secretary determines appropriate;</text>
 </clause></subparagraph><subparagraph id="H7DD072C40D504798B3AD1ED7E9F66697"><enum>(B)</enum><text>the term <quote>in-scope device</quote> means a device within the scope of devices agreed to by the requestor and the accredited person for purposes of a request for certification under this section;</text>
 </subparagraph><subparagraph id="HFFB210512CB84A77ADC89A8CDDE198CB"><enum>(C)</enum><text>the term <quote>quality system</quote> means a quality system described in section 520(f);</text> </subparagraph><subparagraph id="H7127D30AAAE94E41B41938EB7BD5A784"><enum>(D)</enum><text>the term <quote>requestor</quote> means a device manufacturer that is seeking certification under this section of a quality system used by such manufacturer;</text>
 </subparagraph><subparagraph id="H1604CA56F87841C69AF5C573DEA932E3"><enum>(E)</enum><text display-inline="yes-display-inline">the term <quote>Special PMA</quote> means a Special PMA supplement under section 814.39(d) of title 21, Code of Federal Regulations (or any successor regulations); and</text>
 </subparagraph><subparagraph id="H5A9A7B1EA53C45CD9C9A2275924A9CD3"><enum>(F)</enum><text display-inline="yes-display-inline">the term <quote>thirty-day notice</quote> means a notice described in section 515(d)(6).</text> </subparagraph></paragraph><paragraph id="H297BC342897F48289C9C3FE01E9D670B"><enum>(3)</enum><header>Accreditation process; accreditation renewal</header><text>Except as inconsistent with this section, the process and qualifications for accreditation of persons and renewal of such accreditation under section 704(g) shall apply with respect to accreditation of persons and renewal of such accreditation under this section.</text>
									</paragraph><paragraph id="HB620DED02BD84B6EAC7142D184305A1B"><enum>(4)</enum><header>Use of accredited parties to conduct assessments</header>
										<subparagraph id="H66C9F9E1EAAA4521B3B3DFD936128584"><enum>(A)</enum><header>Initiation of assessment services</header>
 <clause id="H86FCF917895743BB985CB0DF56E68C9C"><enum>(i)</enum><header>Date assessments authorized</header><text>Beginning after issuance of the final guidance under paragraph (5), an accredited person may conduct an assessment under this section.</text>
 </clause><clause id="H954ADBA5CB8249B79346E5A24A79B303"><enum>(ii)</enum><header>Initiation of assessments</header><text>Use of one or more accredited persons to assess a requestor’s quality system under this section with respect to in-scope devices shall be at the initiation of the person who registers and lists the devices at issue under section 510.</text>
 </clause></subparagraph><subparagraph id="HB51D8F2921594FF4AE40BC13CCE72735"><enum>(B)</enum><header>Compensation</header><text>Compensation for such accredited persons shall—</text> <clause id="HC3A5E820348243359268A599464EF9B9"><enum>(i)</enum><text>be determined by agreement between the accredited person and the person who engages the services of the accredited person; and</text>
 </clause><clause id="HDB410F1189034C5C95DCA9CAEFFA4CA3"><enum>(ii)</enum><text>be paid by the person who engages such services.</text> </clause></subparagraph><subparagraph id="H7F348EB8954940EB8A803E970ECEF2B3"><enum>(C)</enum><header>Accredited person selection</header><text>Each person who chooses to use an accredited person to assess a requestor’s quality system, as described in this section, shall select the accredited person from a list of such persons published by the Secretary in accordance with section 704(g)(4).</text>
										</subparagraph></paragraph><paragraph id="HFFCEE6F80BB049D695F74BD85FEB6C14"><enum>(5)</enum><header>Guidance; criteria for certification</header>
 <subparagraph id="H52874AE8DD6945C19E58565173B21896"><enum>(A)</enum><header>In general</header><text>The criteria for certification of a quality system under this section shall be as specified by the Secretary in guidance issued under this paragraph.</text>
 </subparagraph><subparagraph id="H3F8D8A3418454868AF4878D221BA98FE"><enum>(B)</enum><header>Contents; certification criteria</header><text>The guidance under this paragraph shall include specification of—</text> <clause id="H2FC8D9856E474AB0B7C13EB420F34254"><enum>(i)</enum><text>evaluative criteria to be used by an accredited person to assess and as applicable certify a requestor’s quality system under this section with respect to in-scope devices ; and</text>
 </clause><clause id="HF7F04B36813F4DCE9710D5A660FD3335"><enum>(ii)</enum><text>criteria for accredited persons to apply a waiver of and exemptions from the certification criteria under clause (i).</text>
 </clause></subparagraph><subparagraph id="H9F19047122814D868ECF2CB59F790B33"><enum>(C)</enum><header>Timeframe for issuing guidance</header><text>The Secretary shall issue under this paragraph—</text> <clause id="H53F0AD2FB1ED494C8FB92D09AD93065F"><enum>(i)</enum><text>draft guidance not later than 12 months after the enactment of the 21st Century Cures Act; and</text>
 </clause><clause id="H8EF01A0078A54B048D2E8EA735DF301F"><enum>(ii)</enum><text>final guidance not later than 12 months after issuance of the draft guidance under clause (i).</text> </clause></subparagraph></paragraph></subsection><subsection id="H714F38B3AE2C46DC8495826F6ECBAA4C"><enum>(b)</enum><header>Use of third-Party assessment</header> <paragraph id="H860F87101C014927BB6BE89CF68CC2D7"><enum>(1)</enum><header>Assessment summary; certification</header> <subparagraph id="H5BF254BFDE5F4420A665FFCBD21C3D30"><enum>(A)</enum><header>Submission of assessment to secretary</header><text>An accredited person who assesses a requestor’s quality system under subsection (a) shall submit to the Secretary a summary of the assessment—</text>
 <clause id="H3F05E1127BA74C0C93B94AD7FB9A208F"><enum>(i)</enum><text>within 30 days of the assessment; and</text> </clause><clause id="HA9CDC5E22CDB426EB540FD3929CFF2E6"><enum>(ii)</enum><text>which as applicable shall include—</text>
 <subclause id="H90E244341A034ED6AFD9108D92A66945"><enum>(I)</enum><text>the accredited person’s certification that the requestor has satisfied the criteria issued under subsection (a)(5) for quality system certification with respect to the in-scope devices at issue; and</text>
 </subclause><subclause id="HB456C85CE47840E998F56B215899B658"><enum>(II)</enum><text>any waivers or exemptions from such criteria applied by the accredited person.</text> </subclause></clause></subparagraph><subparagraph id="H8763BE1A09804A00B4929CD1AB541BB3"><enum>(B)</enum><header>Treatment of assessments</header><text>Subject to action by the Secretary under subparagraph (C), with respect to assessments which include a certification under this section—</text>
 <clause id="HB4BDC0B539C5457FA3C1D958899A8052"><enum>(i)</enum><text>the Secretary’s review of the assessment summary shall be deemed complete on the day that is 30 days after the date on which the Secretary receives the summary under subparagraph (A); and</text>
 </clause><clause id="HEC898D82B0B14EC3B8A7372CABFBC4A7"><enum>(ii)</enum><text>the assessment summary and certification of the requestor shall be deemed accepted by the Secretary on such 30th day.</text>
											</clause></subparagraph><subparagraph id="H05877D96A83145BF92875A9984E43540"><enum>(C)</enum><header>Actions by Secretary</header>
 <clause id="H72E54A6581BE4CA2AD3DD30BEFC9A946"><enum>(i)</enum><header>In general</header><text>Within 30 days of receiving an assessment summary and certification under subparagraph (A), the Secretary may, by written notice to the accredited person submitting such assessment certification, deem any such certification to be provisional beyond such 30-day period, suspended pending further review by the Secretary, or otherwise qualified or cancelled, based on the Secretary’s determination that (as applicable)—</text>
 <subclause id="H806CA6FFFB434F52A95A55A268A99839"><enum>(I)</enum><text>additional information is needed to support such certification;</text> </subclause><subclause id="H71C7B664B36F41688C701C763E66AD6F"><enum>(II)</enum><text>such assessment or certification is unwarranted; or</text>
 </subclause><subclause id="HAAE6D0E8142443398E96DCF210E359DC"><enum>(III)</enum><text>such action with regard to the certification is otherwise justified according to such factors and criteria as the Secretary finds appropriate.</text>
 </subclause></clause><clause id="HF7AFCA699DF444598870D148CD033C6C"><enum>(ii)</enum><header>Acceptance of certification</header><text>If following action by the Secretary under clause (i) with respect to a certification, the Secretary determines that such certification is acceptable, the Secretary shall issue written notice to the applicable accredited person indicating such acceptance.</text>
											</clause></subparagraph></paragraph><paragraph id="HC98083C885AE453BB1FD2F363DFA3A6C"><enum>(2)</enum><header>Notifications to Secretary by certified manufacturers for program evaluation purposes</header>
 <subparagraph id="HB2CC2CDC09CB496C83A9795367451C35"><enum>(A)</enum><header>Periodic notification for manufacturing changes otherwise subject to thirty-day notice</header><text>A requestor certified under this section that effectuates device-related changes with respect to in-scope devices, without prior submission of a thirty-day notice, shall provide notification to the Secretary of such changes in the requestor’s next periodic report under section 814.84(b) of title 21, Code of Federal Regulations (or any successor regulation). Such notification shall—</text>
 <clause id="H21E1785A093B4ADA8E21F287491992C3"><enum>(i)</enum><text>describe the changes made; and</text> </clause><clause id="H9E78DA2AEDD44FE8856CAA7E0509F826"><enum>(ii)</enum><text>indicate the effective dates of such changes.</text>
 </clause></subparagraph><subparagraph id="H524F99D41D5E4718B8FD1DD54226C8C6"><enum>(B)</enum><header>Periodic notification for device-related changes otherwise subject to special pma supplement</header><text>A requestor certified under this section that effectuates device-related changes with respect to in-scope devices, without prior submission of a Special PMA Supplement, shall provide notification to the Secretary of such changes in the requestor’s next periodic report under section 814.84(b) of title 21, Code of Federal Regulations (or any successor regulation). Such notification shall—</text>
 <clause id="H4865817621DC49C992318B38C6144DE9"><enum>(i)</enum><text>describe the changes made, including a full explanation of the basis for the changes; and</text> </clause><clause id="H385EF134BA744834AAF2A559E5D6AE75"><enum>(ii)</enum><text>indicate the effective dates of such changes.</text>
 </clause></subparagraph><subparagraph id="H7F998CEB24614E63AF3F70FC21D3809B"><enum>(C)</enum><header>Use of notifications for program evaluation purposes</header><text>Information submitted to the Secretary under subparagraphs (A) and (B) shall be used by the Secretary for purposes of the program evaluation under subsection (d).</text>
 </subparagraph></paragraph></subsection><subsection id="H92A2E431E3A940B084480A8CC9B6FA59"><enum>(c)</enum><header>Duration and effect of certification</header><text>A certification under this section—</text> <paragraph id="H7AB78E9F333C4888A2F81003DBABC321"><enum>(1)</enum><text>shall remain in effect for a period of two years from the date such certification is accepted by the Secretary, subject to paragraph (6);</text>
 </paragraph><paragraph id="HE2FC296449294F67B8A7DFE55776A0E6"><enum>(2)</enum><text>may be renewed through the process described in subsection (a)(3);</text> </paragraph><paragraph id="HE4C3ABC81F0F4507B5A423B9D465E024"><enum>(3)</enum><text>shall continue to apply with respect to device-related changes made during such 2-year period, provided the certification remains in effect, irrespective of whether such certification is renewed after such 2-year period;</text>
 </paragraph><paragraph id="H3AE857FF03A74A8BAF66567481D08646"><enum>(4)</enum><text>shall have no effect on the need to comply with applicable submission requirements specified in subsection (a)(1)(C) with respect to any change pertaining to in-scope devices which is not a device-related change under subsection (a)(2);</text>
 </paragraph><paragraph id="H9DE54B6C72104D80A37FC22582870E41"><enum>(5)</enum><text>shall have no effect on the authority of the Secretary to conduct an inspection or otherwise determine the requestor’s conformance with the applicable requirements of this Act; and</text>
 </paragraph><paragraph id="HC0B09A4D52C94CC8A53CCAF50932D824"><enum>(6)</enum><text>shall be considered to be revoked if the Secretary provides written notification to the certified requestor that its quality system does not satisfy the certification criteria issued under subsection (a)(5) with respect to the in-scope devices at issue, such that the applicable submission requirements specified in subsection (a)(1)(C) must be met for changes made after receipt of such written notification, with respect to such devices.</text>
									</paragraph></subsection><subsection id="HC6E1597E17AF4E019CB2D74F4485038B"><enum>(d)</enum><header>Program evaluation; sunset</header>
									<paragraph id="H7CEFA0A0FD95475FBBD359A8C5489E13"><enum>(1)</enum><header>Program evaluation and report</header>
 <subparagraph id="H2EFED7D84B054BBC8FEBDC2AA5B0C932"><enum>(A)</enum><header>Evaluation</header><text>The Secretary shall complete an evaluation of the third-party quality system assessment program under this section no later than January 31, 2021, based on—</text>
 <clause id="HBE11EE295A3A432099B9CF16EF172F6D"><enum>(i)</enum><text>analysis of information from a representative group of device manufacturers obtained from notifications provided by certified requestors under subsection (b)(2); and</text>
 </clause><clause id="HEF1EE66030994284B5D82F609C32E03F"><enum>(ii)</enum><text>such other available information and data as the Secretary determines appropriate.</text> </clause></subparagraph><subparagraph id="H45E063D6E8FD4426B24FAD304938BDD1"><enum>(B)</enum><header>Report</header><text>No later than 1 year after completing the evaluation under subparagraph (A), the Secretary shall issue a report of the evaluation’s findings on the website of the Food and Drug Administration, which shall include the Secretary’s recommendations with respect to continuation and as applicable expansion of the program under this section to include additional types of submissions and additional types of changes beyond those identified in subsection (a)(1)(C), including changes to devices cleared under section 510(k). At the discretion of the Secretary, the program may be expanded prior to January 31, 2021.</text>
 </subparagraph></paragraph><paragraph id="H9118AB0124F743B4891AFEF81F39F071"><enum>(2)</enum><header>Sunset</header><text>This section shall cease to be effective October 1, 2022.</text> </paragraph></subsection><subsection id="H00D785365F40435EBBF88F719509C9BB"><enum>(e)</enum><header>Rule of construction</header><text>Nothing in this section shall be construed to limit the authority of the Secretary to request and review the complete assessment of a certified requestor under this section on a for-cause basis.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection><subsection id="H481766CE7B784B2EA50369EFB16FFD8E"><enum>(b)</enum><header>Conforming amendments</header>
 <paragraph id="HC1C3EF78C3A445449D27DDBD7FDE48D2"><enum>(1)</enum><header>Requirements for premarket approval supplements</header><text>Section 515(d)(6)(A)(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e(d)(6)(A)(i)</external-xref>) is amended by inserting <quote>, subject to section 524B,</quote> after <quote>that affects safety or effectiveness</quote>.</text>
 </paragraph><paragraph id="HB334056B46444F9081E2760AFBBB32F5"><enum>(2)</enum><header>Requirements for thirty-day notice</header><text>Section 515(d)(6)(A)(ii) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e(d)(6)(A)(ii)</external-xref>) is amended by inserting <quote>, subject to section 524B,</quote> after <quote>the date on which the Secretary receives the notice</quote>.</text>
 </paragraph></subsection></section><section commented="no" id="H82EA095CEBBF488ABCAD3F2EC0C8D514" section-type="subsequent-section"><enum>2222.</enum><header>Valid scientific evidence</header><text display-inline="no-display-inline">Section 513(a)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c(a)(3)(B)</external-xref>) is amended—</text>
 <paragraph commented="no" id="HF948B22ABC564118BAC579EC32A4190F"><enum>(1)</enum><text>by redesignating clauses (i) and (ii) as subclauses (I) and (II), respectively;</text> </paragraph><paragraph commented="no" id="H00AA14A5B54243898DD74DAC565D909C"><enum>(2)</enum><text>by striking <quote>(B) If the Secretary</quote> and inserting <quote>(B)(i) If the Secretary</quote>; and</text>
 </paragraph><paragraph commented="no" id="H8AD2BDB081EF41ACBE2ACB5C15D4395B"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block id="H8F8216E1786E4F288CE6B12D13C98AD1" style="OLC"> <clause commented="no" id="HD3377C9C0A934A2897704969A478FC82" indent="up1"><enum>(ii)</enum><text>Valid scientific evidence for purposes of clause (i) may include:</text>
 <subclause commented="no" id="HA66AAF645C03474DB23C2B88F0E2805C"><enum>(I)</enum><text>evidence described in well-documented case histories, including registry data, that are collected and monitored under an acceptable protocol;</text>
 </subclause><subclause commented="no" id="H19F2CFB84D814A479BB3CBC4A104276C"><enum>(II)</enum><text>studies published in peer-reviewed journals; and</text> </subclause><subclause commented="no" id="HEA06871590D142CC86816D1665D80D8E"><enum>(III)</enum><text>data collected in countries other than the United States so long as such data otherwise meets the criteria specified in this subparagraph.</text>
 </subclause></clause><clause commented="no" id="H2240374385B14DED9AB50B82C4F59621" indent="up1"><enum>(iii)</enum><text>In the case of a study published in a peer-reviewed journal that is offered as valid scientific evidence for purposes of clause (i), the Secretary may request data underlying the study if—</text>
 <subclause commented="no" id="HCF3B6A897FE34EE5A47270DF16946A88"><enum>(I)</enum><text>the Secretary, in making such request, complies with the requirement of subparagraph (D)(ii) to consider the least burdensome appropriate means of evaluating device effectiveness or subsection (i)(1)(D) to consider the least burdensome means of determining substantial equivalence, as applicable;</text>
 </subclause><subclause commented="no" id="H40EA72550BD34AA48156AD9919823B7D"><enum>(II)</enum><text>the Secretary furnishes a written rationale for so requesting the underlying data together with such request; and</text>
 </subclause><subclause commented="no" id="H520E15AEBF874975AAE5AE273F10C820"><enum>(III)</enum><text>if the requested underlying data for such a study are unavailable, the Secretary shall consider such study to be part of the totality of the evidence with respect to the device, as the Secretary determines appropriate.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></section><section id="H9C1C0759DBF04A77AB35F705086F7C24"><enum>2223.</enum><header>Training and oversight in least burdensome appropriate means concept</header>
 <subsection id="H60AB2122A30D4D63BC00B622794D31E8"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 513 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c</external-xref>) is amended by inserting after subsection (i) the following:</text>
						<quoted-block id="HB8C3FC5028ED4BA09BF3F96347596BB4" style="OLC">
 <subsection id="H919CBEFE0E0F4DEE81BF01F7EDEDE6D2"><enum>(j)</enum><header>Training and oversight in least burdensome appropriate means concept</header><text display-inline="yes-display-inline"></text> <paragraph id="H8A864F22C12C44EF8B6C0C43063AFCA5"><enum>(1)</enum><header>Training</header><text display-inline="yes-display-inline">Each employee of the Food and Drug Administration who is involved in the review of premarket submissions under section 515 or section 510(k), including supervisors, shall receive training regarding the meaning and implementation of the least burdensome appropriate means concept in the context of the use of that term in subsections (a)(3)(D) and (i)(1)(D) of this section and in section 515(c)(5).</text>
								</paragraph><paragraph id="HCDAC1E10F98E4B88BDF8E1CB884AAD56"><enum>(2)</enum><header>Guidance documents</header>
 <subparagraph id="H387EE2DD9A2249F384E5A9FCF0B2F1D6"><enum>(A)</enum><header>Draft updated guidance</header><text display-inline="yes-display-inline">Not later than 12 months after the date of enactment of the <short-title>21st Century Cures Act</short-title>, the Secretary shall issue a draft guidance document updating the October 4, 2002, guidance document entitled <quote>The Least Burdensome Provision of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry</quote>.</text>
 </subparagraph><subparagraph id="H66ED019262C14E1F8C17B9B26327358F"><enum>(B)</enum><header>Meeting of stakeholders</header><text>In developing such draft guidance document, the Secretary shall convene a meeting of stakeholders to ensure a full record to support the publication of such document.</text>
 </subparagraph></paragraph><paragraph id="H96B9CC4BDFE0489D8383E03A845DD8ED"><enum>(3)</enum><header>Ombudsman audit</header><text display-inline="yes-display-inline">Not later than 18 months after the date of issuance of final version of the draft guidance under paragraph (2), the ombudsman for the organizational unit of the Food and Drug Administration responsible for the premarket review of devices shall—</text>
 <subparagraph id="HEB05A1A1C729463888D6AB39CF81AB3C"><enum>(A)</enum><text>conduct, or have conducted, an audit of the training described in paragraph (1); and</text> </subparagraph><subparagraph id="H0B4CFCDD660648878EFECB590CF4F7B2"><enum>(B)</enum><text>include in such audit interviews with a representative sample of persons from industry regarding their experience in the device premarket review process.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H7C29E9A6BE2B4683AFFDA5E9394C3056"><enum>(b)</enum><header>Additional information regarding premarket applications</header><text display-inline="yes-display-inline">Subsection (c) of section 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S. C. 29 360e) is amended by adding at the end the follows:</text>
						<quoted-block display-inline="no-display-inline" id="HAD48080FA6A1404397176B8256C128D0" style="OLC">
							<paragraph id="HC06489B11C2945CA93C4CA95ACB63BA4" indent="up1"><enum>(5)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="H1801B57FC5BE437BA0A0D5D29B0ECCF6"><enum>(A)</enum><text display-inline="yes-display-inline">Whenever the Secretary requests additional information from an applicant regarding an application under paragraph (1), the Secretary shall consider the least burdensome appropriate means necessary to demonstrate device safety and effectiveness, and request information accordingly.</text>
 </subparagraph><subparagraph id="H7AE76C6E9225470CB3844C145CF7DCFE" indent="up1"><enum>(B)</enum><text>For purposes of subparagraph (A), the term <quote>necessary</quote> means the minimum required information that would support a determination by the Secretary that an application provides a reasonable assurance of the safety and effectiveness of the device.</text>
 </subparagraph><subparagraph id="H669CB16CB4124388B04D883D5CEF17D5" indent="up1"><enum>(C)</enum><text>Nothing in this paragraph alters the standards for premarket approval of a device.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection></section><section id="HEC0D9146130F4D1B8889515967C6BC2C"><enum>2224.</enum><header>Recognition of standards</header><text display-inline="no-display-inline">Section 514(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360d">21 U.S.C. 360d(c)</external-xref>) is amended—</text>
 <paragraph id="H778185897F6247A882D6D2B6B67E1D01"><enum>(1)</enum><text>in paragraph (1), by inserting after subparagraph (B) the following new subparagraphs:</text> <quoted-block id="H458EB4CA456D4954AC32896D974F352D" style="OLC"> <subparagraph id="H1FF33EC6D8964573AE68A4DC6F4C867F"><enum>(C)</enum> <clause commented="no" display-inline="yes-display-inline" id="HE8D36D1AB3174C999DE7C8258352D810"><enum>(i)</enum><text>Any person may submit a request for recognition under subparagraph (A) of all or part of an appropriate standard established by a nationally or internationally recognized standard organization.</text>
 </clause><clause id="HF3ACB21F9D9B41BD856AAE1A986988FA" indent="up1"><enum>(ii)</enum><text>Not later than 60 days after the Secretary receives such a request, the Secretary shall—</text> <subclause id="H7C10FFA0AE6D41E1BBEEB843F8B80656"><enum>(I)</enum><text>make a determination to recognize all, part, or none of the standard that is the subject of the request; and</text>
 </subclause><subclause id="HA1FF2104A933465F9C76BE18A247A9D4"><enum>(II)</enum><text>issue to the person who submitted such request a response in writing that states the Secretary’s rationale for that determination, including the scientific, technical, regulatory, or other basis for such determination;</text>
 </subclause></clause><clause id="H51E238561E1449F4B6399BD9E4E81B53" indent="up1"><enum>(iii)</enum><text>The Secretary shall make a response issued under clause (ii)(II) publicly available, in such manner as the Secretary determines appropriate.</text>
 </clause><clause id="H25D7E1A17B31433793B0299B9526E40C" indent="up1"><enum>(iv)</enum><text>The Secretary shall take such actions as may be necessary to implement all or part of a standard recognized under subclause (I), in accordance with subparagraph (A). <italic></italic></text>
 </clause></subparagraph><subparagraph id="H5E4B3ED1223143A6AB65199CBEE9EE23"><enum>(D)</enum><text>The Secretary shall make publicly available, in such manner as the Secretary determines appropriate, the rationale for recognition under subparagraph (A) of part of a standard, including the scientific, technical, regulatory, or other basis for such recognition.<italic></italic></text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HC0BD1F043B604AB192001656C01AC4A6"><enum>(2)</enum><text>by adding at the end the following new paragraphs:</text> <quoted-block id="H9AF2D269348C44DF8DC5343D1CE1E928" style="OLC"> <paragraph id="HE0833009706441DF853C36AFB8875002"><enum>(4)</enum><header>Training on use of standards</header><text display-inline="yes-display-inline">The Secretary shall provide to all employees of the Food and Drug Administration who review premarket submissions for devices periodic training on the concept and use of recognized standards for purposes of meeting a premarket submission requirement or other applicable requirement under this Act, including standards relevant to an employee’s area of device review.</text>
							</paragraph><paragraph id="HBA6D9644720E4601835AB81EA7D1E777"><enum>(5)</enum><header>Guidance</header>
 <subparagraph id="H2C7B2344A2DA4F4EBC89D7D72304EA39"><enum>(A)</enum><header>Draft guidance</header><text>The Secretary shall publish guidance identifying the principles for recognizing standards under this section. In publishing such guidance, the Secretary shall consider the experience with, and reliance on, a standard by other Federal regulatory authorities and the device industry, and whether recognition of a standard will promote harmonization among regulatory authorities in the regulation of devices.</text>
 </subparagraph><subparagraph id="HF243FC9E92C241D79D093F6E3FCC1700"><enum>(B)</enum><header>Timing</header><text display-inline="yes-display-inline">The Secretary shall publish—</text> <clause id="HB3DE5A7807C2473AA9B59791504D3E45"><enum>(i)</enum><text>draft guidance under subparagraph (A) not later than 12 months after the date of the enactment of the 21st Century Cures Act; and</text>
 </clause><clause id="H21D2066342E344BE9440D1805384D170"><enum>(ii)</enum><text display-inline="yes-display-inline">final guidance not later than 12 months of the close of the public comment period for the draft guidance under clause (i).</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></section><section id="H04E36891A1B04EDF9E97796DFA713E47" section-type="subsequent-section"><enum>2225.</enum><header>Easing regulatory burden with respect to certain class I and class II devices</header>
 <subsection id="H0A3A6941600744A8AF5609652E3736F3"><enum>(a)</enum><header>Class I devices</header><text display-inline="yes-display-inline">Section 510(l) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(l)</external-xref>) is amended—</text> <paragraph id="HD2A3C744ECB64E4A9765EC07829D9F42"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>A report under subsection (k)</quote> and inserting <quote>(1) A report under subsection (k)</quote>; and</text>
 </paragraph><paragraph id="H8FC3A2F0E9BB4E33997CA34C564BAADB"><enum>(2)</enum><text>by adding at the end the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="H2E58BE3C0ECB46FFAF42D99B958CC42B" style="traditional"> <paragraph id="HEBCBD5E4497E4D1981DFD7325DBDF578" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">Not later than 120 days after the date of the enactment of the <short-title>21st Century Cures Act</short-title>, the Secretary shall identify, through publication in the Federal Register, any type of class I device that the Secretary determines no longer requires a report under subsection (k) to provide reasonable assurance of safety and effectiveness. Upon such publication—</text>
 <subparagraph id="HEECB52DBB97B47A1BC244E1AF973D958"><enum>(A)</enum><text display-inline="yes-display-inline">each type of class I device so identified shall be exempt from the requirement for a report under subsection (k); and</text>
 </subparagraph><subparagraph id="H6DB7576B2256438B9AC2ADE76A265FD3"><enum>(B)</enum><text display-inline="yes-display-inline">the classification regulation applicable to each such type of device shall be deemed amended to incorporate such exemption.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HC9F9395E116E4508966D86F6EEA4F06B"><enum>(b)</enum><header>Class II devices</header><text display-inline="yes-display-inline">Section 510(m) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(m)</external-xref>) is amended—</text> <paragraph id="H5E4A6C1CB667476EAD792DF76391DAC7"><enum>(1)</enum><text display-inline="yes-display-inline">by striking paragraph (1) and inserting the following new paragraph:</text>
							<quoted-block display-inline="no-display-inline" id="HEE3CD2BD86074A25B216D70C0D5D5078" style="traditional">
 <paragraph id="HA9A078AAE2AB4E1C8AB15F661C829465" indent="up1"><enum>(1)</enum><text>The Secretary shall—</text> <subparagraph id="H1B914C25A51B420C9DECE9F5CE53B4C1"><enum>(A)</enum><text display-inline="yes-display-inline">not later than 60 days after the date of the enactment of the <short-title>21st Century Cures Act</short-title>—</text>
 <clause id="HD3E73CBA21364B2F8620CCD1E9782F51"><enum>(i)</enum><text display-inline="yes-display-inline">publish in the Federal Register a notice that contains a list of each type of class II device that the Secretary determines no longer requires a report under subsection (k) to provide reasonable assurance of safety and effectiveness; and</text>
 </clause><clause id="H3E92A27380A14E05B704D3D1B95867CD"><enum>(ii)</enum><text display-inline="yes-display-inline">provide for a period of not less than 60 days for public comment beginning on the date of the publication of such notice; and</text>
 </clause></subparagraph><subparagraph id="HE2BE18353DC04FF39E95F468D860D42C"><enum>(B)</enum><text display-inline="yes-display-inline">not later than 180 days after the date of the enactment of <short-title>21st Century Cures Act</short-title>, publish in the Federal Register a list representing the Secretary’s final determination with respect to the devices contained in the list published under subparagraph (A).</text></subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H4DB82B5CD2624C54849CA927018936F1"><enum>(2)</enum><text>in paragraph (2)—</text> <subparagraph id="H6502027370AE4785960A964CBF700310"><enum>(A)</enum><text display-inline="yes-display-inline">by striking <quote>1 day after the date of publication of a list under this subsection,</quote> and inserting <quote>1 day after the date of publication of the final list under paragraph (1)(B),</quote>; and</text>
 </subparagraph><subparagraph id="H2911C3E8CED747B2AB9066ABD11609FA"><enum>(B)</enum><text>by striking <quote>30-day period</quote> and inserting <quote>60-day period</quote>; and</text> </subparagraph></paragraph><paragraph id="HDF01C8D773AE49F8A1F857C6B5020852"><enum>(3)</enum><text display-inline="yes-display-inline">by adding at the end the following new paragraph:</text>
							<quoted-block display-inline="no-display-inline" id="H2C61AFEB06A348CAB763E5F0372F9849" style="traditional">
 <paragraph id="HBEED8129787C4956BAF81CE60D948B55" indent="up1"><enum>(3)</enum><text>Upon the publication of the final list under paragraph (1)(B)—</text> <subparagraph id="H75A3D3A2DA824076950EE8C5F131586D"><enum>(A)</enum><text display-inline="yes-display-inline">each type of class II device so listed shall be exempt from the requirement for a report under subsection (k); and</text>
 </subparagraph><subparagraph id="HC40BEBDB5B7D44B989FD4A7DA37A4A62"><enum>(B)</enum><text display-inline="yes-display-inline">the classification regulation applicable to each such type of device shall be deemed amended to incorporate such exemption.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection></section><section id="H0A46E9AE8BDE40A68BBF94244CB6ED58"><enum>2226.</enum><header>Advisory committee process</header>
 <subsection id="HD9914C8DE5E64CE88C49C42647CE2CCF"><enum>(a)</enum><header>Classification panels</header><text>Paragraph (5) of section 513(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c(b)</external-xref>) is amended—</text>
 <paragraph id="H2C25472930E3468CA5BD66B7D4A99BE9"><enum>(1)</enum><text>by striking <quote>(5)</quote> and inserting <quote>(5)(A)</quote>; and</text> </paragraph><paragraph id="H3C64B9A9F66B4D0BB31929A2B0B4EC1D"><enum>(2)</enum><text>by adding at the end the following:</text>
							<quoted-block id="H2520818CD99447E2A80A9F5AAFDE1F25" style="OLC">
 <subparagraph id="H7C7F00373F9944A2A26FFDA505E3B7CC"><enum>(B)</enum><text display-inline="yes-display-inline">When a device is specifically the subject of review by a classification panel, the Secretary shall—</text> <clause id="HCE7FDBF8EE954648A941AF935AFEF871"><enum>(i)</enum><text>ensure that adequate expertise is represented on the classification panel to assess—</text>
 <subclause id="H3C4293294F174C1BBB34E24FBEB1A8A2"><enum>(I)</enum><text>the disease or condition which the device is intended to cure, treat, mitigate, prevent, or diagnose; and</text>
 </subclause><subclause id="H5B09D8B3BB87401997813D3D57E92BBF"><enum>(II)</enum><text>the technology of the device; and</text> </subclause></clause><clause id="HC6360B6E3AFA4AE796A30557AA92038C"><enum>(ii)</enum><text display-inline="yes-display-inline">as part of the process to ensure adequate expertise under clause (i), give due consideration to the recommendations of the person whose premarket submission is subject to panel review on the expertise needed among the voting members of the panel.</text>
 </clause></subparagraph><subparagraph id="HF7AEB9DACD6E4B3088E9838DF4B59D3D"><enum>(C)</enum><text>For review by a classification panel of a premarket submission for a device, the Secretary shall—</text> <clause id="HD51EE03CFF564ED88B4973A5262796F5"><enum>(i)</enum><text display-inline="yes-display-inline">provide an opportunity for the person whose premarket submission is subject to panel review to provide recommendations on the expertise needed among the voting members of the panel; and</text>
 </clause><clause id="HB7675629CA1449EEB4E1F1A4CF45E8A6"><enum>(ii)</enum><text display-inline="yes-display-inline">give due consideration to such recommendations and ensure that adequate expertise is represented on advisory panels to assess—</text>
 <subclause id="H5018D7904D344E9CBC8B9C4288C09760"><enum>(I)</enum><text display-inline="yes-display-inline">the disease or condition for which the device is intended to cure, treat, mitigate, prevent, or diagnose; and</text>
 </subclause><subclause id="H6FEBF122C5B442B3B00E3E63940A46D0"><enum>(II)</enum><text display-inline="yes-display-inline">the technology of the device.</text> </subclause></clause></subparagraph><subparagraph id="H89ED851C0CCB4B7EB336B9A6732CD1A2"><enum>(D)</enum><text>For purposes of subparagraph (B)(ii), the term <quote>adequate expertise</quote> means that the membership of the classification panel reviewing a premarket submission includes—</text>
 <clause id="HB1E210EC24074C51AB15AB21C194A5DC"><enum>(i)</enum><text>two or more voting members, with a specialty or other expertise clinically relevant to the device under review; and</text>
 </clause><clause id="H7E19C276CA684E9A8B801C95073ED715"><enum>(ii)</enum><text>at least one voting member who is knowledgeable about the technology of the device.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></subsection><subsection id="H6D9785284C3C4C56857496E726BA71ED"><enum>(b)</enum><header>Panel review process</header><text>Section 513(b)(6) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360c">21 U.S.C. 360c(b)(6)</external-xref>) is amended—</text>
 <paragraph id="H4FFEFF1FDD744DAFA07B99A2C3E951EB"><enum>(1)</enum><text>in subparagraph (A)(iii), by inserting before the period at the end <quote>, including by designating a representative who will be provided a time during the panel meeting to address the panel individually (or accompanied by experts selected by such representative) for the purpose of correcting misstatements of fact or providing clarifying information, subject to the discretion of panel chairperson.</quote>.</text>
 </paragraph><paragraph id="H28986D1C1EA3489C8E44981E9C841CB2"><enum>(2)</enum><text>by striking subparagraph (B) and inserting the following new subparagraph:</text> <quoted-block id="HB3F32A405D4E4C5B85784252B470752B" style="OLC"> <subparagraph id="H374F8041EC3846B8B86BE7D8C31A23ED"><enum>(B)</enum> <clause commented="no" display-inline="yes-display-inline" id="H7B411D3CF8B74B05A21AF9FB1B066188"><enum>(i)</enum><text display-inline="yes-display-inline">Any meeting of a classification panel for a device that is specifically the subject of review shall—</text>
 <subclause id="H71AC50EEB88C4624B7D87BB93381FF09" indent="up1"><enum>(I)</enum><text display-inline="yes-display-inline">provide adequate time for initial presentations by the person whose device is specifically the subject of a classification panel review and by the Secretary; and</text>
 </subclause><subclause id="H048DEEC0C22144F6ABD19BA906BB8CE6" indent="up1"><enum>(II)</enum><text>encourage free and open participation by all interested persons.</text> </subclause></clause><clause id="HD7BF029032E6461485AEE3D4C496272B" indent="up1"><enum>(ii)</enum><text>Following the initial presentations described in clause (i), the panel may—</text>
 <subclause id="HFDA068B9526F4F4B8A2BF544613C20D3"><enum>(I)</enum><text>pose questions to a designated representative described in subparagraph (A)(iii); and</text> </subclause><subclause id="HC6F737D6292C4D23AFBC13B43CBC8BA5"><enum>(II)</enum><text display-inline="yes-display-inline">consider the responses to such questions in the panel’s review of the device that is specifically the subject of review by the classification panel.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection></section><section id="H9038248F875246BDAD7D125E7B6A5A7A"><enum>2227.</enum><header>Humanitarian device exemption application</header>
 <subsection id="H0AE63E78828E4F9EAA4FFB32DF10F71B"><enum>(a)</enum><header>In general</header><text>Section 520(m) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j</external-xref>) is amended—</text> <paragraph id="H219FB14C99264007B7DA36CF6E576F32"><enum>(1)</enum><text>in paragraph (1) by striking <quote>fewer than 4,000</quote> and inserting <quote>not more than 8,000</quote>;</text>
 </paragraph><paragraph id="HB94ED768081547FFA352FA985D887611"><enum>(2)</enum><text>in paragraph (2)(A) by striking <quote>fewer than 4,000</quote> and inserting <quote>not more than 8,000</quote>; and</text> </paragraph><paragraph id="H7042B839EE5C4C48AB4A6CEC7B7BF267"><enum>(3)</enum><text>in paragraph (6)(A)(ii), by striking <quote>4,000</quote> and inserting <quote>8,000</quote></text>
 </paragraph></subsection><subsection id="H8CA67462F39E4D7A8F6DC05503F8476D"><enum>(b)</enum><header>Guidance document on probable benefit</header><text>Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall publish a draft guidance document that defines the criteria for establishing <quote>probable benefit</quote> as that term is used in section 520(m)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(m)(2)(C)</external-xref>).</text>
					</subsection></section><section id="H2B9EBE91C1BD4A69B3CB2E8220B90B65"><enum>2228.</enum><header>CLIA waiver study design guidance for in vitro diagnostics</header>
 <subsection id="H5C2CC096F2A64D4EA7CAEA28D8939C97"><enum>(a)</enum><header>Draft revised guidance</header><text>Not later than 12 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall publish a draft guidance that—</text>
 <paragraph id="H64E6248AAE924D699A641601C07AA062"><enum>(1)</enum><text>revises section V <quote>Demonstrating Insignificant Risk of an Erroneous Result—<quote>Accuracy</quote></quote> of the guidance entitled <quote>Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices</quote> and dated January 30, 2008; and</text>
 </paragraph><paragraph id="HD74661AF871C4296AAA953C573A2EEB8"><enum>(2)</enum><text>includes guidance on the appropriate use of comparable performance between a waived user and a moderately complex laboratory user to demonstrate accuracy.</text>
 </paragraph></subsection><subsection id="H2B973FC574B34F4F89F1D584F6802A7D"><enum>(b)</enum><header>Final revised guidance</header><text>The Secretary of Health and Human Services shall finalize the draft guidance published under subsection (a) not later than 12 months after the comment period for such draft guidance closes.</text>
					</subsection></section></subtitle><subtitle commented="no" id="HEEEED248ECE94AE8A5CD2D9D396FCEAE"><enum>N</enum><header>Sensible Oversight for Technology Which Advances Regulatory Efficiency</header>
 <section commented="no" id="H40ADF390FEF9414C9E15DB9387D75685"><enum>2241.</enum><header>Health software</header><text display-inline="no-display-inline">Section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block id="H8D0C89F9628943DEB32EAE8182A7CD7C" style="OLC">
						<subsection commented="no" id="H5A479E21F1A8428EB2BBB27D2B8D6DA2"><enum>(ss)</enum>
 <paragraph commented="no" display-inline="yes-display-inline" id="H484E016299E64BFC9F886538FB074A32"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>health software</quote> means software that does not, through use of an in vitro diagnostic device or signal acquisition system, acquire, process, or analyze an image or physiological signal, is not an accessory, is not an integral part of a device necessary to support the use of the device, is not used in the manufacture and transfusion of blood and blood components to assist in the prevention of disease in humans, and—</text>
 <subparagraph commented="no" id="H3B09555C534B48C1870118647F82B677"><enum>(A)</enum><text display-inline="yes-display-inline">is intended for use for administrative or operational support or the processing and maintenance of financial records;</text>
 </subparagraph><subparagraph commented="no" id="H4138840811054826AE76F8273CFD69E7"><enum>(B)</enum><text>is intended for use in clinical, laboratory, or administrative workflow and related recordkeeping;</text> </subparagraph><subparagraph commented="no" id="H82EBB8B3005B4BE49D2516954E7F8F4C"><enum>(C)</enum> <clause commented="no" display-inline="yes-display-inline" id="H2DB7C5397016422F9F29E56748320A5D"><enum>(i)</enum><text>is intended for use solely in the transfer, aggregation, conversion (in accordance with a present specification), storage, management, retrieval, or transmission of data or information;</text>
 </clause><clause commented="no" id="HF542A49DB86449D585B0346AD45ACB07" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">utilizes a connectivity software platform, electronic or electrical hardware, or a physical communications infrastructure; and</text>
 </clause><clause commented="no" id="HBDBA687F18214561BA98B502A9C48F75" indent="up1"><enum>(iii)</enum><text display-inline="yes-display-inline">is not intended for use—</text> <subclause commented="no" id="HB73802B3F00C4FC9B0FCD74041A6F4EA"><enum>(I)</enum><text display-inline="yes-display-inline">in active patient monitoring; or</text>
 </subclause><subclause commented="no" id="HD5014DF2B9A641E5A2185D81284100DE"><enum>(II)</enum><text display-inline="yes-display-inline">in controlling or altering the functions or parameters of a device that is connected to such software;</text>
 </subclause></clause></subparagraph><subparagraph commented="no" id="HD5A1B63E394B4E698AB97011657FF133"><enum>(D)</enum><text display-inline="yes-display-inline">is intended for use to organize and present information for health or wellness education or for use in maintaining a healthy lifestyle, including medication adherence and health management tools;</text>
 </subparagraph><subparagraph commented="no" id="HB600FFF34B7D4480946E82975F224277"><enum>(E)</enum><text display-inline="yes-display-inline">is intended for use to analyze information to provide general health information that does not include patient-specific recommended options to consider in the prevention, diagnosis, treatment, cure, or mitigation of a particular disease or condition; or</text>
 </subparagraph><subparagraph commented="no" id="HC0C6D36724564F5B9D597B7771B60055"><enum>(F)</enum><text display-inline="yes-display-inline">is intended for use to analyze information to provide patient-specific recommended options to consider in the prevention, diagnosis, treatment, cure, or mitigation of a particular disease or condition.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HD42DAF2ECEFE4260B4AFDAE96FABEAA8" indent="up1"><enum>(2)</enum><text>The term <quote>accessory</quote> means a product that—</text> <subparagraph commented="no" id="HAAE2AEEED39B4B3D84FC1828032F030A"><enum>(A)</enum><text>is intended for use with one or more parent devices;</text>
 </subparagraph><subparagraph commented="no" id="HF134B0006C9346098292B852027BE7E3"><enum>(B)</enum><text display-inline="yes-display-inline">is intended to support, supplement, or augment the performance of one or more parent devices; and</text> </subparagraph><subparagraph commented="no" id="H4D1DC745E33346B1B63DA93DDD84D0D7"><enum>(C)</enum><text>shall be classified by the Secretary—</text>
 <clause commented="no" id="HA746477BEA6B45E1A040AD0D3E63A768"><enum>(i)</enum><text>according to its intended use; and</text> </clause><clause commented="no" id="H93BD65E2912A43ABABC7E523092A9B34"><enum>(ii)</enum><text>independently of any classification of any parent device with which it is used.</text></clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section commented="no" id="H4369F70167C74BD09132147A9C9A5D7C"><enum>2242.</enum><header>Applicability and inapplicability of regulation</header><text display-inline="no-display-inline">Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="HC5CB27F2C9D14B82B51A72DB12700476" style="OLC">
						<section commented="no" id="H7B07466DF9924FBF81A0176957753D65"><enum>524B.</enum><header>Health software</header>
 <subsection commented="no" id="H5153359159904966AE65B46E5C2FB63F"><enum>(a)</enum><header>Inapplicability of regulation to health software</header><text display-inline="yes-display-inline">Except as provided in subsection (b), health software shall not be subject to regulation under this Act.</text>
							</subsection><subsection commented="no" id="H1E89FAAC0FFE431F977F2CEDB4D517B9"><enum>(b)</enum><header>Exception</header>
 <paragraph id="H9D652FD03D824F9A9512CE486CB2C5AF"><enum>(1)</enum><header>In general</header><text>Subsection (a) shall not apply with respect to a software product—</text> <subparagraph id="H78D7151C14264FB49CF5C1BDEECBCA82"><enum>(A)</enum><text>of a type described in subparagraph (F) of section 201(ss)(1); and</text>
 </subparagraph><subparagraph id="H50D8F07604E34D0EA1C8664008125308"><enum>(B)</enum><text>that the Secretary determines poses a significant risk to patient safety.</text> </subparagraph></paragraph><paragraph id="HBD9AFBD6A2054EB0973AB381E91D48F3"><enum>(2)</enum><header>Considerations</header><text>In making a determination under subparagraph (B) of paragraph (1) with respect to a product to which such paragraph applies, the Secretary shall consider the following:</text>
 <subparagraph commented="no" id="H9BA2FCCC5DE1410E96967D8F03800B60"><enum>(A)</enum><text display-inline="yes-display-inline">The likelihood and severity of patient harm if the product were to not perform as intended.</text> </subparagraph><subparagraph commented="no" id="H0F146D0395BC4EC0983BA12101053183"><enum>(B)</enum><text display-inline="yes-display-inline">The extent to which the product is intended to support the clinical judgment of a medical professional.</text>
 </subparagraph><subparagraph commented="no" id="H34B303255F894576B2E6856E7EA00873"><enum>(C)</enum><text display-inline="yes-display-inline">Whether there is a reasonable opportunity for a medical professional to review the basis of the information or treatment recommendation provided by the product.</text>
 </subparagraph><subparagraph commented="no" id="HC51E56D87E6C47139A50B51BF244A66E"><enum>(D)</enum><text display-inline="yes-display-inline">The intended user and user environment, such as whether a medical professional will use a software product of a type described in subparagraph (F) of section 201(ss)(1).</text>
 </subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H0F4AD36320164DFCBCFAA6299D49BAA2"><enum>(c)</enum><header>Delegation</header><text display-inline="yes-display-inline">The Secretary shall delegate primary jurisdiction for regulating a software product determined under subsection (b) to be subject to regulation under this Act to the center at the Food and Drug Administration charged with regulating devices. <italic></italic></text>
							</subsection><subsection commented="no" id="HC1744E926B8942E49239E25EC7BBC56A"><enum>(d)</enum><header>Regulation of software</header>
 <paragraph commented="no" id="HCA72498B3D004005B5CB4879173D4A55"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall review existing regulations and guidance regarding the regulation of software under this Act. The Secretary may implement a new framework for the regulation of software and shall, as appropriate, modify such regulations and guidance or issue new regulations or guidance.</text>
 </paragraph><paragraph commented="no" id="H8C73CE8CD4C547778E57C364474BC48B"><enum>(2)</enum><header>Issuance by order</header><text>Notwithstanding subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code, the Secretary may modify or issue regulations for the regulation of software under this Act by administrative order published in the Federal Register following the publication of a proposed order.</text>
 </paragraph><paragraph commented="no" id="H0AB2FA1FA2A448C985FC2878A6000CE5"><enum>(3)</enum><header>Areas under review</header><text>The review of existing regulations and guidance under paragraph (1) may include review of the following areas:</text>
 <subparagraph commented="no" id="HAA1967AC383D4696954BD67C474F7EFA"><enum>(A)</enum><text display-inline="yes-display-inline">Classification of software.</text> </subparagraph><subparagraph commented="no" id="H47829FEC18A8422B85EE6A571958109D"><enum>(B)</enum><text>Standards for development of software.</text>
 </subparagraph><subparagraph commented="no" id="H64C2A9314DE54AD7B03914A47CAB0375"><enum>(C)</enum><text>Standards for validation and verification of software.</text> </subparagraph><subparagraph commented="no" id="H6FD9F244959D4247B1196AEF4CB6A73D"><enum>(D)</enum><text>Review of software.</text>
 </subparagraph><subparagraph commented="no" id="HBDE77F1C46454A3DA02C90096A89B5E2"><enum>(E)</enum><text>Modifications to software.</text> </subparagraph><subparagraph commented="no" id="HAF1282C291DF494084C2D8A1D0820589"><enum>(F)</enum><text>Manufacturing of software.</text>
 </subparagraph><subparagraph commented="no" id="H5860C6DE3A9948DFB213E85835272444"><enum>(G)</enum><text>Quality systems for software.</text> </subparagraph><subparagraph commented="no" id="H7705B2273BEF4EA4B84DC24BB3BBFF7F"><enum>(H)</enum><text>Labeling requirements for software.</text>
 </subparagraph><subparagraph commented="no" id="HB589AAAF066F422BA86159DC44BF9692"><enum>(I)</enum><text>Postmarketing requirements for reporting of adverse events.</text> </subparagraph></paragraph><paragraph commented="no" id="HD11EA5D49DB94F898BFFBC02905D3D6B"><enum>(4)</enum><header>Process for issuing proposed regulations, administrative order, and guidance</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this section, the Secretary shall consult with external stakeholders (including patients, industry, health care providers, academia, and government) to gather input before issuing regulations, an administrative order, and guidance under this subsection.</text>
 </paragraph></subsection><subsection id="H87FC6267B2384184ACEA5B90AA2544B0"><enum>(e)</enum><header>Rule of construction</header><text>Nothing in this section shall be construed as providing the Secretary with the authority to regulate under this Act any health software product of the type described in subparagraph (F) of section 201(ss)(1) unless and until the Secretary has made a determination described in subsection (b)(1)(B) with respect to such product.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section commented="no" id="H30B6A7B764E94C54814B39F74E295BD3"><enum>2243.</enum><header>Exclusion from definition of device</header><text display-inline="no-display-inline">Section 201(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>) is amended—</text> <paragraph commented="no" id="H5F4258C00C644F9A84B69B8FF3E1D018"><enum>(1)</enum><text>in subparagraph (2), by striking <quote>or</quote> after <quote>or other animals,</quote>;</text>
 </paragraph><paragraph commented="no" id="H0842C05A755D440687B4DDAD06BB5730"><enum>(2)</enum><text>in subparagraph (3), by striking <quote>and</quote> and inserting <quote>or</quote>; and</text> </paragraph><paragraph commented="no" id="H7552105585834D88A3FCB2B8CABF22D4"><enum>(3)</enum><text>by inserting after subparagraph (3) the following:</text>
						<quoted-block display-inline="no-display-inline" id="H7E38BB22AECF4F99838FEEF3CF005778" style="OLC">
 <paragraph commented="no" id="HC311378811134A00AB3A65E9DF5C8060"><enum>(4)</enum><text display-inline="yes-display-inline">is not health software (other than software determined to be a risk to patient safety under section 524B(b)), and</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></section></subtitle><subtitle id="HC3AC028E78C74D23B3BF1283368B9EBD"><enum>O</enum><header>Streamlining Clinical Trials</header>
				<section id="HFAC71E4CFA1946D9AA9B7C92F3238320"><enum>2261.</enum><header>Protection of human subjects in research; applicability of rules</header>
 <subsection id="HFCE25E13FBED455DBFD33792816A335E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">In order to simplify and facilitate compliance by researchers with applicable regulations for protection of human subjects in research, the Secretary of Health and Human Services shall, to the extent possible and consistent with other statutory provisions, harmonize differences between the HHS Human Subject Regulations and the FDA Human Subject Regulations in accordance with subsection (b).</text>
					</subsection><subsection commented="no" id="H8FBCC6DD63D445EBA54FA040CFAEC365"><enum>(b)</enum><header>Avoiding regulatory duplication and unnecessary delays</header>
 <paragraph commented="no" id="H05CC625994414F73AAEE4B3EB9E474A7"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall—</text> <subparagraph commented="no" id="H1D7AE725E68E4344998D0540A5CA1410"><enum>(A)</enum><text>make such modifications to the provisions of the HHS Human Subject Regulations and the vulnerable-populations rules as may be necessary—</text>
 <clause commented="no" id="HA7971F90D5FC4ACD99043C3755C8650D"><enum>(i)</enum><text>to reduce regulatory duplication and unnecessary delays;</text> </clause><clause commented="no" id="HAB819CF975FB4DBA88EE7B609F13D97F"><enum>(ii)</enum><text>to modernize such provisions in the context of multisite and cooperative research projects; and</text>
 </clause><clause commented="no" id="HD9CED84ADF804D7FB5F13376EA5B8361"><enum>(iii)</enum><text display-inline="yes-display-inline">to incorporate local considerations, community values, and mechanisms to protect vulnerable populations; and</text>
 </clause></subparagraph><subparagraph commented="no" id="H51CAA1FE5E3D4794867E6C52B64BFCA4"><enum>(B)</enum><text display-inline="yes-display-inline">ensure that human subject research that is subject to the HHS Human Subject Regulations or to the FDA Human Subject Regulations may—</text>
 <clause commented="no" id="HA17AC16AC0544B2A95E5CE1C1D956471"><enum>(i)</enum><text>use joint or shared review;</text> </clause><clause commented="no" id="H92857282C1D84451A7987CF80B9FAC35"><enum>(ii)</enum><text>rely upon the review of—</text>
 <subclause commented="no" id="HEE7BAF6E1A7E436D9274C7B74E775602"><enum>(I)</enum><text>an independent institutional review board; or</text> </subclause><subclause commented="no" id="H58FDFB86A6D34E42A9A11C6C959B87A0"><enum>(II)</enum><text>an institutional review board of an entity other than the sponsor of the research; or</text>
 </subclause></clause><clause commented="no" id="H9095907C3D8E4BCF9FA34FA22F3E4AB5"><enum>(iii)</enum><text>use similar arrangements to avoid duplication of effort.</text> </clause></subparagraph></paragraph><paragraph commented="no" id="H7474D736E03D45F18BB879FBD7C232D8"><enum>(2)</enum><header>Regulations and guidance</header><text display-inline="yes-display-inline">Not later than 12 months after the date of enactment of this <short-title>Act</short-title>, the Secretary, acting through the relevant agencies and offices of the Department of Health and Human Services, including the Office for Human Research Protections and relevant agencies and offices of the Food and Drug Administration, shall issue such regulations and guidance and take such other actions as may be necessary to implement this section and help facilitate the broader use of single, central, or lead institutional review boards. Such regulations and guidance shall include clarification of requirements and policies relating to the following:</text>
 <subparagraph commented="no" id="HE2EC69198B214048842A4F53BA1EEF26"><enum>(A)</enum><text>Arrangements to avoid duplication described in paragraph (1)(A)(i), including—</text> <clause commented="no" id="H75BDA8263CAD4BB9A92CCFB3DA66FAF7"><enum>(i)</enum><text display-inline="yes-display-inline">delineating the roles of institutional review boards in multisite or cooperative, multisite studies where one or more local institutional review boards are relied upon, or similar arrangements are used;</text>
 </clause><clause commented="no" id="H631C3A5DB6D04594B6EDE4CD26DA67F3"><enum>(ii)</enum><text>the risks and benefits to human subjects;</text> </clause><clause commented="no" id="H451125614D2A4AF1AC27CB15E4BBC084"><enum>(iii)</enum><text>standardization of informed consent and other processes and legal documents; and</text>
 </clause><clause commented="no" id="HECE3893D70234FBCA885BC165AF8847A"><enum>(iv)</enum><text>incorporating community values through the use of local institutional review boards while continuing to use central or lead institutional review boards.</text>
 </clause></subparagraph><subparagraph commented="no" id="H5AB9F067E42349498505F6223BB6C1CE"><enum>(B)</enum><text display-inline="yes-display-inline">Concerns about regulatory and legal liability contributing to decisions by the sponsors of research to rely on local institutional review boards for multisite research.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H4909E80384CA4488946AE991F253BC84"><enum>(3)</enum><header>Consultation</header><text>In issuing regulations or guidance pursuant to paragraph (2), the Secretary shall consult with stakeholders (including researchers, academic organizations, hospitals, institutional research boards, pharmaceutical, biotechnology and medical device developers, clinical research organizations, patient groups, and others).</text>
 </paragraph></subsection><subsection id="H73E7E8E4E9CD4431A326FE1855BD7C08"><enum>(c)</enum><header>Timing</header><text display-inline="yes-display-inline">The Secretary shall complete the harmonization described in subsection (a) not later than 36 months after the date of enactment of this Act.</text>
 </subsection><subsection id="H22EA038C3F8D4B5AB611D834BEDCA186"><enum>(d)</enum><header>Progress report</header><text display-inline="yes-display-inline">Not later than 24 months after the date of enactment of this Act, the Secretary shall submit to Congress a report on the progress made towards completing such harmonization.</text>
					</subsection><subsection id="HD8164C5885824CB5AE4A20AC201DF4A9"><enum>(d)</enum><header>Definitions</header>
 <paragraph id="H452A5CF328714AAABA43A87FEE430C1F"><enum>(1)</enum><header>Human subject regulations</header><text display-inline="yes-display-inline">In this section:</text> <subparagraph id="H36CC56B7FA514BAF8BEBCCE1FFB737AC"><enum>(A)</enum><header>FDA human subject regulations</header><text>The term <quote>FDA Human Subject Regulations</quote> means the provisions of parts 50, 56, 312, and 812 of title 21, Code of Federal Regulations (or any successor regulations).</text>
 </subparagraph><subparagraph id="H291C78234DE84095A1C04ECF7AD75FC4"><enum>(B)</enum><header>HHS human subject regulations</header><text display-inline="yes-display-inline">The term <quote>HHS Human Subject Regulations</quote> subject to clause (ii), means the provisions of subpart A of part 46 of title 45, Code of Federal Regulations (or any successor regulations).</text>
 </subparagraph><subparagraph id="H454DAC46017347A8888C2C3AD71336FB"><enum>(C)</enum><header>Vulnerable-populations rules</header><text display-inline="yes-display-inline">The term <quote>vulnerable-populations rules</quote>—</text> <clause id="H729585BFD8D2454092280790C2E3D207"><enum>(i)</enum><text>subject to clause (ii), means the provisions of subparts B through D of such part 46 (or any successor regulations); or</text>
 </clause><clause id="H3CC296F10E3D4A7396E4883EA2104476"><enum>(ii)</enum><text>as applicable to the human subjects involved in research described in subparagraph (B), means the provisions applicable to vulnerable populations under part 56 of such title 21 (or any successor regulations) and subpart D of part 50 of such title 21 (or any successor regulations).</text>
								</clause></subparagraph></paragraph><paragraph id="H58375A97143144488F77725AEBF9B468"><enum>(2)</enum><header>Human subject research</header>
 <subparagraph id="H42AC14616B2C431AB38682A25082C24B"><enum>(A)</enum><text display-inline="yes-display-inline">Except as provided in subparagraph (B), the term <quote>human subject research</quote> means research, as defined in subpart A of part 46 of title 45, Code of Federal Regulations (or any successor regulations), that involves a human subject, as defined in such subpart A (or any successor regulations); and</text>
 </subparagraph><subparagraph id="H9CA133E5FA7A4DD7AD14EDD4E45F65D2"><enum>(B)</enum><text display-inline="yes-display-inline">In the case of an investigation that is subject to the provisions of part 50 of title 21, Code of Federal Regulations (or any successor regulations), the term <quote>human subject</quote> has the meaning given such term in such part 50, and the term <quote>human subject research</quote> means a clinical investigation as defined in such part 50.</text>
 </subparagraph></paragraph><paragraph id="H15F8FE1ECFE746BDB0B87C5BEABF7F9D"><enum>(3)</enum><header>Other definitions</header><text display-inline="yes-display-inline">In this section:</text> <subparagraph id="H4C8D3FA5A6204D32804337CCDD722641"><enum>(A)</enum><header>Institutional review board</header><text display-inline="yes-display-inline">The term <quote>institutional review board</quote> has the meaning that applies to the term <quote>institutional review board</quote> under the HHS Human Subject Regulations.</text>
 </subparagraph><subparagraph id="H90BF8E3770974A33B9A6BC1E2C93EA47"><enum>(B)</enum><header>Lead institutional review board</header><text>The term <quote>lead institutional review board</quote> means an institutional review board that otherwise meets the requirements of the HHS Human Subject Regulations and enters into a written agreement with an institution, another institutional review board, a sponsor, or a principal investigator to approve and oversee human subject research that is conducted at multiple locations. References to an institutional review board include an institutional review board that serves a single institution as well as a lead institutional review board.</text>
							</subparagraph></paragraph></subsection></section><section id="H6EB5257560704273A5424B058B38A584"><enum>2262.</enum><header>Use of non-local institutional review boards for review of investigational device exemptions and
			 human device exemptions</header>
 <subsection id="H49386CBF3CA8490EB08C05DF61FF0455"><enum>(a)</enum><header>In general</header><text>Section 520 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(j)</external-xref>) is amended—</text> <paragraph id="H3CD939E85A6C42A2B2F89FB57510F3B2"><enum>(1)</enum><text>in subsection (g)(3)—</text>
 <subparagraph id="HE473500A57E744318B63C07858B33246"><enum>(A)</enum><text>by striking <quote>local</quote> each place it appears; and</text> </subparagraph><subparagraph id="HA8207B5E48C14F81BA867DB566B94E42"><enum>(B)</enum><text>in subparagraph (A)(i), by striking <quote>which has been</quote>; and</text>
 </subparagraph></paragraph><paragraph id="H2F71E35122C24D8A95DCF093C8931A05"><enum>(2)</enum><text>in subsection (m)(4)—</text> <subparagraph id="HA878321FD23A48C6A0F96B1CEF52991B"><enum>(A)</enum><text>by striking <quote>local</quote> each place it appears; and</text>
 </subparagraph><subparagraph id="HDC0635D8F2894B45AFE6186FCB04A893"><enum>(B)</enum><text>by striking subparagraph (A) and inserting the following new subparagraph:</text> <quoted-block id="H44E7691D08914C6090937A352B508AE0" style="OLC"> <subparagraph id="H66C3C29323354BFB8CD69B79E108D3A0" indent="up1"><enum>(A)</enum><text>in facilities in which clinical testing of devices is supervised by an institutional review committee established in accordance with the regulations of the Secretary, and</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph></subsection><subsection id="H525A5EB1FD814DE1ABC7AEB7BDA60BF8"><enum>(b)</enum><header>Regulations</header><text>Not later than 12 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall revise or issue such regulations or guidance as may be necessary to carry out the amendments made by subsection (a).</text>
					</subsection></section><section id="HE84697CA1F754B7D97B25A6118CA08A4"><enum>2263.</enum><header>Alteration or waiver of informed consent for clinical investigations</header>
 <subsection id="H7D49C4539D7B4374AC205B58247EC2D4"><enum>(a)</enum><header>Devices</header><text display-inline="yes-display-inline">Section 520(g)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(g)(3)</external-xref>) is amended—</text> <paragraph id="H8976C21695BE4F9694F6847BD59A38AE"><enum>(1)</enum><text>in subparagraph (D), by striking <quote>except where subject to such conditions as the Secretary may prescribe, the investigator</quote> and inserting the following:</text>
							<quoted-block display-inline="yes-display-inline" id="H038F3D9E9DC245F3ABE8310175CAF8F6" style="OLC">
 <text>except where, subject to such conditions as the Secretary may prescribe—</text><clause id="H18BB197906FA4F87990275BC6103A300"><enum>(i)</enum><text display-inline="yes-display-inline">the proposed clinical testing poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of the human subject; or</text>
 </clause><clause id="H49EB05D5539E404F97F344E2C79FB4BF"><enum>(ii)</enum><text display-inline="yes-display-inline">the investigator</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block> </paragraph><paragraph id="HF4CC2F0594AD482E826677381C1B65F9"><enum>(2)</enum><text>in the matter following subparagraph (D), by striking <quote>subparagraph (D)</quote> and inserting <quote>subparagraph (D)(ii)</quote>.</text>
 </paragraph></subsection><subsection id="H1D70EB7B5AE545F6BDB6895EB258A04F"><enum>(b)</enum><header>Drugs</header><text display-inline="yes-display-inline">Section 505(i)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)(4)</external-xref>) is amended by striking <quote>except where it is not feasible or it is contrary to the best interests of such human beings</quote> and inserting <quote>except where it is not feasible, it is contrary to the best interests of such human beings, or the proposed clinical testing poses no more than minimal risk to such human beings and includes appropriate safeguards as prescribed to protect the rights, safety, and welfare of such human beings</quote>.</text>
					</subsection></section></subtitle><subtitle id="HBA64A44EA434413A8B7B6AE2BC6C32F7"><enum>P</enum><header>Improving Scientific Expertise and Outreach at FDA</header>
				<section id="HDF7368CE140C4B10916057A82517D058"><enum>2281.</enum><header>Silvio O. Conte Senior Biomedical Research Service</header>
 <subsection id="H971DBF722D944D56800CA4D84342DC0D"><enum>(a)</enum><header>Hiring and retention authority</header><text>Section 228 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/237">42 U.S.C. 237</external-xref>) is amended—</text> <paragraph id="HF4DF738F326A4949A83ED0A217DCE6AC"><enum>(1)</enum><text>in the section heading, by inserting <quote><header-in-text level="section" style="traditional">and Biomedical Product Assessment</header-in-text></quote> after <quote><header-in-text level="section" style="traditional">Research</header-in-text></quote>;</text>
 </paragraph><paragraph id="H42A22775218A4AE296B4AA3A8128925D"><enum>(2)</enum><text>in subsection (a)(1), by striking <quote>Silvio O. Conte Senior Biomedical Research Service, not to exceed 500 members</quote> and inserting <quote>Silvio O. Conte Senior Biomedical Research and Biomedical Product Assessment Service (in this section referred to as the <quote>Service</quote>), the purpose of which is to recruit and retain competitive and qualified scientific and technical experts outstanding in the field of biomedical research, clinical research evaluation, and biomedical product assessment</quote>;</text>
 </paragraph><paragraph commented="no" id="H914A57D0D74645ECBC4454C4E3BF7E58"><enum>(3)</enum><text display-inline="yes-display-inline">by amending subsection (a)(2) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H4022E81CAB4441D381B8A38D3D6331CA" style="OLC"> <paragraph id="H08C88EFE117647338FC6B8B4BDD34728" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">The authority established in paragraph (1) may not be construed to require the Secretary to reduce the number of employees serving under any other employment system in order to offset the number of members serving in the Service.</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HC32537D86D8D43AA85FD93173703B388"><enum>(4)</enum><text>in subsection (b)—</text> <subparagraph id="HFB86782F80AD44F286F8853D79D776FE"><enum>(A)</enum><text>in the matter preceding paragraph (1), by striking <quote>or clinical research evaluation</quote> and inserting <quote>, clinical research evaluation or biomedical product assessment</quote> after <quote>evaluation</quote>; and</text>
 </subparagraph><subparagraph id="HDB2D32F0675D4D28B816F124A11A528E"><enum>(B)</enum><text>in paragraph (1), by inserting <quote>or a master's level degree in engineering, bioinformatics, or a related or emerging field,</quote> after the comma;</text> </subparagraph></paragraph><paragraph id="HFB455001796C4C559F5D35F62C8082F2"><enum>(5)</enum><text>in subsection (d), by striking <quote>and shall not exceed the rate payable for level I of the Executive Schedule unless approved by the President under section 5377(d)(2) of title 5, United States Code</quote> and inserting <quote>and shall not exceed the rate payable for the President</quote>;</text>
 </paragraph><paragraph id="HE117287EACA648D9A7A4A91721C1F1ED"><enum>(6)</enum><text display-inline="yes-display-inline">by striking subsection (e); and</text> </paragraph><paragraph id="HF85E45AFCF4647B58407C1A6FF417920"><enum>(7)</enum><text>by redesignating subsections (f) and (g) as subsections (e) and (f), respectively.</text>
 </paragraph></subsection><subsection id="H588905EA53B742D791A8EE68B943E8E3"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 3 years after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit, and publish on the website of the Department of Health and Human Services a report on the implementation of the amendments made by subsection (a), including whether the amendments have improved the ability of the Food and Drug Administration to hire and retain qualified experts to fulfill obligations specified under user fee agreements.</text>
 </subsection></section><section commented="no" id="HF8E56FA9EE264844AE44E70A9372EF9C"><enum>2282.</enum><header>Enabling FDA scientific engagement</header><text display-inline="no-display-inline">It is the sense of Congress that participation in or sponsorship of scientific conferences and meetings is essential to the mission of the Food and Drug Administration.</text>
				</section><section id="HAD3F4113A9BE4D11990A1311D9478E42"><enum>2283.</enum><header>Reagan-Udall Foundation for the Food and Drug Administration</header>
					<subsection id="H00861EB4369347B09DFCD71DAF8B8E8E"><enum>(a)</enum><header>Board of Directors</header>
 <paragraph id="HBA64F8C34EF1416EA5161CDC8209B21A"><enum>(1)</enum><header>Composition and size</header><text>Section 770(d)(1)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379dd">21 U.S.C. 379dd(d)(1)(C)</external-xref>) is amended—</text>
 <subparagraph id="H8B689A544FCD4E41967D44D2D5FED71F"><enum>(A)</enum><text>by redesignating clause (ii) as clause (iii);</text> </subparagraph><subparagraph id="HF1EA54144F7B4A4CAE1B976DF63FB790"><enum>(B)</enum><text>by inserting after clause (i) the following:</text>
								<quoted-block display-inline="no-display-inline" id="H93929CEC6FAE4EA49214404ADEB101A3" style="OLC">
 <clause commented="no" id="HA052EF73256244F6A291010DB5F4B37E"><enum>(ii)</enum><header>Additional members</header><text display-inline="yes-display-inline">The Board, through amendments to the bylaws of the Foundation, may provide that the number of voting members of the Board shall be a number (to be specified in such amendment) greater than 14. Any Board positions that are established by any such amendment shall be appointed (by majority vote) by the individuals who, as of the date of such amendment, are voting members of the Board and persons so appointed may represent any of the categories specified in subclauses (I) through (V) of clause (i), so long as no more than 30 percent of the total voting members of the Board (including members whose positions are established by such amendment) are representatives of the general pharmaceutical, device, food, cosmetic, and biotechnology industries.</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="H8AA1C9BD466943F69FF77DF8B42D34FB"><enum>(C)</enum><text>in clause (iii)(I), as redesignated by subparagraph (A), by striking <quote>The ex officio members shall ensure</quote> and inserting <quote>The ex officio members, acting pursuant to clause (i), and the Board, acting pursuant to clause (ii), shall ensure</quote>.<italic></italic></text>
 </subparagraph></paragraph><paragraph id="HA44000B28134431AA97FBCAC7C700722"><enum>(2)</enum><header>Federal employees allowed to serve on Board</header><text display-inline="yes-display-inline">Clause (iii)(II) of section 770(d)(1)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379dd">21 U.S.C. 379dd(d)(1)(C)</external-xref>), as redesignated by paragraph (1)(A), is amended by adding at the end the following: <quote>For purposes of this section, the term <quote>employee of the Federal Government</quote> does not include a <quote>special Government employee</quote>, as that term is defined in section 202(a) of title 18, United States Code.</quote>.</text>
 </paragraph><paragraph id="HE869F0C7F3C649DC972A662ACAAF6631"><enum>(3)</enum><header>Staggered terms</header><text display-inline="yes-display-inline">Subparagraph (A) of section 770(d)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379dd">21 U.S.C. 379dd(d)(3)</external-xref>) is amended to read as follows:</text>
							<quoted-block display-inline="no-display-inline" id="HF6115514F5564156A5803855941A3A31" style="OLC">
 <subparagraph commented="no" id="H082B09ABB1514E908D30758E10C05BF5"><enum>(A)</enum><header>Term</header><text display-inline="yes-display-inline">The term of office of each member of the Board appointed under paragraph (1)(C)(i), and the term of office of any member of the Board whose position is established pursuant to paragraph (1)(C)(ii), shall be 4 years, except that—</text>
 <clause commented="no" id="H0FE44E6949EB432FABDC8610F259F582"><enum>(i)</enum><text>the terms of offices for the members of the Board initially appointed under paragraph (1)(C)(i) shall expire on a staggered basis as determined by the ex officio members; and</text>
 </clause><clause commented="no" id="HB38CA6E306B44E5488267D9212A0C669"><enum>(ii)</enum><text display-inline="yes-display-inline">the terms of office for the persons initially appointed to positions established pursuant to paragraph (1)(C)(ii) may be made to expire on a staggered basis, as determined by the individuals who, as of the date of the amendment establishing such positions, are members of the Board.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H5AAA80A8F8784352BCDAC36D54DED412"><enum>(b)</enum><header>Executive Director compensation</header><text display-inline="yes-display-inline">Section 770(g)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379dd">21 U.S.C. 379dd(g)(2)</external-xref>) is amended by striking <quote>but shall not be greater than the compensation of the Commissioner</quote>.</text>
 </subsection><subsection id="HB3548DBCD61F439090400C0EE3443BBB"><enum>(c)</enum><header>Separation of Funds</header><text display-inline="yes-display-inline">Section 770(m) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379dd">21 U.S.C. 379dd(m)</external-xref>) is amended by striking <quote>are held in separate accounts from funds received from entities under subsection (i)</quote> and inserting <quote>are managed as individual programmatic funds under subsection (i), according to best accounting practices</quote>.</text>
 </subsection></section><section id="H439B98A959E34C7E95CDCD8419EC1356" section-type="subsequent-section"><enum>2284.</enum><header>Collection of certain voluntary information exempted from Paperwork Reduction Act</header><text display-inline="no-display-inline">Chapter VII of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 708 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379">21 U.S.C. 379</external-xref>) the following:</text>
					<quoted-block display-inline="no-display-inline" id="H52A259A2F6CD49D1914B140B19500A3C" style="OLC">
 <section id="HAABFA40851CF487A8EB17B4332571635"><enum>708A.</enum><header>Collection of certain voluntary information exempted from Paperwork Reduction Act</header><text display-inline="no-display-inline"><external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/35">Chapter 35</external-xref> of title 44, United States Code, shall not apply to the collection from patients, industry, academia, and other stakeholders, of voluntary information such as through voluntary surveys or questionnaires, initiated by the Secretary.</text></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle></title><title id="HE47AC840EE1B4A349798FB9E8E6C459D"><enum>III</enum><header>Delivery</header>
			<subtitle id="HC34FE10F22154B9A9DF35ED448747734"><enum>A</enum><header>Interoperability</header>
				<section id="H66C23E4AD7B748BCBAD6DCDCBAE4E4C0" section-type="subsequent-section"><enum>3001.</enum><header>Ensuring interoperability of health information technology</header>
					<subsection id="H0485E3A312E14B328EA12593DF0D0A48"><enum>(a)</enum><header>Interoperability standards</header>
 <paragraph id="H2FEF1B9C68414A3A908A1C70C136896E"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subtitle A of title XXX of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-11">42 U.S.C. 300jj–11 et seq.</external-xref>) is amended by adding at the end the following new section:</text>
							<quoted-block display-inline="no-display-inline" id="H79CF0B8E1EC9474CBB8A8ED9E41E4C3F" style="OLC">
								<section id="HB939491055A6457698965EDCFC040E9F"><enum>3010.</enum><header>Ensuring interoperability of health information technology</header>
 <subsection id="H7899E1C1F87D40F69CC04A36970917B6"><enum>(a)</enum><header>Interoperability</header><text display-inline="yes-display-inline">In order for health information technology to be considered interoperable, such technology must satisfy the following criteria:</text>
 <paragraph id="HA3C2BEC21C394A979AC0C15F3435370B"><enum>(1)</enum><header>Secure transfer</header><text display-inline="yes-display-inline">The technology allows the secure transfer of the entirety of a patient’s data from any and all health information technology for authorized use under applicable law.</text>
 </paragraph><paragraph id="H62D762B4CCED4F79B6AD5274028FB9BD"><enum>(2)</enum><header>Complete Access to Health Data</header><text>The technology allows access to the entirety of a patient’s available data for authorized use under applicable law without special effort, as defined by recommendations adopted in accordance with this section, by the requestor of such data unless such data is not disclosable under applicable law.</text>
 </paragraph><paragraph id="HD4A10C7792D84D4F884B6E7C289715F2"><enum>(3)</enum><header>No information blocking</header><text display-inline="yes-display-inline">The technology is not configured, set up, or implemented to engage in information blocking, as defined in section 3010A(f).</text>
 </paragraph></subsection><subsection id="H31CDB01CE7F247A8ADFE5B29205C81C0"><enum>(b)</enum><header>Categories for interoperability standards</header><text>The categories described in this subsection, with respect to standards for determining if health information technology is interoperable, consistent with the criteria described in subsection (a), include the following categories of standards:</text>
 <paragraph id="H6F2781F2FF6D499A9FAB2F78E6B52E19"><enum>(1)</enum><text>Standards with respect to vocabulary and terminology.</text> </paragraph><paragraph id="HFC7539CA41694A12B296B7A7A344AB8F"><enum>(2)</enum><text>Standards with respect to content and structure.</text>
 </paragraph><paragraph id="H28089B5989CA492E937C3CD658B0A9DE"><enum>(3)</enum><text>Standards with respect to transport of information.</text> </paragraph><paragraph id="H883124397D4D493897E05C26E3EDB9E1"><enum>(4)</enum><text>Security standards.</text>
 </paragraph><paragraph id="HF0FF9CE1F75A4E6286EFA0B6F9FC811F"><enum>(5)</enum><text>Service standards.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph><paragraph id="H4495C01407BA4577871ABB7F225FE0C5"><enum>(2)</enum><header>Guidance</header><text>Not later than January 1, 2017, the Secretary of Health and Human Services, through the National Coordinator of the Office of the National Coordinator for Health Information Technology, shall issue guidance with respect to the implementation of section 3010 of the Public Health Service Act, as added by paragraph (1), including with respect to defining and providing examples of authorized use of health information technology, as described in such section.</text>
						</paragraph></subsection><subsection id="H7508FB6843C5475FBB79C8A0321F16F1"><enum>(b)</enum><header>Improvements to recommendation process</header>
 <paragraph id="H1C7D29390BF44E5ABBECCEE95E2D8058"><enum>(1)</enum><header>HIT Policy Committee to incorporate policies for updates to interoperability standards</header><text display-inline="yes-display-inline">Section 3002 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-12">42 U.S.C. 300jj–12</external-xref>) is amended—</text> <subparagraph id="HEB9B065B5B904156ADD758B561F6C04C"><enum>(A)</enum><text>in subsection (a)—</text>
 <clause id="H527C2269D77C4C0E9B13FD7175E9D2D8"><enum>(i)</enum><text>by striking <quote>National Coordinator</quote> and inserting <quote>Secretary, in consultation with the National Coordinator,</quote>; and</text> </clause><clause id="HC5692568377F409F8B50D95D9D4DDCE1"><enum>(ii)</enum><text>by adding at the end the following new sentence: <quote>The HIT Policy Committee is authorized only to provide policy and priority recommendations to the Secretary and not authorized to otherwise affect the development or modification of any standard, implementation specification, or certification criterion under this title.</quote>; and</text>
 </clause></subparagraph><subparagraph id="H4B1404F4ADF9474BA5FEF980A108DE9A"><enum>(B)</enum><text>in subsection (b)(2)—</text> <clause id="HFF0914978A0940DC9893012969133F9C"><enum>(i)</enum><text>in subparagraph (A), in the first sentence—</text>
 <subclause id="HF69B78CA827B439D9E1CC207810D04CA"><enum>(I)</enum><text>by striking <quote>The HIT Policy Committee</quote> and inserting <quote>Subject to subparagraph (D), the HIT Policy Committee</quote>; and</text> </subclause><subclause id="HBC6AF096F7C740559DC9AEA082163259"><enum>(II)</enum><text>by inserting <quote>(including the areas in which modifications and additions to interoperability standards under section 3010 are needed for the electronic exchange and use of health information for purposes of adoption of such modifications and additions under section 3004)</quote> after <quote>section 3004</quote>.</text>
 </subclause></clause><clause id="H8C65129C364548DAB982A93034F3A37C"><enum>(ii)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="HF8B6F804617648C88000A66BE8FA7AED" style="OLC"> <subparagraph id="HCD9C1FEC53C84B7E9AF050A3FE2A156F"><enum>(D)</enum><header>Special rule related to interoperability</header><text display-inline="yes-display-inline">Any recommendation made by the HIT Policy Committee on or after the date of the enactment of this subparagraph with respect to interoperability of health information technology shall be consistent with the criteria described in subsection (a) of section 3010.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph display-inline="no-display-inline" id="H9DF202B06E824CD2AA963021AAEB9E94"><enum>(2)</enum><header>Sunset of HIT Standards Committee</header><text display-inline="yes-display-inline">Section 3003 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-13">42 U.S.C. 300jj–13</external-xref>) is amended by adding at the end the following new subsection:</text>
							<quoted-block display-inline="no-display-inline" id="HB1082A1802C546978CD9631B14671DFC" style="OLC">
 <subsection id="H5C4C71145AAE44C6B703C1240CBA286A"><enum>(f)</enum><header>Termination</header><text display-inline="yes-display-inline">The HIT Standards Committee shall terminate on the date that is 90 days after the date of the enactment of this subsection.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H289B87209FB4478283DC2D5C5364A19F"><enum>(3)</enum><header>Standards development organizations</header><text>Title XXX of the Public Health Service Act is amended by inserting after section 3003 the following new section:</text>
							<quoted-block display-inline="no-display-inline" id="H3D05979E8CCB441A9DD8B27AFF718EA8" style="OLC">
								<section id="HEF3BE11D3A864F0E9545E9973FF37698"><enum>3003A.</enum><header>Recommendations for standards through contract with standards development organizations</header>
 <subsection id="HED16EB5C88C04FC8BE7557C7337654D9"><enum>(a)</enum><header>Contract</header><text display-inline="yes-display-inline"></text> <paragraph id="H8989EE77BCB54CB39F641A190CF86D21"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">For purposes of activities conducted under this title, the Secretary shall enter into contracts with health care standards development organizations accredited by the American National Standards Institute to carry out the duties described in subsection (b), as applicable.</text>
 </paragraph><paragraph id="H8E966EC1977141AEB22597BFD8FA3AF3"><enum>(2)</enum><header>Timing for first contract</header><text>As soon as practicable after the date of the enactment of this section, the Secretary shall enter into the first contract under paragraph (1).</text>
 </paragraph><paragraph id="H0D75C9C77560403FBA30522C2429CDAE"><enum>(3)</enum><header>Period of contract</header><text>Each contract under paragraph (1) shall be for a period determined necessary by the Secretary, in consultation with the National Coordinator, to carry out the applicable duties described in subsection (b).</text>
 </paragraph><paragraph id="H35B4272A2D6B442D9D9BFDC0FAE5C224"><enum>(4)</enum><header>Appropriate organizations</header><text>The Secretary shall ensure the most appropriate organizations described in paragraph (1) are selected for each contract under paragraph (1).</text>
										</paragraph></subsection><subsection id="H4F88A7D23E094670AD4C2C49928F3737"><enum>(b)</enum><header>Duties</header>
 <paragraph id="HF016AB8ECBCE438F90185E80E46391FD"><enum>(1)</enum><header>Initial contract</header><text display-inline="yes-display-inline">Under the initial contract under subsection (a)(1), the standards development organizations—</text> <subparagraph id="H69209306A49646BB9DBB9614A508C74D"><enum>(A)</enum><text>shall provide to the Secretary, in consultation with the National Coordinator, for adoption under section 3004, recommendations, in accordance with section 3010, for interoperability standards consistent with the criteria described in subsection (a) of such section and with respect to the categories described in subsection (b)(1) of such section; and</text>
 </subparagraph><subparagraph id="H18EE49847D394907878DCC5B765C51AF"><enum>(B)</enum><text>may provide to the Secretary, in consultation with the National Coordinator, recommendations described in paragraph (2).</text>
 </subparagraph></paragraph><paragraph id="H98B220033F344278A69D890E3C51492B"><enum>(2)</enum><header>Subsequent contracts</header><text display-inline="yes-display-inline">Under each subsequent contract, the organizations shall provide to the Secretary, in consultation with the National Coordinator, for adoption under section 3004 recommendations for any standards (including interoperability criteria), implementation specifications, and certification criteria (and modifications, including additions to such standards, specifications, and criteria), which are in accordance with the policies and priorities developed by the Secretary, in consultation with the National Coordinator.</text>
										</paragraph></subsection><subsection id="HDD67E0DC795A454F883DDF39036C4AD0"><enum>(c)</enum><header>Modifications and subsequent contracts</header>
 <paragraph id="H5178A304E1F8457A8CA9CC426147C305"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, in consultation with the National Coordinator, shall periodically conduct hearings to evaluate and review the standards, implementation specification, and certification criteria adopted under section 3004 for purposes of determining if modifications, including any additions, are needed with respect to such standards, specifications, and criteria.</text>
 </paragraph><paragraph id="H38181B3067D342B19248337CDE80157C"><enum>(2)</enum><header>Contract trigger</header><text>Based on the needs for standards, implementation specifications, and certification criteria (and modifications, including additions to such standards, specifications, and criteria) under this title, as determined by the Secretary, in consultation with the National Coordinator, the Secretary shall, as needed, enter into contracts under subsection (a) in addition to the initial contract.</text>
 </paragraph></subsection><subsection id="HDA7162C9AF9B450084A715D1D4307CF9"><enum>(d)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There is authorized to be appropriated $10,000,000 for contracts under subsection (a), to remain available until expended.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H3B3BCAC9B6644DDCA89FAE889CD99B8A"><enum>(4)</enum><header>Modifications to role of ONCHIT</header><text>Section 3001(c)(1)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-11">42 U.S.C. 300jj–11(c)(1)(A)</external-xref>) is amended by inserting <quote>for recommendations made before the date of the enactment of the 21st Century Cures Act,</quote> before <quote>review and determine</quote>.</text>
 </paragraph></subsection><subsection id="H294BAD17C7614D16B0DF4565851ABFEF"><enum>(c)</enum><header>Adoption</header><text>Section 3004 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-14">42 U.S.C. 300jj–14</external-xref>) is amended—</text> <paragraph id="H4FD26AA5E4D147B69499851225A960B3"><enum>(1)</enum><text>in subsection (a)—</text>
 <subparagraph id="H9E9BA2A1C99145BB9B56D98FEE71C8B3"><enum>(A)</enum><text>in paragraph (1), by inserting after <quote>section 3001(c)</quote> the following: <quote>(or, subject to subsection (c), in the case of a standard, specification, or criterion recommended on or after the date of the enactment of the 21st Century Cures Act, after the date of submission of the recommendation to the Secretary under section 3003A)</quote>; and</text>
 </subparagraph><subparagraph id="H88EA47541F4E4657B1158BEB1C9FD922"><enum>(B)</enum><text>in paragraph (2), by striking <quote>and the HIT Standards Committee</quote>;</text> </subparagraph></paragraph><paragraph id="H20597DC47F604C1C9B1CEB80E9C085FA"><enum>(2)</enum><text>in subsection (b), by adding at the end the following new paragraph:</text>
							<quoted-block display-inline="no-display-inline" id="H8C98958D564F49D69FF20DDAD21106DF" style="OLC">
 <paragraph id="HAC97B774DC8E4189BC97BCA567269B98"><enum>(4)</enum><header>Limitation</header><text display-inline="yes-display-inline">The Secretary may not adopt any standards, implementation specifications, or certification criteria under this subsection or subsection (a) that are inconsistent with or duplicative of an interoperability standard adopted under this section, in accordance with section 3010. In the case of a standard, specification, or criterion that has been adopted under this section and is inconsistent or duplicative of such an interoperability standard that is subsequently adopted under this section, such interoperability standard shall supercede such other standard, specification, or criterion and such other standard, specification, or criterion shall no longer be considered adopted under this section beginning on the date that such interoperability standard becomes effective.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H4A0B81E2B80C43499CED6B67A1AA6582"><enum>(3)</enum><text>by adding at the end the following new subsections:</text> <quoted-block display-inline="no-display-inline" id="H18FE99A6400D4D30A109493DB4F969AC" style="OLC"> <subsection display-inline="no-display-inline" id="HC7DEE5494216450F97BFAF8605E459C8"><enum>(c)</enum><header>Adoption of initial interoperability standards</header><text display-inline="yes-display-inline">Notwithstanding the previous subsections of this section, the following shall apply in the case of the initial set of interoperability standards recommended under section 3003A:</text>
 <paragraph id="H851DD11104784F4991381ACFF21555B7"><enum>(1)</enum><header>Review of standards</header><text display-inline="yes-display-inline">Not later than 90 days after the date of receipt of recommendations for such interoperability standards, the Secretary, in consultation with the National Coordinator and representatives of other relevant Federal agencies, shall jointly review such standards and shall determine whether or not to propose adoption of such standards.</text>
 </paragraph><paragraph id="H49F9E0F784654F48A08C4865E785E237"><enum>(2)</enum><header>Determination to adopt</header><text>If the Secretary determines—</text> <subparagraph id="H43C9E972AF474F0DAFBF46628D6B3491"><enum>(A)</enum><text>to propose adoption of such standards, the Secretary shall, by regulation under section 553 of title 5, United States Code, determine whether or not to adopt such standards; or</text>
 </subparagraph><subparagraph id="HFE03F83B898D4B3794A3F670E3AEF38A"><enum>(B)</enum><text>not to propose adoption of such standards, the Secretary shall notify the National Coordinator and the standards development organizations under section 3003A in writing of such determination and the reasons for not proposing the adoption of the recommendation for such standards.</text>
 </subparagraph></paragraph><paragraph id="HC7A735A02E944A5F83EA989378931EE7"><enum>(3)</enum><header>Publication</header><text>The Secretary shall provide for publication in the Federal Register of all determinations made by the Secretary under paragraph (1).</text>
 </paragraph><paragraph id="H4B115BB0E0CD481B999E0E0780D1119E"><enum>(4)</enum><header>Application</header><text display-inline="yes-display-inline">Any standard adopted under this subsection shall be effective 12 months after the date of publication of the determination to adopt such standard.</text>
 </paragraph></subsection><subsection id="H2DFABD41C71446B292CA0ADFE388B276"><enum>(c)</enum><header>Rules for adoption</header><text display-inline="yes-display-inline">In the case of a standard (including interoperability standard), implementation specification, or certification criteria adopted under this section on or after the date of the enactment of the 21st Century Cures Act, the following shall apply:</text>
 <paragraph id="H93B47B74A0B34816A257CEE27C548A97"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Except as provided in paragraph (2), any such standard (including interoperability standard), implementation specification, or certification criteria shall be a standard, specification, or criterion that has been recommended by the standards development organizations with which the Secretary has entered into a contract under section 3003A.</text>
 </paragraph><paragraph id="HE3CEF4279DD44554B9F76904B1F6BA4B"><enum>(2)</enum><header>Special rule if no standard, specification, or criterion recommended</header><text>If no standard is recommended under paragraph (1)—</text> <subparagraph id="H2B337AA967924E7CA240EBC8E519A101"><enum>(A)</enum><text>in the case of interoperability standards, relating to a category described in section 3010(b)—</text>
 <clause id="H8AAFC25983BD4D959A57D188B5FDAC9D"><enum>(i)</enum><text>paragraph (1) shall not apply; and</text> </clause><clause id="HBD6D9E83A8EB4E9AAE00632A56CFAFA4"><enum>(ii)</enum><text>paragraph (4) shall apply; or</text>
 </clause></subparagraph><subparagraph id="HFB8815337A4E456EA588AEAACA526EC3"><enum>(B)</enum><text>in the case of any other standard, implementation specification, or certification criteria, relating to a policy or priority to carry out this title, as determined by the Secretary, in consultation with the National Coordinator—</text>
 <clause id="HA1E34B1D73994E70940A4A6953802988"><enum>(i)</enum><text>paragraph (1) shall not apply; and</text> </clause><clause id="HB090F10217EF47B79A880A79130BFCD4"><enum>(ii)</enum><text>paragraph (4) shall apply.</text>
 </clause></subparagraph></paragraph><paragraph id="HC7D3DA6E2D5F44629628844BCD1E2EC1"><enum>(3)</enum><header>Effective date</header><text display-inline="yes-display-inline">Any standard, implementation specification, or certification criterion adopted under this section shall be effective 12 months after the date of publication of the final rule to adopt such standard, implementation specification, or certification criteria.</text>
 </paragraph><paragraph id="H323C2F48FCED429B96A1538E79DA3358"><enum>(4)</enum><header>Assistance to the Secretary</header><text display-inline="yes-display-inline">In complying with the requirements of this subsection, the Secretary shall rely on the recommendations of the National Committee on Vital and Health Statistics established under section 306(k), and shall consult with appropriate Federal and State agencies and private organizations. The Secretary shall publish in the Federal Register any recommendation of the National Committee on Vital and Health Statistics regarding the adoption of a standard implementation specification, or certification criterion under this section. Any standard, implementation specification, or certification criterion adopted pursuant to this paragraph shall be promulgated in accordance with the rulemaking procedures of subchapter III of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H231338FB5FA14001B8578729CECAC582"><enum>(d)</enum><header>Reports and notifications</header><text display-inline="yes-display-inline">Section 3010 of the Public Health Service Act, as added by subsection (a), is amended by adding at the end the following new subsection:</text>
						<quoted-block display-inline="no-display-inline" id="HAAA2B245AF1A4B07832688EEDE482EDA" style="OLC">
							<subsection commented="no" id="HC49CDF7824A4488EBA6B07EBAB93E3B3"><enum>(c)</enum><header>Dissemination of information</header>
 <paragraph id="H37DB92731E0941DBBFD2DDC82A80BE95"><enum>(1)</enum><header>Initial summary report</header><text>Not later than July 1, 2017, the Secretary, after consultation with relevant stakeholders, shall submit to Congress and provide for publication in the Federal Register and the posting on the Internet website of the Office of the National Coordinator for Health Information Technology of a report on the following:</text>
 <subparagraph commented="no" id="H544B7B5343D84F05A09CC08CB2A71A51"><enum>(A)</enum><text>The initial set of interoperability standards adopted under section 3004(c).</text> </subparagraph><subparagraph id="H431C79E86CC64D038A67EFADC08915B8"><enum>(B)</enum><text>The strategies for achieving widespread interoperability.</text>
 </subparagraph><subparagraph id="H95744A78459843C3B41C5297B7036F2B"><enum>(C)</enum><text>An overview of the extent to which electronic health records and health information technology offered as of such date satisfy such initial set.</text>
 </subparagraph><subparagraph id="H42D44C61B8634995B8297E0AD0AE3232"><enum>(D)</enum><text>Any barriers that are preventing widespread interoperability.</text> </subparagraph><subparagraph id="H3BFC6F1F151443118521EDD1D065F200"><enum>(E)</enum><text display-inline="yes-display-inline">The plan and milestones, including specific steps, to achieve widespread interoperability.</text>
 </subparagraph></paragraph><paragraph id="HC0A87A1938DC44A49714E7C8D219E02D"><enum>(2)</enum><header>Follow-up determination and report on widespread interoperability</header><text>Not later than December 31, 2019, the Secretary shall provide for publication in the Federal Register and the posting on the Internet website of the Office of the National Coordinator for Health Information Technology of the following:</text>
 <subparagraph id="H2DEC7DD8C5674816913AB2746A43FDCF"><enum>(A)</enum><text>A determination by the Secretary whether the goal of widespread interoperability has been achieved.</text> </subparagraph><subparagraph id="H81274183DD5F424AB8B61F98EB4AAA78"><enum>(B)</enum><text display-inline="yes-display-inline">A list identifying the vendors of, or other entities offering, qualified electronic health records, which categorizes such entities, with respect to such records, as in compliance or not in compliance with the certification criteria described in section 3001(c)(5)(B)(ii) and with the requirements under clause (i) of section 3001(c)(5)(C) (including with the terms of the attestation and other requirements under such clause).</text>
 </subparagraph><subparagraph id="HCF1CC44D626540C8B8E9FF2CCA2710C0"><enum>(C)</enum><text>Actions that may be taken by entities identified under subparagraph (B) as not being in compliance with such criteria and requirements in order for such entities to become in compliance with such criteria and requirements.</text>
 </subparagraph><subparagraph id="H87E821345D914FE7983B9C1115F89B11"><enum>(D)</enum><text display-inline="yes-display-inline">Penalties described in section 3010A(d) to which entities, with respect to such qualified electronic health records, beginning January 1, 2019, are subject if such technology and entities are not in compliance with the certification criteria described in section 3001(c)(5)(B)(ii) and with the requirements under clause (i) of section 3001(c)(5)(C), respectively.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HAB99C77D8454473E98A521C769C4BB06"><enum>(3)</enum><header>Ongoing publication of recommendations</header><text display-inline="yes-display-inline">The Secretary shall provide for publication in the Federal Register and the posting on the Internet website of the Office of the National Coordinator for Health Information Technology of all recommendations made under this section.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
					</subsection><subsection id="H39BA14DB29C74CD28B1E61F9F223E1B3"><enum>(e)</enum><header>Certification and other enforcement provisions</header>
 <paragraph id="HCA0DFEE82420456581C082F3D11477EE"><enum>(1)</enum><header>Certification of qualified electronic health records</header><text display-inline="yes-display-inline"></text> <subparagraph id="H7ABAB12728C341D293AD4DB7A8A17B41"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Section 3007(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-17">42 U.S.C. 300jj–17(b)</external-xref>) is amended by striking <quote>under section 3001(c)(3) to be in compliance with</quote> and all that follows through the period at the end and inserting</text>
								<quoted-block display-inline="yes-display-inline" id="H8FE326C8D7084C03BE8AEE2E1E2AC491" style="OLC">
 <text>under section 3001(c)(3)—</text><paragraph id="HC6C4CD74510A46D3965E7B8B79B6E791"><enum>(1)</enum><text display-inline="yes-display-inline">for certifications made before January 1, 2018, to be in compliance with applicable standards adopted under subsections (a) and (b) of section 3004; and</text>
 </paragraph><paragraph id="H27174C219C434A5F9935BE0DB6C68EA2"><enum>(2)</enum><text display-inline="yes-display-inline">for certifications made on or after January 1, 2018, to be in compliance with applicable standards adopted under subsections (a) and (b) of section 3004 and to be interoperable in accordance with section 3010, including by being in compliance with interoperability standards adopted under section 3004.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="H06CFFDCEA08B4A9090CD3802BCABAC4F"><enum>(B)</enum><header>Requirements of Secretary</header><text display-inline="yes-display-inline">Section 3001(c)(5) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-11">42 U.S.C. 300jj–11(c)(5)</external-xref>) is amended—</text> <clause id="HD4AD9D31BD244EF38B7A8CC81A760CF8"><enum>(i)</enum><text>by amending subparagraph (B) of such section to read as follows:</text>
									<quoted-block display-inline="no-display-inline" id="H5F62060E05AF4551AA42A6FBFF397635" style="OLC">
 <subparagraph id="H576A7CF50BFE46F3BE8A0B130CB48150"><enum>(B)</enum><header>Certification criteria described</header><text display-inline="yes-display-inline">In this title, the term <quote>certification criteria</quote> means, with respect to qualified electronic health records—</text> <clause id="H384E566110AA4BC696365251F0CC9F7D"><enum>(i)</enum><text display-inline="yes-display-inline">for certifications made before January 1, 2018, criteria to establish that the records meet standards and implementation specifications adopted under subsections (a) and (b) of section 3004 for qualified electronic health records; and</text>
 </clause><clause id="H8E96116103C947B2AB692EFB825C9D63"><enum>(ii)</enum><text display-inline="yes-display-inline">for certifications made on or after January 1, 2018, criteria described in clause (i) and criteria to establish that the records are interoperable, in accordance with section 3010, including by being in compliance with interoperability standards adopted under section 3004.</text></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause><clause id="H547093FA038A4B1C8BACC7E0B587ABDB"><enum>(ii)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="HA2FD3E67C6B842CF8D5CC99892C50391" style="OLC"> <subparagraph id="HCC492F38AA88440499A1303372BEBAF9"><enum>(C)</enum><header>Enforcement; decertifications</header> <clause id="H634DF47AF1674AE2B81068EB9ED35974"><enum>(i)</enum><header>Requirements</header><text display-inline="yes-display-inline">Under any program kept or recognized under subparagraph (A), the Secretary shall ensure that any vendor of or other entity offering qualified electronic health records seeking a certification of such records under such program on or after January 1, 2018, shall, as a condition of certification (and maintenance of certification) of such a record under such program—</text>
 <subclause id="H079AC95AFD2A48A18B274FB53C5DFFE3"><enum>(I)</enum><text>provide to the Secretary an attestation—</text> <item id="H6C9B52CF08364EF7A7CEBEC134941253"><enum>(aa)</enum><text display-inline="yes-display-inline">that the entity, unless for a legitimate purpose specified by the Secretary, has not taken any action, including through any financial, administrative, or technological barrier, which the entity knows or should know (as defined in section 1128A(i)(7) of the Social Security Act), is to limit or restrict the exchange of information or to prevent or disincentivize widespread interoperability between any providers using such records or other health information technology in connection with such record;</text>
 </item><item id="HD8FB5634ABA547A083A22E2D91915500"><enum>(bb)</enum><text display-inline="yes-display-inline">on the pricing information described in clause (v) for purposes of the portal created under paragraph (9), that such information will be available on a public Web site of such entity and in marketing materials, communications statements, and other assertions of such entity related to such record, and that the entity will voluntarily provide such information to customers prior to providing any qualified electronic health records or related product or service (including subsequent updates, add-ons, or additional products or services to be provided during the course of an on-going contract), prospective customers (such as persons who request or receive a quotation, estimate, or other similar marketing or promotional material), and other persons who request such information;</text>
 </item><item id="H34B7425F9D8B469CA648577B5E9478E5"><enum>(cc)</enum><text display-inline="yes-display-inline">that the software with respect to such records have published application programming interfaces for medical records data, search and indexing, semantic harmonization and vocabulary translation, and user interface applications;</text>
 </item><item id="H70550AA067B14860A8146BCE3E75E88E"><enum>(dd)</enum><text>that the entity has successfully tested the use of the record in the type of setting in which it would be marketed;</text>
 </item><item id="HB32847BB2E384B13A266D64328518508"><enum>(ee)</enum><text>the entity has in place implementation guidelines for such record that support interoperability, consistent with section 3010; and</text>
 </item><item id="H23590A517ECF4C80836B67E9F598D033"><enum>(ff)</enum><text display-inline="yes-display-inline">that the entity has in place data sharing programs or capabilities based on common data elements through application programming interfaces without the requirement for vendor-specific interfaces;</text>
 </item></subclause><subclause id="HA076D20C5C624B55A6054CBF96AFAE68"><enum>(II)</enum><text>publish application programming interfaces and associated documentation, with respect to such records, for medical records data, search and indexing, semantic harmonization and vocabulary translation, and user interface applications; and</text>
 </subclause><subclause id="H15319FE7A37F4DD99F9A3A95F651C053"><enum>(III)</enum><text display-inline="yes-display-inline">demonstrate to the satisfaction of the Secretary that data from such records is able to be exchanged through the use of application programming interfaces and used in a manner that allows for exchange and everyday use, as authorized under applicable law, of such record.</text>
 </subclause></clause><clause id="H26987A7F33FA4B49B20CFCE3C5A33650"><enum>(ii)</enum><header>Decertification</header><text display-inline="yes-display-inline">Under any program kept or recognized under subparagraph (A), the Secretary shall ensure that beginning January 1, 2019, any qualified electronic health records that do not satisfy the certification criteria described in section 3001(c)(5)(B)(ii) or with respect to which the vendor or other entity described in clause (i) does not satisfy the requirements under such clause (or is determined to be in violation of the terms of the attestation or other requirements under such clause) shall no longer be considered as certified under such program.</text>
 </clause><clause id="H3F42072202C04490B780BE3B015167BB"><enum>(iii)</enum><header>Annual publication</header><text display-inline="yes-display-inline">For 2019 and each subsequent year, the Secretary shall post on the public Internet website of the Department of Health and Human Services a list of any vendors of or other entities offering qualified electronic health records with respect to which certification has been withdrawn under clause (ii) during such year.</text>
 </clause><clause id="H8B5E7326FDBA4C66B51A724FB628EEC7"><enum>(iv)</enum><header>Periodic review</header><text display-inline="yes-display-inline">The Secretary shall periodically review and confirm that vendors of and other entities offering qualified electronic health records have publicly published application programming interfaces and associated documentation as required by clause (i)(II) for purposes of certification and maintaining certification under any program kept or recognized under subparagraph (A).</text>
 </clause><clause id="H85C3C05E7875433084AFAF88D14F1DF2"><enum>(v)</enum><header>Pricing information</header><text display-inline="yes-display-inline">For purposes of clause (i)(I)(bb), the pricing information described in this clause, with respect to a vendor of or other entity offering a qualified electronic health record, is the following:</text>
 <subclause id="H383CC7831F764603951674A31977E2A1"><enum>(I)</enum><text display-inline="yes-display-inline">Additional types of costs or fees (whether fixed, recurring, transaction based, or otherwise) imposed by the entity (or any third-party from whom the entity purchases, licenses, or obtains any technology, products, or services in connection with the qualified electronic health record) to purchase, license, implement, maintain, upgrade, use, or otherwise enable and support the use of capabilities to which such record is to be certified under this section; or in connection with any data generated in the course of using any capability to which the record is to be so certified.</text>
 </subclause><subclause id="HDB657E42FCFF4000BB7CA5BBDC3F9A91"><enum>(II)</enum><text>Limitations, whether by contract or otherwise, on the use of any capability to which the record is to be certified under this section for any purpose within the scope of the record’s certification; or in connection with any data generated in the course of using any capability to which the record is to be certified under this section.</text>
 </subclause><subclause id="H73AF05DC7A3E4376967274C3B350D67F"><enum>(III)</enum><text>Limitations, including technical or practical limitations of technology or its capabilities, that could prevent or impair the successful implementation, configuration, customization, maintenance, support, or use of any capabilities to which the record is to be certified under this section; or that could prevent or limit the use, exchange, or portability of any data generated in the course of using any capability to which the record is to be so certified.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph id="H7D8F739917F74414B35B2AC3091530A1"><enum>(2)</enum><header>Additional enforcement provisions under the Public Health Service Act</header><text>Subtitle A of title XXX of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-11">42 U.S.C. 300jj–11 et seq.</external-xref>), as amended by subsection (a)(1), is further amended by adding at the end the following new section:</text>
							<quoted-block display-inline="no-display-inline" id="H07E3C02E8F8E4881AC4915DB55C7303D" style="OLC">
								<section id="H9BA32EF009204308A4CA8068B1405EDA"><enum>3010A.</enum><header>Enforcement mechanisms</header>
 <subsection id="HF235A7144AA94998AE024A1DDD906D02"><enum>(a)</enum><header>Inspector General authority</header><text display-inline="yes-display-inline">The Inspector General of the Department of Health and Human Services shall have the authority to investigate claims of—</text>
 <paragraph id="HBAB37BF5EC5C4A38BCCADB9DEBA0431E"><enum>(1)</enum><text display-inline="yes-display-inline">vendors of, or other entities offering, qualified electronic health records—</text> <subparagraph id="HC6FCC9C0EE0E40E69BB480523A5C4257"><enum>(A)</enum><text>being in violation of an attestation made under section 3001(c)(5)(C)(i)(I), with respect to the use of such records by a health care provider under a specified meaningful use incentive program; and</text>
 </subparagraph><subparagraph id="H37A30478A9204611A0B487FECC3790EA"><enum>(B)</enum><text display-inline="yes-display-inline">having engaged in information blocking (as defined in subsection (f)), unless for a legitimate purpose specified by the Secretary, with respect to the use of such records by a health care provider under such a program;</text>
 </subparagraph></paragraph><paragraph id="H1DAABDBABBED405C9645F53D94E65D0F"><enum>(2)</enum><text display-inline="yes-display-inline">health care providers, with respect to the use of such records under a specified meaningful use incentive program, having, unless for a legitimate purpose specified by the Secretary, engaged in information blocking (as so defined);</text>
 </paragraph><paragraph id="H39DDEBB6BDC4419799F3D41CEA30DD12"><enum>(3)</enum><text display-inline="yes-display-inline">health information system providers described in subsection (b) having engaged in information blocking (as so defined), unless for a legitimate purpose specified by the Secretary, with respect to the use of such records under a specified meaningful use incentive program; and</text>
 </paragraph><paragraph id="HA50025CA31D94B2EB12D08AAF4B88CE5"><enum>(4)</enum><text>vendors of, or other entities offering, health information technology (other than technology described in paragraph (1)), health care providers, with respect to the use of such technology, and health information system providers, with respect to such technology, unless for a legitimate purpose specified by the Secretary, having engaged in information blocking (as so defined).</text>
 </paragraph></subsection><subsection commented="no" id="H768D5F25CC084A659AEF3A584F0B3462"><enum>(b)</enum><header>Health information system providers</header><text display-inline="yes-display-inline">The Inspector General of the Department of Health and Human Services shall, in coordination with the Federal Trade Commission, ensure that health information system providers (such as operators of health information exchanges and other systems that facilitate the exchange of information) investigate claims of information blocking, with respect to the use of such records under a specified meaningful use incentive program.</text>
									</subsection><subsection commented="no" id="H8DF92CABF4E14826AC5BCE0EC862D234"><enum>(c)</enum><header>Information sharing provisions</header>
 <paragraph commented="no" id="HFB7A8ECB5234482AB5CEC4EC2BE7C4E6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The National Coordinator may serve as a technical consultant to the Inspector General of the Department of Health and Human Services and the Federal Trade Commission for purposes of carrying out this section. As such technical consultant, the National Coordinator may, notwithstanding any other provision of law, share information related to claims or investigations under subsection (a) or (b) with the Inspector General and Federal Trade Commission for purposes of such investigations.</text>
 </paragraph><paragraph commented="no" id="H6EE6C1C64F554DA981C8693A9EDC3F84"><enum>(2)</enum><header>Protection from disclosure of information</header><text>Any information shared by the National Coordinator under paragraph (1) shall not be subject to the provisions of section 552 of title 5, United States Code (commonly referred to as the Freedom of Information Act). Any information acquired pursuant to paragraph (1) shall be held in confidence and shall not be disclosed to any person except as may be necessary to carry out the purposes of subsection (a).</text>
 </paragraph><paragraph commented="no" id="HEB3B022F30DF4621AD9EC62F7A775F79"><enum>(3)</enum><header>Non-application of Paperwork Reduction Act</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/35">Chapter 35</external-xref> of title 44, United States Code (commonly referred to as the Paperwork Reduction Act of 1995) shall not apply to the National Coordinator or to the Office of the National Coordinator for Health Information Technology with respect to the collection of complaints relating to claims described in subsection (a).</text>
 </paragraph></subsection><subsection id="H625753CF65D7479FAFBF48606476D20E"><enum>(d)</enum><header>Penalty</header><text display-inline="yes-display-inline">Any person or entity determined to have committed an act described in paragraph (1), (2), or (3) of subsection (a), in connection with a specified meaningful use incentive program, shall be subject to a civil monetary penalty of not more than $10,000 for each such act. The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty applied under this subsection in the same manner as they apply to a civil money penalty or proceeding under section 1128A(a).</text>
 </subsection><subsection id="H5562D0F73E9740A191CEFF8AA516708C"><enum>(e)</enum><header>Specified meaningful use incentive program</header><text>For purposes of this section, the term <quote>specified meaningful use incentive program</quote> includes the following:</text> <paragraph id="HAB23FB05D1134D08BB5AD9C70641D169"><enum>(1)</enum><text>The incentive payments under subsection (o) of section 1848 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-4">42 U.S.C. 1395w–4</external-xref>) and adjustments under subsection (a)(7) of such section.</text>
 </paragraph><paragraph id="H9543620286BB4EE9B99F23B7C5130E55"><enum>(2)</enum><text>The incentive payments under subsection (n) of section 1848 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww</external-xref>) and adjustments under subsection (b)(3)(B) of such section.</text>
 </paragraph><paragraph id="H36E0E90F335F494683EEE886AD2B2B6A"><enum>(3)</enum><text>The incentive payments and adjustments made under subsections (l) and (m) of section 1853 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-23">42 U.S.C. 1395w–23</external-xref>).</text>
 </paragraph><paragraph id="HD6323268F3954BD89C22489543C05315"><enum>(4)</enum><text>The incentive payment under paragraph (3) of section 1814(l) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395f">42 U.S.C. 1395f(l)</external-xref>) and adjustment under paragraph (4) of such section.</text>
 </paragraph><paragraph id="HB2F27F07FAAA4E6E9061874826CA1C08"><enum>(5)</enum><text>The shared savings program under section 1899 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395jjj">42 U.S.C. 1395jjj</external-xref>).</text> </paragraph><paragraph id="HAED2B5D3E97A4F6B90B3A6127705DDF7"><enum>(6)</enum><text>The payments to Medicaid providers described in section 1903(t) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396b">42 U.S.C. 1396b(t)</external-xref>).</text>
										</paragraph></subsection><subsection id="HFB4553C77CAD444FBB6A66A76265FA7A"><enum>(f)</enum><header>Information blocking</header>
 <paragraph id="H839C0C0BE86A4A2691C2C9E1EC2946DB"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">For purposes of this section and section 3010, the term <quote>information blocking</quote> means, with respect to the use of qualified electronic health records or other health information technology under a specified meaningful use incentive program, business, technical, and organizational practices, including practices described in paragraph (2), that—</text>
 <subparagraph id="H44E8C966C5794DBC8C934BCA62ECBDED"><enum>(A)</enum><text>prevent or materially discourage the exchange of electronic health information;</text> </subparagraph><subparagraph id="H43EFEEE633CF4A71A56627749BEAB5A9"><enum>(B)</enum><text display-inline="yes-display-inline">the actor knows or should know (as defined in section 1128A(i)(7) of the Social Security Act) is likely to interfere with the exchange or use of electronic health information; and</text>
 </subparagraph><subparagraph id="H0AFF585E7D8A47D5BCCBEB343B9BAE1A"><enum>(C)</enum><text>do not serve to protect patient safety, maintain the privacy and security of individuals’ health information or promote competition and consumer welfare.</text>
 </subparagraph></paragraph><paragraph id="H6950EA498E7B41ADA32EB3415183BAD2"><enum>(2)</enum><header>Practices described</header><text display-inline="yes-display-inline">For purposes of paragraph (1), the practices described in this paragraph are the following:</text> <subparagraph id="HAE6DCB1C97CF4CB488FD6B686C1982D0"><enum>(A)</enum><text>Contract terms, policies, or other business or organizational practices that restrict individuals’ access to their electronic health information or restrict the exchange or use of that information for treatment and other permitted purposes.</text>
 </subparagraph><subparagraph id="H64BC7438E8234FB690C849E1D6B1426D"><enum>(B)</enum><text>Charging prices or fees (such as for data exchange, portability, and interfaces) that make exchanging and using electronic health information cost prohibitive.</text>
 </subparagraph><subparagraph id="HED59B18743354EC49C45E8F87C907226"><enum>(C)</enum><text>Developing or implementing health information technology in non-standard ways that are likely to substantially increase the costs, complexity, or burden of sharing electronic health information, especially in cases in which relevant interoperability standards or methods to measure interoperability have been adopted by the Secretary.</text>
 </subparagraph><subparagraph id="HC3BFF321A1DF4675B02B6181F1FE0DCB"><enum>(D)</enum><text>Developing or implementing health information technology in ways that are likely to lock in users or electronic health information, such as not allowing for the full export of data; lead to fraud, waste, or abuse; or impede innovations and advancements in health information exchange and health information technology-enabled care delivery.</text>
 </subparagraph></paragraph></subsection><subsection commented="no" id="H17B3CBF5FB7C46ECAC9BC9647C151D0D"><enum>(g)</enum><header>Treatment of vendors with respect to patient safety organizations</header><text display-inline="yes-display-inline">In applying part C of title IX—</text> <paragraph commented="no" id="H52D88E54E9A44B658169CAF44035D337"><enum>(1)</enum><text>vendors shall be treated as a provider (as defined in section 921) for purposes of reporting requirements under such part, to the extent that such reports are related to attestation requirements under section 3001(c)(5)(C)(i)(I);</text>
 </paragraph><paragraph commented="no" id="H3EBF274853694A61811B9174664F560F"><enum>(2)</enum><text>claims of information blocking described in subsection (a) shall be treated as a patient safety activity under such part for purposes of reporting requirements under such part; and</text>
 </paragraph><paragraph commented="no" id="HB9F4FCF7306641CF8078705C97FFCE0A"><enum>(3)</enum><text>health care providers that are not members of patient safety organizations shall be treated in the same manner as health care providers that are such members for purposes of such reporting requirements with respect to claims of information blocking described in subsection (a).</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph><paragraph commented="no" id="H4538E79B3B3042AFA104787DB285C8FA"><enum>(3)</enum><header>ONCHIT</header>
 <subparagraph commented="no" id="H22E1479FC9E942F7AD6583C05CFB4E41"><enum>(A)</enum><header>Portal</header><text display-inline="yes-display-inline">Section 3001(c) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-11">42 U.S.C. 300jj–11(c)</external-xref>) is amended by adding at the end the following new paragraph:</text>
								<quoted-block display-inline="no-display-inline" id="H91EBA6DEF691475C848EE5AD2682D725" style="OLC">
 <paragraph id="H769D94EA6AFA46E9B0932C56A3C3939F"><enum>(9)</enum><header>Portal</header><text display-inline="yes-display-inline">Not later than January 1, 2019, the National Coordinator shall create a portal to make the information described in paragraph (5)(C)(I)(i)(bb) available to the public in a manner that allows for comparison of price information among health information technology products and that aids in making informed decisions for purchasing such a product.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph><subparagraph commented="no" id="H0B253F28F8594263A04A8F6714030B90"><enum>(B)</enum><header>Information blocking</header><text>Not later than 12 months after the date of the enactment of this Act, the National Coordinator shall, through rulemaking, implement the provisions of this section, and amendments made by this section, relating to information blocking.</text>
 </subparagraph><subparagraph commented="no" id="H638BEBC9FD054B828F5986E0DFF9B768"><enum>(C)</enum><header>HIPAA</header><text>Not later than January 1, 2017, the National Coordinator shall publish guidance to clarify the relationship of the HIPAA privacy and security law, as defined in section 3009(a)(2) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-19">42 U.S.C. 300jj–19(a)(2)</external-xref>) as such provisions relate to information blocking (as defined in section 3010A(f) of such Act, as added by paragraph (2), including examples of how such provisions may result in information blocking.</text>
 </subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HAF5AD13B38B749CDB0193B17FC07AF3A"><enum>(4)</enum><header>Demonstration required for meaningful EHR use incentives under Medicare</header><text display-inline="yes-display-inline"></text> <subparagraph commented="no" id="H05E9A8116CF34329AAE19FAA259A9DAC"><enum>(A)</enum><header>Incentives for professionals</header> <clause id="H6077F2F3672246968A22CD183FDDD450"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1848(o)(2)(C) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-4">42 U.S.C. 1395w–4(o)(2)(C)</external-xref>) is amended by adding at the end the following new clause:</text>
									<quoted-block display-inline="no-display-inline" id="H84EDC622F49E44F69AAF03D0F37E074D" style="OLC">
 <clause commented="no" id="H86BA0393A1274B51B25E535706786284"><enum>(iii)</enum><header>Interoperability</header><text display-inline="yes-display-inline">With respect to EHR reporting periods for payment years beginning with 2018, the means described in clause (i) specified by the Secretary shall include a demonstration, through means such as an attestation, that the professional has not taken any action described in subsection (a)(2) of section 3010A of the Public Health Service Act with respect to which the professional, with respect to the use of any certified EHR technology.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </clause><clause id="H57C077FA0AA549FEAC0537B206A5252D"><enum>(ii)</enum><header>Hardship exemption in case of decertified EHR</header><text display-inline="yes-display-inline">Subparagraph (B) of section 1848(a)(7) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-4">42 U.S.C. 1395w–4(a)(7)(B)</external-xref>) is amended to read as follows:</text>
									<quoted-block display-inline="no-display-inline" id="H1DBDF569D5974E858EE84D6C9FA64643" style="OLC">
										<subparagraph id="H71F8860B6E474D989D8F26F52565A67F"><enum>(B)</enum><header>Significant hardship exception</header>
 <clause id="H679EF04AACB1463BBE28117BC229A30B"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may, on a case-by-case basis, exempt an eligible professional from the application of the payment adjustment under subparagraph (A) if the Secretary determines, subject to annual renewal, that compliance with the requirement for being a meaningful EHR user would result in a significant hardship, such as in the case of an eligible professional who practices in a rural area without sufficient Internet access.</text>
											</clause><clause id="H26608EEB2922466FB09E014761B51ED3"><enum>(ii)</enum><header>Decertification</header>
 <subclause id="HFBF71097049D443D97CECC58425E3FB3"><enum>(I)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may, on a case-by-case basis, exempt an eligible professional from the application of the payment adjustment under subparagraph (A) if the Secretary determines that such professional was determined to not be a meaningful EHR user because the qualified electronic health record used by such professional was decertified under section 3001(c)(5)(C) of the Public Health Service Act. An exemption under the previous sentence may be applied to an eligible professional only, subject to subclause (II), during the first payment year with respect to the first EHR reporting period to which such decertification applies.</text>
												</subclause><subclause id="HB45C65D0FA5F4CE4A30F71BF0B24D019"><enum>(II)</enum><header>Duration</header>
 <item id="H982B00C4F5A945FB8D69FBB42F28588E"><enum>(aa)</enum><header>In general</header><text display-inline="yes-display-inline">In no case shall an exemption by reason of this clause be for a period of less than 12 months.</text> </item><item id="HAE7019951FB249FC90E43B38AD59E1E9"><enum>(bb)</enum><header>Extension</header><text>An exemption under this clause may be extended for a period of an additional 12 months subject to the limitation described in clause (ii).</text>
 </item></subclause></clause><clause id="H29A83924F5364883B945A9FDCF830ABA"><enum>(iii)</enum><header>Limitation</header><text>Subject to clause (ii)(II)(aa), in no case may an eligible professional be granted an exemption under this subparagraph for more than 5 years.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
								</clause></subparagraph><subparagraph commented="no" id="H388E3A2C97A8446F9E17DDB0DA1C5DD1"><enum>(B)</enum><header>Incentives for hospitals</header>
 <clause id="H564A263F9D8547CB8818370B6378AD4A"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1886(o)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(o)(1)</external-xref>) is amended—</text> <subclause commented="no" id="HBCF5C96BAD0A41B3AB2D991EF5DB0245"><enum>(I)</enum><text>in subparagraph (A), by inserting before the period at the end the following: <quote>and, for performance periods for fiscal year 2018 or a subsequent fiscal year, that provide a demonstration described in subparagraph (D) to the Secretary</quote>; and</text>
 </subclause><subclause commented="no" id="H9F97CFA2609541BD8A8576C84DB36EB9"><enum>(II)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="HC8D6DE93E0CC494BB8751907A1A4DA18" style="OLC"> <subparagraph commented="no" id="H0E577B4271B04DACB46217A16E12F27B"><enum>(D)</enum><header>Demonstration described</header><text display-inline="yes-display-inline">The demonstration described in this subparagraph is a demonstration, through means such as an attestation, that the hospital has not taken any action described in subsection (a)(2) of section 3010A of the Public Health Service Act with respect to which the hospital, with respect to the use of any certified EHR technology.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subclause></clause><clause id="H793E3DD17DC34EEEA2C4C26B36188B25"><enum>(ii)</enum><header>Hardship exemption in case of decertified EHR</header><text display-inline="yes-display-inline">Subclause (II) of section 1886(b)(3)(B)(ix) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(b)(3)(B)(ix)</external-xref>) is amended to read as follows:</text>
									<quoted-block display-inline="no-display-inline" id="H82BACF4E56DD4D66930D3D2EFB373984" style="OLC">
										<subclause id="H5037682C7B894D9AB10A6A83DA6B6F53"><enum>(II)</enum>
 <item commented="no" display-inline="yes-display-inline" id="H0731DCDCF3EE4823AAC40BD4ABDB6BBC"><enum>(aa)</enum><text display-inline="yes-display-inline">The Secretary may, on a case-by-case basis, exempt a subsection (d) hospital from the application of subclause (I) with respect to a fiscal year if the Secretary determines, subject to annual renewal, that requiring such hospital to be a meaningful EHR user during such fiscal year would result in a significant hardship, such as in the case of a hospital in a rural area without sufficient Internet access.</text>
 </item><item id="H314E2E54C32D4F59B6DB5DE4B3DC5887" indent="up1"><enum>(bb)</enum><text display-inline="yes-display-inline">The Secretary may, on a case-by-case basis, exempt a subsection (d) hospital from the application of subclause (I) with respect to a fiscal year if the Secretary determines, subject to annual renewal, that such hospital was determined to not be a meaningful EHR user because the qualified electronic health record used by such hospital was decertified under section 3001(c)(5)(C) of the Public Health Service Act. An exemption under the previous sentence may be applied to a subsection (d) hospital only, subject to items (cc) and (dd), during the first payment year with respect to the first EHR reporting period to which such decertification applies.</text>
 </item><item id="HD8CC934703534CF7B3797DD3932BA3C3" indent="up1"><enum>(cc)</enum><text>In no case shall an exemption by reason of item (bb) be for a period of less than 12 months.</text> </item><item id="HA5461F1464EF46D4B543E9C536C8F658" indent="up1"><enum>(dd)</enum><text>An exemption under item (bb) may be extended for a period of an additional 12 months subject to the limitation described in item (ee).</text>
 </item><item id="HCF845982D7D04F59BF723ED6A9D82D99" indent="up1"><enum>(ee)</enum><text>Subject to item (cc), in no case may a hospital be granted an exemption under this subclause for more than 5 years.</text></item></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
 </clause></subparagraph><subparagraph commented="no" id="H8C2D277DE5E64FB7BB281D376767BDE5"><enum>(C)</enum><header>Demonstration required for meaningful EHR use incentives under Medicaid</header><text>Section 1903(t)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396b">42 U.S.C. 1396b(t)(2)</external-xref>) is amended by adding at the end the following: <quote>An eligible professional shall not qualify as a Medicaid provider under this subsection, with respect to a year beginning with 2018, unless such provider demonstrates to the Secretary, through means such as an attestation, that the provider has not taken any action described in subsection (a)(2) of section 3010A of the Public Health Service Act with respect to which the provider knows or should know (as defined in section 1128A(i)(7) of the Social Security Act) about, with respect to the use of any certified EHR technology.</quote>.</text>
							</subparagraph></paragraph></subsection><subsection id="HAB2FA0298FCE4EF08CDC5D9C62ABF4FB"><enum>(f)</enum><header>Definitions</header>
 <paragraph id="H3B50C1DE36F54F2680994322429599CD"><enum>(1)</enum><header>Certified EHR technology</header><text>Paragraph (1) of section 3000 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj">42 U.S.C. 300jj</external-xref>) is amended to read as follows:</text>
							<quoted-block display-inline="no-display-inline" id="HDB82EEE939674EE494944CFAE8FF5166" style="OLC">
 <paragraph id="HEE13AAD6867A49F6ADDB6482F85AE357"><enum>(1)</enum><header>Certified EHR technology</header><text display-inline="yes-display-inline">The term <quote>certified EHR technology</quote> means a qualified electronic health record that is certified pursuant to section 3001(c)(5) as meeting the certification criteria defined in subparagraph (B) of such section that are applicable to the type of record involved (as determined by the Secretary, such as an ambulatory electronic health record for office-based physicians or an inpatient hospital electronic health record for hospitals) including, beginning January 1, 2018, with respect to which the vendor or other entity offering such technology is in compliance with the requirements under section 3001(c)(5)(C)(i).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HFEC6619B17F2445EA7634F18E3A8E8DF"><enum>(2)</enum><header>Widespread interoperability</header><text display-inline="yes-display-inline">Section 3000 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj">42 U.S.C. 300jj</external-xref>) is amended by adding at the end the following new paragraph:</text>
							<quoted-block display-inline="no-display-inline" id="H3D1DDCEA02C04975B048BEBEC51ACB99" style="OLC">
 <paragraph id="H44AF6F169E0F4FFB926C7AFBB92C181F"><enum>(15)</enum><header>Widespread interoperability</header><text display-inline="yes-display-inline">The term <quote>widespread interoperability</quote> means that, on a nationwide basis—</text> <subparagraph id="H81CC46BBF2E94A96A7718AFCAFDD4AC2"><enum>(A)</enum><text>health information technology are interoperable, in accordance with section 3010, including as measured by the methods adopted under such section; and</text>
 </subparagraph><subparagraph id="HAD1EC6FB941245E88C39847379042094"><enum>(B)</enum><text>such records are employed by meaningful EHR users under the specified meaningful use incentive programs (as defined in section 3010A(e)) and other clinicians and health care providers.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph></subsection><subsection id="HB1485660EE3C4D64BE85AE5E0C28844F"><enum>(g)</enum><header>Conforming amendments</header>
 <paragraph id="H6EBB541BC314487D8F29EC22C05EF777"><enum>(1)</enum><header>Voluntary use of standards</header><text display-inline="yes-display-inline">Section 3006 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-16">42 U.S.C. 300jj–16</external-xref>) is amended—</text> <subparagraph id="HD3F5828CF6BC4401A465DC37261FF808"><enum>(A)</enum><text>in subsection (a)(1), by inserting <quote>including an interoperability standard adopted under section 3004</quote> after <quote>section 3004</quote>.</text>
 </subparagraph><subparagraph id="HA35F3E59C2A94B2795FC7DA9B77A73BD"><enum>(B)</enum><text>in subsection (b), by inserting <quote>including the interoperability standards adopted under section 3004</quote> after <quote>section 3004</quote>.</text> </subparagraph></paragraph><paragraph id="HFED388FAFC20412F9A0EC57D21EB4762"><enum>(2)</enum><header>HIPAA privacy and security law definition correction</header><text display-inline="yes-display-inline">Section 3009(a)(2)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300jj-19">42 U.S.C. 300jj–19(a)(2)(A)</external-xref>) is amended by striking <quote>title IV</quote> and inserting <quote>title XIII</quote>.</text>
 </paragraph><paragraph id="H9EBC2B661EF146A79C00A0962DE1EB57"><enum>(3)</enum><header>Coordination of Federal activities</header><text>Section 13111 of the HITECH Act is amended—</text> <subparagraph id="HD54956306BAC4FDD89B099F28E16ED2D"><enum>(A)</enum><text>in subsection (a), by inserting before the period at the end the following: <quote>(and, beginning on January 1, 2018, that are also interoperable under section 3010 of such Act, including by being in compliance with interoperability standards adopted under section 3004 of such Act)</quote>; and</text>
 </subparagraph><subparagraph id="HBABF6B32D2914340A6F0E6D740FABA02"><enum>(B)</enum><text>in subsection (b), by inserting <quote>(and, beginning on January 1, 2018, including an interoperability standard adopted under section 3004 of such Act)</quote> before <quote>the President</quote>.</text>
 </subparagraph></paragraph><paragraph id="HCEDEBA6860C64CE18C467A5441A24844"><enum>(4)</enum><header>Application to private entities</header><text>Section 13112 of the HITECH Act is amended by inserting before the period at the end the following <quote>(and, beginning on January 1, 2018, that are also interoperable under section 3010 of such Act, including by being in compliance with interoperability standards adopted under section 3004 of such Act)</quote>.</text>
 </paragraph><paragraph id="H38CB66C0D5294D2AA921CCC77F7D5605"><enum>(5)</enum><header>Coordination with recommendations for achieving widespread EHR interoperability</header><text display-inline="yes-display-inline">Section 106 of the Medicare Access and CHIP Reauthorization Act of 2015 (<external-xref legal-doc="public-law" parsable-cite="pl/114/10">Public Law 114–10</external-xref>) is amended by striking subsection (b).</text>
 </paragraph></subsection><subsection id="H14B23EC04DBC4A6E810FCE3B96255097"><enum>(h)</enum><header>Patient empowerment</header><text display-inline="yes-display-inline">It is the sense of Congress that—</text> <paragraph id="H77AAF47E9AA341C8A3BEA9340F7646FE"><enum>(1)</enum><text>patients have the right to the entirety of the health information of such patient, including such information contained in an electronic health record of such patient;</text>
 </paragraph><paragraph id="H05270E553991410F83670E017C83B754"><enum>(2)</enum><text>such right extends to both structured and unstructured data; and</text> </paragraph><paragraph id="H53D7FCC453744F97B77BBA21432DE93D"><enum>(3)</enum><text>to further facilitate patient ownership over health information of such patient—</text>
 <subparagraph id="HD8706119FDA44FDA8AED221709F91382"><enum>(A)</enum><text>health care providers should not have the ability to deny a patient’s request for access to the entirety of such health information of such patient; and</text>
 </subparagraph><subparagraph id="H5001CC48941747528DA602CC8173069D"><enum>(B)</enum><text display-inline="yes-display-inline">health care providers do not need the consent of their patients to share personal health information of such patients with other covered entities, in compliance with the HIPAA privacy regulations promulgated pursuant to section 264(c) of the Health Insurance Portability and Accountability Act of 1996 for the purposes of supporting patient care, except in situations where consent is specifically required under such regulations, such as in cases related to the psychiatric records of the patient.</text>
							</subparagraph></paragraph></subsection></section></subtitle><subtitle id="H02B594E18AA04C8CB4C044E0F648477F"><enum>B</enum><header>Telehealth</header>
				<section id="H2C474EE1F5174FF5AF83E373FD819AD8" section-type="subsequent-section"><enum>3021.</enum><header>Telehealth services under the Medicare program</header>
 <subsection id="H09E1AE058DAD4C4EAC1458BACC05F3A2"><enum>(a)</enum><header>Provision of information by Centers for Medicare &amp; Medicaid Services</header><text display-inline="yes-display-inline">Not later than one year after the date of the enactment of this Act, the Administrator of the Centers for Medicare &amp; Medicaid Services shall provide to the committees of jurisdiction of the House of Representatives and the Senate information on the following:</text>
 <paragraph id="H11B8FB8792A045A18676854902A8D122"><enum>(1)</enum><text display-inline="yes-display-inline">The populations of Medicare beneficiaries, such as those who are dually eligible for the Medicare program under title XVIII of the Social Security Act and the Medicaid program under title XIX of such Act and those with chronic conditions, whose care may be improved most in terms of quality and efficiency by the expansion, in a manner that meets or exceeds the existing in-person standard of care under the Medicare program under title XVIII of such Act, of telehealth services under section 1834(m)(4) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(m)(4)</external-xref>).</text>
 </paragraph><paragraph id="H6639E6C477C34175A13014CB9B405D63"><enum>(2)</enum><text display-inline="yes-display-inline">Activities by the Center for Medicare and Medicaid Innovation which examine the use of telehealth services in models, projects, or initiatives funded through section 1115A of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1315a">42 U.S.C. 1315a</external-xref>).</text>
 </paragraph><paragraph id="HB6A4D77816C24E7088E6C28E61229C6C"><enum>(3)</enum><text display-inline="yes-display-inline">The types of high volume procedures codes or diagnoses under such title XVIII which might be suitable to the furnishing of services via telehealth.</text>
 </paragraph><paragraph id="H8DC584B093464B82828A616E19B16464"><enum>(4)</enum><text>Barriers that might prevent the expansion of telehealth services under section 1834(m)(4) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(m)(4)</external-xref>) beyond such services that are in effect as of the date of the enactment of this Act.</text>
 </paragraph></subsection><subsection id="H843FEB0E522B448FA38C3C8136157669"><enum>(b)</enum><header>Provision of information by MedPAC</header><text display-inline="yes-display-inline">Not later than one year after the date of the enactment of this Act, the Medicare Payment Advisory Commission established under section 1805 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395b-6">42 U.S.C. 1395b–6</external-xref>) shall, using data from the Medicare Advantage program under part C of title XVIII of such Act, provide information to the committees of jurisdiction of the House of Representatives and the Senate that identifies—</text>
 <paragraph id="H33E6044D4D434E04844F1C413C3EE314"><enum>(1)</enum><text>services—</text> <subparagraph id="HAA7D4E4D2E6443D491AC127AD33EDA3D"><enum>(A)</enum><text>for which payment could not be made, as of the date of the enactment of this Act, under the fee-for-service program under parts A and B of such title by reason of any limitation imposed under section 1834(m) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(m)</external-xref>); and</text>
 </subparagraph><subparagraph id="H2D4955CEEAA84FD3B191C3ED012014DF"><enum>(B)</enum><text>that are services that are recommended by the Commission to be included as telehealth services for which payment may be made under the fee-for-service program under parts A and B of such title; and</text>
 </subparagraph></paragraph><paragraph id="H35544AD8CBE54FED89F838F24ADCE469"><enum>(2)</enum><text>barriers to furnishing telehealth services for which payment may be made under such title XVIII and solutions to address such barriers.</text>
 </paragraph></subsection><subsection id="H0125E4ED337E41259A793AD1F62D0E3A"><enum>(c)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of Congress that—</text> <paragraph id="H3D6DC3C5F4834DFC823932AD11EF468A"><enum>(1)</enum><text display-inline="yes-display-inline">States should collaborate, through the use of State health board compacts or other mechanisms, to create common licensure requirements services in order to facilitate multistate practices and allow for health care providers to provide such services across State lines;</text>
 </paragraph><paragraph id="H977EA5322AD342EBB70087CF7343ED68"><enum>(2)</enum><text>health care providers should be appropriately licensed in the physical location where the patient is receiving services;</text>
 </paragraph><paragraph id="HAAF382561207451D847538E8754ACFDC"><enum>(3)</enum><text display-inline="yes-display-inline">eligible originating sites should be expanded beyond those originating sites described in section 1834(m)(4)(C) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(m)(4)(C)</external-xref>); and</text>
 </paragraph><paragraph id="H64392793E4D44AD5A2C704083E5A7D20"><enum>(4)</enum><text>any expansion of telehealth services under the Medicare program should—</text> <subparagraph id="H7215EEB44B2E4602955E6D8F843CB941"><enum>(A)</enum><text display-inline="yes-display-inline">recognize that telemedicine is the delivery of safe, effective, quality health care services, by a health care provider, using technology as the mode of care delivery;</text>
 </subparagraph><subparagraph id="H0B2E8932E3234AD5B5723230F0F04B83"><enum>(B)</enum><text display-inline="yes-display-inline">meet or exceed the conditions of coverage and payment with respect to the Medicare program under title XVIII unless specifically address in subsequent statute, of such Act if the service were furnished in person, including standards of care; and</text>
 </subparagraph><subparagraph id="H785250AE43224E60B181DE9C8FAA9864"><enum>(C)</enum><text display-inline="yes-display-inline">involve clinically appropriate means to furnish such services.</text> </subparagraph></paragraph></subsection></section></subtitle><subtitle id="H0C146A8F3E6E4739BB4422811DF4646D"><enum>C</enum><header>Encouraging Continuing Medical Education for Physicians</header> <section commented="no" id="H3875530BFDCC4C8DAC5B8DCD35E26BBB" section-type="subsequent-section"><enum>3041.</enum><header>Exempting from manufacturer transparency reporting certain transfers used for educational purposes</header> <subsection commented="no" id="H11AC3CCC54C3454180E9D3E4BE8DE2FC"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1128G(e)(10)(B) of the Social Security Act (42 U.S.C. 1320a–7h(e)(10)(B)) is amended—</text>
 <paragraph commented="no" id="H2C3D2220A940436EA5815635822571B5"><enum>(1)</enum><text display-inline="yes-display-inline">in clause (iii), by inserting <quote>, including peer-reviewed journals, journal reprints, journal supplements, medical conference reports, and medical textbooks</quote> after <quote>patient use</quote>; and</text>
 </paragraph><paragraph commented="no" id="H491C6C41691F4A91A412764C4C854231"><enum>(2)</enum><text>by adding at the end the following new clause:</text> <quoted-block display-inline="no-display-inline" id="H8851B0A0F8C14851BAC930EEFB5A50C8" style="OLC"> <clause commented="no" id="HE3C868B9D02E4824B4A8EC58D30F3DCB"><enum>(xiii)</enum><text display-inline="yes-display-inline">In the case of a covered recipient who is a physician, an indirect payment or transfer of value to the covered recipient—</text>
 <subclause commented="no" id="H59A3D64784C9489E84AEAE717627741D"><enum>(I)</enum><text>for speaking at, or preparing educational materials for, an educational event for physicians or other health care professionals that does not commercially promote a covered drug, device, biological, or medical supply; or</text>
 </subclause><subclause commented="no" id="H566EB031BB644783BCABB4F801515016"><enum>(II)</enum><text>that serves the sole purpose of providing the covered recipient with medical education, such as by providing the covered recipient with the tuition required to attend an educational event or with materials provided to physicians at an educational event.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection commented="no" id="H7DAFD942DF4B4B83B649BCB8C3FA6881"><enum>(b)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendments made by this section shall apply with respect to transfers of value made on or after the date of the enactment of this Act.</text>
					</subsection></section></subtitle><subtitle id="H4A8163D4282942DF97EE7274ED39BF31"><enum>D</enum><header>Disposable Medical Technologies</header>
				<section id="HFB81D616CC084E5187E9F38264171020" section-type="subsequent-section"><enum>3061.</enum><header>Treatment of certain items and devices</header>
					<subsection id="H6058F5530F144E24B19731987B70F0B6"><enum>(a)</enum><header>Payment for durable medical items (DMI)</header>
 <paragraph id="HF733963AD91B41CAAE4878029C37D9E6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1861(s)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(s)(2)</external-xref>) is amended—</text> <subparagraph id="H16FEEFB4512E4A288D9AFE75E8A6E97F"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (EE), by striking <quote>and</quote> at the end;</text>
 </subparagraph><subparagraph id="H9E61043624894F8499132353401BA1A8"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (FF), by inserting <quote>and</quote> at the end; and</text> </subparagraph><subparagraph id="H1FD29571D08548C197B7FBF65099AC36"><enum>(C)</enum><text>by adding at the end the following new subparagraph:</text>
								<quoted-block display-inline="no-display-inline" id="H5E964B6F7EC74EE6BEFC58DCB1C71F80" style="OLC">
 <subparagraph id="H6B98FA01607B46AF91189068B399AC06" indent="up1"><enum>(GG)</enum><text display-inline="yes-display-inline">a durable medical item that administers a drug described in section 1927(k)(2)(C) that would otherwise be self-administered multiple times per day and includes a disposable component and at least one component that can withstand repeated use, and supplies used in conjunction with such item (including the drug administered by such item);</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
							</subparagraph></paragraph><paragraph id="H2782583E833F425C989FA060F80C02AD"><enum>(2)</enum><header>Payment</header>
 <subparagraph id="HF7F68CDE873947D79EF810912A92A0E1"><enum>(A)</enum><header>Payment amount for DMI</header><text display-inline="yes-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text>
								<quoted-block display-inline="no-display-inline" id="HAB2D820784454DE2AAB89DBC4C38ACB7" style="OLC">
 <subsection id="HEBA919DF774641F18C262263A82DAC5A"><enum>(r)</enum><header>Payment methodology for durable medical items (DMI)</header><text display-inline="yes-display-inline">The Secretary shall establish a payment methodology for a durable medical item described in section 1861(s)(2)(GG) and supplies used in conjunction with such item (other than a drug administered by such item) such that the estimated average total payment per individual for such items and supplies does not exceed the estimated average total payment per individual that would otherwise be made (taking into account the application of section 1847) for the durable medical equipment for which it is a substitute and for supplies used in conjunction with such equipment (other than such a drug) as determined appropriate by the Secretary.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="H9E5B327FAEF54B6299E92B9668564CA8"><enum>(B)</enum><header>Payment for drug</header><text>Section 1842(o)(1)(D) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395u">42 U.S.C. 1395u(o)(1)(D)</external-xref>) is amended—</text> <clause id="HB1887102A0484442955EEF19C5A77B0D"><enum>(i)</enum><text>in clause (i), by inserting <quote>or drugs administered by a durable medical item covered under section 1861(s)(2)(GG) on or after January 1, 2017,</quote> after <quote>after January 1, 2004,</quote>; and</text>
 </clause><clause id="H6105142E7CB44F348B167786CF090548"><enum>(ii)</enum><text>in clause (ii), by striking <quote>infusion</quote>.</text> </clause></subparagraph><subparagraph id="HEB9D7313F94440709FFB9DBCC587B212"><enum>(C)</enum><header>Competitive acquisition</header><text display-inline="yes-display-inline">Section 1847(a)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-3">42 U.S.C. 1395w–3(a)(2)</external-xref>) is amended by adding at the end the following new subparagraph:</text>
								<quoted-block display-inline="no-display-inline" id="H468E411D8A924B238E8854F4974C8975" style="OLC">
 <subparagraph id="HAF81FD2588ED4D5AAA67501BAE77611D"><enum>(D)</enum><header>Durable medical item</header><text display-inline="yes-display-inline">A durable medical item and supplies used in conjunction with such item, described in section 1861(s)(2)(GG).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="H4FB82F4867CC4BEAB9271C090F630D28"><enum>(3)</enum><header>Conforming amendment</header><text>Section 1833(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)</external-xref>) is amended—</text> <subparagraph id="H408756A50C5A4F6A8E1669B9E25FDEB8"><enum>(A)</enum><text>by striking <quote>and</quote> before <quote>(Z)</quote>; and</text>
 </subparagraph><subparagraph id="HD18C1DC57EE146509E91073EEBDE2920"><enum>(B)</enum><text>by inserting before the semicolon at the end the following: <quote>, and (AA) with respect to durable medical items described in section 1861(s)(2)(GG), the amount paid shall be equal to 80 percent of the lesser of the actual charge or the amount determined under section 1834(r)</quote>.</text>
 </subparagraph></paragraph><paragraph id="H7A2B487039AB4DAF9172644E82F6145B"><enum>(4)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendments made by this subsection shall apply to items furnished on or after January 1, 2017.</text> </paragraph></subsection><subsection id="H9A4DC046F916405490537CBFB67D8926"><enum>(b)</enum><header>Payment for certain disposable devices</header> <paragraph id="HE84E1AE71E8A4FFD80A7D3B4DDE52972"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>), as amended by subsection (a)(2), is further amended by adding at the end the following new subsection:</text>
							<quoted-block display-inline="no-display-inline" id="H6D375881D42A43B8A5BE7245E29DD1F7" style="OLC">
								<subsection id="HF2ED67A9B40A4D5EADD3D334CE958834"><enum>(s)</enum><header>Payment for certain disposable devices</header>
 <paragraph id="H463DB8798963480CB774B14EE375E945"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall make separate payment in the amount established under paragraph (3) to a home health agency for a device described in paragraph (2) when furnished to an individual who receives home health services for which payment is made under section 1895(b).</text>
 </paragraph><paragraph id="H21CBD107B9174B7782D1AC4623C7B45E"><enum>(2)</enum><header>Device described</header><text display-inline="yes-display-inline">For purposes of paragraph (1), a device described in this paragraph is a disposable device for which, as of January 1, 2015, there is—</text>
 <subparagraph id="H58395D8551E84ED9B02151BE479A055F"><enum>(A)</enum><text display-inline="yes-display-inline">a Level I Healthcare Common Procedure Coding System (HCPCS) code for which the description for a professional service includes the furnishing of such device; and</text>
 </subparagraph><subparagraph id="HFE2ED4CFA5024D1086E92D76ED1FEACF"><enum>(B)</enum><text>a separate Level I HCPCS code for a professional service that uses durable medical equipment instead of such device.</text>
 </subparagraph></paragraph><paragraph id="HCA880F57881C4211A80B14CC83473083"><enum>(3)</enum><header>Payment amount</header><text display-inline="yes-display-inline">The Secretary shall establish the separate payment amount for such a device such that such amount does not exceed the payment that would be made for the HCPCS code described in paragraph (2)(A) under section 1833(t) (relating to payment for covered OPD services).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HF301FD054F1B442A954D9830CE2E347C"><enum>(2)</enum><header>Conforming amendment</header><text display-inline="yes-display-inline">Section 1861(m)(5) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(m)(5)</external-xref>) is amended by inserting <quote>and devices described in section 1834(s)(2)</quote> after <quote>durable medical equipment</quote>.</text> </paragraph><paragraph id="H69FD28B7614A44C5AFEA461AD580CCC6"><enum>(3)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendments made by this subsection shall apply to devices furnished on or after January 1, 2017.</text>
						</paragraph></subsection></section></subtitle><subtitle id="H8F7E549A022149588140535BB3160F41"><enum>E</enum><header>Local coverage decision reforms</header>
				<section commented="no" id="H2AD977BBF6E24E5D9ED349A954290801" section-type="subsequent-section"><enum>3081.</enum><header>Improvements in the Medicare local coverage determination (LCD) process</header>
 <subsection commented="no" id="H0F986631BFE34CB199AB1954CB2525E7"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1862(l)(5) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(l)(5)</external-xref>) is amended by adding at the end the following new subparagraph:</text>
						<quoted-block display-inline="no-display-inline" id="HF85A2830DE5A447486841B447C08C2F5" style="OLC">
 <subparagraph commented="no" id="H81CC9E9059BE44DB9685684AE8D47F48"><enum>(D)</enum><header>Local coverage determinations</header><text display-inline="yes-display-inline">The Secretary shall require each medicare administrative contractor that develops a local coverage determination to make available on the website of such contractor and in the coverage database on the Medicare website, at least 45 days before the effective date of such determination, the following information:</text>
 <clause commented="no" id="H0F727C77C23F4C9B99D33D1643217082"><enum>(i)</enum><text display-inline="yes-display-inline">Such determination in its entirety.</text> </clause><clause commented="no" id="H89B9EC76EADE4679B950A6450D103952"><enum>(ii)</enum><text>Where and when the proposed determination was first made public.</text>
 </clause><clause commented="no" id="H3D26C63207CC4544A8E5D606F264E77E"><enum>(iii)</enum><text>Links to the proposed determination and a response to comments submitted to the contractor with respect to such proposed determination.</text>
 </clause><clause commented="no" id="HD09A18CE107244B0A67CCE5FDEE03DB3"><enum>(iv)</enum><text>A summary of evidence that was considered by the contractor during the development of such determination and a list of the sources of such evidence.</text>
 </clause><clause commented="no" id="H1C3FDA1B24CD4DD6840056ECAAA59265"><enum>(v)</enum><text>An explanation of the rationale that supports such determination.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection commented="no" id="HA6908AD71B1845F3906554237E387B4D"><enum>(b)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendment made by subsection (a) shall apply with respect to local coverage determinations that are proposed or revised on or after the date that is 180 days after the date of the enactment of this Act.</text>
					</subsection></section></subtitle><subtitle id="H8741C6606BE64649B332DF4F63A7884F"><enum>F</enum><header>Medicare Pharmaceutical and Technology Ombudsman</header>
 <section id="H9195E09868454103971F3079FEC99645" section-type="subsequent-section"><enum>3101.</enum><header>Medicare pharmaceutical and technology ombudsman</header><text display-inline="no-display-inline">Section 1808(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395b-9">42 U.S.C. 1395b–9(c)</external-xref>) is amended by adding at the end the following new paragraph:</text>
					<quoted-block display-inline="no-display-inline" id="HE28EF058600E4466845C27F44DC76442" style="OLC">
 <paragraph id="HE2FB979ED0DB44268E53B7BCFB568C3E"><enum>(4)</enum><header>Pharmaceutical and technology ombudsman</header><text display-inline="yes-display-inline">Not later than 12 months after the date of the enactment of this paragraph, the Secretary shall provide for a pharmaceutical and technology ombudsman within the Centers for Medicare &amp; Medicaid Services who shall receive and respond to complaints, grievances, and requests that—</text>
 <subparagraph id="H709B51B8A58C4E528D7CD7E58AEDFAB2"><enum>(A)</enum><text display-inline="yes-display-inline">are from entities that manufacture pharmaceutical, biotechnology, medical device, or diagnostic products that are covered or for which coverage is being sought under this title; and</text>
 </subparagraph><subparagraph id="HFA3C49D0723F4169A8D5C5F395AB8A6E"><enum>(B)</enum><text>regard coverage, coding, or payment under this title for such products.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </section></subtitle><subtitle commented="no" id="HDDBC17EE482547C7B616D9BFC26B426C"><enum>G</enum><header>Medicare site-of-Service price transparency</header> <section commented="no" id="HCA6C98C710E94BFE87774A8BF90159EB" section-type="subsequent-section"><enum>3121.</enum><header>Medicare site-of-Service price transparency</header><text display-inline="no-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text>
					<quoted-block display-inline="no-display-inline" id="HFCF0FD858BD44404A6DB002B57F982BD" style="OLC">
						<subsection commented="no" id="H987465F649C3491AB6393599463107E9"><enum>(r)</enum><header>Site-of-service price transparency</header>
 <paragraph commented="no" id="HD8C1C29AEFFD46349D932476C9643325"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In order to facilitate price transparency with respect to items and services for which payment may be made either to a hospital outpatient department or to an ambulatory surgery center under this title, the Secretary shall, for 2017 and each year thereafter, make available to the public via a searchable website, with respect to an appropriate number of such items and services—</text>
 <subparagraph commented="no" id="HAFA10225DDE4414EA302F66305CA86DE"><enum>(A)</enum><text display-inline="yes-display-inline">the estimated payment amount for such items and services under the outpatient department fee schedule under subsection (t) of section 1833 and the ambulatory surgical center payment system under subsection (i) of such section; and</text>
 </subparagraph><subparagraph commented="no" id="HAFF7851D12114AFC850243CDBA28BF5B"><enum>(B)</enum><text>the estimated amount of beneficiary liability applicable to such an item or service.</text> </subparagraph></paragraph><paragraph commented="no" id="H57EB74FF9B824C598EB3079E5BA0AB75"><enum>(2)</enum><header>Calculation of estimated beneficiary liability</header><text display-inline="yes-display-inline">For purposes of paragraph (1)(B), the estimated amount of beneficiary liability, with respect to an item or service, is the amount for such item or service for which an individual who does not have coverage under a medicare supplemental policy certified under section 1882 or any other supplemental insurance coverage is responsible.</text>
 </paragraph><paragraph commented="no" display-inline="no-display-inline" id="H17504EF8C3D14C36866A90219DDE61F4"><enum>(3)</enum><header>Implementation</header><text display-inline="yes-display-inline">In carrying out this subsection, the Secretary—</text> <subparagraph commented="no" id="H42AF2D1C4E124DB5A5934EAABCD745A3"><enum>(A)</enum><text display-inline="yes-display-inline">shall include in the notice described in section 1804(a) a notification of the availability of the estimated amounts made available under paragraph (1); and</text>
 </subparagraph><subparagraph commented="no" id="H627A2B448DA746FC9E987294912883EA"><enum>(B)</enum><text display-inline="yes-display-inline">may utilize existing mechanisms, such as the portion of the website of the Centers for Medicare &amp; Medicaid Services on which information comparing physician performance is posted (commonly referred to as the Physician Compare website), to make available such estimated amounts under such paragraph.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HCAC485CCC19441DCBBEC3D4CB216A244"><enum>(4)</enum><header>Funding</header><text display-inline="yes-display-inline">For purposes of implementing this subsection, the Secretary shall provide for the transfer, from the Supplemental Medical Insurance Trust Fund under section 1841 to the Centers for Medicare &amp; Medicaid Services Program Management Account, of $6,000,000 for fiscal year 2015, to remain available until expended.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</section></subtitle><subtitle commented="no" id="HA992C319BFCA4C99B991A643B0804079"><enum>H</enum><header>Medicare Part D Patient Safety and Drug Abuse Prevention</header>
				<section id="HC1CF106758AF48A492E1B9D655472648" section-type="subsequent-section"><enum>3141.</enum><header>Programs to prevent prescription drug abuse under Medicare parts C and D</header>
					<subsection id="H7F4058095A954A19B2ABC96C8E8604F0"><enum>(a)</enum><header>Drug management program for at-Risk beneficiaries</header>
 <paragraph id="H08214956F0D9461AB76EE22CA94E26E9"><enum>(1)</enum><header>In general</header><text>Section 1860D–4(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-10">42 U.S.C. 1395w–10(c)</external-xref>) is amended by adding at the end the following:</text>
							<quoted-block id="H24C867B681A84DF79EEB3EFDB2416190" style="OLC">
								<paragraph id="HF6D542264DF4407EB7C7BA112E88B7BE"><enum>(5)</enum><header>Drug management program for at-risk beneficiaries</header>
 <subparagraph id="HD29E268B09F24DB4A453F7E2BF360329"><enum>(A)</enum><header>Authority to establish</header><text display-inline="yes-display-inline">A PDP sponsor may establish a drug management program for at-risk beneficiaries under which, subject to subparagraph (B), the PDP sponsor may, in the case of an at-risk beneficiary for prescription drug abuse who is an enrollee in a prescription drug plan of such PDP sponsor, limit such beneficiary’s access to coverage for frequently abused drugs under such plan to frequently abused drugs that are prescribed for such beneficiary by one or more prescribers selected under subparagraph (D), and dispensed for such beneficiary by one or more pharmacies selected under such subparagraph.</text>
									</subparagraph><subparagraph id="H30F545F6DDB54F7995BBF7B70CB79B34"><enum>(B)</enum><header>Requirement for notices</header>
 <clause id="H802D777382C040E298BDDA43B50523A2"><enum>(i)</enum><header>In general</header><text>A PDP sponsor may not limit the access of an at-risk beneficiary for prescription drug abuse to coverage for frequently abused drugs under a prescription drug plan until such sponsor—</text>
 <subclause id="H13C1A32281C245C294B260AF1F56F8C9"><enum>(I)</enum><text>provides to the beneficiary an initial notice described in clause (ii) and a second notice described in clause (iii); and</text>
 </subclause><subclause id="H7F09F2FF2F9A4CEB81E2C4EC2D6D604B"><enum>(II)</enum><text display-inline="yes-display-inline">verifies with the providers of the beneficiary that the beneficiary is an at-risk beneficiary for prescription drug abuse.</text>
 </subclause></clause><clause commented="no" id="HE39D90178D5849C7913D6F9BDEE6C0CF"><enum>(ii)</enum><header>Initial notice</header><text display-inline="yes-display-inline">An initial notice described in this clause is a notice that provides to the beneficiary—</text> <subclause commented="no" id="HF951FD5DAEE24DDAB6FCF4696135C79D"><enum>(I)</enum><text>notice that the PDP sponsor has identified the beneficiary as potentially being an at-risk beneficiary for prescription drug abuse;</text>
 </subclause><subclause commented="no" id="H621A86D4A548453C8102F32E61586B99"><enum>(II)</enum><text display-inline="yes-display-inline">information describing all State and Federal public health resources that are designed to address prescription drug abuse to which the beneficiary has access, including mental health services and other counseling services;</text>
 </subclause><subclause id="H19B44EB06C33455E9B148E6EEDFA534A"><enum>(III)</enum><text display-inline="yes-display-inline">notice of, and information about, the right of the beneficiary to appeal such identification under subsection (h) and the option of an automatic escalation to external review;</text>
 </subclause><subclause id="HA398F72EA4B14F60B2AFF80BB45AFD43"><enum>(IV)</enum><text display-inline="yes-display-inline">a request for the beneficiary to submit to the PDP sponsor preferences for which prescribers and pharmacies the beneficiary would prefer the PDP sponsor to select under subparagraph (D) in the case that the beneficiary is identified as an at-risk beneficiary for prescription drug abuse as described in clause (iii)(I);</text>
 </subclause><subclause id="HABD57537F3AD444FA9D4556B30D806EC"><enum>(V)</enum><text display-inline="yes-display-inline">an explanation of the meaning and consequences of the identification of the beneficiary as potentially being an at-risk beneficiary for prescription drug abuse, including an explanation of the drug management program established by the PDP sponsor pursuant to subparagraph (A);</text>
 </subclause><subclause id="HAED3B740856240F5AFC5488DFDED76B6"><enum>(VI)</enum><text display-inline="yes-display-inline">clear instructions that explain how the beneficiary can contact the PDP sponsor in order to submit to the PDP sponsor the preferences described in subclause (IV) and any other communications relating to the drug management program for at-risk beneficiaries established by the PDP sponsor; and</text>
 </subclause><subclause id="H3F2875F92B7C46159B49EE3909EEAF13"><enum>(VII)</enum><text display-inline="yes-display-inline">contact information for other organizations that can provide the beneficiary with assistance regarding such drug management program (similar to the information provided by the Secretary in other standardized notices provided to part D eligible individuals enrolled in prescription drug plans under this part).</text>
 </subclause></clause><clause id="HED9F5AEDE7584B2AB6308E41DAD1E8E3"><enum>(iii)</enum><header>Second notice</header><text>A second notice described in this clause is a notice that provides to the beneficiary notice—</text> <subclause id="HD64F86357371472E842106499D9E1AF6"><enum>(I)</enum><text display-inline="yes-display-inline">that the PDP sponsor has identified the beneficiary as an at-risk beneficiary for prescription drug abuse;</text>
 </subclause><subclause id="H8755033EDB9C4F4D947354825BCCA8EE"><enum>(II)</enum><text display-inline="yes-display-inline">that such beneficiary is subject to the requirements of the drug management program for at-risk beneficiaries established by such PDP sponsor for such plan;</text>
 </subclause><subclause id="H7F7570032529482BAB8B820B8ED484C5"><enum>(III)</enum><text display-inline="yes-display-inline">of the prescriber (or prescribers) and pharmacy s(or pharmacies) elected for such individual under <internal-xref idref="HD4FAA7E48359463F99D7C796CFBC830A" legis-path="(4)(D)">subparagraph (D)</internal-xref>;</text> </subclause><subclause id="HF76229D493CB4D0B81341F56728A1AF3"><enum>(IV)</enum><text display-inline="yes-display-inline">of, and information about, the beneficiary’s right to appeal such identification under subsection (h) and the option of an automatic escalation to external review;</text>
 </subclause><subclause commented="no" id="H561BD04318E74A13B58A212B157F26AA"><enum>(V)</enum><text display-inline="yes-display-inline">that the beneficiary can, in the case that the beneficiary has not previously submitted to the PDP sponsor preferences for which prescribers and pharmacies the beneficiary would prefer the PDP sponsor select under subparagraph (D), submit such preferences to the PDP sponsor; and</text>
 </subclause><subclause id="H024608C808104A10A6BCC0648AC1215E"><enum>(VI)</enum><text display-inline="yes-display-inline">that includes clear instructions that explain how the beneficiary can contact the PDP sponsor.</text> </subclause></clause><clause id="H5F9D8A8D7B7D4138B0B32ABD53852BAC"><enum>(iv)</enum><header>Timing of notices</header> <subclause id="H1143222A79AD4808944FB276AB07AC4D"><enum>(I)</enum><header>In general</header><text>Subject to subclause (II), a second notice described in clause (iii) shall be provided to the beneficiary on a date that is not less than 60 days after an initial notice described in clause (ii) is provided to the beneficiary.</text>
 </subclause><subclause id="H81267C9C8ABA4CA48DA4A432B9CF1851"><enum>(II)</enum><header>Exception</header><text display-inline="yes-display-inline">In the case that the PDP sponsor, in conjunction with the Secretary, determines that concerns identified through rulemaking by the Secretary regarding the health or safety of the beneficiary or regarding significant drug diversion activities require the PDP sponsor to provide a second notice described in clause (iii) to the beneficiary on a date that is earlier than the date described in subclause (II), the PDP sponsor may provide such second notice on such earlier date.</text>
											</subclause></clause></subparagraph><subparagraph id="HD2189BF1A96E48828FCC9A79BA97A752"><enum>(C)</enum><header>At-risk beneficiary for prescription drug abuse</header>
 <clause id="H23112B247A1B4B5C892644F7939F273B"><enum>(i)</enum><header>In general</header><text>For purposes of this paragraph, the term <quote>at-risk beneficiary for prescription drug abuse</quote> means a part D eligible individual who is not an exempted individual described in clause (ii) and—</text> <subclause display-inline="no-display-inline" id="H0A02461965A3409A8A52E791A831641B"><enum>(I)</enum><text display-inline="yes-display-inline">who is identified through the use of clinical guidelines developed by the Secretary in consultation with PDP sponsors and other stakeholders described in section 3141(f)(2)(A) of the 21st Century Cures Act; or</text>
 </subclause><subclause id="H961969DC706A43DF934464C9911972D9"><enum>(II)</enum><text display-inline="yes-display-inline">with respect to whom the PDP sponsor of a prescription drug plan, upon enrolling such individual in such plan, received notice from the Secretary that such individual was identified under this paragraph to be an at-risk beneficiary for prescription drug abuse under the prescription drug plan in which such individual was most recently previously enrolled and such identification has not been terminated under subparagraph (F).</text>
 </subclause></clause><clause id="HB4909AF1A26B4AC584B6F8A639374695"><enum>(ii)</enum><header>Exempted individual described</header><text>An exempted individual described in this clause is an individual who—</text> <subclause id="H31ED5647CA06447582BDD26667ABE97E"><enum>(I)</enum><text display-inline="yes-display-inline">receives hospice care under this title;</text>
 </subclause><subclause id="HFD9A63F4DF194A948B9176A58460C399"><enum>(II)</enum><text>is a resident of a long-term care facility, of an intermediate care facility for the mentally retarded, or of another facility for which frequently abused drugs are dispensed for residents through a contract with a single pharmacy; or</text>
 </subclause><subclause commented="no" id="HD67356EAE2364534B2E6595653F4A9BD"><enum>(III)</enum><text>the Secretary elects to treat as an exempted individual for purposes of clause (i).</text> </subclause></clause></subparagraph><subparagraph id="HD4FAA7E48359463F99D7C796CFBC830A"><enum>(D)</enum><header>Selection of prescribers and pharmacies</header> <clause id="H4328381FF85C45B8B100DE12F614A43F"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">With respect to each at-risk beneficiary for prescription drug abuse enrolled in a prescription drug plan offered by such sponsor, a PDP sponsor shall, based on the preferences submitted to the PDP sponsor by the beneficiary pursuant to clauses (ii)(IV) and (iii)(V) of subparagraph (B), select—</text>
 <subclause id="H912E5E6F5FA94FB398B58FB3B5B72078"><enum>(I)</enum><text display-inline="yes-display-inline">one or more individuals who are authorized to prescribe frequently abused drugs (referred to in this paragraph as <quote>prescribers</quote>) who may write prescriptions for such drugs for such beneficiary; and</text>
 </subclause><subclause id="H2DAB2CC6F1B84F17ABE72D27BF2B30F6"><enum>(II)</enum><text>one or more pharmacies that may dispense such drugs to such beneficiary.</text> </subclause></clause><clause id="HBAB229E6F6544E83B2B6ADA59E5E9B85"><enum>(ii)</enum><header>Reasonable access</header><text display-inline="yes-display-inline">In making the selections under this subparagraph—</text>
 <subclause id="H9932851AADC44707A0E607188A87BF25"><enum>(I)</enum><text>a PDP sponsor shall ensure that the beneficiary continues to have reasonable access to drugs described in subparagraph (G), taking into account geographic location, beneficiary preference, impact on cost-sharing, and reasonable travel time; or</text>
 </subclause><subclause id="H73CA02F1A7A4443DB805E8DB9975C79A"><enum>(II)</enum><text>a PDP sponsor shall ensure such access to prescribers and pharmacies in the case of individuals with multiple residences and in the case of natural disasters and similar emergency situations.</text>
											</subclause></clause><clause id="HE4A9470EC4D2410DA9763AE13F1AFFF4"><enum>(iii)</enum><header>Beneficiary preferences</header>
 <subclause id="HE7343CB0AAF74AB4AC57D010E6C5AC3B"><enum>(I)</enum><header>In general</header><text>If an at-risk beneficiary for prescription drug abuse submits preferences for which in-network prescribers and pharmacies the beneficiary would prefer the PDP sponsor select in response to a notice under subparagraph (B), the PDP sponsor shall—</text>
 <item id="H76889825BE7F405A9223D4A09743D44A"><enum>(aa)</enum><text>review such preferences;</text> </item><item id="H2F934B1A5517473880BF019AEDD61470"><enum>(bb)</enum><text>select or change the selection of prescribers and pharmacies for the beneficiary based on such preferences; and</text>
 </item><item id="H4DD1CF33478C4D39BF3C8ED0412BEF77"><enum>(cc)</enum><text>inform the beneficiary of such selection or change of selection.</text> </item></subclause><subclause id="H7565B961682B4FA589763314EF02EC9B"><enum>(II)</enum><header>Exception</header><text display-inline="yes-display-inline">In the case that the PDP sponsor determines that a change to the selection of prescriber or pharmacy under item (bb) by the PDP sponsor is contributing or would contribute to prescription drug abuse or drug diversion by the beneficiary, the PDP sponsor may change the selection of prescriber or pharmacy for the beneficiary without regard to the preferences of the beneficiary described in subclause (I).</text>
 </subclause></clause><clause id="HC0EDB447AA42494698F7F56FB82BB919"><enum>(iv)</enum><header>Confirmation</header><text display-inline="yes-display-inline">Before selecting a prescriber (or prescribers) or pharmacy (or pharmacies) under this subparagraph, a PDP sponsor must request and receive confirmation from such a prescriber or pharmacy acknowledging and accepting that the beneficiary involved is in the drug management program for at-risk beneficiaries.</text>
 </clause></subparagraph><subparagraph id="H08A756962B944E5CB6F75FC72B4A0CAD"><enum>(E)</enum><header>Terminations and appeals</header><text display-inline="yes-display-inline">The identification of an individual as an at-risk beneficiary for prescription drug abuse under this paragraph, a coverage determination made under a drug management program for at-risk beneficiaries, and the selection of prescriber or pharmacy under subparagraph (D) with respect to such individual shall be subject to reconsideration and appeal under subsection (h) and the option of an automatic escalation to external review to the extent provided by the Secretary.</text>
									</subparagraph><subparagraph id="H921A480CECEA41379DAC324509402091"><enum>(F)</enum><header>Termination of identification</header>
 <clause id="H864CA99D8677478283CE44913E498937"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall develop standards for the termination of identification of an individual as an at-risk beneficiary for prescription drug abuse under this paragraph. Under such standards such identification shall terminate as of the earlier of—</text>
 <subclause id="H0B1BB793E567456A966B877C7B935424"><enum>(I)</enum><text display-inline="yes-display-inline">the date the individual demonstrates that the individual is no longer likely, in the absence of the restrictions under this paragraph, to be an at-risk beneficiary for prescription drug abuse described in subparagraph (C)(i); or</text>
 </subclause><subclause id="H028C45A14CCC423483857CB33D890C73"><enum>(II)</enum><text>the end of such maximum period of identification as the Secretary may specify.</text> </subclause></clause><clause id="H5B39868ACC454D30ADCB9669A850880D"><enum>(ii)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in clause (i) shall be construed as preventing a plan from identifying an individual as an at-risk beneficiary for prescription drug abuse under subparagraph (C)(i) after such termination on the basis of additional information on drug use occurring after the date of notice of such termination.</text>
 </clause></subparagraph><subparagraph id="H4B0AA39A7DB147B6A13AEC3E76346789"><enum>(G)</enum><header>Frequently abused drug</header><text display-inline="yes-display-inline">For purposes of this subsection, the term <term>frequently abused drug</term> means a drug that is a controlled substance that the Secretary determines to be frequently abused or diverted.</text>
 </subparagraph><subparagraph id="H1FBFEFA6ED904C48913810A5EABA77DE"><enum>(H)</enum><header>Data disclosure</header><text display-inline="yes-display-inline">In the case of an at-risk beneficiary for prescription drug abuse whose access to coverage for frequently abused drugs under a prescription drug plan has been limited by a PDP sponsor under this paragraph, such PDP sponsor shall disclose data, including any necessary individually identifiable health information, in a form and manner specified by the Secretary, about the decision to impose such limitations and the limitations imposed by the sponsor under this part.</text>
 </subparagraph><subparagraph id="HD21B3931AF6F4C2193601108074329ED"><enum>(I)</enum><header>Education</header><text display-inline="yes-display-inline">The Secretary shall provide education to enrollees in prescription drug plans of PDP sponsors and providers regarding the drug management program for at-risk beneficiaries described in this paragraph, including education—</text>
 <clause id="HBA2A6CEC1E1B44EE8A7D6326EF77BA68"><enum>(i)</enum><text>provided by medicare administrative contractors through the improper payment outreach and education program described in section 1874A(h); and</text>
 </clause><clause id="H963174EFD20E4CC69C6E649E8789E4E5"><enum>(ii)</enum><text display-inline="yes-display-inline">through current education efforts (such as State health insurance assistance programs described in subsection (a)(1)(A) of section 119 of the Medicare Improvements for Patients and Providers Act of 2008 (<external-xref legal-doc="usc" parsable-cite="usc/42/1395b-3">42 U.S.C. 1395b–3</external-xref> note)) and materials directed toward such enrollees.</text>
 </clause></subparagraph><subparagraph id="H0D4B309EBA214580848C3EBB85E227A1"><enum>(J)</enum><header>Application under MA–PD plans</header><text>Pursuant to section 1860D—21(c)(1), the provisions of this paragraph apply under part D to MA organizations offering MA–PD plans to MA eligible individuals in the same manner as such provisions apply under this part to a PDP sponsor offering a prescription drug plan to a part D eligible individual.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HD9735E76E1B444809A0EC5CF34887943"><enum>(2)</enum><header>Information for consumers</header><text display-inline="yes-display-inline">Section 1860D–4(a)(1)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(a)(1)(B)</external-xref>) is amended by adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="HBE6D462664834804B7B0497666E1D419" style="OLC">
 <clause id="H28D5A2FA89504946B02A0AEB5C75A89D"><enum>(v)</enum><text display-inline="yes-display-inline">The drug management program for at-risk beneficiaries under subsection (c)(5).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></subsection><subsection id="HCB7A8B248FB5415E93BC56F318E1D625"><enum>(b)</enum><header>Utilization management programs</header><text display-inline="yes-display-inline">Section 1860D–4(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(c)</external-xref>), as amended by subsection (a)(1), is further amended—</text>
 <paragraph id="HA30EB4FBA96D4CF98CFE125121A5474C"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (1), by inserting after subparagraph (D) the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="HE01D748C46EB48D7A25D09454A496B44" style="OLC"> <subparagraph id="HE628B330E987463CA59B41B4F78ABD42"><enum>(E)</enum><text display-inline="yes-display-inline">A utilization management tool to prevent drug abuse (as described in paragraph (6)(A)).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HC9B58AD9CD7840F68C4CC73652284C10"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="HFD9C68EAE6BC4CA5B2B750793C36C6A5" style="OLC"> <paragraph id="H4054DBD921484971AEBFA178F0DF1872"><enum>(6)</enum><header>Utilization management tool to prevent drug abuse</header> <subparagraph id="H315F363520C24982A9BC893EA437B5E2"><enum>(A)</enum><header>In general</header><text>A tool described in this paragraph is any of the following:</text>
 <clause id="H7AAAB20E0E704B4EAF70E99C3A0C3D82"><enum>(i)</enum><text>A utilization tool designed to prevent the abuse of frequently abused drugs by individuals and to prevent the diversion of such drugs at pharmacies.</text>
 </clause><clause id="HDB28F3F6BDC84A908823864A91FFEFD4"><enum>(ii)</enum><text>Retrospective utilization review to identify—</text> <subclause id="HF2B289090E764A52BF1D16C37C6F590E"><enum>(I)</enum><text display-inline="yes-display-inline">individuals that receive frequently abused drugs at a frequency or in amounts that are not clinically appropriate; and</text>
 </subclause><subclause id="H22BBA126F90D48C0A657244B39C5BD8B"><enum>(II)</enum><text>providers of services or suppliers that may facilitate the abuse or diversion of frequently abused drugs by beneficiaries.</text>
 </subclause></clause><clause id="HDE46BB79592F4F49871E4C3186EDC268"><enum>(iii)</enum><text>Consultation with the contractor described in subparagraph (B) to verify if an individual enrolling in a prescription drug plan offered by a PDP sponsor has been previously identified by another PDP sponsor as an individual described in clause (ii)(I).</text>
 </clause></subparagraph><subparagraph id="HF90FD46913654BCE9E450A223A61506B"><enum>(B)</enum><header>Reporting</header><text>A PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) in a State shall submit to the Secretary and the Medicare drug integrity contractor with which the Secretary has entered into a contract under section 1893 with respect to such State a report, on a monthly basis, containing information on—</text>
 <clause id="H8A9202190705456DAC2F37965B75B1C2"><enum>(i)</enum><text>any provider of services or supplier described in subparagraph (A)(ii)(II) that is identified by such plan sponsor (or organization) during the 30-day period before such report is submitted; and</text>
 </clause><clause id="H5E2F328754944E739DD528A01E79A66D"><enum>(ii)</enum><text>the name and prescription records of individuals described in paragraph (5)(C).</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></subsection><subsection id="H935323988F6C47F786BB8FF2BCF0BA06"><enum>(c)</enum><header>Expanding Activities of Medicare Drug Integrity Contractors (MEDICs)</header> <paragraph id="H57B663B233A44679A04BA0A4AD126260"><enum>(1)</enum><header>In general</header><text>Section 1893 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ddd">42 U.S.C. 1395ddd</external-xref>) is amended by adding at the end the following new subsection:</text>
							<quoted-block display-inline="no-display-inline" id="H175FD4B11ADD4C8A9837DA0DF061B94E" style="OLC">
								<subsection id="HE1537CAF281E47B2BFB45C3CE0BD7E7F"><enum>(j)</enum><header>Expanding Activities of Medicare Drug Integrity Contractors (MEDICs)</header>
 <paragraph id="H1BB89DA84D4E4A84910F076F6B7CA074"><enum>(1)</enum><header>Access to information</header><text display-inline="yes-display-inline">Under contracts entered into under this section with Medicare drug integrity contractors, the Secretary shall authorize such contractors to directly accept prescription and necessary medical records from entities such as pharmacies, prescription drug plans, MA–PD plans, and physicians with respect to an individual in order for such contractors to provide information relevant to the determination of whether such individual is an at-risk beneficiary for prescription drug abuse, as defined in section 1860D–4(c)(5)(C).</text>
 </paragraph><paragraph commented="no" id="H7830713C8B9E40EEBFC6DB8270E9811D"><enum>(2)</enum><header>Requirement for acknowledgment of referrals</header><text display-inline="yes-display-inline">If a PDP sponsor or MA organization refers information to a contractor described in paragraph (1) in order for such contractor to assist in the determination described in such paragraph, the contractor shall—</text>
 <subparagraph commented="no" id="HD84F10B2F3D74CF6AB3DD1897D87644E"><enum>(A)</enum><text>acknowledge to the sponsor or organization receipt of the referral; and</text> </subparagraph><subparagraph commented="no" id="H78417D5F90A34B7E984537D5824D7E46"><enum>(B)</enum><text>in the case that any PDP sponsor or MA organization contacts the contractor requesting to know the determination by the contractor of whether or not an individual has been determined to be an individual described such paragraph, shall inform such sponsor or organization of such determination on a date that is not later than 15 days after the date on which the sponsor or organization contacts the contractor.</text>
										</subparagraph></paragraph><paragraph id="HF5CD680F16964AF3942D012FAD65EAB2"><enum>(3)</enum><header>Making data available to other entities</header>
 <subparagraph id="HF921B7B0B39B408090A28454EC4B1F87"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For purposes of carrying out this subsection, subject to subparagraph (B), the Secretary shall authorize MEDICs to respond to requests for information from PDP sponsors and MA organizations, State prescription drug monitoring programs, and other entities delegated by such sponsors or organizations using available programs and systems in the effort to prevent fraud, waste, and abuse.</text>
 </subparagraph><subparagraph id="HD1DD79D82EC54D67A928EB48E7378611"><enum>(B)</enum><header>HIPAA compliant information only</header><text display-inline="yes-display-inline">Information may only be disclosed by a MEDIC under subparagraph (A) if the disclosure of such information is permitted under the Federal regulations (concerning the privacy of individually identifiable health information) promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (<external-xref legal-doc="usc" parsable-cite="usc/42/1320d-2">42 U.S.C. 1320d–2</external-xref> note).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</paragraph><paragraph id="H4B5AE6883EB44D5680AB9267A7CC9A54"><enum>(2)</enum><header>OIG study and report on effectiveness of MEDICs</header>
 <subparagraph id="H09E1596D3C5C4259B0876626C4E8B6F3"><enum>(A)</enum><header>Study</header><text>The Inspector General of the Department of Health and Human Services shall conduct a study on the effectiveness of Medicare drug integrity contractors in identifying combating, and preventing fraud under the Medicare program, including under the authority provided under section 1893(j) of the Social Security Act, added by paragraph (1).</text>
 </subparagraph><subparagraph id="H6FAFA6EB5C3549F7A1CE609195C33A6A"><enum>(B)</enum><header>Report</header><text>Not later than 1 year after the date of the enactment of this Act, the Inspector General shall submit to Congress a report on the study conducted under subparagraph (A). Such report shall include such recommendations for improvements in the effectiveness of such contractors as the Inspector General determines appropriate.</text>
 </subparagraph></paragraph></subsection><subsection commented="no" id="H852720058308421BAB6820CDCAACDA37"><enum>(d)</enum><header>Treatment of certain complaints for purposes of quality or performance assessment</header><text display-inline="yes-display-inline">Section 1860D–42 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-152">42 U.S.C. 1395w–152</external-xref>) is amended by adding at the end the following new subsection:</text>
						<quoted-block display-inline="no-display-inline" id="H38938203540A479ABCE5002197613027" style="OLC">
 <subsection id="H7DB88FF573C8421D94545A2211BF3314"><enum>(d)</enum><header>Treatment of certain complaints for purposes of quality or performance assessment</header><text display-inline="yes-display-inline">In conducting a quality or performance assessment of a PDP sponsor, the Secretary shall develop or utilize existing screening methods for reviewing and considering complaints that are received from enrollees in a prescription drug plan offered by such PDP sponsor and that are complaints regarding the lack of access by the individual to prescription drugs due to a drug management program for at-risk beneficiaries.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H1D29526B13304D718846DE3E454574AD"><enum>(e)</enum><header>Sense of congress regarding use of technology tools To combat fraud</header><text display-inline="yes-display-inline">It is the sense of Congress that MA organizations and PDP sponsors should consider using e-prescribing and other health information technology tools to support combating fraud under MA–PD plans and prescription drug plans under parts C and D of the Medicare program.</text>
					</subsection><subsection id="HEB201E15846D45BD8B8E94301BA8E819"><enum>(f)</enum><header>Effective date</header>
 <paragraph id="HF1DA8A9DE8EF44188A4E624C7B9F3D31"><enum>(1)</enum><header>In general</header><text>The amendments made by this section shall apply to prescription drug plans (and MA–PD plans) for plan years beginning more than 1 year after the date of the enactment of this Act.</text>
						</paragraph><paragraph id="HFF663987E078435CAC2B28A58F941DFD"><enum>(2)</enum><header>Stakeholder meetings prior to effective date</header>
 <subparagraph id="H1EB77E87559A42349E5DF65B62EEEB06"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than January 1, 2016, the Secretary of Health and Human Services shall convene stakeholders, including individuals entitled to benefits under part A of title XVIII of the Social Security Act or enrolled under part B of such title of such Act, advocacy groups representing such individuals, physicians, pharmacists, and other clinicians, retail pharmacies, plan sponsors, entities delegated by plan sponsors, and biopharmaceutical manufacturers for input regarding the topics described in subparagraph (B).</text>
 </subparagraph><subparagraph commented="no" id="HA1441EF2E1CF455BABD9374CD33FFF80"><enum>(B)</enum><header>Topics described</header><text display-inline="yes-display-inline">The topics described in this subparagraph are the topics of—</text> <clause id="HAC290D32363849ED9CFCD29705D07A84"><enum>(i)</enum><text display-inline="yes-display-inline">the impact on cost-sharing and ensuring accessibility to prescription drugs for enrollees in prescription drug plans of PDP sponsors, and enrollees in MA–PD plans, who are at-risk beneficiaries for prescription drug abuse (as defined in subparagraph (C) of paragraph (5) of section 1860D–4(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(c)</external-xref>));</text>
 </clause><clause id="H69DEC6F4317746058A45EC439487CDBB"><enum>(ii)</enum><text>the use of an expedited appeals process under which such an enrollee may appeal an identification of such enrollee as an at-risk beneficiary for prescription drug abuse under such paragraph (similar to the processes established under the Medicare Advantage program under part C of title XVIII of the Social Security Act that allow an automatic escalation to external review of claims submitted under such part);</text>
 </clause><clause id="HB9750948D4364AD29E148030C574EC98"><enum>(iii)</enum><text>the types of enrollees that should be treated as exempted individuals, as described in subparagraph (C)(ii) of such paragraph;</text>
 </clause><clause id="HED05E2A692574FF9A174E4216944F7E0"><enum>(iv)</enum><text display-inline="yes-display-inline">the manner in which terms and definitions in such paragraph should be applied, such as the use of clinical appropriateness in determining whether an enrollee is an at-risk beneficiary for prescription drug abuse as defined in subparagraph (C) of such paragraph;</text>
 </clause><clause id="HC640A20E8E504A9BA88BC892A9C601F7"><enum>(v)</enum><text>the information to be included in the notices described in subparagraph (B) of such paragraph and the standardization of such notices; and</text>
 </clause><clause id="H04C79EAEB9CD4E1BAC339FD5DF23AD40"><enum>(vi)</enum><text display-inline="yes-display-inline">with respect to a PDP sponsor (or Medicare Advantage organization) that establishes a drug management program for at-risk beneficiaries under such paragraph, the responsibilities of such PDP sponsor (or organization) with respect to the implementation of such program.</text>
 </clause></subparagraph></paragraph></subsection><subsection id="H56E6B3862CB74418A453B31A3A7498A1"><enum>(g)</enum><header>Rulemaking</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall promulgate regulations based on the input gathered pursuant to subsection (f)(2)(A).</text>
					</subsection></section></subtitle></title></legis-body>
</bill>


